// ============================================
// DATA.JS - OpenOnco Consolidated Data
// Last updated: 2026-01-07
// ============================================
//
// ⚠️  READ SUBMISSION_PROCESS.md BEFORE MAKING ANY CHANGES
//     Location: /Users/adickinson/Documents/GitHub/V0/SUBMISSION_PROCESS.md
//
// ┌─────────────────────────────────────────────────────────────────┐
// │                        QUICK REFERENCE                          │
// ├─────────────────────────────────────────────────────────────────┤
// │ SECTION                    │ START LINE  │ NOTES               │
// ├─────────────────────────────────────────────────────────────────┤
// │ VENDOR_VERIFIED            │ ~463        │ Vendor verification │
// │ VENDOR_ASSISTANCE_PROGRAMS │ ~515        │ Patient assistance  │
// │ MRD Tests                  │ ~750        │ mrd-26 next         │
// │ MRD IVD Kits               │ ~1900       │ mrd-kit-4 next      │
// │ ECD Tests                  │ ~2020       │ ecd-23 next         │
// │ TRM Tests                  │ ~3140       │ trm-15 next         │
// │ TDS Tests                  │ ~3490       │ tds-28 next         │
// │ TDS IVD Kits               │ ~4370       │ tds-kit-16 next     │
// │ DATABASE_CHANGELOG         │ ~5060       │ --                  │
// └─────────────────────────────────────────────────────────────────┘
//
// ============================================
// TEMPLATES - Copy, fill in, paste at insertion point
// ============================================

/*
┌─────────────────────────────────────────────────────────────────┐
│ FIELD SEMANTICS NOTES                                           │
├─────────────────────────────────────────────────────────────────┤
│ approach ("Tumor-informed" vs "Tumor-naïve"):                   │
│   - Tumor-informed: Test uses patient-specific variants         │
│     identified from a baseline sample (tumor tissue, bone       │
│     marrow, or high-disease-burden blood)                       │
│   - Tumor-naïve: Test uses fixed panels without patient-        │
│     specific customization                                      │
│                                                                 │
│ requiresTumorTissue ("Yes" vs "No"):                            │
│   - Indicates whether SOLID TUMOR TISSUE biopsy is required     │
│   - Hematologic MRD tests (clonoSEQ, LymphoVista) may be        │
│     tumor-informed but use blood/marrow, not tissue biopsies    │
│   - A test can be tumor-informed with requiresTumorTissue: "No" │
│     if it uses blood/marrow samples for baseline genotyping     │
│                                                                 │
│ slug (optional):                                                │
│   - Explicit URL slug when auto-generated slug would collide    │
│   - Example: Tempus xF+ has slug: "tempus-xf-plus" to avoid     │
│     collision with Tempus xF (both → "tempus-xf" otherwise)     │
└─────────────────────────────────────────────────────────────────┘
*/

/*
┌─────────────────────────────────────────────────────────────────┐
│ BASELINE COMPLETE (BC) QUALITY STANDARD                         │
├─────────────────────────────────────────────────────────────────┤
│ All tests must meet Baseline Complete (BC) requirements before  │
│ being added to the database. BC tests have ALL minimum fields   │
│ filled in for their category. Check MINIMUM_PARAMS in App.jsx   │
│ for the specific fields required per category.                  │
│                                                                 │
│ Key BC fields typically include:                                │
│   - MRD: sensitivity, specificity, lod, initialTat, followUpTat,│
│          fdaStatus, reimbursement, numPublications              │
│   - ECD: sensitivity, specificity, fdaStatus, reimbursement,    │
│          numPublications                                        │
│   - TDS: genesAnalyzed, fdaStatus, tat, reimbursement,          │
│          numPublications                                        │
│   - TRM: sensitivity, specificity, fdaStatus, tat,              │
│          reimbursement, numPublications                         │
│                                                                 │
│ Citation requirements for 100% sens/spec values:                │
│   - If sensitivity or specificity = 100%, check validation data │
│   - For small cohorts (<200 patients): set smallSampleWarning   │
│   - For analytical validation only: set analyticalValidation-   │
│     Warning = true                                              │
│   - Always prefer PubMed/peer-reviewed citations over vendor    │
│     websites for clinical performance data                      │
└─────────────────────────────────────────────────────────────────┘
*/

/*
┌─────────────────────────────────────────────────────────────────┐
│ MRD TEST TEMPLATE                                               │
│ Insert before: "// IVD KITS - Laboratory kits"                  │
│ Search for: "// INSERT NEW MRD TEST HERE"                       │
└─────────────────────────────────────────────────────────────────┘
  {
    "id": "mrd-XX",
    "sampleCategory": "Blood/Plasma",
    "name": "",
    "vendor": "",
    "approach": "Tumor-informed",  // or "Tumor-naïve"
    "method": "",
    "cancerTypes": [],
    "indicationsNotes": "",
    "sensitivity": null,
    "sensitivityNotes": "",
    "specificity": null,
    "specificityNotes": "",
    "lod": "",
    "lodNotes": "",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "",
    "initialTat": null,
    "initialTatNotes": "",
    "followUpTat": null,
    "followUpTatNotes": "",
    "bloodVolume": null,
    "bloodVolumeNotes": "",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "",
    "cptCodes": "",
    "clinicalAvailability": "",
    "clinicalTrials": "",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "totalParticipants": null,
    "numPublications": null
  },

┌─────────────────────────────────────────────────────────────────┐
│ ECD TEST TEMPLATE                                               │
│ Insert before: "// IVD KITS - Self-Collection"                  │
│ Search for: "// INSERT NEW ECD TEST HERE"                       │
└─────────────────────────────────────────────────────────────────┘
  {
    "id": "ecd-XX",
    "sampleCategory": "Blood/Plasma",
    "name": "",
    "vendor": "",
    "testScope": "Single-cancer (TYPE)",  // or "Multi-cancer (MCED)"
    "approach": "Blood-based cfDNA screening (plasma)",
    "method": "",
    "cancerTypes": [],
    "targetPopulation": "",
    "indicationGroup": "",
    "sensitivity": null,
    "sensitivityCitations": "",
    "stageISensitivity": null,
    "stageIISensitivity": null,
    "stageIIISensitivity": null,
    "stageIVSensitivity": null,
    "specificity": null,
    "specificityCitations": "",
    "ppv": null,
    "npv": null,
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "",
    "clinicalAvailability": "",
    "availableRegions": ["US"],
    "tat": "",
    "sampleType": "",
    "cptCode": "",
    "listPrice": null,
    "screeningInterval": "",
    "clinicalTrials": "",
    "totalParticipants": null,
    "numPublications": null
  },

┌─────────────────────────────────────────────────────────────────┐
│ TRM TEST TEMPLATE                                               │
│ Insert before: "];" that ends trmTestData                       │
│ Search for: "// INSERT NEW TRM TEST HERE"                       │
└─────────────────────────────────────────────────────────────────┘
  {
    "id": "trm-XX",
    "sampleCategory": "Blood/Plasma",
    "name": "",
    "vendor": "",
    "approach": "Tumor-naïve",  // or "Tumor-informed"
    "method": "",
    "cancerTypes": [],
    "targetPopulation": "",
    "responseDefinition": "",
    "indicationsNotes": "",
    "sensitivity": null,
    "specificity": null,
    "lod": "",
    "lodNotes": "",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "",
    "clinicalAvailability": "",
    "availableRegions": ["US"],
    "tat": "",
    "bloodVolume": null,
    "clinicalTrials": "",
    "totalParticipants": null,
    "numPublications": null,
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No"
  },

┌─────────────────────────────────────────────────────────────────┐
│ TDS TEST TEMPLATE (Central Lab Service)                         │
│ Insert before: "// IVD KITS - Laboratory Kits for TDS"          │
│ Search for: "// INSERT NEW TDS TEST HERE"                       │
└─────────────────────────────────────────────────────────────────┘
  {
    "id": "tds-XX",
    "name": "",
    "vendor": "",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",  // or "Blood/Plasma"
    "approach": "Tissue CGP",  // or "Liquid CGP", "Gene Expression Profiling"
    "method": "",
    "methodCitations": "",
    "genesAnalyzed": null,
    "geneListUrl": "",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI"],
    "cancerTypes": ["All solid tumors"],
    "targetPopulation": "",
    "fdaStatus": "CLIA LDT",
    "fdaCompanionDxCount": null,
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentIndications": [],
    "vendorNCCNAlignmentNotes": "",
    "tat": "",
    "sampleRequirements": "",
    "reimbursement": "Medicare",
    "reimbursementNote": "",
    "listPrice": null,
    "cptCodes": "",
    "clinicalAvailability": "",
    "numPublications": null
  },

┌─────────────────────────────────────────────────────────────────┐
│ TDS IVD KIT TEMPLATE                                            │
│ Insert before: "];" that ends tdsTestData                       │
│ Search for: "// INSERT NEW TDS KIT HERE"                        │
└─────────────────────────────────────────────────────────────────┘
  {
    "id": "tds-kit-XX",
    "name": "",
    "vendor": "",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "",
    "genesAnalyzed": null,
    "cancerTypes": [],
    "indicationsNotes": "",
    "fdaStatus": "FDA-approved",  // or "CE-IVD", "RUO"
    "reimbursement": "",
    "clinicalAvailability": "",
    "technologyDifferentiator": ""
  },

┌─────────────────────────────────────────────────────────────────┐
│ CHANGELOG ENTRY TEMPLATE                                        │
│ Insert at TOP of DATABASE_CHANGELOG array                       │
│ Search for: "export const DATABASE_CHANGELOG"                   │
└─────────────────────────────────────────────────────────────────┘
  {
    date: 'Mon DD, YYYY',
    type: 'added',  // or 'updated', 'feature'
    testId: 'xxx-XX',
    testName: '',
    vendor: '',
    category: 'TDS',  // MRD, ECD, TRM, TDS
    description: '',
    contributor: null,  // or 'Name'
    affiliation: 'OpenOnco',  // or 'Vendor Name (vendor)'
    citation: null  // or 'https://...'
  },
*/

// ============================================
// COMPANY CONTRIBUTIONS - CC Badge Tracking
// Maps test IDs to company rep submissions/communications
// Includes: new test nominations + vendor-submitted corrections/updates
// ============================================
export const COMPANY_CONTRIBUTIONS = {
  // Vendor Changelog Entries (22 tests - Dec 11-19)
  'mrd-26': {  // MRDVision
    name: 'Sandra Balladares',
    company: 'Inocras',
    date: '2026-01-06',
    verifiedDate: '2026-01-06',
    note: 'Vendor-verified submission. WGS-based MRD with 1 ppm LOD using Ultima Genomics ppmSeq.'
  },
  'ecd-27': {  // OncoXPLORE+
    name: 'Christophe Van Huffel',
    company: 'OncoDNA',
    date: '2025-12-09',
    note: 'Vendor submission. Multi-modal MCED (mutations + CNV + fragmentomics) from KU Leuven research. OncNGS Phase 3 finalist. Currently RUO.'
  },
  'ecd-26': {  // Trucheck Intelli
    name: 'Jigar Pandya',
    company: 'Datar Cancer Genetics',
    date: '2026-01-07',
    note: 'Expert submission. CTC-based MCED for 70+ cancer types.'
  },
  'tds-26': {  // CellSight DNA
    name: 'Kyle Dunn',
    company: 'Cancer Cell Dx',
    date: '2026-01-07',
    verifiedDate: '2026-01-07',
    note: 'Vendor-verified submission. CTC-based 500+ gene CGP panel.'
  },
  'tds-27': {  // CancerVision
    name: 'Sandra Balladares',
    company: 'Inocras',
    date: '2026-01-05',
    verifiedDate: '2026-01-05',
    note: 'Vendor-verified submission. WGS CGP with ~90% clinical utility.'
  },
  'tds-22': {  // LiquidHALLMARK
    name: 'Jeremy Au',
    company: 'Lucence',
    date: '2025-12-19',
    verifiedDate: '2026-01-07',
    note: 'Vendor verified 2026-01-07. TAT updated to 7 Business Days; biomarkers clarified for cfDNA+cfRNA sources.'
  },
  'tds-kit-12': {  // Hedera Profiling 2
    name: 'Thomas Vetterli',
    company: 'Hedera Dx',
    date: '2025-12-18'
  },
  'tds-20': {  // Liquid Trace Solid Tumor
    name: 'Jeffrey Owen',
    company: 'Genomic Testing Cooperative',
    date: '2025-12-17'
  },
  'tds-21': {  // Liquid Trace Hematology
    name: 'Jeffrey Owen',
    company: 'Genomic Testing Cooperative',
    date: '2025-12-17'
  },
  'trm-13': {  // Liquid Trace (Therapy Monitoring)
    name: 'Jeffrey Owen',
    company: 'Genomic Testing Cooperative',
    date: '2025-12-17'
  },
  'ecd-21': {  // OverC Multi-Cancer Detection Blood Test
    name: 'Liankai Chi',
    company: 'Burning Rock Dx',
    date: '2025-12-22'
  },
  'mrd-25': {  // CanCatch Custom
    name: 'Liankai Chi',
    company: 'Burning Rock Dx',
    date: '2025-12-22'
  },
  'ecd-20': {  // Avantect Pancreatic
    name: 'Adrian Vilalta',
    company: 'ClearNote Health',
    date: '2025-12-16'
  },
  'ecd-19': {  // IUrisure
    name: 'Tingting Li',
    company: 'Wuhan Ammunition Life Technology',
    date: '2025-12-16'
  },
  'ecd-18': {  // IHepcomf
    name: 'Tingting Li',
    company: 'Wuhan Ammunition Life Technology',
    date: '2025-12-16'
  },
  'ecd-17': {  // IEsohunter
    name: 'Tingting Li',
    company: 'Wuhan Ammunition Life Technology',
    date: '2025-12-16'
  },
  'ecd-16': {  // IColohunter
    name: 'Tingting Li',
    company: 'Wuhan Ammunition Life Technology',
    date: '2025-12-16'
  },
  'ecd-14': {  // IColocomf
    name: 'Tingting Li',
    company: 'Wuhan Ammunition Life Technology',
    date: '2025-12-16'
  },
  'ecd-15': {  // GALEAS Bladder
    name: 'Christopher Sale',
    company: 'Nonacus',
    date: '2025-12-16'
  },
  'tds-kit-1': {  // TruSight Oncology Comprehensive
    name: 'Samyuktha Dasari',
    company: 'Illumina',
    date: '2025-12-15'
  },
  'mrd-24': {  // CancerVista
    name: 'Jens Winter',
    company: 'LIQOMICS',
    date: '2025-12-15',
    verifiedDate: '2025-12-28',
    note: 'Vendor verified 2025-12-28'
  },
  'mrd-23': {  // LymphoVista (vendor correction)
    name: 'Jens Winter',
    company: 'LIQOMICS',
    date: '2025-12-13',
    verifiedDate: '2025-12-28',
    note: 'Corrected turnaround times; vendor verified 2025-12-28'
  },
  'mrd-15': {  // Foresight CLARITY Lymphoma (vendor update)
    name: 'John Truesdell',
    company: 'Natera',
    date: '2025-12-13',
    note: 'Updated LOD95 and validation data'
  },
  'tds-16': {  // Northstar Select (vendor update)
    name: 'David Huland',
    company: 'BillionToOne',
    date: '2025-12-12',
    note: 'Updated Medicare reimbursement'
  },
  'trm-12': {  // Reveal TRM (new vendor submission)
    name: 'Brandon Guida PhD',
    company: 'Guardant Health',
    date: '2025-12-12'
  },
  'mrd-6': {  // Reveal MRD (vendor rename/update)
    name: 'Brandon Guida PhD',
    company: 'Guardant Health',
    date: '2025-12-12',
    note: 'Renamed from Reveal; expanded cancer types'
  },
  'mrd-2': {  // NeXT Personal Dx (vendor correction)
    name: 'Dan Norton',
    company: 'Personalis',
    date: '2025-12-12',
    note: 'Corrected turnaround times'
  },
  'tds-17': {  // Guardant360 Liquid (new vendor submission)
    name: 'Brandon Guida PhD',
    company: 'Guardant Health',
    date: '2025-12-11'
  },
  'mrd-19': {  // clonoSEQ (vendor clarification)
    name: 'Christine Hanley',
    company: 'Adaptive Biotechnologies',
    date: '2025-12-11',
    note: 'Clarified sample requirements'
  },
  
  // Direct Company Nominations (18 tests - Dec 8-18)
  // (These were added separately but may now overlap with changelog entries above)
  'mrd-21': {  // Latitude
    name: 'Sunghoon Heo',
    company: 'IMBdx/Independent Expert',
    date: '2025-12-10',
    note: 'Submission for Natera'
  },
  'mrd-22': {  // CancerDetect
    name: 'Sunghoon Heo',
    company: 'IMBdx, Inc.',
    date: '2025-12-10',
    verifiedDate: '2025-12-29',
    note: 'Vendor verified with bloodVolume and cfdnaInput updates'
  }
};

// ============================================
// VENDOR VERIFIED - Full Validation Badge Tracking
// Tests where vendor rep completed the Vendor Test Validation flow
// These get the premium green "VENDOR VERIFIED" badge and sort priority
// ============================================
export const VENDOR_VERIFIED = {
  // Add test IDs here after vendors complete the validation flow
  'mrd-26': {  // MRDVision
    name: 'Sandra Balladares',
    company: 'Inocras',
    verifiedDate: '2026-01-07',
    editsSubmitted: 0
  },
  'tds-26': {  // CellSight DNA
    name: 'Kyle Dunn',
    company: 'Cancer Cell Dx',
    verifiedDate: '2026-01-07',
    editsSubmitted: 0
  },
  'tds-27': {  // CancerVision
    name: 'Sandra Balladares',
    company: 'Inocras',
    verifiedDate: '2026-01-07',
    editsSubmitted: 0
  },
  'tds-22': {  // LiquidHALLMARK
    name: 'Jeremy Au',
    company: 'Lucence',
    verifiedDate: '2026-01-07',
    editsSubmitted: 2
  },
  'mrd-25': {  // CanCatch Custom
    name: 'Liankai Chi',
    company: 'Burning Rock Dx',
    verifiedDate: '2025-12-24',
    editsSubmitted: 4
  },
  'mrd-6': {  // Reveal MRD
    name: 'Brandon Guida',
    company: 'Guardant Health',
    verifiedDate: '2026-01-06',
    editsSubmitted: 1
  },
  'tds-17': {  // Guardant360 Liquid
    name: 'Brandon Guida',
    company: 'Guardant Health',
    verifiedDate: '2026-01-06',
    editsSubmitted: 1
  },
  'ecd-20': {  // Avantect Pancreatic Cancer Test
    name: 'Adrian Vilalta',
    company: 'ClearNote Health',
    verifiedDate: '2026-01-07',
    editsSubmitted: 0
  },
  'mrd-23': {  // LymphoVista
    name: 'Jens Winter',
    company: 'LIQOMICS',
    verifiedDate: '2025-12-28',
    editsSubmitted: 1
  },
  'mrd-24': {  // CancerVista
    name: 'Jens Winter',
    company: 'LIQOMICS',
    verifiedDate: '2026-01-08',
    editsSubmitted: 0
  },
};

// ============================================
// VENDOR PATIENT ASSISTANCE PROGRAMS
// Source: Web research, verified 2026-01-07
// Programs change frequently - verify with vendor before relying on them
// ============================================
export const VENDOR_ASSISTANCE_PROGRAMS = {
  'Natera': {
    programName: 'Compassionate Care / Financial Assistance Program',
    hasProgram: true,
    tests: ['Signatera', 'Altera', 'CLARITY Lymphoma', 'Signatera Genome', 'Latitude'],
    description: 'Financial assistance and payment plan options to reduce patient out-of-pocket cost for qualifying patients.',
    eligibility: 'Based on household size and income (Federal Poverty Level guidelines).',
    maxOutOfPocket: null,
    paymentPlans: 'Interest-free payment plans starting at $25/month',
    applicationUrl: 'https://www.natera.com/oncology/billing/',
    contactPhone: '650-489-9050 (select 2 for patients, then 4 for billing)',
    contactEmail: 'signaterapc@natera.com',
    dedicatedCoordinators: true,
    lastVerified: '2026-01-07'
  },
  'Guardant Health': {
    programName: 'Guardant Access Program',
    hasProgram: true,
    tests: ['Guardant360 CDx', 'Guardant360 Liquid', 'Guardant360 Tissue', 'Guardant Reveal', 'Guardant360 Response', 'Shield'],
    description: 'Helps patients navigate insurance coverage, billing, and financial assistance eligibility; aims to minimize surprise bills.',
    eligibility: 'Based on medical and financial need.',
    maxOutOfPocket: null,
    selfPayRates: { 'Guardant360': '$5,000', 'GuardantReveal': '$3,500' },
    applicationUrl: 'https://guardanthealth.com/precision-oncology/for-patients/',
    contactPhone: '855-722-7335 ext. 1, then press 2',
    contactEmail: 'screeningpatient@guardanthealth.com',
    autoEnrollment: 'Patients enroll by signing the Testing Requisition form',
    lastVerified: '2026-01-07'
  },
  'Foundation Medicine': {
    programName: 'FoundationAccess Financial Assistance Program',
    hasProgram: true,
    tests: ['FoundationOne CDx', 'FoundationOne Liquid CDx', 'FoundationOne Heme', 'FoundationOne RNA', 'FoundationOne Tracker'],
    description: 'Reimbursement and financial assistance support to help patients access Foundation Medicine tests.',
    eligibility: 'Based on medical and financial need.',
    maxOutOfPocket: '$100 lifetime maximum for qualifying patients',
    selfPayRate: '$3,500 per test',
    coverageStats: '65% of commercially insured and 94% of Medicare patients pay $0',
    applicationUrl: 'https://aid.foundationmedicine.com/',
    contactPhone: '888-988-3639',
    contactEmail: 'client.services@foundationmedicine.com',
    lastVerified: '2026-01-07'
  },
  'GRAIL': {
    programName: 'Financial Assistance Program',
    hasProgram: true,
    tests: ['Galleri'],
    description: 'Financial assistance to reduce out-of-pocket cost for eligible individuals taking the Galleri test.',
    eligibility: 'Based on income/financial need (Federal Poverty Level-based criteria).',
    maxOutOfPocket: null,
    paymentOptions: 'Check, credit card, HSA/FSA eligible',
    coverageNotes: 'Limited insurance coverage currently; TRICARE covers with prior authorization',
    applicationUrl: 'https://www.galleri.com/patient/the-galleri-test/cost',
    contactPhone: '833-694-2553',
    contactEmail: 'patient-advocate@grailbio.com',
    patientAdvocate: true,
    lastVerified: '2026-01-07'
  },
  'Exact Sciences': {
    programName: 'Patient Assistance Program',
    hasProgram: true,
    tests: ['Cologuard', 'Cologuard Plus', 'Oncotype DX Breast', 'Oncotype DX Colon', 'OncoExTra', 'Cancerguard', 'Oncoguard Liver'],
    description: 'Patient financial assistance and coverage support resources.',
    eligibility: 'At or below 400% of Federal Poverty Level (FPL).',
    coverageNotes: 'At or below FPL may receive testing at no cost',
    applicationUrl: 'https://www.exactsciences.com/cancer-testing/coverage-financial-assistance',
    estimatorTool: 'https://precisiononcology.exactsciences.com/patients-and-caregivers/testing-and-treating/cost-and-financial-resources',
    contactPhone: '866-267-2322',
    contactEmail: 'help@exactsciences.com',
    inNetworkPlans: ['Aetna', 'Anthem', 'Cigna', 'Humana', 'UnitedHealthcare'],
    lastVerified: '2026-01-07'
  },
  'Tempus': {
    programName: 'Financial Assistance Program',
    hasProgram: true,
    tests: ['Tempus xT', 'Tempus xT CDx', 'Tempus xF', 'Tempus xR', 'Oncodetect', 'Tempus xM MRD'],
    description: 'Financial assistance based on household income and circumstances.',
    eligibility: 'Based on household income, household size, and circumstances.',
    applicationUrl: 'https://access.tempus.com',
    contactPhone: '888-988-8832',
    lastVerified: '2026-01-07'
  },
  'Caris Life Sciences': {
    programName: 'Patient Financial Assistance',
    hasProgram: true,
    tests: ['Caris MI Profile', 'Caris Assure'],
    description: 'Financial assistance for qualifying patients to cover out-of-pocket costs.',
    eligibility: 'Based on financial need assessment.',
    applicationUrl: 'https://www.carismolecularintelligence.com/patients/financial-assistance/',
    contactPhone: '888-979-8669',
    lastVerified: '2026-01-07'
  },
  'Myriad Genetics': {
    programName: 'Myriad Financial Assistance Program',
    hasProgram: true,
    tests: ['MyChoice CDx', 'BRACAnalysis CDx'],
    description: 'Income-based financial assistance up to 100% discount for qualifying patients.',
    eligibility: 'Based on Federal Poverty Level guidelines.',
    maxOutOfPocket: '$0 for patients at or below 400% FPL',
    applicationUrl: 'https://myriad.com/affordability/financial-assistance/',
    contactPhone: '800-469-7423',
    restrictions: 'Not available for federally funded insurance (Medicare, Medicaid, TRICARE, Medicare Advantage)',
    lastVerified: '2026-01-07'
  },
  'Labcorp': {
    programName: 'Financial Assistance Program / Patient Assistance Program',
    hasProgram: true,
    tests: ['Invitae PCM', 'Labcorp Plasma Detect'],
    description: 'Billing support and financial assistance options; published ceiling self-pay prices.',
    eligibility: 'Based on income and circumstances.',
    typicalCost: 'Out-of-pocket typically less than $100 for insured patients',
    maxBillToInsurance: '$1,500 per clinical area - lower than most providers',
    familyVariantTesting: 'Free for family members of patients who used Financial Assistance Program',
    applicationUrl: 'https://www.invitae.com/us/individual-faqs/billing',
    contactPhone: '833-941-0828',
    contactEmail: 'LcGeneticsBilling@labcorp.com',
    uninsuredCeilingPrices: { 'Cancer': '$250', 'Rare Disease': '$299' },
    lastVerified: '2026-01-07'
  },
  'Quest Diagnostics': {
    programName: 'Patient Financial Assistance Program',
    hasProgram: true,
    tests: ['Haystack MRD'],
    description: 'Tiered discounts and payment plans; specific hereditary cancer financial assistance cap.',
    eligibility: 'Based on income and family size (HHS/FPL guidelines).',
    maxOutOfPocket: '$200 out-of-pocket cap for qualifying Quest hereditary cancer tests',
    freeForPoverty: 'Testing at $0 for patients at or below Federal Poverty Level',
    paymentPlans: '0% financing for 12-month period',
    applicationUrl: 'https://www.questdiagnostics.com/patients/billing-insurance/financial-assistance',
    contactPhone: '866-436-3463 (866-GENE-INFO)',
    processingTime: 'Approximately 2 weeks to process applications',
    lastVerified: '2026-01-07'
  },
  'Adaptive Biotechnologies': {
    programName: 'Adaptive Assist',
    hasProgram: true,
    tests: ['clonoSEQ'],
    description: 'Helps patients with insurance/coverage and assesses eligibility for financial assistance.',
    eligibility: 'Based on medical and financial need.',
    coverageNotes: 'Most patients have no out-of-pocket cost; qualification for $0 may be valid for one year',
    applicationUrl: 'https://www.clonoseq.com/patient/other-blood-cancers/adaptive-assist/',
    contactPhone: '855-236-9230',
    contactEmail: 'support@clonoseq.com',
    lastVerified: '2026-01-07'
  },
  'NeoGenomics': {
    programName: 'NeoGenomics Financial Assistance Program',
    hasProgram: true,
    tests: ['RaDaR', 'NEO PanTracer'],
    description: 'Financial assistance application for patients who certify that testing would cause financial hardship.',
    eligibility: 'Assessed via application; approval not guaranteed.',
    applicationPdf: 'https://cms.neogenomics.com/sites/default/files/2025-01/FAA_Form_English_010925_Final_FF.pdf',
    lastVerified: '2026-01-07'
  },
  'Burning Rock Dx': {
    programName: null,
    hasProgram: false,
    tests: ['OncoScreen Plus', 'OverC MCDBT', 'BR Prophet', 'CanCatch Custom'],
    description: 'No US-based patient financial assistance program identified.',
    notes: 'Primarily serves China market; China is largely an out-of-pocket market for these tests',
    contactUrl: 'https://www.brbiotech.com/en/',
    lastVerified: '2026-01-07'
  }
};

// Helper function to check if a test has assistance program by vendor name
export const hasAssistanceProgram = (vendorName) => {
  if (!vendorName) return false;
  // Direct match
  if (VENDOR_ASSISTANCE_PROGRAMS[vendorName]?.hasProgram) return true;
  // Partial match (e.g., "Foundation Medicine / Natera" should match)
  for (const vendor of Object.keys(VENDOR_ASSISTANCE_PROGRAMS)) {
    if (vendorName.includes(vendor) && VENDOR_ASSISTANCE_PROGRAMS[vendor]?.hasProgram) {
      return true;
    }
  }
  return false;
};

// Helper to get assistance program details for a vendor
export const getAssistanceProgramForVendor = (vendorName) => {
  if (!vendorName) return null;
  // Direct match first
  if (VENDOR_ASSISTANCE_PROGRAMS[vendorName]) {
    return VENDOR_ASSISTANCE_PROGRAMS[vendorName];
  }
  // Partial match
  for (const vendor of Object.keys(VENDOR_ASSISTANCE_PROGRAMS)) {
    if (vendorName.includes(vendor)) {
      return VENDOR_ASSISTANCE_PROGRAMS[vendor];
    }
  }
  return null;
};

// Additional resources for all patients
export const PATIENT_ASSISTANCE_RESOURCES = [
  {
    name: 'Cancer Financial Assistance Coalition (CFAC)',
    url: 'https://cancerfac.org',
    description: 'Consortium of organizations helping patients manage financial challenges from cancer diagnosis'
  },
  {
    name: 'CancerCare',
    url: 'https://www.cancercare.org/financial_assistance',
    description: 'Financial assistance for cancer-related costs and co-pays; professional oncology social workers'
  },
  {
    name: 'Patient Advocate Foundation',
    url: 'https://www.patientadvocate.org/connect-with-services/financial-aid-funds/',
    description: 'Various funds for specific cancer types including Merkel Cell Carcinoma, Ovarian Cancer, etc.'
  },
  {
    name: 'American Cancer Society',
    url: 'https://www.cancer.org',
    description: 'Resources for finding financial help for cancer patients'
  }
];

// ============================================
// TEST DATA ARRAYS START HERE
// ============================================

// MRD Tests
export const mrdTestData = [
  {
    "id": "mrd-1",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 30,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 3,
    "sampleCollectionNotes": "Quest test directory for Haystack MRD monitoring lists three 10 mL cfDNA tubes (≈30 mL total) as standard collection; minimum acceptable volume ~24 mL.",
    "sampleCitations": "https://testdirectory.questdiagnostics.com/",
    "name": "Haystack MRD",
    "vendor": "Quest Diagnostics",
    "approach": "Tumor-informed",
    "method": "Whole-genome–derived personalized panel; ~50 variants tracked; low error suppression",
    "cancerTypes": [
      "Multi-solid"
    ],
    "indicationsNotes": "Tumor-informed MRD assay for multiple common and rare solid tumors; Quest/Resolution MRD platform, FDA Breakthrough Device designation.",
    "sensitivity": 95.0,
    "sensitivityCitations": "https://haystackmrd.com/",
    "sensitivityNotes": "Headline 95% sensitivity is analytical; clinical sensitivity by stage not yet published from large prospective cohorts.",
    "sensitivityStagesReported": "Analytical validation (stages not specified)",
    "specificity": 100.0,
    "specificityCitations": "https://haystackmrd.com/clinicians/ | https://doi.org/10.1016/S1525-1578(24)00232-0",
    "specificityNotes": "Analytical specificity of 100% with zero false positives reported. ⚠️ Analytical validation; clinical specificity from large cohorts pending. (J Mol Diagn 2024;26(11):S100)",
    "analyticalValidationWarning": true,
    "validationCohortStudy": "J Mol Diagn 2024 (analytical validation)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "FDA Breakthrough Device designation specifically for Stage II CRC (Aug 2025); stage-specific clinical sensitivity data expected from ongoing trials.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III-specific data not yet published; NCT07125729 head-to-head vs Signatera includes Stage II–IV CRC.",
    "landmarkSensitivityCitations": "https://haystackmrd.com/faq/",
    "longitudinalSensitivityCitations": "https://haystackmrd.com/",
    "lod": "6 ppm",
    "lod95": "6 ppm (≈0.0006% tumor fraction)",
    "lod95Citations": "https://testdirectory.questdiagnostics.com/test/test-guides/TS_HaystackMRD/haystack-mrd",
    "lodCitations": "https://haystackmrd.com/ | https://testdirectory.questdiagnostics.com/test/test-guides/TS_HaystackMRD/haystack-mrd",
    "lodNotes": "LoD95 (95% limit of detection) is ~6 ppm (0.0006% tumor fraction). This represents the ctDNA level at which 95% of replicates are detected as positive in analytical validation studies.",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "50",
    "variantsTrackedCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "variantsTrackedNotes": "Up to ~50 tumor-specific variants selected from tumor and matched-normal whole-exome sequencing; variants filtered to avoid CHIP-associated regions.",
    "initialTat": 30.0,
    "initialTatCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "initialTatNotes": "Baseline tumor+normal whole-exome profiling and panel design typically ~4 weeks (~30 days) from sample receipt.",
    "followUpTat": 7.0,
    "followUpTatCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "followUpTatNotes": "Post-baseline MRD blood draws generally reported within about 5–7 days (Quest/Haystack FAQs; Quest Q&A sometimes quotes 7–10 days).",
    "bloodVolume": 30.0,
    "bloodVolumeCitations": "https://testdirectory.questdiagnostics.com/test/test-detail/13151/haystack-mrd-monitoring",
    "bloodVolumeNotes": "Quest test directory for Haystack MRD monitoring lists three 10 mL cfDNA tubes (≈30 mL total) as standard collection; minimum acceptable volume ~24 mL.",
    "tat": 30.0,
    "tatCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "tatNotes": "Overall paradigm: ~4 weeks for initial panel build, ~1 week for subsequent MRD timepoints.",
    "fdaStatus": "CLIA LDT (Quest Diagnostics); FDA Breakthrough Device designation for stage II colorectal cancer (Aug 2025).",
    "reimbursement": "Coverage emerging (~70% of tests reimbursed); Medicare pilot for CRC plus growing commercial coverage.",
    "reimbursementNote": "As of mid-2025, Quest reports ~70% of Haystack MRD tests are reimbursed across payers. Medicare pilot coverage in place for CRC, with active engagement with CMS for broader LCD. Commercial payer coverage growing; patient access programs available.",
    "cptCodes": "0561U",
    "clinicalAvailability": "Clinical LDT – shipping",
    "clinicalTrials": "NCT07125729 (150; resectable stage II–IV CRC; Haystack vs Signatera head-to-head); NCT06979661 (25; MRD-PORT trial; post-op stage II–III NSCLC; Haystack MRD-guided RT); NCT05798663/AFT-57 (158; unresectable stage III NSCLC; atezolizumab ± tiragolumab CRT; Haystack MRD used for correlative MRD analyses)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT07125729 | https://clinicaltrials.gov/study/NCT06979661 | https://clinicaltrials.gov/study/NCT05798663",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD assessment and longitudinal surveillance. Clinical trials focus on post-operative and surveillance settings in CRC and NSCLC.",
    "totalParticipants": 333,
    "numPublications": 17
  },
  {
    "id": "mrd-2",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Monitoring commonly uses two 10 mL Streck cfDNA tubes (≈20 mL total); baseline also requires FFPE tumor tissue and matched-normal blood.",
    "sampleCitations": "https://www.personalis.com/next-personal/",
    "name": "NeXT Personal Dx",
    "vendor": "Personalis",
    "approach": "Tumor-informed",
    "method": "Tumor-informed, whole-genome-based MRD assay: WGS of tumor and matched normal identifies up to ~1,800 patient-specific variants, which are tracked at high depth in plasma to detect ctDNA down to ~1–3 parts per million (ppm).",
    "cancerTypes": [
      "Breast",
      "Colorectal",
      "NSCLC"
    ],
    "indicationsNotes": "Personalis NeXT Personal Dx tumor-informed MRD assay. Medicare-covered for early-stage breast cancer recurrence monitoring; clinical data also reported in colorectal cancer and NSCLC.",
    "sensitivity": 100,
    "sensitivityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "sensitivityNotes": "100% sensitivity reported in validation cohort (n=493). Value represents analytical validation; larger clinical cohorts ongoing.",
    "analyticalValidationWarning": true,
    "sensitivityStagesReported": "Not separately reported (small validation cohort)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "Stage-specific sensitivity not reported; validation cohort too small for stage breakdown.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage-specific sensitivity not reported.",
    "specificity": 99.9,
    "specificityPlus": true,
    "specificityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "specificityNotes": ">99.9% specificity in validation cohort (n=493).",
    "validationCohortSize": 493,
    "validationCohortStudy": "Personalis analytical validation cohort (2024)",
    "longitudinalSensitivity": null,
    "longitudinalSensitivityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "longitudinalSensitivityNotes": "Reported as 100% in validation cohort; value set to null pending larger studies.",
    "longitudinalSpecificity": null,
    "longitudinalSpecificityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "longitudinalSpecificityNotes": "Reported as 100% in validation cohort; value set to null pending larger studies.",
    "lod": "1.67 ppm",
    "lod95": "3.45 ppm",
    "lod95Citations": "https://www.personalis.com/next-personal-assay-performance/",
    "lodCitations": "Northcott et al. Oncotarget 2024; https://www.personalis.com/next-personal-assay-performance/",
    "lodNotes": "Detection threshold is 1.67 ppm; LOD95 (95% confidence) is 3.45 ppm. The gap between these values means serial testing can catch lower-level disease.",
    "leadTimeVsImaging": 450.0,
    "leadTimeVsImagingCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas et al. Ann Oncol 2025; TRACERx NSCLC data",
    "leadTimeVsImagingNotes": "450 days (15 months) is the median lead time from the Garcia-Murillas et al. Ann Oncol 2025 early-stage breast cancer cohort (range 0.9-61.5 months). This is the median from this specific study, not a universal NeXT median across all indications. NSCLC TRACERx data showed ~6 months.",
    "vendorRequestedChanges": "2025-12-03: Personalis requested lead time update to 15 months (450 days) based on Ann Oncol 2025 breast cancer paper (Garcia-Murillas et al.). Verified against source and updated.",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "1800",
    "variantsTrackedCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10939476/",
    "variantsTrackedNotes": "Personalized panels track on the order of 1,800 tumor-specific variants per patient based on tumor/normal whole-genome sequencing, with additional investigational content in some implementations.",
    "initialTat": 21.0,
    "initialTatCitations": "Vendor data (Dan Norton, Personalis, Dec 2025)",
    "initialTatNotes": "Initial report turnaround is 21 days per vendor (Dan Norton, Personalis, Dec 2025).",
    "followUpTat": 10.0,
    "followUpTatCitations": "Vendor data (Dan Norton, Personalis, Dec 2025)",
    "followUpTatNotes": "Follow-up monitoring draws reported within 10 days per vendor (Dan Norton, Personalis, Dec 2025).",
    "bloodVolume": 20.0,
    "bloodVolumeCitations": "https://www.personalis.com/asset/specimen-preparation-guide-blood/",
    "bloodVolumeNotes": "Monitoring commonly uses two 10 mL Streck cfDNA tubes (≈20 mL total); baseline also requires FFPE tumor tissue and matched-normal blood.",
    "tat": 21.0,
    "tatCitations": "Vendor data (Dan Norton, Personalis, Dec 2025)",
    "tatNotes": "Initial report: 21 days; follow-up monitoring: 10 days (vendor-confirmed Dec 2025).",
    "fdaStatus": "CLIA LDT (early access / clinical offering)",
    "reimbursement": "Medicare coverage for stage II-III breast cancer MRD surveillance; additional solid tumor coverage via Tempus xM collaboration expanding.",
    "cptCodes": "MolDX with DEX Z-code",
    "clinicalAvailability": "Clinical LDT – shipping (initial market availability)",
    "exampleTestReport": "https://www.personalis.com/wp-content/uploads/2024/07/NeXT-Personal-Dx-Clinical-Report-Template-DOC-002568B.pdf",
    "clinicalTrials": "NCT06230185 (422); VICTORI study interim cohort (~71)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06230185",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD, post-adjuvant assessment, and longitudinal surveillance. Medicare coverage specifically for breast cancer recurrence monitoring/surveillance setting.",
    "totalParticipants": 493,
    "numPublications": 4,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-3",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "LBgard",
    "sampleCollectionNotes": "3 LBgard cfDNA tubes required for blood draw; tissue required at baseline",
    "name": "Oncodetect",
    "vendor": "Exact Sciences",
    "approach": "Tumor-informed",
    "method": "Tumor-informed hybrid-capture ctDNA assay: tumor plus matched-normal sequencing to select up to ~200 somatic variants per patient, followed by targeted hybrid-capture NGS with CHIP-aware filtering.",
    "cancerTypes": [
      "Multi-solid"
    ],
    "indicationsNotes": "Exact Sciences Oncodetect tumor-informed circulating tumor DNA (ctDNA) MRD test, marketed for use across solid tumors; designed for post-surgical and surveillance use cases.",
    "sensitivity": 91.0,
    "sensitivityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "sensitivityNotes": "In CRC, results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively.",
    "sensitivityStagesReported": "Stage II–III combined (CRC)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "Stage II-specific CRC sensitivity not separately reported in Alpha-CORRECT publications; combined with Stage III. Stage-specific breakdowns would be informative for treatment decisions.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Alpha-CORRECT cohort primarily Stage III CRC; stage-specific breakdown not published.",
    "stageDataExpected": true,
    "specificity": 94.0,
    "specificityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "specificityNotes": "In CRC (Alpha-CORRECT study), Oncodetect demonstrated specificities of 80% at the post-surgical timepoint and 94% during surveillance monitoring.",
    "ppv": 50.0,
    "ppvCitations": "https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/white-papers/oncodetect_mrd-informed_post-surgical_crc_white-paper_04-2024_updated_05-2025.pdf",
    "ppvNotes": "CRC postsurgical 3y PPV 50% (Alpha-/Beta-CORRECT).",
    "npv": 96.0,
    "npvCitations": "https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/white-papers/oncodetect_mrd-informed_post-surgical_crc_white-paper_04-2024_updated_05-2025.pdf",
    "npvNotes": "CRC postsurgical 3y NPV 96%.",
    "landmarkSensitivity": 78.0,
    "landmarkSensitivityCitations": "https://investor.exactsciences.com/news-releases/news-release-details/exact-sciences-reports-first-quarter-2025-financial-results",
    "landmarkSensitivityNotes": "CRC postsurgical sensitivity.",
    "landmarkSpecificity": 80.0,
    "landmarkSpecificityCitations": "https://investor.exactsciences.com/news-releases/news-release-details/exact-sciences-reports-first-quarter-2025-financial-results",
    "longitudinalSensitivity": 91.0,
    "longitudinalSensitivityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "longitudinalSensitivityNotes": "CRC surveillance sensitivity.",
    "longitudinalSpecificity": 94.0,
    "longitudinalSpecificityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "longitudinalSpecificityNotes": "CRC surveillance specificity.",
    "lod": "15 ppm",
    "lod95": "15 ppm",
    "lod95Citations": "https://www.exactsciences.com/cancer-testing/oncodetect-mrd-providers | https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/validation/oncodetect_limit-of-detection_08-2024_updated_05-2025.pdf",
    "lodNotes": "LoD 15 ppm (0.0015% tumor fraction) with high-end inputs. Observed detection down to 2 ppm seen in clinical validation studies. Per Exact Sciences: 'To minimize false negatives in most clinical scenarios, the limit of detection should be below 100 PPM (0.01% TF).'",
    "lodCitations": "https://www.exactsciences.com/cancer-testing/oncodetect-mrd-providers | https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/validation/oncodetect_limit-of-detection_08-2024_updated_05-2025.pdf",
    "leadTimeVsImaging": 317.0,
    "leadTimeVsImagingNotes": "Median lead time ~10.4 months (~317 days) from first MRD-positive Oncodetect result to radiologic recurrence in the α-CORRECT stage III CRC cohort. This is the median from this specific study, not a universal value across all indications.",
    "leadTimeVsImagingCitations": "https://investor.exactsciences.com/news-releases/news-release-details/exact-sciences-announces-positive-topline-results-alpha-correct | Exact Sciences α-CORRECT press release",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "White paper: WES tumor + matched-normal buffy coat.",
    "variantsTracked": "200",
    "variantsTrackedNotes": "Panel tracks up to 200 tumor-specific variants per patient (median ~170) with roadmap to higher-plex designs.",
    "initialTat": 28.0,
    "initialTatNotes": "Provider-facing materials describe baseline tissue+normal discovery and panel creation in roughly 4 weeks.",
    "followUpTat": 10.0,
    "followUpTatNotes": "Monitoring blood draws typically result within about 10 days after sample receipt.",
    "bloodVolumeNotes": "3 LBgard cfDNA tubes required for blood draw; tissue required at baseline",
    "tat": 28.0,
    "tatNotes": "Approximate baseline TAT ~4 weeks; subsequent MRD timepoints ~10 days.",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Medicare (CRC only)",
    "reimbursementNote": "Medicare MolDX coverage for colorectal cancer MRD only (announced July 2025). Not covered for other cancer types. Broader payer adoption evolving.",
    "cptCodes": "PLA pending",
    "cptCodesNotes": "Payer policies vary.",
    "clinicalAvailability": "Clinical LDT – shipping",
    "independentValidation": "Yes",
    "independentValidationNotes": "Prospective Alpha-/Beta-CORRECT CRC cohorts.",
    "exampleTestReport": "https://www.exactsciences.com/-/media/project/headless/one-exact-web/documents/products-services/oncodetect/providers/sample-report-stage-iii-escalation.pdf?rev=10365d7a28c8467eb25d253943ce8fe9",
    "clinicalTrials": "NCT06398743 (416); α-CORRECT observational study (124)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06398743",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD assessment (78% sensitivity) and longitudinal surveillance (91% sensitivity) in CRC per Alpha-CORRECT study.",
    "totalParticipants": 540,
    "numPublications": 1,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-4",
    "sampleCategory": "Blood/Plasma",
    "name": "Pathlight",
    "vendor": "SAGA Diagnostics",
    "approach": "Tumor-informed",
    "method": "Tumor-informed MRD platform using whole-genome profiling to identify structural variants (SVs) and other truncal events, which are then tracked using sensitive digital PCR and/or NGS in serial plasma samples.",
    "cancerTypes": [
      "Breast",
      "Multi-solid"
    ],
    "indicationsNotes": "SAGA Diagnostics Pathlight tumor-informed MRD assay. Medicare coverage announced for breast cancer across all subtypes (HR+/HER2-, HER2+, and triple-negative); platform positioned as multi-cancer MRD.",
    "sensitivity": 100,
    "sensitivityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "sensitivityNotes": "100% sensitivity in TRACER study validation cohort (n=100, stage I-III breast cancer). ⚠️ Small cohort size; larger validation ongoing.",
    "specificity": 100,
    "specificityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "specificityNotes": "100% specificity in TRACER study validation cohort (n=100). ⚠️ Small cohort size; larger validation ongoing.",
    "smallSampleWarning": true,
    "validationCohortSize": 121,
    "validationCohortStudy": "TRACER study (Clinical Cancer Research, Jan 2025; expanded cohort SABCS 2025)",
    "landmarkSensitivity": null,
    "landmarkSpecificity": null,
    "longitudinalSensitivity": 100,
    "longitudinalSensitivityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "longitudinalSensitivityNotes": "100% longitudinal sensitivity in TRACER breast cohort (n=100).",
    "longitudinalSpecificity": 100,
    "longitudinalSpecificityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "longitudinalSpecificityNotes": "100% longitudinal specificity in TRACER breast cohort (n=100).",
    "lod": "0.001% VAF",
    "lod95": "~5 ppm",
    "lod95Citations": "https://sagadiagnostics.com/wp-content/uploads/2024/12/SABCS-Poster_v3.pdf",
    "lodCitations": "https://sagadiagnostics.com/wp-content/uploads/2024/12/SABCS-Poster_v3.pdf",
    "lodNotes": "Detection threshold ~0.001% VAF (~10 ppm); LoD95 ~5 ppm in analytical studies of SV-based assays.",
    "leadTimeVsImaging": 411.0,
    "leadTimeVsImagingCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "leadTimeVsImagingNotes": "Early-stage breast cancer cohort data highlight median lead time ≈13.7 months (~411 days) between MRD positivity and clinical/radiologic recurrence.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Tumor-informed (WGS of tumor); structural variants tracked by dPCR.",
    "requiresMatchedNormal": "Yes",
    "initialTat": 14,
    "initialTatCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "initialTatNotes": "~2 weeks for initial result; faster than many tumor-informed assays due to SV-based approach.",
    "followUpTat": 5,
    "followUpTatCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "followUpTatNotes": "Subsequent blood tests typically ~3-5 days.",
    "tat": 14,
    "tatNotes": "Initial results in ~2 weeks; follow-up monitoring in ~3-5 days.",
    "fdaStatus": "CLIA LDT (US) with international laboratory service offerings.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via MolDX (Palmetto GBA) positive determination July 30, 2025. Covered for recurrence monitoring in stage II-III breast cancer across all subtypes (HR+/HER2-, HER2+, TNBC) for up to 6 years surveillance. Coverage based on TRACER study evidence (100% sens/spec, 13.7-month lead time).",
    "reimbursementCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-medicare-coverage-for-pathlight-mrd-test-in-breast-cancer-across-all-subtypes/ | https://www.genomeweb.com/cancer/saga-diagnostics-mrd-test-receives-medicare-coverage-breast-cancer-recurrence-monitoring",
    "cptCodes": "No dedicated PLA as of 2025; payer-specific coding applies.",
    "cptCodesNotes": "Contact vendor for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – shipping (select geographies)",
    "clinicalTrials": "TRACER study (cTdna evaluation in eaRly breAst canCER); Clinical Cancer Research Jan 2025 (n=100), SABCS 2025 expanded cohort (n=121). CLAIRE (NCT pending - surveillance study in ER+/HER2- breast). CATER (MRD-guided capecitabine trial).",
    "clinicalTrialsCitations": "https://doi.org/10.1158/1078-0432.CCR-24-3472 | https://www.businesswire.com/news/home/20251201531260/en/SAGA-Diagnostics-Showcases-New-Pathlight-MRD-Data-at-SABCS-2025",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "TRACER study validated longitudinal MRD surveillance in early-stage breast cancer with lead time ~13.7 months vs imaging.",
    "totalParticipants": 121,
    "totalParticipantsNotes": "TRACER expanded cohort (SABCS 2025): 121 patients with TNBC, HER2+, or ER+/HER2- early breast cancer.",
    "numPublications": 8,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-5",
    "sampleCategory": "Blood/Plasma",
    "name": "RaDaR ST",
    "vendor": "NeoGenomics",
    "approach": "Tumor-informed",
    "method": "Tumor-informed MRD assay on the InVision/ RaDaR platform: tumor and matched-normal sequencing identify up to 48 variants, which are tracked by deep NGS with error suppression.",
    "cancerTypes": [
      "Breast",
      "Head & Neck",
      "Multi-solid"
    ],
    "indicationsNotes": "NeoGenomics RaDaR ST tumor-informed MRD assay with Medicare coverage for HR+/HER2- breast cancer (including late recurrence >5 years) and HPV-negative head and neck cancer; supportive data across multiple solid tumors.",
    "sensitivity": 95.7,
    "sensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10870111/",
    "sensitivityNotes": "RaDaR ST demonstrated 97% concordance and maintained equivalent sensitivity with RaDaR 1.0. In breast, 95.7% sensitivity and 91.0% specificity.",
    "specificity": 91.0,
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10870111/",
    "specificityNotes": "RaDaR ST demonstrated 97% concordance with RaDaR 1.0. In breast cancer validation, specificity was 91.0%.",
    "lod": "~10 ppm",
    "lodCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/310/neogenomics-to-present-radar-st-bridging-study-at-islb-2025-demonstrating-reliable-mrd-detection-across-solid-tumors",
    "lodNotes": "Analytical validation for the RaDaR assay supports reliable detection around 10 ppm with ≥70–90% sensitivity at that level in contrived samples.",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Buffy coat matched normal used for germline filtering in studies.",
    "variantsTracked": "48",
    "variantsTrackedNotes": "Tracks up to 48 patient-specific variants.",
    "initialTat": 35.0,
    "initialTatNotes": "NeoGenomics materials typically describe baseline discovery and panel build in ~5 weeks.",
    "followUpTat": 7.0,
    "followUpTatNotes": "Serial MRD monitoring blood draws generally reported within ~7 days after receipt.",
    "tat": 35.0,
    "tatNotes": "Approximate TAT ~5 weeks baseline, ~1 week longitudinally.",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Medicare coverage for selected indications; MolDX framework applied.",
    "reimbursementNote": "LCDs describe coverage in specific solid tumors (e.g., breast and HPV-negative head & neck cancer) with broader multi-tumor positioning in trials.",
    "commercialPayers": ["Blue Shield of California"],
    "commercialPayersCitations": "https://www.decibio.com/",
    "commercialPayersNotes": "Blue Shield of California covers RaDaR for MRD testing. Coverage continues to expand as clinical evidence builds.",
    "cptCodes": "PLA under consideration.",
    "cptCodesNotes": "Contact vendor for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – shipping",
    "clinicalTrials": "ISLB 2025 bridging study, 'Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types'; 166 patients across 15 solid tumor types; 97% concordance with RaDaR 1.0",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD, post-adjuvant, and surveillance monitoring. Medicare coverage for HR+/HER2- breast cancer (including late recurrence >5 years) and HPV-negative head and neck cancer.",
    "totalParticipants": 166,
    "numPublications": 10,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-6",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleVolumeCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Commonly collected as two 10 mL Streck cfDNA tubes (≈20 mL).",
    "sampleCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "name": "Reveal MRD",
    "vendor": "Guardant Health",
    "approach": "Tumor-naïve",
    "method": "Tumor-naïve, blood-only ctDNA MRD test using epigenetic tumor fraction (epiTF) detection on Guardant Infinity platform. Analyzes over 19,000 differentially methylated loci for mutation-agnostic ctDNA detection. Detects residual disease and recurrence without requiring tumor tissue.",
    "cancerTypes": [
      "Colorectal",
      "Breast",
      "Non-small cell lung cancer (NSCLC)"
    ],
    "indicationsNotes": "Guardant Reveal MRD tumor-naïve ctDNA test for early-stage cancer MRD detection and recurrence monitoring after curative-intent treatment. Medicare coverage for CRC; breast and NSCLC coverage expanding.",
    "sensitivity": 81.0,
    "sensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11443202/",
    "sensitivityNotes": "COSMOS 2024 longitudinal sensitivity for stage II+ CRC is ~81%. Earlier landmark/Reinert 2021 data showed 55-63% sensitivity. Headline value reflects current COSMOS longitudinal performance.",
    "sensitivityStagesReported": "Stage II–IV combined",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "Stage II-specific sensitivity not separately reported; combined with stages III–IV in headline figures. Stage-specific data would help clinicians counsel Stage II patients.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III-specific sensitivity not separately reported.",
    "stageDataExpected": true,
    "specificity": 98.0,
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11443202/",
    "specificityNotes": "COSMOS 2024 longitudinal specificity is 98% for CRC. Earlier landmark data showed 100% specificity but with serial/longitudinal testing, 91-98% is more representative.",
    "landmarkSensitivity": 63.0,
    "landmarkSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/",
    "landmarkSensitivityNotes": "CRC landmark sensitivity (stage II–III).",
    "landmarkSpecificity": 98.0,
    "landmarkSpecificityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/",
    "landmarkSpecificityNotes": "CRC landmark specificity (stage II–III); updated from 100% to align with longitudinal data.",
    "longitudinalSensitivity": 81.0,
    "longitudinalSensitivityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",
    "longitudinalSpecificity": 98.0,
    "longitudinalSpecificityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",
    "lod": "0.005% Tumor Fraction",
    "lod95": "0.005% Tumor Fraction",
    "lodCitations": "https://www.guardantcomplete.com",
    "lodNotes": "Detection threshold 0.005% Tumor Fraction (~50 ppm); methylation-based detection (epiTF) enables tumor-naïve ctDNA detection at very low tumor fractions. Updated from 0.01% VAF per vendor validation (Jan 2026).",
    "leadTimeVsImaging": 159.0,
    "leadTimeVsImagingCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",
    "leadTimeVsImagingNotes": "CRC median 4.77 months from MRD+ to recurrence.",
    "requiresTumorTissue": null,
    "requiresTumorTissueNotes": "Plasma-only (tissue-free) MRD assay; tumor tissue is not required for panel design.",
    "requiresMatchedNormal": null,
    "requiresMatchedNormalNotes": "Does not require a matched-normal blood sample.",
    "initialTat": 7.0,
    "initialTatCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "initialTatNotes": "Vendor-reported 7-day median TAT.",
    "followUpTat": 7.0,
    "followUpTatCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "followUpTatNotes": "Vendor-reported 7-day median TAT.",
    "bloodVolume": 20.0,
    "bloodVolumeCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "bloodVolumeNotes": "Commonly collected as two 10 mL Streck cfDNA tubes (≈20 mL).",
    "tat": 7.0,
    "tatCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "tatNotes": "Guardant reports a typical ~7-day turnaround from sample receipt for Reveal.",
    "fdaStatus": "CLIA LDT; not FDA cleared/approved as of 2025.",
    "reimbursement": "Medicare (CRC only)",
    "reimbursementNote": "Medicare MolDX coverage for colorectal cancer MRD only - post-surgical and surveillance settings after curative-intent treatment. Not covered for other cancer types. Commercial coverage expanding via select BCBS plans.",
    "commercialPayers": ["BCBS Louisiana", "Geisinger Health Plan"],
    "commercialPayersCitations": "https://www.businesswire.com/news/home/20230720806084/en/Guardant-Health-receives-first-commercial-payor-coverage-for-Guardant-Reveal%E2%84%A2-test-from-Blue-Cross-and-Blue-Shield-of-Louisiana/",
    "commercialPayersNotes": "Blue Cross Blue Shield of Louisiana became first commercial payer to cover Guardant Reveal in July 2023. Geisinger Health Plan added coverage later in 2023. Additional BCBS plans (including BCBS Massachusetts) appear to have medical policies; verify with specific plan.",
    "cptCodes": "0569U (Guardant Reveal PLA code from mid-2025).",
    "cptCodesNotes": "Guardant Reveal PLA (2025).",
    "availableRegions": ["US"],
    "clinicalAvailability": "Clinical LDT – shipping",
    "exampleTestReport": "https://learn.colontown.org/wp-content/uploads/2022/01/Reveal-Sample-Report_postsurgery-positive-2-v2.pdf",
    "clinicalTrials": "NCCTG N0147 adjuvant FOLFOX trial (>2000; Guardant Reveal ctDNA analysis)",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical landmark assessment (63% sensitivity) and longitudinal surveillance (81% sensitivity) in CRC. Medicare coverage for both post-surgical and surveillance settings.",
    "totalParticipants": 2000,
    "numPublications": 10,
    "numPublicationsPlus": true,
    "vendorVerified": true,
    "vendorRequestedChanges": "2026-01-06: Vendor validation by Brandon Guida (Guardant Health) - updated LOD from 0.01% VAF to 0.005% Tumor Fraction per guardantcomplete.com."
  },
  {
    "id": "mrd-7",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Commonly two Streck cfDNA tubes (~10 mL each) for monitoring; tissue + matched normal required at baseline",
    "sampleCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/",
    "name": "Signatera",
    "vendor": "Natera",
    "approach": "Tumor-informed",
    "method": "Tumor-informed, multiplex PCR–NGS ctDNA assay: tumor and matched-normal WES identify personal SNVs, and a 16-variant (or higher in newer versions) customized panel is tracked in serial plasma at high depth.",
    "cancerTypes": [
      "Colorectal",
      "Breast",
      "Bladder",
      "NSCLC",
      "Ovarian/Fallopian/Primary peritoneal",
      "Pan-solid ICI"
    ],
    "indicationsNotes": "Natera Signatera tumor-informed MRD assay with Medicare coverage for multiple solid-tumor indications: CRC (stage II–IV & oligometastatic, adjuvant & recurrence), breast cancer (neoadjuvant and stage IIb+ adjuvant & recurrence), bladder cancer (MIBC), NSCLC (stage I–III surveillance), and ovarian/fallopian/primary peritoneal cancer (adjuvant & recurrence), plus pan-solid tumor immune-checkpoint inhibitor (ICI) response monitoring.",
    "sensitivity": 94.0,
    "sensitivityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "sensitivityNotes": "Recurrence Surveillance: CRC: 88-93% sens., 98% spec. Breast: 88-89% sens., 95-99% spec. Lung: 80-99% sens., 96-99% spec. Bladder: 99% sens., 98% spec. Ovarian: 99% sens.",
    "sensitivityStagesReported": "Stage II–IV combined (varies by cancer type)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "CRC Stage II landmark ~65-73% in CIRCULATE-Japan; longitudinal higher. Stage II not separately reported for other cancer types. Stage-specific breakdowns would help inform treatment decisions.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III typically shows higher sensitivity than Stage II due to higher tumor burden; specific values combined with other stages in most publications.",
    "stageDataExpected": true,
    "specificity": 98.0,
    "specificityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "specificityNotes": "Specificity ranges by cancer type: CRC 98%, Breast 95-99%, Lung 96-99%, Bladder 98%. Headline value of 98% reflects typical performance across indications.",
    "ppv": 98.0,
    "ppvCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "ppvNotes": "Overall PPV >98% (vendor, multi-tumor).",
    "npv": 96.0,
    "npvCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "npvNotes": "NSCLC distant/extracranial single timepoint NPV.",
    "landmarkSensitivity": 75.0,
    "landmarkSensitivityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "landmarkSensitivityNotes": "NSCLC distant/extracranial single timepoint sensitivity.",
    "longitudinalSensitivity": 94.0,
    "longitudinalSensitivityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "longitudinalSensitivityNotes": "NSCLC distant/extracranial longitudinal sensitivity.",
    "longitudinalSpecificity": 98.0,
    "longitudinalSpecificityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "longitudinalSpecificityNotes": "Longitudinal specificity across cancer types ranges 96-99%; 98% represents typical performance.",
    "lod": "~0.01% VAF",
    "lodCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "lodNotes": "Natera reports analytical sensitivity to ~0.01% tumor fraction with high specificity using integrated digital error suppression.",
    "leadTimeVsImaging": 300.0,
    "leadTimeVsImagingCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "leadTimeVsImagingNotes": "Ovarian ~10 months; NSCLC >7 months earlier than imaging.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Tumor-informed; needs primary tumor tissue.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Matched normal blood required.",
    "variantsTracked": "16",
    "variantsTrackedNotes": "Original commercial design tracks 16 somatic variants per patient; some research/“Genome” configurations track more (e.g., 64) but 16 remains the standard clinical panel.",
    "variantsTrackedCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "initialTat": 28.0,
    "initialTatNotes": "Baseline tumor/normal sequencing and panel design typically require ~3–4 weeks.",
    "initialTatCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "followUpTat": 9.0,
    "followUpTatNotes": "Longitudinal MRD blood draws generally reported within ~7–10 days.",
    "followUpTatCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "bloodVolume": 20.0,
    "bloodVolumeNotes": "Commonly two Streck cfDNA tubes (~10 mL each) for monitoring; tissue + matched normal required at baseline",
    "bloodVolumeCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "tat": 28.0,
    "tatCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/",
    "tatNotes": "Overall paradigm: ~4 weeks for initial build, ~1–1.5 weeks for follow-up tests.",
    "fdaStatus": "CLIA LDT; not FDA-cleared/approved as of late 2025 (clinical validation via numerous peer-reviewed studies).",
    "reimbursement": "Medicare (CRC, Breast, Bladder, NSCLC, Ovarian, ICI)",
    "reimbursementNote": "Medicare MolDX coverage for: CRC (stage II-IV, oligometastatic), breast cancer (neoadjuvant, stage IIb+ adjuvant/recurrence), bladder (MIBC), NSCLC (stage I-III surveillance), ovarian/fallopian/peritoneal, and pan-solid ICI response monitoring. ADLT pricing. Coverage varies by indication - verify specific cancer type with payer.",
    "commercialPayers": ["UnitedHealthcare", "Cigna", "Anthem BCBS", "BCBS Louisiana", "Blue Shield of California"],
    "commercialPayersCitations": "https://www.natera.com/oncology/billing/",
    "commercialPayersNotes": "Natera is in-network with most major health plans including Cigna, UnitedHealthcare, and Blue Shield of California. BCBS Louisiana provides explicit coverage. Note: Aetna lists Signatera codes as in-network but current policies show non-covered; verify with plan.",
    "cptCodes": "0340U (ADLT)",
    "cptCodesNotes": "Signatera PLA (ADLT pricing).",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "International"],
    "clinicalAvailability": "Clinical LDT – shipping",
    "independentValidation": "Yes",
    "independentValidationNotes": "Multiple peer-reviewed and prospective studies across tumors.",
    "exampleTestReport": "https://www.natera.com/resource-library/signatera/signatera-patient-test-sample-report/",
    "clinicalTrials": "BESPOKE CRC (NCT04264702); multicentre prospective observational study of ~2,000 stage I–IV colorectal cancer patients at up to 200 U.S. sites (MRD and surveillance cohorts)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04264702",
    "clinicalSettings": ["Neoadjuvant", "Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Most broadly validated across clinical settings. Neoadjuvant: breast cancer (I-SPY2 trial, Medicare covered). Post-surgery: landmark ~4 weeks (75% NSCLC sens). Post-adjuvant: after chemo completion. Surveillance: longitudinal monitoring (94% NSCLC sens). Medicare covers all settings for CRC, breast, bladder, NSCLC, ovarian.",
    "totalParticipants": 2000,
    "totalParticipantsCitations": "https://clinicaltrials.gov/study/NCT04264702",
    "numPublications": 100,
    "numPublicationsCitations": "https://www.natera.com/company/news/natera-announces-publication-of-over-100-peer-reviewed-papers-on-signateratm/",
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colon Cancer, Rectal Cancer, Merkel Cell Carcinoma V.2.2025",
    "nccnGuidelinesNotes": "NCCN V.2.2025 update specifically references Signatera publications. CRC: ctDNA included as high risk factor for recurrence. MCC: positive recommendation for ctDNA monitoring in surveillance, citing Signatera data.",
    "nccnGuidelinesCitations": "https://www.natera.com/company/news/nccn-strengthens-guidance-on-ctdna-in-colon-cancer-rectal-cancer-and-merkel-cell-carcinoma/"
  },
  {
    "id": "mrd-8",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 17,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "RUO specimen overview describes two 8.5 mL Streck cfDNA tubes (~17 mL total) per timepoint.",
    "sampleCitations": "https://www.tempus.com/wp-content/uploads/2024/01/Tempus-LS_xM-RUO-Overview.pdf",
    "name": "Tempus xM MRD",
    "vendor": "Tempus",
    "approach": "Tumor-naïve",
    "method": "Tumor-naïve MRD assay that combines variant-based ctDNA detection with methylation/fragmentomics signals in a dual-workflow, blood-only design; current clinical positioning focuses on colorectal cancer.",
    "cancerTypes": [
      "Colorectal"
    ],
    "indicationsNotes": "Tempus xM tumor-naïve MRD assay currently marketed for colorectal cancer, with coverage and data focused on CRC; separate Tempus xM (NeXT Personal Dx) tumor-informed offering for solid tumors, including breast.",
    "sensitivity": 61.1,
    "sensitivityNotes": "Landmark sensitivity 61.1% from GALAXY (CIRCULATE-Japan) 80-patient CRC subset. Longitudinal sensitivity 83.3%. Headline uses landmark value.",
    "sensitivityCitations": "https://www.businesswire.com/news/home/20240515005320/en/",
    "specificity": 94.0,
    "specificityCitations": "https://www.businesswire.com/news/home/20240515005320/en/",
    "specificityNotes": "Landmark specificity 94% from GALAXY subset. Longitudinal specificity 89.5%.",
    "landmarkSensitivity": 61.1,
    "landmarkSensitivityNotes": "CRC landmark sensitivity from GALAXY (CIRCULATE-Japan) subset analysis of 80 resected stage II-III colorectal cancer patients.",
    "landmarkSensitivityCitations": "https://www.businesswire.com/news/home/20240515005320/en/ | Tempus BusinessWire press release May 2024",
    "landmarkSpecificity": 94.0,
    "landmarkSpecificityNotes": "CRC landmark specificity from GALAXY (CIRCULATE-Japan) subset analysis.",
    "landmarkSpecificityCitations": "https://www.businesswire.com/news/home/20240515005320/en/ | Tempus BusinessWire press release May 2024",
    "longitudinalSensitivity": 83.3,
    "longitudinalSensitivityCitations": "https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",
    "longitudinalSpecificity": 89.5,
    "longitudinalSpecificityCitations": "https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",
    "lod": "0.01% VAF",
    "lodCitations": "https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",
    "lodNotes": "Detection threshold approximately 0.01% VAF based on GALAXY/CIRCULATE-Japan trial performance.",
    "requiresTumorTissue": null,
    "requiresMatchedNormal": null,
    "initialTat": 12,
    "initialTatCitations": "https://www.tempus.com/oncology/genomic-profiling/xm/",
    "initialTatNotes": "10-14 days TAT; tumor-naïve design enables faster turnaround than tissue-dependent assays.",
    "followUpTatNotes": "Public materials emphasize rapid repeat testing from blood-only workflows; specific day counts vary by context and are not standardized in a single published metric.",
    "bloodVolume": 17.0,
    "bloodVolumeCitations": "https://www.tempus.com/wp-content/uploads/2024/01/Tempus-LS_xM-RUO-Overview.pdf",
    "bloodVolumeNotes": "RUO specimen overview describes two 8.5 mL Streck cfDNA tubes (~17 mL total) per timepoint.",
    "tatNotes": "Overall TAT is marketed as faster than tumor-informed assays due to avoiding tissue sequencing, but a precise canonical value is not available.",
    "fdaStatus": "CLIA LDT (for clinical xM portfolio) with RUO offering for biopharma; not FDA cleared/approved as of 2025.",
    "reimbursement": "Coverage emerging; verify payer-specific policies.",
    "reimbursementNote": "xM MRD is newer than some competitors; commercial and Medicare coverage are evolving and may currently be more limited than for Signatera or Guardant Reveal.",
    "cptCodes": "Contact vendor for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – shipping for colorectal cancer; RUO version also available via Tempus Life Sciences.",
    "clinicalTrials": "GALAXY (CIRCULATE-Japan) subset analysis; 80 resected stage II–III colorectal cancer patients randomly selected and enriched for recurrence; Tempus xM tumor-naïve MRD assay with methylation + variant classifiers",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical landmark (61% sens, 94% spec) and longitudinal surveillance (83% sens, 90% spec) in CRC via GALAXY/CIRCULATE-Japan.",
    "totalParticipants": 80,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-9",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Two 10 mL Streck blood collection tubes (BCT) for plasma and buffy coat at the landmark time point; plasma-only draws (Streck tubes) for longitudinal monitoring.",
    "sampleCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "name": "Labcorp Plasma Detect",
    "vendor": "Labcorp",
    "approach": "Tumor-informed",
    "method": "Tumor-informed whole-genome sequencing (WGS) ctDNA MRD assay: WGS of tumor tissue, buffy coat (germline) and plasma at a landmark time point is used with a proprietary machine-learning pipeline to identify thousands of high-confidence, patient-specific somatic variants (median ~5000 SNVs), which are then tracked longitudinally in cell-free DNA without bespoke panel design.",
    "cancerTypes": [
      "Colon cancer (Stage III)",
      "Lung cancer (in validation)",
      "Bladder cancer (in validation)",
      "Multi-solid (expanding)"
    ],
    "indicationsNotes": "Labcorp Plasma Detect WGS-based MRD assay. Clinically validated for post-surgery and post-adjuvant MRD assessment in stage III colon cancer (PROVENC3); clinical use launched April 2025 via Early Experience Program. Expanding to additional solid tumors including lung and bladder cancer.",
    "sensitivity": 95,
    "sensitivityNotes": "Clinical sensitivity ~95% in PROVENC3 stage III colon cancer validation; analytical sensitivity characterized via WGS of thousands of tumor-specific variants.",
    "sensitivityCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect | https://www.nature.com/articles/s41591-024-03078-8",
    "specificity": 99.4,
    "specificityCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "specificityNotes": "Analytical specificity ~99.4% for ctDNA-negative reference specimens in internal validation; clinical specificity for recurrence is still being characterized (PROVENC3 and related studies).",
    "lod": "10 ppm (LOD50)",
    "lod95": "50 ppm (0.005%)",
    "lod95Citations": "https://www.prnewswire.com/news-releases/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions-302435767.html | https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "lodCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect | https://www.prnewswire.com/news-releases/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions-302435767.html",
    "lodNotes": "LOD95 of 0.005% (50 ppm) per Labcorp official specifications. LOD50 ≈ 0.001% (10 ppm). WGS approach tracks thousands of tumor-specific variants (vs 18-50 for WES-based approaches), enabling improved sensitivity at low ctDNA levels.",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingCitations": "Labcorp press releases Nov 2025.",
    "leadTimeVsImagingNotes": "Detects disease progression up to 18 months earlier than standard clinical measures (median 2.3 months lead time in chemotherapy monitoring study).",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires FFPE tumor tissue at the landmark time point for WGS to define the tumor-informed MRD signature plus buffy coat for germline/CHIP filtering.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Uses buffy coat (PBMC) germline DNA to filter germline and non–tumor-specific variants; germline input is required for assay design.",
    "variantsTracked": "5000",
    "variantsTrackedCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "variantsTrackedNotes": "Median of ~5000 high-confidence tumor-specific single nucleotide variants (SNVs) per patient in the MRD signature, tracked longitudinally. No bespoke panel manufacturing required.",
    "initialTat": 14.0,
    "initialTatCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "initialTatNotes": "Landmark ctDNA MRD result available in as few as 14 days from sample receipt. Standardized WGS workflow eliminates custom reagent delays.",
    "followUpTat": 7.0,
    "followUpTatCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "followUpTatNotes": "Longitudinal surveillance time points reported in as few as 7 days from sample receipt.",
    "bloodVolume": 20.0,
    "bloodVolumeCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "bloodVolumeNotes": "Two 10 mL Streck blood collection tubes (BCT) for plasma and buffy coat at the landmark time point; plasma-only draws (Streck tubes) for longitudinal monitoring.",
    "tat": 14.0,
    "tatCitations": "https://clpmag.com/disease-states/cancer/labcorp-plasma-detect-and-pgdx-elio-plasma-focus-dx-launched/ | https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "tatNotes": "Landmark (initial) MRD result in as few as 14 days and longitudinal MRD results in as few as 7 days from sample receipt (Plasma Detect assay specifications).",
    "fdaStatus": "CLIA LDT",
    "fdaStatusCitations": "Labcorp press release April 2025.",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "Clinical use launched April 2025 for stage III colon cancer via Early Experience Program. Reimbursement pathways in development. No public Medicare LCD or dedicated PLA code as of 2025.",
    "cptCodesNotes": "No public PLA/CPT code specific to Labcorp Plasma Detect as of 2025; contact Labcorp for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – Early Experience Program (stage III colon cancer); Research Use for other indications",
    "independentValidation": "Yes",
    "independentValidationNotes": "Clinically validated in the PROVENC3 stage III colon cancer cohort (AACR 2024) and related ASCO/ESMO presentations assessing post-surgery and post-adjuvant ctDNA status and recurrence risk.",
    "clinicalTrials": "PROVENC3 (colon cancer validation with NKI); MEDOCC-CrEATE (stage II colon ACT); 10+ additional clinical studies in US and internationally",
    "clinicalTrialsCitations": "Labcorp press releases; Nature Medicine 2025; Clinical Cancer Research 2025.",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated in PROVENC3 for post-surgical and post-adjuvant ctDNA assessment in stage III colon cancer. Longitudinal surveillance also validated.",
    "totalParticipants": 236,
    "totalParticipantsNotes": "236 patients in PROVENC3; currently evaluated in 10+ clinical studies across multiple cancer types.",
    "numPublications": 2,
    "numPublicationsCitations": "Nature Medicine 2025 (mesothelioma); Clinical Cancer Research 2025 (head and neck).",
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Developed under PGDx quality management system and design control. Clinical use for stage III colon cancer; research use for other solid tumors. Expanding indications expected."
  },
  {
    "id": "mrd-10",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Foundation does not publish a fixed blood volume; typical mPCR ctDNA workflows use two Streck tubes (~20 mL whole blood).",
    "name": "FoundationOne Tracker (MRD)",
    "vendor": "Foundation Medicine / Natera",
    "approach": "Tumor-informed",
    "method": "Personalized ctDNA assay derived from FoundationOne CDx tumor sequencing; uses 2-16 patient-specific somatic variants to detect and quantify mean tumor molecules per mL (MTM/mL) in serial plasma samples via multiplex PCR workflow.",
    "cancerTypes": [
      "Multi-solid tumors"
    ],
    "indicationsNotes": "Tissue-informed ctDNA MRD assay for early- and late-stage solid tumors. Uses archival or new tumor tissue profiled by FoundationOne CDx to build a patient-specific panel, then quantifies MTM/mL in serial plasma samples for MRD detection and surveillance after curative-intent therapy. Note: The TRM application has separate clinical availability with Medicare coverage; the MRD application remains investigational.",
    "sensitivity": 100,
    "sensitivityCitations": "Zollinger DR et al. PLoS One 2024;19:e0302129; IMpower131 trial data (Kasi PM et al. Clin Cancer Res 2023).",
    "sensitivityNotes": "100% analytical sensitivity in dilution series at ≥5 MTM/mL when at least two tumor variants are monitored (>97.3% at lower levels). ⚠️ Analytical validation (dilution series); clinical MRD sensitivity is indication- and timepoint-specific.",
    "analyticalValidationWarning": true,
    "validationCohortStudy": "Zollinger DR et al. PLoS One 2024 (analytical validation)",
    "specificity": 99.6,
    "specificityCitations": "Zollinger DR et al. PLoS One 2024;19:e0302129.",
    "specificityNotes": "Sample-level analytical specificity was 99.6% in contrived and clinical samples.",
    "lod": "0.01% VAF",
    "lodCitations": "Zollinger DR et al. PLoS One 2024;19:e0302129.",
    "lodNotes": "Detection threshold approximately 0.01% VAF; performance reported in MTM/mL units with analytical sensitivity ≥5 MTM/mL with ≥2 variants monitored.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires prior or concurrent tumor CGP by FoundationOne CDx to identify 2-16 patient-specific somatic variants for personalized panel design.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Germline and CHIP filtering performed computationally without mandatory matched-normal sequencing.",
    "initialTat": 8,
    "initialTatCitations": "Foundation Medicine website; Zollinger DR et al. PLoS One 2024.",
    "initialTatNotes": "7-10 days from sample receipt and variant design to result; initial result requires completed FoundationOne CDx.",
    "followUpTat": null,
    "followUpTatNotes": "Serial MRD timepoints reuse the established patient-specific panel with similar turnaround.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Foundation does not publish a fixed blood volume; typical mPCR ctDNA workflows use two Streck tubes (~20 mL whole blood).",
    "fdaStatus": "FDA Breakthrough Device designation (Feb 2022) for MRD detection in early-stage solid tumors; investigational/early access assay – NOT yet FDA cleared.",
    "fdaStatusCitations": "Foundation Medicine press release, February 3, 2022.",
    "reimbursement": "Not applicable",
    "reimbursementNote": "MRD applications are investigational; not routinely billed to payers. Note: TRM use has separate Medicare coverage (see TRM category).",
    "cptCodesNotes": "None for MRD investigational use.",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "Investigational use available via Foundation Medicine and Roche global network for biopharma collaborations.",
    "clinicalAvailability": "Investigational / early access program via Foundation Medicine for MRD applications; biopharma and academic collaborations globally.",
    "clinicalTrials": "Used in translational and interventional cohorts for MRD (e.g., early bladder cancer post-cystectomy, stage II/III CRC) correlating ctDNA dynamics with outcomes.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Investigational MRD application validated in post-surgical and surveillance settings across multiple solid tumors. FDA Breakthrough Device designation for MRD detection.",
    "totalParticipants": null,
    "numPublications": 3,
    "numPublicationsPlus": true,
    "isRUO": false,
    "isInvestigational": true,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Holds FDA Breakthrough Device designation for MRD but is not yet FDA cleared. The underlying assay platform is a clinical LDT (same technology as FoundationOne Tracker TRM which has Medicare coverage), but MRD-specific applications remain investigational."
  },
  {
    "id": "mrd-11",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Standard ctDNA plasma volumes; explicit whole-blood volume not specified publicly.",
    "name": "Foundation TI-WGS MRD (RUO)",
    "vendor": "Foundation Medicine",
    "approach": "Tumor-informed",
    "method": "Tissue-informed whole-genome sequencing MRD assay; WGS of tumor tissue and longitudinal plasma combined with a proprietary bioinformatics algorithm to detect and quantify ctDNA tumor fraction by monitoring hundreds to thousands of tumor-specific variants.",
    "cancerTypes": [
      "Multi-solid tumors"
    ],
    "indicationsNotes": "Sensitive MRD assay offered for research use in early- and late-stage solid tumors. Available through Foundation's FlexOMx Lab for drug-development studies requiring deep ctDNA detection (e.g., early-stage or low-shedding cancers).",
    "sensitivity": 90,
    "sensitivityCitations": "Foundation Medicine press release, September 23, 2025; https://www.foundationmedicine.com/monitoring-portfolio",
    "sensitivityNotes": "90% analytical sensitivity at 10 ppm tumor fraction threshold in feasibility studies; cross-indication sensitivity values are study-specific.",
    "specificity": 100,
    "specificityCitations": "Foundation Medicine Monitoring Portfolio technical specifications.",
    "specificityNotes": "100% analytical specificity reported in feasibility data. ⚠️ Feasibility data only; clinical specificity study- and tumor-specific.",
    "analyticalValidationWarning": true,
    "validationCohortStudy": "Foundation Medicine feasibility studies (RUO)",
    "lod": "10 ppm (≈0.001%)",
    "lodCitations": "https://www.foundationmedicine.com/monitoring-portfolio",
    "lodNotes": "Reported to detect ctDNA tumor fraction down to 10 ppm in both early- and late-stage cancer.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires WGS of tumor tissue to build the patient-specific genomic signature; typically uses the same FFPE block as FoundationOne CDx.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Product highlights emphasize that matched-normal samples are NOT required for CHIP/germline filtering.",
    "initialTat": 14,
    "initialTatCitations": "Foundation Medicine FlexOMx Lab specifications.",
    "initialTatNotes": "Approximately 14 days TAT; depends on WGS depth and study design.",
    "followUpTat": null,
    "followUpTatNotes": "Follow-up draws reuse the existing tumor-informed signature; timelines negotiated at study level.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Standard ctDNA plasma volumes; explicit whole-blood volume not specified publicly.",
    "fdaStatus": "Research Use Only (RUO) – CLIA-certified, CAP-accredited FlexOMx Lab; NOT FDA cleared.",
    "fdaStatusCitations": "Foundation Medicine press release, September 23, 2025.",
    "fdaStatusNotes": "RUO assay for biopharma research partnerships only. Not available for clinical ordering. Foundation Medicine has not announced plans for FDA clearance or clinical LDT launch.",
    "reimbursement": "Not applicable",
    "reimbursementNote": "RUO only; costs are sponsor-funded in research/clinical-development collaborations.",
    "cptCodesNotes": "None (RUO research assay).",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "RUO available globally via Foundation's FlexOMx Lab for biopharma and academic partnerships.",
    "clinicalAvailability": "Available globally to biopharma and academic partners as a central-lab RUO MRD solution via Foundation's FlexOMx Lab. Launched September 2025.",
    "clinicalTrials": "Positioned for MRD assessment and ctDNA kinetics in oncology drug-development studies, particularly early-stage or low-shed settings.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "RUO platform for research use in post-surgical MRD assessment and longitudinal surveillance, particularly in early-stage or low-shedding tumors.",
    "totalParticipants": null,
    "numPublications": 0,
    "numPublicationsPlus": false,
    "isRUO": true,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "Research Use Only assay launched September 2025 through FlexOMx Lab; offered for retrospective clinical trials and research studies, not for diagnostic use."
  },
  {
    "id": "mrd-12",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 4,
    "sampleTubeCount": 1,
    "sampleCollectionNotes": "Requires less than one tube of blood (as little as 3-4 mL blood or 1-2 mL plasma).",
    "sampleCitations": "https://www.guardanthealth.com/",
    "name": "Veracyte MRD (C2i Genomics platform)",
    "vendor": "Veracyte (C2i Genomics)",
    "approach": "Tumor-informed",
    "method": "Whole-genome sequencing (WGS) of tumor tissue and germline DNA combined with AI-driven pattern recognition to create patient-specific ctDNA signatures; subsequent blood samples are analyzed via WGS and AI to detect residual cancer.",
    "cancerTypes": [
      "Muscle-invasive bladder cancer (first indication)",
      "Multi-solid (planned expansion)"
    ],
    "indicationsNotes": "WGS-based MRD testing platform acquired by Veracyte from C2i Genomics in February 2024. First clinical test planned for muscle-invasive bladder cancer (MIBC) with launch expected H1 2026.",
    "sensitivity": 91,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36270894/ | Nordentoft I et al. Eur Urol 2023; EAU25 Abstract A0162",
    "sensitivityNotes": "Prior publication showed 91% sensitivity at 92% specificity in urothelial carcinoma. TOMBOLA trial data presented at EAU25 demonstrated higher accuracy than ddPCR.",
    "specificity": 88,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/36270894/ | EAU25 presentation, TOMBOLA trial (Abstract A0162)",
    "specificityNotes": "TOMBOLA trial showed 88% specificity at 6-month milestone vs 62% for ddPCR; detected recurrence 93 days earlier than imaging.",
    "lod": "0.001% TF",
    "lodCitations": "Veracyte investor communications; C2i Genomics technical specifications.",
    "lodNotes": "Detection threshold approximately 0.001% tumor fraction (10 ppm) via WGS-based approach.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires WGS of tumor tissue and germline DNA to establish patient-specific signature.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "WGS of germline (non-tumor) DNA is part of the workflow to distinguish somatic from germline variants.",
    "initialTat": 14,
    "initialTatNotes": "Sample to result in approximately 2 weeks per acquisition announcement.",
    "followUpTat": 14,
    "followUpTatNotes": "Follow-up samples analyzed via WGS with similar turnaround.",
    "bloodVolume": 4,
    "bloodVolumeCitations": "GEN Edge January 2024; C2i acquisition announcement.",
    "bloodVolumeNotes": "Requires less than one tube of blood (as little as 3-4 mL blood or 1-2 mL plasma).",
    "fdaStatus": "Pre-commercial research platform; NOT FDA cleared. First clinical test (MIBC) expected H1 2026.",
    "fdaStatusNotes": "Pre-commercial research platform acquired from C2i Genomics in Feb 2024. Clinical launch for muscle-invasive bladder cancer planned H1 2026. Not yet available for clinical ordering.",
    "fdaStatusCitations": "Veracyte Q1 2025 earnings; GenomeWeb May 2025; EAU25 presentation.",
    "reimbursement": "Not applicable",
    "reimbursementNote": "Pre-commercial; Veracyte plans to leverage established urology channel for MIBC indication.",
    "cptCodesNotes": "None (pre-commercial).",
    "clinicalAvailability": "Pre-commercial research platform. Clinical launch planned H1 2026 for muscle-invasive bladder cancer.",
    "clinicalTrials": "TOMBOLA trial (NCT04138628) – multicenter interventional in MIBC (100 patients); UMBRELLA trial (enrolled Q1 2025) for pancreatic cancer, sarcoma, CRC, NSCLC.",
    "clinicalTrialsCitations": "Veracyte Q1 2025 earnings; EAU25 presentation.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "TOMBOLA trial validates post-surgical and surveillance MRD in muscle-invasive bladder cancer. Detected recurrence 93 days earlier than imaging.",
    "totalParticipants": 100,
    "numPublications": 2,
    "numPublicationsPlus": true,
    "isRUO": true,
    "isInvestigational": true,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "Pre-commercial investigational WGS-based MRD platform acquired by Veracyte (Feb 2024, $70M + $25M milestones). TOMBOLA trial supports validation. First clinical test for MIBC expected H1 2026."
  },
  {
    "id": "mrd-13",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 4,
    "sampleTubeCount": 1,
    "sampleCollectionNotes": "CRC MRD study used median 4 mL plasma (range 1-4 mL).",
    "sampleCitations": "https://www.guardanthealth.com/",
    "name": "Guardant LUNAR (RUO platform)",
    "vendor": "Guardant Health",
    "approach": "Tumor-naïve",
    "method": "Plasma-only ctDNA assay integrating genomic alterations (SNVs, indels) with epigenomic cancer signatures (aberrant DNA methylation) to detect MRD without requiring tumor tissue sequencing. Originally called LUNAR-1.",
    "cancerTypes": [
      "Colorectal cancer (primary validation)",
      "Multi-solid (research)"
    ],
    "indicationsNotes": "Research platform that evolved into the clinical Guardant Reveal LDT. Designed to detect MRD without prior knowledge of patient's tumor mutations by combining genomic and methylation signatures.",
    "sensitivity": 56,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021;27:5586-5594",
    "sensitivityNotes": "In CRC cohort (n=84 evaluable): landmark sensitivity 56% (1 month post-therapy), longitudinal sensitivity 69%. Integrating epigenomic analysis enhanced sensitivity by 25-36%.",
    "specificity": 100,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021;27:5586-5594",
    "specificityNotes": "Landmark specificity ~100% with 100% PPV (all 15 patients with detectable ctDNA recurred); longitudinal specificity ~91%. ⚠️ 100% PPV from very small subset (n=15).",
    "smallSampleWarning": true,
    "validationCohortSize": 103,
    "validationCohortStudy": "Parikh AR et al. Clin Cancer Res 2021 (n=103 total, n=84 evaluable, n=15 ctDNA+)",
    "lod": "0.01% VAF",
    "lodCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021",
    "lodNotes": "Detection threshold approximately 0.01% allele frequency; combines genomic alterations with epigenomic methylation signatures.",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Explicitly designed as plasma-only assay, not requiring sequencing of tumor tissue – a key differentiator from tissue-informed approaches.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Plasma-only assay uses integrated genomic and epigenomic signatures without matched-normal sequencing; filters CHIP variants computationally.",
    "initialTat": 10,
    "initialTatCitations": "https://guardanthealth.com/solutions/guardant-reveal/",
    "initialTatNotes": "7-10 days TAT; research platform TAT was study-specific but clinical derivative (Guardant Reveal) reports similar turnaround.",
    "followUpTat": null,
    "followUpTatNotes": "Follow-up draws processed via same plasma-only workflow.",
    "bloodVolume": 4,
    "bloodVolumeCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021",
    "bloodVolumeNotes": "CRC MRD study used median 4 mL plasma (range 1-4 mL).",
    "fdaStatus": "Research-use-only MRD platform; clinical implementation transitioned to Guardant Reveal LDT.",
    "fdaStatusNotes": "RUO research platform (formerly LUNAR-1). Clinical implementation has transitioned to Guardant Reveal, which is available as a clinical LDT. LUNAR platform retained for research collaborations.",
    "fdaStatusCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021; https://guardanthealth.com/ | Guardant Health website",
    "reimbursement": "Not applicable",
    "reimbursementNote": "RUO platform; costs study-funded. Clinical product Guardant Reveal has separate reimbursement pathway.",
    "cptCodesNotes": "None (research platform; Guardant Reveal is the clinical LDT).",
    "clinicalAvailability": "Available to academic and biopharma partners as research platform. Guardant Reveal is the clinical LDT derived from this technology.",
    "clinicalTrials": "CRC MRD study at Massachusetts General (Parikh et al. 2021, n=103); COSMOS study; PEGASUS trial; COBRA trial.",
    "clinicalTrialsCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021;27:5586-5594",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "RUO platform validated for post-therapy landmark (56% sens at 1 month) and longitudinal surveillance (69% sens) in CRC.",
    "totalParticipants": 103,
    "numPublications": 5,
    "numPublicationsPlus": true,
    "isRUO": true,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "Research/development platform (originally LUNAR-1); the patient-facing MRD offering is Guardant Reveal (tracked separately as CLIA LDT). Demonstrated feasibility of tumor-uninformed plasma-only MRD detection."
  },
  {
    "id": "mrd-14",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 1,
    "sampleCollectionNotes": "One 10-mL Streck tube of whole blood required.",
    "sampleCitations": "https://www.biodesix.com/",
    "name": "NavDx",
    "vendor": "Naveris",
    "approach": "Tumor-naïve",
    "method": "Proprietary quantitative digital droplet PCR assay detecting tumor tissue modified viral (TTMV)-HPV DNA fragments in plasma; detects HPV genotypes 16, 18, 31, 33, and 35; reports TTMV Score (normalized TTMV-HPV DNA fragments/mL plasma).",
    "cancerTypes": [
      "HPV+ oropharyngeal (head & neck) cancer",
      "Anal squamous cell carcinoma (ASCC)",
      "HPV-driven gynecologic cancers (via NavDx+Gyn)"
    ],
    "indicationsNotes": "First and only clinically validated circulating TTMV-HPV DNA blood test. Detects MRD and recurrence in HPV-driven cancers before clinical or radiographic evidence. Used across the care continuum: pre-treatment baseline, treatment response assessment, post-treatment MRD surveillance, and recurrence detection.",
    "leadTimeVsImaging": 120,
    "leadTimeVsImagingCitations": "https://pubmed.ncbi.nlm.nih.gov/32017652/ | Chera BS et al. J Clin Oncol 2020;38:1050-1058",
    "leadTimeVsImagingNotes": "Median ~4 months (~120 days) lead time vs imaging for recurrence detection in HPV-driven oropharyngeal cancer surveillance cohorts.",
    "sensitivity": 90.4,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37422913/ | Ferrandino RN et al. JAMA Otolaryngol 2023; https://pubmed.ncbi.nlm.nih.gov/37566241/ | Hanna GJ et al. Clin Cancer Res 2023",
    "sensitivityNotes": "Clinical sensitivity 90.4% for recurrent HPV-associated OPSCC; 91.5% for pre-treatment diagnosis; 79.2-89% for surveillance depending on timepoint. For ASCC, multi-center study showed high accuracy.",
    "specificity": 98.6,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37422913/ | Ferrandino RN et al. JAMA Otolaryngol 2023; https://pubmed.ncbi.nlm.nih.gov/37566241/ | Hanna GJ et al. Clin Cancer Res 2023",
    "specificityNotes": "Clinical specificity 98.6% for OPSCC; 97-100% in surveillance cohorts. Reliably distinguishes TTMV-HPV DNA from non-cancerous HPV DNA sources.",
    "ppv": 98,
    "ppvCitations": "https://navdx.com/physician-faqs",
    "ppvNotes": "Per-test PPV of 98% for ASCC; 97.9% for OPSCC. ≥95% PPV for cancer recurrence when patients had at least one positive test result.",
    "npv": 95,
    "npvCitations": "https://navdx.com/physician-faqs",
    "npvNotes": "Per-test NPV of 95% for ASCC; 95.7-98% for OPSCC surveillance. ≥98% of patients whose TTMV Score remained negative had no recurrence.",
    "lod": "0-1.10 copies/µL",
    "lodCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9955790/ | Diagnostics 2023;13:725",
    "lodNotes": "Analytical LOD: 0-1.10 copies/μL across HPV types 16, 18, 31, 33, 35. LOQ: <1.20-4.11 copies/μL. LOB: 0-0.32 copies/μL. Per analytical validation paper in Diagnostics (PMC9955790).",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tumor-naïve approach; does not require prior tumor sequencing. Detects HPV-derived ctDNA directly without need for patient-specific panel design. For patients without pre-treatment NavDx, primary tumor tissue may be tested to confirm HPV genotype.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "No matched normal required; TTMV-HPV DNA biomarker is tumor-specific by nature.",
    "initialTat": 7,
    "initialTatNotes": "Reports issued within 7 calendar days from sample receipt per Naveris physician ordering information. No baseline panel design required (tumor-naïve approach).",
    "followUpTat": 7,
    "followUpTatNotes": "Serial monitoring uses same 7-day TAT; consistent turnaround for all tests.",
    "tat": "7 days",
    "tatCitations": "https://naveris.com/physicians/",
    "bloodVolume": 10,
    "bloodVolumeCitations": "NavDx physician ordering information.",
    "bloodVolumeNotes": "One 10-mL Streck tube of whole blood required.",
    "fdaStatus": "Clinical LDT – CLIA high-complexity test; CAP and NYSDOH accredited; NOT FDA cleared",
    "fdaStatusCitations": "Naveris website; Diagnostics 2023;13:725.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via Palmetto GBA MolDX: HPV+ oropharyngeal cancer (Nov 2023), anal squamous cell carcinoma (Nov 2025). CMS ADLT designation effective April 2024.",
    "commercialPayers": ["Highmark", "Blue Shield of California"],
    "commercialPayersCitations": "Naveris press releases Feb 2024, July 2024.",
    "commercialPayersNotes": "Highmark coverage announced Feb 2024; Blue Shield of California coverage effective July 1, 2024.",
    "cptCodes": "0356U",
    "cptCodesNotes": "CPT 0356U for TTMV-HPV DNA testing; ADLT status effective April 1, 2024.",
    "codeType": "PLA",
    "medicareRate": 1800,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available in US. Integrated into clinical practice by >1,000 healthcare providers at >400 medical sites. ~100,000 patient-physician encounters.",
    "clinicalTrials": "Phase II MRD+ study at Memorial Sloan Kettering (HB-200 intervention for HPV16+ HNSCC with molecular relapse); multiple validation cohorts.",
    "clinicalTrialsCitations": "https://www.naveris.com/ | Naveris press release April 2024; https://pubmed.ncbi.nlm.nih.gov/32017652/ | Chera BS et al. J Clin Oncol 2020;38:1050-1058; https://pubmed.ncbi.nlm.nih.gov/35914212/ | Berger BM et al. Clin Cancer Res 2022;28:4292-4301",
    "clinicalSettings": ["Neoadjuvant", "Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Used across entire care continuum for HPV+ cancers: pre-treatment baseline, treatment response during neoadjuvant/adjuvant therapy, post-treatment MRD assessment, and long-term surveillance. Median 4-month lead time vs imaging.",
    "totalParticipants": 1076,
    "totalParticipantsNotes": "Multi-center surveillance cohort of 1,076 patients with PPV 95% (76/80) and NPV 95% (1,198/1,256) per Naveris clinical performance data. Additional validation across multiple published cohorts.",
    "numPublications": 35,
    "numPublicationsPlus": true,
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "First MRD test with Medicare coverage for HPV-driven cancers. Clinical LDT with ADLT designation. Unique tumor-naïve approach detecting viral-derived ctDNA rather than somatic mutations. Proven clinical utility in 35+ peer-reviewed publications."
  },
  {
    "id": "mrd-15",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Standard blood draw volume; specific volume not publicly disclosed.",
    "name": "Foresight CLARITY Lymphoma",
    "vendor": "Natera",
    "vendorOriginal": "Foresight Diagnostics",
    "approach": "Tumor-informed",
    "method": "PhasED-Seq (Phased variant Enrichment and Detection Sequencing): 150kb fixed capture panel leveraging somatic hypermutation in B-cell malignancies. Off-the-shelf panel (no custom reagent design) interrogates phased variants in stereotypical genomic regions. Requires concordant detection of ≥2 phased non-reference variants on same DNA molecule. Background error rate ~1.95E-08.",
    "cancerTypes": [
      "Diffuse large B-cell lymphoma (DLBCL)",
      "Large B-cell lymphoma (LBCL)",
      "Follicular lymphoma",
      "Classic Hodgkin lymphoma",
      "Multiple myeloma"
    ],
    "indicationsNotes": "Sensitive MRD assay for B-cell malignancies leveraging phased variant technology in somatic hypermutation regions. First ctDNA-MRD test included in NCCN Guidelines for B-Cell Lymphomas (Dec 2024). Acquired by Natera December 2025. Solid tumor version (up to 5,000 variants, 0.3 ppm LOD) in development but not yet clinically available.",
    "sensitivity": 90.62,
    "sensitivityCitations": "https://www.oncotarget.com/article/28654/text/ | Boehm N et al. Oncotarget 2025;16:329-336",
    "sensitivityNotes": "Positive percent agreement 90.62% (95% CI 74.98-98.02%) in DLBCL analytical validation. End-of-treatment MRD detection identified 90% of patients who later relapsed vs 45% for PET/CT.",
    "specificity": 97.65,
    "specificityCitations": "https://www.oncotarget.com/article/28654/text/ | Boehm N et al. Oncotarget 2025;16:329-336",
    "specificityNotes": "Negative percent agreement 97.65% (95% CI 87.43-99.94%) in DLBCL validation. False positive rate 0.24%.",
    "lod": "0.7 ppm",
    "lod95": "0.7 ppm",
    "lod95Citations": "https://www.natera.com/company/news/natera-acquires-foresight-diagnostics/",
    "lodCitations": "Boehm N et al. Oncotarget 2025;16:329-336; https://www.natera.com/company/news/natera-acquires-foresight-diagnostics/",
    "lodNotes": "LOD95 = 0.7 ppm per vendor and analytical validation paper. Solid tumor version (in development) achieves 0.3 ppm.",
    "leadTimeVsImaging": 200,
    "leadTimeVsImagingCitations": "https://www.natera.com/oncology/signatera-mrd-test/clarity/ | Foresight CLARITY product page",
    "leadTimeVsImagingNotes": "Detects relapse approximately 200 days earlier than PET/CT imaging in DLBCL. PhasED-Seq correctly identified 90% of patients who later relapsed vs 45% identified by PET/CT.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor-derived material but flexible source: pre-treatment PLASMA (when tumor is shedding) OR tumor tissue. No tissue biopsy required if adequate pre-treatment plasma available.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Requires matched normal sample per vendor confirmation.",
    "variantsTracked": "100s",
    "variantsTrackedNotes": "Fixed 150kb panel interrogates hundreds of phased variants in somatic hypermutation regions. No custom reagent design required (unlike solid tumor WGS approaches).",
    "initialTat": 8,
    "initialTatNotes": "8-10 days for new patient baseline. Off-the-shelf panel eliminates custom reagent design delay.",
    "followUpTat": 8,
    "followUpTatNotes": "8-10 days for MRD monitoring timepoints. Same turnaround as baseline due to fixed panel approach.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Standard blood draw volume; specific volume not publicly disclosed.",
    "fdaStatus": "CLIA LDT – NOT FDA cleared/approved",
    "fdaStatusCitations": "Foresight website; CAP: 9346637, CLIA: 06D2287941",
    "reimbursement": "Not established",
    "reimbursementNote": "Research/trial use primarily. NCCN guideline inclusion may support future reimbursement pathway. Clinical launch expected 2026 post-Natera integration.",
    "cptCodes": null,
    "clinicalAvailability": "Research/trial use; limited clinical ordering. Central CLIA lab (Boulder, CO). Clinical launch expected 2026.",
    "clinicalTrials": "NCT06500273 (ALPHA3 - MRD+ LBCL patients post-remission); NCT06693830 (SHORTEN-ctDNA - ctDNA-guided chemotherapy de-escalation); multiple biopharma and academic partnerships",
    "clinicalTrialsCitations": "Foresight Diagnostics press releases 2025; ClinicalTrials.gov",
    "totalParticipants": 300,
    "totalParticipantsPlus": true,
    "totalParticipantsNotes": "300+ participants across multiple studies. JCO pooled analysis included 137 DLBCL patients from 5 prospective studies; additional patients in ongoing trials.",
    "numPublications": 40,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "Foresight website; Natera acquisition announcement noted 15 abstracts at ASH 2025.",
    "clinicalSettings": ["Neoadjuvant", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for MRD assessment during/after frontline therapy in DLBCL and surveillance monitoring. First ctDNA-MRD test in NCCN Guidelines for DLBCL. Used to adjudicate PET-positive results at end of therapy.",
    "isRUO": false,
    "isInvestigational": true,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-registered laboratory (CAP: 9346637, CLIA: 06D2287941). First ctDNA-MRD test in NCCN B-Cell Lymphoma guidelines. Acquired by Natera Dec 5, 2025 for $275M upfront + $175M earnouts.",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN B-Cell Lymphomas V.2.2025 (Dec 2024)",
    "nccnGuidelinesNotes": "First ctDNA-MRD test named in NCCN Guidelines. Recommended to adjudicate PET-positive results at end of frontline DLBCL therapy (assay LOD <1ppm required).",
    "vendorDataSource": "John Truesdell (Natera/Foresight) Dec 2025; https://pubmed.ncbi.nlm.nih.gov/40353795/",
    "solidTumorVersionNotes": "Foresight CLARITY for solid tumors is in development (not clinically available). Uses WGS baseline with up to 5,000 phased+low-error variants and achieves 0.3 ppm LOD. Requires custom reagent design like other MRD products.",
    "acquisitionDetails": {
      "acquirer": "Natera",
      "date": "2025-12-05",
      "upfrontValueUSD": 275000000,
      "earnoutPotentialUSD": 175000000
    }
  },
  {
    "id": "mrd-16",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Standard collection: two 10mL Streck cfDNA tubes (20mL total).",
    "sampleCitations": "https://oncology.labcorp.com/",
    "name": "Invitae PCM",
    "vendor": "Labcorp (Invitae)",
    "approach": "Tumor-informed",
    "method": "Tumor-informed, whole-exome sequencing-based MRD assay: WES of tumor and matched normal identifies 18-50 patient-specific variants, which are tracked at high depth in plasma using Anchored Multiplex PCR (AMP) chemistry with error correction.",
    "cancerTypes": [
      "NSCLC",
      "Breast",
      "Colorectal",
      "Pancreatic",
      "Head and neck",
      "Multi-solid"
    ],
    "indicationsNotes": "Invitae Personalized Cancer Monitoring (PCM) pan-cancer tumor-informed MRD assay, now part of Labcorp following Aug 2024 acquisition. Co-developed with TRACERx consortium. FDA Breakthrough Device designation. Not indicated for hematological malignancies, CNS malignancies, or sarcomas.",
    "sensitivity": 76.9,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas I et al. Ann Oncol 2025; TRACERx lung cancer studies",
    "sensitivityNotes": "76.9% clinical sensitivity in breast cancer monitoring phase for patients who relapsed. TRACERx NSCLC showed 93% (13/14) prediction of relapse post-resection.",
    "specificity": 100,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas I et al. Ann Oncol 2025",
    "specificityNotes": "100% specificity in breast cancer monitoring cohort (n=61). ⚠️ Small clinical cohort; no false positives reported.",
    "smallSampleWarning": true,
    "validationCohortSize": 61,
    "validationCohortStudy": "Garcia-Murillas I et al. Ann Oncol 2025 (n=61 breast cancer)",
    "lod": "80 ppm",
    "lod95": null,
    "lodCitations": "https://www.labcorp.com/tests/480840/invitae-personalized-cancer-monitoring | Labcorp Invitae PCM specifications",
    "lodNotes": "LOD of 0.008% VAF (80 ppm) with 60ng cfDNA input and 18-50 variants at baseline threshold. LOD of 0.05% VAF (500 ppm) with 10ng cfDNA and 18 variants at monitoring threshold.",
    "leadTimeVsImaging": 351,
    "leadTimeVsImagingCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas I et al. Ann Oncol 2025",
    "leadTimeVsImagingNotes": "Median lead time 11.7 months (351 days) before clinical relapse in breast cancer. TRACERx NSCLC showed median 70 days, up to 136 days in follow-up cohort.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires FFPE tumor tissue plus matched-normal blood for baseline WES panel design.",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "18-50",
    "variantsTrackedNotes": "Invitae algorithm selects 18-50 tumor-specific variants from WES results. Range allows balance of sensitivity in low vs high mutational burden cancers.",
    "initialTat": 21,
    "initialTatNotes": "Approximately 3 weeks for baseline panel design from tumor/normal WES.",
    "followUpTat": 10,
    "followUpTatNotes": "Monitoring timepoints typically reported within 10 days.",
    "bloodVolume": 20,
    "bloodVolumeNotes": "Standard collection: two 10mL Streck cfDNA tubes (20mL total).",
    "fdaStatus": "CLIA LDT; FDA Breakthrough Device designation",
    "fdaStatusCitations": "Invitae/Labcorp website; FDA BDD program.",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "Under Novitas MAC jurisdiction (not MolDX/Palmetto). Labcorp pursuing coverage pathways post-acquisition.",
    "cptCodes": null,
    "clinicalAvailability": "Clinical LDT – shipping (Metro Park, NJ laboratory)",
    "clinicalTrials": "TRACERx (NSCLC, ~850 pts); MARIA (pan-tumor); ARTEMIS (pancreatic); multiple breast and GI studies",
    "clinicalTrialsCitations": "Invitae/Labcorp press releases; ClinicalTrials.gov",
    "totalParticipants": 1000,
    "totalParticipantsNotes": "TRACERx alone enrolled ~850 pts; additional studies in breast, pancreatic, colorectal.",
    "numPublications": 15,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "TRACERx consortium publications; Garcia-Murillas et al.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "TRACERx consortium validated post-surgical MRD assessment (93% recurrence prediction in NSCLC) and longitudinal surveillance (median 11.7 month lead time in breast cancer).",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CAP-accredited, CLIA-certified laboratory (Metro Park, NJ). Acquired by Labcorp Aug 2024 via Invitae bankruptcy sale ($239M)."
  },
  {
    "id": "mrd-18",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Approximately 20mL whole blood; plasma and buffy coat analyzed separately.",
    "sampleCitations": "https://www.carislifesciences.com/products-and-services/assure/",
    "name": "Caris Assure",
    "vendor": "Caris Life Sciences",
    "approach": "Tumor-naïve MRD (WES/WTS cfDNA + cfRNA)",
    "method": "AI-enabled whole exome and whole transcriptome sequencing (WES/WTS) from plasma cfDNA/cfRNA and buffy coat WBC DNA/RNA with machine learning MRD model; CHIP subtraction for accuracy",
    "methodCitations": "https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/physicians/physician-tests/caris-assure/",
    "cancerTypes": ["All solid tumors"],
    "targetPopulation": "Cancer patients requiring MRD detection and disease monitoring; tumor-naïve approach does not require prior tissue profiling",
    "indicationsNotes": "Multi-functional platform validated for MRD detection across solid tumors. Disease-free survival stratification: HR=33.4 (p<0.005) for MRD-positive vs MRD-negative patients. Also supports therapy selection and treatment response monitoring on same platform.",
    "sensitivity": 93.8,
    "sensitivityNotes": "93.8% sensitivity in MRD model validation. Trained on 3,439 patients and validated on independent set of 86 MRD patients. Tumor-naïve approach using AI-derived features from plasma.",
    "sensitivityCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "specificity": 99.6,
    "specificityNotes": "99.6% specificity (>99.9% in some cohorts) in MRD/monitoring validation.",
    "specificityCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "lod": "0.05% VAF",
    "lodCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "lodNotes": "Detection threshold approximately 0.05% VAF via WES/WTS cfDNA analysis.",
    "performanceNotes": "For MRD detection, disease-free survival of patients predicted to have an event (MRD-positive) was significantly shorter than those predicted MRD-negative (HR=33.4, p<0.005). For monitoring, HR=4.39, p=0.008. Uses tumor-naïve approach - no prior tissue profiling required.",
    "performanceCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage expanding; contact Caris for current payer coverage.",
    "clinicalAvailability": "Commercially available in US since late 2022",
    "availableRegions": ["US"],
    "initialTat": 14,
    "initialTatNotes": "Initial MRD assessment typically 10-14 business days.",
    "followUpTat": 14,
    "sampleType": "Whole blood",
    "bloodVolume": 20,
    "bloodVolumeNotes": "Approximately 20mL whole blood; plasma and buffy coat analyzed separately.",
    "clinicalTrials": "MRD model validated on 86 patients; monitoring validated on 101 patients; 3,439 training samples",
    "totalParticipants": 3626,
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD assessment (HR=33.4 for MRD+ vs MRD-) and longitudinal disease monitoring (HR=4.39). Tumor-naïve approach enables testing without prior tissue profiling.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "technologyDifferentiator": "Tumor-naïve MRD approach using AI/ML on WES/WTS data - no prior tissue profiling required. Only liquid biopsy sequencing both plasma and buffy coat for CHIP subtraction, improving accuracy over plasma-only assays."
  },
  {
    "id": "mrd-19",
    "sampleCategory": "Bone Marrow/Blood",
    "sampleTubeType": "EDTA",
    "sampleCollectionNotes": "Bone marrow: 1 mL aspirate recommended. Blood (CLL): 2 mL whole blood. Sample requirements vary by specimen type.",
    "sampleCitations": "https://www.adaptivebiotech.com/clonoseq/",
    "name": "clonoSEQ",
    "vendor": "Adaptive Biotechnologies",
    "approach": "Tumor-informed (Immunosequencing)",
    "method": "NGS-based immunosequencing of B-cell (IGH, IGK, IGL) and T-cell receptor gene rearrangements. Identifies patient-specific clonal DNA sequences ('barcodes') at diagnosis, then tracks these sequences in subsequent samples to quantify MRD with sensitivity to 10⁻⁶ (1 cancer cell per million).",
    "methodCitations": "https://www.clonoseq.com/about-clonoseq/ | https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer",
    "cancerTypes": [
      "Multiple myeloma",
      "B-cell ALL",
      "CLL",
      "DLBCL",
      "Mantle cell lymphoma",
      "Other lymphoid malignancies"
    ],
    "cancerTypesNotes": "FDA-cleared for MM (bone marrow), B-ALL (bone marrow), and CLL (blood or bone marrow). Available as CLIA-validated LDT for DLBCL, MCL, and other lymphoid cancers.",
    "cancerTypesCitations": "https://www.clonoseq.com/technical-summary/",
    "targetPopulation": "Patients with lymphoid malignancies (like Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma) requiring MRD assessment during and after treatment to evaluate prognosis, monitor remission, and detect potential relapse.",
    "indicationsNotes": "First and only FDA-cleared MRD test for hematologic malignancies. Uses NGS immunosequencing to detect residual cancer cells at 100x greater sensitivity than standard flow cytometry. Two-step testing: Clonality (ID) test identifies trackable sequences at diagnosis; Tracking (MRD) tests monitor those sequences in subsequent samples.",
    "sensitivity": 95,
    "sensitivityPlus": true,
    "sensitivityNotes": "~95%+ clinical sensitivity. Detects MRD at 10⁻⁶ sensitivity (1 cancer cell per 1 million healthy cells) given sufficient sample input (20 μg DNA). This is 100x more sensitive than standard flow cytometry (10⁻⁴). Sensitivity is sample-dependent based on DNA input quantity.",
    "sensitivityCitations": "https://www.clonoseq.com/about-clonoseq/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "specificity": 99,
    "specificityPlus": true,
    "specificityNotes": "~99%+ analytical specificity. Validation demonstrated high specificity with well-characterized limit of blank (LoB) to minimize false positives from non-malignant clones.",
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "lod": "10⁻⁶ (1 in 1 million cells)",
    "lodNotes": "LoD of 1.9 malignant cells at 20 μg DNA input. Sensitivity scales with DNA input - higher DNA input enables deeper detection. Maximum sensitivity of 10⁻⁶ achievable with sufficient sample material.",
    "lodCitations": "https://www.clonoseq.com/wp-content/uploads/2021/08/PNL-10027-03_clonoSEQ-Technical-Information.pdf",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Does not require solid tumor tissue. Requires high-disease-burden baseline sample (fresh or archived) for initial Clonality (ID) test to identify trackable sequences: Fresh or archived sample from bone marrow aspirate, peripheral blood, or soft tissue. Subsequent clonoSEQ Tracking (MRD) uses standard fresh bone marrow or blood samples.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Does not require separate matched normal sequencing. Clonality criteria (≥3% of like sequences, ≥0.2% of total cells, etc.) distinguish malignant from normal B/T-cell populations.",
    "initialTat": 14,
    "initialTatNotes": "Initial Clonality (ID) test to identify trackable sequences: ~14 days from sample receipt.",
    "initialTatCitations": "https://www.clonoseq.com/ordering-clonoseq/ | https://www.childrensmn.org/references/lab/pathology/clonoseq.pdf",
    "followUpTat": 7,
    "followUpTatNotes": "Serial MRD monitoring (Tracking tests): ~7 days from sample receipt. Requires prior valid Clonality result.",
    "followUpTatCitations": "https://www.clonoseq.com/ordering-clonoseq/ | https://www.childrensmn.org/references/lab/pathology/clonoseq.pdf",
    "bloodVolume": null,
    "bloodVolumeNotes": "Bone marrow: 1 mL aspirate recommended. Blood (CLL): 2 mL whole blood. Sample requirements vary by specimen type.",
    "sampleRequirements": "Bone marrow aspirate (1 mL EDTA), peripheral blood (2 mL EDTA for CLL), or archived FFPE/slides. Fresh specimens preferred; stored specimens accepted with longer TAT.",
    "sampleRequirementsCitations": "https://www.clonoseq.com/ordering-clonoseq/",
    "fdaStatus": "FDA De Novo cleared (Sept 2018 for MM and B-ALL; Aug 2020 expanded for CLL in blood and bone marrow). CE-IVDR Class C certified (Aug 2024) - first IVDR-certified MRD test for lymphoid malignancies in EU. First FDA-cleared NGS-based MRD test.",
    "fdaApprovalDate": "2018-09-28",
    "fdaStatusCitations": "https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer | https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-receives-expanded-fda-clearance",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Multiple Myeloma, ALL, CLL Guidelines",
    "nccnGuidelinesNotes": "NCCN Category 2A recommendation. NGS-based MRD assessment specifically named for MM (at each treatment stage), ALL, and CLL.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for MM, B-ALL, CLL, DLBCL, and MCL via MolDX program. Medicare CLFS rate: $2,007 per test (PLA 0364U); episode pricing $8,029 across all covered indications. Positive coverage from major commercial insurers for MM and ALL. 90% of patients pay $0 for testing.",
    "reimbursementCitations": "https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-clinical-lab-fee-schedule",
    "cptCodes": "0364U",
    "codeType": "PLA",
    "medicareRate": 2007,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "listPrice": 2007,
    "listPriceNotes": "Medicare CLFS rate $2,007 per test as of January 2025. Episode pricing (full testing series) $8,029.",
    "listPriceCitations": "https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-clinical-lab-fee-schedule",
    "clinicalAvailability": "Commercially available in US since 2018. Single-site assay performed at Adaptive Biotechnologies laboratory in Seattle, WA.",
    "clinicalAvailabilityCitations": "https://www.clonoseq.com/ordering-clonoseq/",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "US: FDA-cleared IVD via Seattle lab. EU: CE-marked, available via Roche and regional partners. International availability via MedGenome (India) and other distributors.",
    "clinicalTrials": "Validated in major phase III trials including ALCYONE (706 pts, transplant-ineligible NDMM), POLLUX (569 pts, R/R MM), MASTER (daratumumab-KRd MRD-guided discontinuation), DETERMINATION (RVd ± ASCT), multiple ALL and CLL studies. Used in 25 of 28 NCCN cancer centers.",
    "clinicalTrialsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/ | https://www.clonoseq.com/multiple-myeloma/",
    "totalParticipants": 5000,
    "totalParticipantsNotes": "Estimated >5,000 patients across published clinical validation studies. ALCYONE alone included 706 patients.",
    "totalParticipantsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/ | https://www.clonoseq.com/multiple-myeloma/",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Extensive peer-reviewed evidence including validation studies in MM, ALL, CLL, lymphomas. Clinical data incorporated into FDA drug approvals and NCCN guidelines.",
    "clinicalSettings": ["Neoadjuvant", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated across treatment phases for hematologic malignancies: during induction/consolidation therapy, after treatment completion, and long-term surveillance. NCCN recommends MRD assessment at each treatment stage in MM.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "FDA-cleared IVD for MM, B-ALL, CLL. Additionally available as CLIA-validated LDT for DLBCL, MCL, and other lymphoid malignancies. Only FDA-cleared MRD test for hematologic malignancies.",
    "technologyDifferentiator": "Hematologic MRD test using immunosequencing of B/T-cell receptor genes - fundamentally different from solid tumor ctDNA assays. First and only FDA-cleared MRD test. 10⁻⁶ sensitivity (100x more sensitive than flow cytometry). Quantitative results track disease burden over time, not just positive/negative. Blood-based testing available for CLL reduces need for bone marrow biopsies."
  },
  {
    "id": "mrd-20",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Same sample requirements as standard Signatera (two Streck tubes).",
    "name": "Signatera Genome",
    "vendor": "Natera",
    "approach": "Tumor-informed (WGS)",
    "method": "Whole-genome sequencing-informed tumor-informed ctDNA assay using mPCR-NGS. WGS identifies patient-specific variants, then 64 clonal variants are selected and tracked via multiplex PCR with ultra-deep sequencing (up to 350,000x coverage per variant). Same proven mPCR workflow as standard Signatera but with enhanced sensitivity.",
    "methodCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "cancerTypes": [
      "Breast cancer",
      "NSCLC",
      "Melanoma",
      "Renal cell carcinoma",
      "Colorectal cancer",
      "Multi-solid tumors"
    ],
    "targetPopulation": "Patients with solid tumors requiring ultrasensitive MRD detection, particularly those where standard Signatera sensitivity may be insufficient or where maximal lead time to recurrence is desired",
    "indicationsNotes": "Genome-scale version of Signatera offering enhanced sensitivity (1 ppm LOD) and increased lead time to recurrence. Uses WGS instead of WES for variant identification, enabling selection of optimal 64 clonal variants for tracking. Same Medicare coverage as standard Signatera for covered indications.",
    "sensitivity": 94,
    "sensitivityNotes": "94% longitudinal sensitivity for detecting distant, extracranial recurrence in pan-cancer validation cohort (392 patients, >2,600 plasma samples across breast, NSCLC, melanoma, RCC, and CRC).",
    "sensitivityCitations": "https://www.natera.com/oncology/signatera-mrd-test/genome/ | George M, et al. ASCO 2025 poster",
    "specificity": 100,
    "specificityNotes": "100% specificity for distant, extracranial recurrence detection in pan-cancer validation cohort (n=392 patients, >2,600 samples).",
    "specificityCitations": "https://www.natera.com/oncology/signatera-mrd-test/genome/ | George M, et al. ASCO 2025 poster",
    "validationCohortSize": 392,
    "validationCohortStudy": "Pan-cancer cohort ASCO 2025 (392 patients, >2,600 samples across 5 tumor types)",
    "lod": "1 ppm",
    "lod95": "1 ppm",
    "lod95Citations": "https://www.natera.com/oncology/signatera-genome/",
    "lodNotes": "Ultra-sensitive detection down to 1 part per million (1 ppm), representing ~100x improvement over standard WES-based Signatera. Achieved through tracking 64 variants (vs 16) with ultra-deep sequencing.",
    "lodCitations": "https://www.natera.com/oncology/signatera-genome/",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "Increased lead times to recurrence compared to standard Signatera due to enhanced sensitivity. ctDNA-positive patients had 36x higher risk of relapse than ctDNA-negative patients.",
    "leadTimeVsImagingCitations": "https://www.natera.com/oncology/signatera-mrd-test/genome/ | George M, et al. ASCO 2025 poster",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor tissue for whole-genome sequencing to identify patient-specific variants. Same sample requirements as standard Signatera.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Matched normal (blood) required for germline filtering.",
    "variantsTracked": "64",
    "variantsTrackedNotes": "64 highly curated clonal variants selected for optimized balance of ultra-sensitivity and high specificity (vs 16 variants in standard Signatera).",
    "variantsTrackedCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "initialTat": 28,
    "initialTatNotes": "Initial result in approximately 4 weeks (vs ~2 weeks for standard Signatera) due to WGS requirement.",
    "followUpTat": 7,
    "followUpTatNotes": "Subsequent monitoring results in 7-10 days, same as standard Signatera.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Same sample requirements as standard Signatera (two Streck tubes).",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory-developed test. Uses same Medicare coverage pathway as FDA-cleared Signatera for covered indications.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "vendorNCCNAlignmentNotes": "Vendor claims same NCCN alignment as standard Signatera. NCCN recommends ctDNA testing concepts but does not specifically name Signatera Genome by brand.",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colon Cancer, Rectal Cancer V.2.2025 (same as Signatera)",
    "nccnGuidelinesNotes": "Shares Signatera citations and validation data referenced in NCCN guidelines. Same ctDNA platform with expanded variant tracking.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Same Medicare coverage as standard Signatera for covered indications: Stage II-IV CRC, Stage IIb+ breast cancer, MIBC, Stage I-III NSCLC surveillance, Stage II-IV ovarian cancer, and ICI response monitoring for any solid tumor.",
    "reimbursementCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "cptCodes": "0239U",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "adltStatus": true,
    "listPrice": 3500,
    "listPriceNotes": "Expected same pricing as standard Signatera ($3,500 Medicare CLFS rate).",
    "clinicalAvailability": "Commercially available via Natera. Can only be ordered for new patients (cannot convert existing Signatera orders).",
    "clinicalAvailabilityCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "clinicalTrials": "Pan-cancer validation in 392 patients with breast, NSCLC, melanoma, RCC, and CRC across >2,600 plasma samples (ASCO 2025).",
    "clinicalTrialsCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3142",
    "totalParticipants": 392,
    "totalParticipantsNotes": "392 patients in initial pan-cancer validation cohort with >2,600 plasma samples analyzed.",
    "numPublications": 1,
    "numPublicationsNotes": "Initial clinical data presented at ASCO 2025. Backed by >100 publications for standard Signatera platform.",
    "clinicalSettings": ["Neoadjuvant", "Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Same clinical settings as standard Signatera with enhanced 1 ppm sensitivity. Validates across neoadjuvant, post-surgical, post-adjuvant, and surveillance settings in breast, NSCLC, melanoma, RCC, CRC.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-certified LDT leveraging Natera's established Signatera infrastructure. Uses proven mPCR-NGS workflow with WGS-informed variant selection for enhanced sensitivity.",
    "technologyDifferentiator": "WGS-informed evolution of Signatera tracking 64 variants (vs 16) at 1 ppm LOD (vs ~100 ppm). Ultra-deep sequencing up to 350,000x coverage per variant. Designed for cases requiring maximum sensitivity and lead time. Same trusted mPCR workflow backed by >1M Signatera tests."
  },
  {
    "id": "mrd-21",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Standard blood collection; specific volume not publicly disclosed.",
    "name": "Latitude",
    "vendor": "Natera",
    "approach": "Tumor-naïve (methylation)",
    "method": "Tissue-free, blood-based MRD test using targeted methylation panel composed of differentially methylated regions (DMRs) specifically designed for colorectal cancer. Does not require tumor tissue - analyzes cfDNA methylation patterns directly from blood.",
    "methodCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "CRC patients requiring MRD detection when tumor tissue is unavailable, insufficient, or when faster turnaround is needed",
    "indicationsNotes": "Tissue-free MRD test for colorectal cancer. Ideal for patients where tumor tissue is not available for Signatera. Uses methylation-based approach rather than somatic variant tracking. Currently CRC-only; expansion to other cancers expected.",
    "sensitivity": 81,
    "sensitivityNotes": "81% longitudinal sensitivity (84% for colon cancer specifically). 58% single time point sensitivity. Validated in CIRCULATE-JAPAN GALAXY Study.",
    "sensitivityCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/ | CIRCULATE-JAPAN GALAXY Study",
    "specificity": 97,
    "specificityNotes": "97% sample-level specificity in validation cohort.",
    "specificityCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "lod": "0.01% VAF",
    "lodCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "lodNotes": "Detection threshold approximately 0.01% VAF via methylation-based approach.",
    "leadTimeVsImaging": 4.6,
    "leadTimeVsImagingNotes": "4.6 months median lead time before radiographic relapse in validation study.",
    "leadTimeVsImagingCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tissue-free assay - does not require tumor tissue. Key differentiator from Signatera.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Methylation-based approach does not require matched normal for variant filtering.",
    "variantsTracked": null,
    "variantsTrackedNotes": "Uses methylation markers (DMRs) rather than somatic variants.",
    "initialTat": 7,
    "initialTatCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "initialTatNotes": "Fast turnaround time (~7 days) since no tumor sequencing required.",
    "followUpTat": 7,
    "followUpTatNotes": "Subsequent monitoring with same fast TAT as initial test.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Standard blood collection; specific volume not publicly disclosed.",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory-developed test. Not FDA cleared.",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Reimbursement status for Latitude specifically not yet established. May be covered under existing MRD codes for CRC.",
    "clinicalAvailability": "Commercially available via Natera for colorectal cancer patients",
    "clinicalAvailabilityCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "clinicalTrials": "Validated in CIRCULATE-JAPAN GALAXY Study: 195 CRC patients, 1,300+ plasma samples. Latitude-positive patients had HR=10 for DFS (p<0.001). Latitude-positive patients who did not receive ACT had 100% relapse rate (26/26 PPV).",
    "clinicalTrialsCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Tissue-free CRC MRD validated for post-surgical and post-adjuvant assessment, plus surveillance monitoring. GALAXY study showed HR=10 for recurrence in MRD+ patients.",
    "totalParticipants": 195,
    "totalParticipantsNotes": "195 patients in CIRCULATE-JAPAN GALAXY validation study with 1,300+ plasma samples.",
    "numPublications": 2,
    "numPublicationsNotes": "Validation data from CIRCULATE-JAPAN GALAXY Study. Part of Natera's extensive MRD publication portfolio.",
    "numPublicationsCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-certified LDT from Natera. Complements Signatera for cases where tumor tissue is unavailable.",
    "technologyDifferentiator": "Tissue-free MRD for CRC - no tumor tissue required. Uses methylation-based detection rather than somatic variant tracking. Enables MRD testing when tissue is unavailable, insufficient, or degraded. Part of Natera's comprehensive MRD portfolio alongside Signatera and Signatera Genome."
  },
  {
    "id": "mrd-22",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "20 mL whole blood required. 1-10 mL plasma used for cfDNA extraction.",
    "name": "CancerDetect",
    "vendor": "IMBdx",
    "approach": "Tumor-informed (hybrid)",
    "method": "Tumor-informed hybrid approach combining large-scale personalized mutation tracking (up to 300 patient-specific variants from tumor WES) with tumor-agnostic hotspot regions covering 58 clinically actionable mutations across 15 genes. Uses hybridization capture with UMI-based error suppression and ultra-deep sequencing (~100,000x). Proprietary HQS technology for false positive reduction.",
    "methodCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282 | https://www.nature.com/articles/s41416-023-02300-3",
    "cancerTypes": [
      "Colorectal cancer",
      "Breast cancer",
      "Gastric cancer"
    ],
    "targetPopulation": "Stage II-III solid tumor patients requiring MRD detection post-surgery, particularly CRC, breast, and gastric cancer",
    "indicationsNotes": "Korean-developed tumor-informed MRD test using large-scale mutation profiling strategy. Tracks median 185 variants per patient (up to 300). Designated as 'Innovative Medical Technology' by Korean Ministry of Health and Welfare (similar to FDA Breakthrough Device). Used in nationwide phase III interventional trial (NCT05534087) for MRD-guided treatment escalation.",
    "sensitivity": 61.9,
    "sensitivityNotes": "Clinical sensitivity 61.9% for predicting recurrence within 3 years at postoperative 3-week timepoint. In silico simulation shows increased sensitivity with more monitoring variants.",
    "sensitivityCitations": "https://www.nature.com/articles/s41416-023-02300-3",
    "specificity": 99.9,
    "specificityNotes": "99.9% analytical specificity for bespoke (personalized) regions. 95% specificity for hotspot regions. ⚠️ Analytical validation; clinical cohort n=98.",
    "specificityCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",
    "smallSampleWarning": true,
    "validationCohortSize": 98,
    "validationCohortStudy": "British Journal of Cancer 2023 (n=98 CRC patients)",
    "lod": "0.0005% VAF",
    "lod95": "0.001%",
    "lod95Citations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302129",
    "lodNotes": "Detection threshold ~0.0005% VAF (5 ppm) for bespoke regions; LOD95 of 0.001% (10 ppm). Limit of blank 0.0003% for bespoke regions. Achieved through large-scale mutation tracking combined with ultra-deep sequencing.",
    "lodCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302129",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "Postoperative MRD positivity strongly associated with recurrence (adjusted HR 8.40, 95% CI 3.49-20.2). Patients with MRD clearance after adjuvant therapy showed significantly better outcomes.",
    "leadTimeVsImagingCitations": "https://www.nature.com/articles/s41416-023-02300-3",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor tissue for whole-exome sequencing to identify patient-specific variants. Fresh frozen tissue preferred.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "PBMC sequencing used to filter germline variants and CHIP mutations from cfDNA results.",
    "variantsTracked": "Up to 300",
    "variantsTrackedNotes": "Median 185 variants tracked per patient (range 116-300). Large-scale mutation profiling strategy shown to improve sensitivity at low ctDNA fractions (<0.01%).",
    "variantsTrackedCitations": "https://www.nature.com/articles/s41416-023-02300-3",
    "initialTat": 28,
    "initialTatNotes": "Initial TAT 28 days (4 weeks). Reduced from previous 8-10 weeks in earlier version.",
    "followUpTat": 14,
    "followUpTatNotes": "Follow-up monitoring TAT 14 days (2 weeks).",
    "bloodVolume": "20 mL",
    "bloodVolumeNotes": "20 mL whole blood required. 1-10 mL plasma used for cfDNA extraction.",
    "bloodVolumeCitations": "https://www.imbdx.com/eng/about/detect.php",
    "cfdnaInput": "30 ng",
    "cfdnaInputCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",
    "fdaStatus": "Not FDA cleared",
    "fdaStatusNotes": "Korean 'Innovative Medical Technology' designation from Ministry of Health and Welfare (analogous to FDA Breakthrough Device Designation). Not FDA cleared for US market.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.cancerdetect.com/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Korean national health insurance coverage under Innovative Medical Technology pathway. Not available in US market.",
    "clinicalAvailability": "Commercially available in South Korea via IMBdx",
    "clinicalAvailabilityCitations": "https://www.imbdx.com/eng/",
    "availableRegions": ["South Korea"],
    "availableRegionsNotes": "Currently available in South Korea. International expansion potential.",
    "clinicalTrials": "Phase III interventional trial (NCT05534087) for MRD-guided treatment escalation in CRC. Validation studies in breast cancer (AACR 2025, SABCS 2023/2025) and gastric cancer (AACR 2025). Original CRC validation: 98 patients, Stage II-III, median 36.3 months follow-up.",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05534087 | https://www.nature.com/articles/s41416-023-02300-3",
    "totalParticipants": 98,
    "totalParticipantsNotes": "98 patients in primary CRC validation study. Phase III trial (NCT05534087) enrolling ~1,200 CRC patients.",
    "numPublications": 2,
    "numPublicationsNotes": "British Journal of Cancer 2023 (clinical validation), PLOS One 2025 (analytical validation). Multiple conference abstracts at AACR 2025, SABCS 2023/2025.",
    "numPublicationsCitations": "https://www.nature.com/articles/s41416-023-02300-3 | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for postoperative MRD assessment at 3 weeks (61.9% sens for recurrence) and after adjuvant therapy. MRD clearance post-adjuvant associated with better outcomes. Phase III interventional trial (NCT05534087) for MRD-guided treatment.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Commercially available in South Korea with Innovative Medical Technology designation. Previously known as AlphaLiquid®Detect.",
    "technologyDifferentiator": "Large-scale mutation tracking (up to 300 variants vs typical 16-50) combined with tumor-agnostic hotspot panel. Korean-developed with strong regulatory pathway. Ultra-sensitive detection (0.001% LOD) through expanded variant coverage rather than deeper sequencing alone. Hybrid approach enables detection of both original tumor mutations and de novo resistance mutations.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-29: Vendor verified by Sunghoon Heo (sunghoon.heo@imbdx.com), IMBdx. Updated bloodVolume to 20 mL, added cfdnaInput 30 ng per vendor with citations."
  },
  {
    "id": "mrd-23",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "20 mL blood in cfDNA tubes required for testing.",
    "name": "LymphoVista",
    "vendor": "LIQOMICS",
    "approach": "Tumor-informed (ctDNA sequencing)",
    "method": "Targeted ctDNA sequencing using duplex barcodes and disease-specific gene panels optimized for lymphomas. Incorporates non-coding regions with highly frequent genetic alterations. Two variants: LymphoVista (B-cell lymphomas, 83 kbp panel) and LymphoVista HL (Hodgkin lymphoma, modified panel). Two-step workflow: initial genotyping identifies patient-specific mutations, followed by serial MRD monitoring.",
    "methodCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://liqomics.com/en/lymphovista/",
    "cancerTypes": [
      "Diffuse large B-cell lymphoma (DLBCL)",
      "Follicular lymphoma",
      "Mantle cell lymphoma",
      "Marginal zone lymphoma",
      "Burkitt lymphoma",
      "CNS lymphomas",
      "Hodgkin lymphoma (via LymphoVista HL)"
    ],
    "cancerTypesNotes": "LymphoVista covers all B-cell lymphomas. LymphoVista HL uses a slightly modified gene panel specifically optimized for Hodgkin lymphoma genomics.",
    "cancerTypesCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping",
    "targetPopulation": "Patients with B-cell lymphomas or Hodgkin lymphoma requiring MRD assessment during treatment (e.g., after 2 cycles), post-treatment surveillance, or monitoring after CAR-T cell therapy or salvage chemotherapy.",
    "indicationsNotes": "Designed for both interim response assessment during active treatment AND post-treatment MRD monitoring. Validated in relapsed/refractory DLBCL patients post-CAR-T/chemo and in advanced-stage Hodgkin lymphoma (HD21 trial). Addresses lymphoma-specific MRD needs distinct from solid tumor ctDNA assays.",
    "sensitivity": 100,
    "sensitivityNotes": "At MRD level of 7.0×10⁻⁵: 100% sensitivity, 93% specificity, 94% accuracy (LymphoVista). ⚠️ Validation cohort n=160 (72 HL + 88 DLBCL). For variant detection (genotyping) at ≥0.5% mAF: 93.86% sensitivity / 99.999% specificity.",
    "sensitivityCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "smallSampleWarning": true,
    "validationCohortSize": 160,
    "validationCohortStudy": "HD21 trial (n=72 HL) + EHA 2024 DLBCL (n=88)",
    "specificity": 93,
    "specificityNotes": "93% specificity at MRD level of 7.0×10⁻⁵. For variant detection (genotyping): 99.999% specificity (LymphoVista) and 99.99% specificity (LymphoVista HL).",
    "specificityCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "ppv": 92.1,
    "ppvNotes": "92.1% PPV determined in relapsed/refractory DLBCL patients treated with various therapies including CAR-T cells and high-dose chemotherapy (Schleifenbaum et al. EHA 2024).",
    "ppvCitations": "https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "lod": "6.69 × 10⁻⁶",
    "lodNotes": "Limit of detection 6.69 × 10⁻⁶ (LymphoVista) and 6.54 × 10⁻⁶ (LymphoVista HL). 100% accuracy for MRD values >3.04 × 10⁻⁵ (LymphoVista) and >1.76 × 10⁻⁵ (LymphoVista HL). Duplex sequencing enables ultrasensitive detection.",
    "lodCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "MRD positivity after 2 cycles of treatment (MRD-2) strongly predictive of outcomes. In HD21 trial, MRD-2-positive patients had 72.2% vs 95.3% 4-year PFS (HR 6.9, p<0.0001). MRD status prognostic even in PET-2-negative patients, suggesting molecular assessment adds value beyond imaging.",
    "leadTimeVsImagingCitations": "Mattlener et al. ASH 2024",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Blood-based assay. Initial genotyping can use blood sample (ctDNA) or tissue if available. Does not require solid tumor biopsy.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Genotyping identifies lymphoma-specific mutations from ctDNA without requiring matched normal sequencing.",
    "initialTat": "10 days",
    "initialTatNotes": "Initial genotyping test to identify patient-specific mutations: 10 days.",
    "followUpTat": "10 days",
    "followUpTatNotes": "Serial MRD monitoring of known mutations: 10 days from sample receipt.",
    "bloodVolume": "20 mL",
    "bloodVolumeNotes": "20 mL blood in cfDNA tubes required for testing.",
    "sampleRequirements": "20 mL blood in cfDNA preservation tubes",
    "sampleRequirementsCitations": "https://liqomics.com/en/lymphovista/",
    "fdaStatus": "Not FDA-approved (EU/International LDT)",
    "fdaStatusNotes": "Laboratory-developed test offered from LIQOMICS laboratory in Cologne, Germany. CE marking status not specified. Primarily serves European market.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://lymphovista.com/",
    "vendorNCCNAlignmentNotes": "ctDNA testing for MRD in DLBCL recently added to NCCN Guidelines (December 2024) following Foresight CLARITY inclusion. LymphoVista not specifically named but methodology aligns with emerging guideline recommendations for ctDNA-based MRD in lymphoma.",
    "reimbursement": "Not established (EU)",
    "reimbursementNote": "Pricing: €2,965 for initial genotyping, €1,985 per MRD monitoring sample. Reimbursement varies by EU country and healthcare system. Not available in US market.",
    "reimbursementCitations": "https://liqomics.com/en/lymphovista/",
    "listPrice": 2965,
    "listPriceNotes": "€2,965 for initial genotyping test; €1,985 per subsequent MRD monitoring sample. Pricing in EUR.",
    "listPriceCitations": "https://liqomics.com/en/lymphovista/",
    "clinicalAvailability": "Commercially available in Europe via LIQOMICS laboratory (Cologne, Germany). Single-site assay.",
    "clinicalAvailabilityNotes": "Academic spin-off from University of Cologne, founded 2021. Strong ties to German Hodgkin Study Group (GHSG). Available for clinical use and research collaborations.",
    "clinicalAvailabilityCitations": "https://liqomics.com/en/about/",
    "availableRegions": ["EU", "Germany"],
    "availableRegionsNotes": "Primary market is Europe. Based in Cologne, Germany. International availability via direct ordering.",
    "clinicalTrials": "HD21 Phase III trial (Hodgkin lymphoma, BrECADD vs eBEACOPP, 72 patients in MRD validation subset); EHA 2024 DLBCL validation (88 patients, 326 samples, r/r setting including CAR-T); ISHL13 2024 presentations",
    "clinicalTrialsCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "totalParticipants": 160,
    "totalParticipantsNotes": "72 patients in HD21 Hodgkin lymphoma validation (ASH 2024); 88 patients in DLBCL validation (EHA 2024, 326 samples).",
    "numPublications": 2,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Key conference presentations: Mattlener et al. ASH 2024 (LymphoVista HL validation in Hodgkin lymphoma); Schleifenbaum et al. EHA 2024 (LymphoVista validation in DLBCL). Peer-reviewed manuscripts under review/in submission as of December 2025.",
    "numPublicationsCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping",
    "clinicalSettings": ["Neoadjuvant", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for interim response assessment (after 2 treatment cycles), post-treatment MRD assessment, and long-term surveillance. HD21 trial showed MRD-2 positivity prognostic even in PET-negative patients (HR 6.9 for PFS).",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "European LDT offered from CLIA-equivalent laboratory in Germany. Strong academic validation via GHSG HD21 trial data. Not FDA-approved; no current US market presence.",
    "technologyDifferentiator": "Lymphoma-specific ctDNA MRD test addressing an underserved niche - most competitors focus on solid tumors or use immunosequencing (clonoSEQ) for heme malignancies. Uses duplex sequencing with disease-optimized gene panels for lymphoma genomics. Founded by Sven Borchmann MD/PhD, a leading Hodgkin lymphoma researcher at University of Cologne/GHSG. Dual utility: both interim assessment during treatment and post-treatment MRD surveillance. Positioned as ctDNA alternative to PET for molecular response assessment in lymphoma.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-28: Vendor verified by Jens Winter (jens.winter@liqomics.com), LIQOMICS. No edits requested - all data confirmed accurate."
  },
  {
    "id": "mrd-24",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "20 mL blood in cfDNA preservation tubes required.",
    "name": "CancerVista",
    "vendor": "LIQOMICS",
    "approach": "Tumor-agnostic",
    "method": "Technically validated ctDNA assay for multi-solid tumor MRD detection. Optimized characteristic mutations across diverse solid tumors.",
    "cancerTypes": [
      "Bladder",
      "Brain",
      "Breast",
      "Cervix",
      "Colorectal",
      "Esophagus",
      "Head and neck",
      "Kidney",
      "Liver",
      "Lung",
      "Ovary",
      "Pancreas",
      "Prostate",
      "Skin",
      "Stomach",
      "Thyroid",
      "Uterus"
    ],
    "cancerTypesNotes": "Multi-solid tumor assay covering 17 anatomical sites including bladder, brain, breast, cervix, colorectal, esophagus, head and neck, kidney, liver, lung, ovary, pancreas, prostate, skin, stomach, thyroid, and uterus.",
    "indicationsNotes": "Technically validated assay for MRD detection across multiple solid tumor types. Gene spectrum optimized for characteristic mutations of diverse solid tumors.",
    "sensitivity": 80,
    "sensitivityNotes": "MRD Detection: 80% sensitivity at detection threshold of 2.5×10⁻⁵ for MRD levels >5.1×10⁻⁵. Variant Detection: 93.17% sensitivity for variants with minor allele frequency (mAF) ≥1%.",
    "sensitivityCitations": "https://liqomics.com/en/cancervista/ | Vendor data (Jens Winter, LIQOMICS, Dec 2025)",
    "specificity": 96.7,
    "specificityNotes": "MRD Detection: 96.7% specificity at detection threshold of 2.5×10⁻⁵. Variant Detection: >99% specificity for variants with mAF ≥1%.",
    "specificityCitations": "https://liqomics.com/en/cancervista/ | Vendor data (Jens Winter, LIQOMICS, Dec 2025)",
    "accuracy": 94.3,
    "accuracyNotes": "94.3% accuracy for MRD levels >5.1×10⁻⁵ at detection threshold of 2.5×10⁻⁵.",
    "lod": "3.30 × 10⁻⁶",
    "lodNotes": "Limit of detection 3.30×10⁻⁶. Detection threshold set at 2.5×10⁻⁵ for clinical reporting.",
    "lodCitations": "https://liqomics.com/en/cancervista/ | Vendor data (Jens Winter, LIQOMICS, Dec 2025)",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tumor-agnostic blood-based assay; does not require prior tumor tissue.",
    "requiresMatchedNormal": "No",
    "initialTat": "10 days",
    "initialTatNotes": "10 days from sample receipt to result.",
    "followUpTat": "10 days",
    "followUpTatNotes": "10 days for follow-up monitoring samples.",
    "bloodVolume": "20 mL",
    "bloodVolumeNotes": "20 mL blood in cfDNA preservation tubes required.",
    "sampleRequirements": "20 mL blood in cfDNA tubes",
    "fdaStatus": "Not FDA-approved (EU/International LDT)",
    "fdaStatusNotes": "Technically validated assay offered from LIQOMICS laboratory in Cologne, Germany. Primarily serves European market.",
    "reimbursement": "Not established (EU)",
    "reimbursementNote": "Reimbursement varies by EU country and healthcare system. Not available in US market.",
    "clinicalAvailability": "Commercially available in Europe via LIQOMICS laboratory (Cologne, Germany).",
    "clinicalAvailabilityNotes": "Academic spin-off from University of Cologne, founded 2021. Available for clinical use.",
    "clinicalAvailabilityCitations": "https://liqomics.com/",
    "availableRegions": ["EU", "Germany"],
    "availableRegionsNotes": "Primary market is Europe. Based in Cologne, Germany.",
    "clinicalTrials": null,
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Technically validated for MRD detection; clinical utility studies ongoing.",
    "numPublications": 1,
    "numPublicationsNotes": "Analytical validation complete; peer-reviewed publications pending. Conference presentations at LIQOMICS scientific meetings.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Technically validated assay. European LDT offered from LIQOMICS laboratory in Germany.",
    "technologyDifferentiator": "Multi-solid tumor MRD assay from LIQOMICS (same vendor as lymphoma-focused LymphoVista). Ultra-sensitive detection with LoD of 3.30×10⁻⁶. Covers 17 anatomical sites with optimized mutation panels for diverse solid tumors.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-15: Initial entry created based on specifications provided by Jens Winter (LIQOMICS). Includes analytical validation data for variant detection and MRD detection performance. 2025-12-28: Vendor verified by Jens Winter (jens.winter@liqomics.com), LIQOMICS. No edits requested - all data confirmed accurate."
  },
  {
    "id": "mrd-25",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 16,
    "sampleVolumeMin": 16,
    "sampleTubeType": "Cell-Free DNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": ">16ml blood volume required per vendor.",
    "sampleCitations": "https://www.brbiotech.com/",
    "name": "CanCatch Custom",
    "vendor": "Burning Rock Dx (brbiotech)",
    "approach": "Tumor-informed",
    "method": "Tumor-informed personalized MRD assay (also known as PROPHET - Patient-specific pROgnostic and Potential tHErapeutic marker Tracking). WES of tumor and matched normal identifies up to 50 patient-specific variants, which are tracked at 100,000x ultra-deep sequencing in plasma.",
    "methodCitations": "https://doi.org/10.1016/j.ccell.2023.08.010 | https://pubmed.ncbi.nlm.nih.gov/37683638/",
    "cancerTypes": [
      "NSCLC",
      "Colorectal",
      "Esophageal",
      "GIST"
    ],
    "cancerTypesNotes": "Clinical data published in NSCLC (Cancer Cell 2023), esophageal squamous cell carcinoma (Molecular Cancer 2025), colorectal cancer, and gastrointestinal stromal tumors (ASCO 2025).",
    "indicationsNotes": "Tumor-informed personalized MRD assay from Burning Rock Dx (NASDAQ: BNR). Tracks up to 50 patient-specific variants identified from tumor/normal WES. Commercial trade name is CanCatch Custom; also referred to as PROPHET in academic publications.",
    "sensitivity": 98.7,
    "sensitivityCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "sensitivityNotes": "98.7% sensitivity reported by vendor. In MEDAL NSCLC study (n=181), preoperative ctDNA detection rates were: Stage IA 15.7%, IB 40%, II 75%, III 82.6%. Landmark sensitivity (3-30 days post-surgery) was 45%.",
    "sensitivityStagesReported": "IA: 15.7%, IB: 40%, II: 75%, III: 82.6% (preoperative)",
    "stageIISensitivity": 75,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37683638/ | Chen et al. Cancer Cell 2023",
    "stageIISensitivityNotes": "75% preoperative detection rate in Stage II NSCLC patients (Chen et al., Cancer Cell 2023).",
    "stageIIISensitivity": 82.6,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37683638/ | Chen et al. Cancer Cell 2023",
    "stageIIISensitivityNotes": "82.6% preoperative detection rate in Stage III NSCLC patients (Chen et al., Cancer Cell 2023).",
    "landmarkSensitivity": 45,
    "landmarkSensitivityNotes": "45% sensitivity at landmark timepoint (3-30 days post-surgery) in NSCLC cohort.",
    "landmarkSensitivityCitations": "https://doi.org/10.1016/j.ccell.2023.08.010",
    "specificity": 99,
    "specificityPlus": true,
    "specificityCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "specificityNotes": ">99.0% specificity reported by vendor.",
    "validationCohortSize": 181,
    "validationCohortStudy": "MEDAL study (NCT03634826) - 181 patients, 760 plasma samples",
    "lod": "0.004%",
    "lod95": "0.004%",
    "lodCitations": "https://doi.org/10.1016/j.ccell.2023.08.010 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "lodNotes": "LoD as low as 0.004% (4 ppm) per vendor. Analytical validation using Seracare ctDNA MRD Panel Mix confirmed similar performance.",
    "leadTimeVsImaging": 299,
    "leadTimeVsImagingCitations": "https://doi.org/10.1016/j.ccell.2023.08.010",
    "leadTimeVsImagingNotes": "Median lead time of 299 days (~10 months) to radiologically confirmed recurrence in NSCLC cohort (Chen et al., Cancer Cell 2023).",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor tissue for WES-based personalized panel design.",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "50",
    "variantsTrackedNotes": "Up to 50 highly ranked patient-specific markers selected from tumor/normal WES. Panel designed to cover selected markers with 100,000x ultra-deep sequencing.",
    "initialTat": 14,
    "initialTatNotes": "14 days TAT per vendor.",
    "followUpTat": 14,
    "followUpTatNotes": "14 days TAT for monitoring samples per vendor.",
    "tat": 14,
    "tatNotes": "14 days turnaround time per vendor submission.",
    "listPrice": "$4,000",
    "listPriceNotes": "List price $4,000 (may vary depending on test package) per vendor.",
    "fdaStatus": "Not FDA-approved (China/International LDT)",
    "fdaStatusNotes": "Offered as laboratory service from Burning Rock Dx laboratory in Guangzhou, China. Not available in US market.",
    "reimbursement": "Not established (China/International)",
    "reimbursementNote": "Primarily serves Chinese and international markets. US reimbursement not applicable.",
    "clinicalAvailability": "Commercially available in China and international markets via Burning Rock Dx laboratory.",
    "clinicalAvailabilityNotes": "Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) is headquartered in Guangzhou, China.",
    "clinicalAvailabilityCitations": "https://www.brbiotech.com/ | https://ir.brbiotech.com/",
    "availableRegions": ["China", "International"],
    "availableRegionsNotes": "Primary market is China. International availability through central laboratory services.",
    "clinicalTrials": "NCT03634826 (MEDAL study); NCT05213312; NCT03937362; NCT06143644; NCT05244213; NCT05024266",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT03634826 | https://doi.org/10.1016/j.ccell.2023.08.010 | https://pubmed.ncbi.nlm.nih.gov/40375301/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11293361/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11163755/",
    "clinicalSettings": ["Post-Surgery", "Surveillance", "Neoadjuvant Response"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD detection, longitudinal surveillance, and assessment of neoadjuvant therapy response. OSCC study showed utility in guiding adjuvant immunotherapy decisions.",
    "bloodVolume": ">16",
    "bloodVolumeNotes": ">16ml blood volume required per vendor.",
    "totalParticipants": 871,
    "numPublications": 8,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/37683638/ | https://doi.org/10.1016/j.ccell.2023.08.010 | https://pubmed.ncbi.nlm.nih.gov/40375301/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12490249/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11293361/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11163755/",
    "numPublicationsNotes": "8 publications including: Chen et al., Cancer Cell 2023; Molecular Cancer (OSCC, 2025); and ASCO/AACR conference presentations.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Clinical LDT offered from Burning Rock laboratory in China. Not FDA-approved; primarily serves Chinese and international markets.",
    "technologyDifferentiator": "Personalized tumor-informed MRD assay from leading Chinese NGS company. 100,000x ultra-deep sequencing with LoD of 0.004%. Demonstrated 299-day median lead time vs imaging in NSCLC. Head-to-head comparisons show superior performance vs tumor-agnostic and tumor-informed fixed-panel assays.",
    "vendorRequestedChanges": "2025-12-22: Initial entry created based on vendor submission from Liankai Chi (Burning Rock Dx). Performance metrics from submission and Cancer Cell 2023 publication (Chen et al., PMID 37683638). | 2025-12-24: Vendor validation with edits - updated clinicalTrials (+5 NCTs), numPublications (3→8), totalParticipants (181→871), added bloodVolume (>16ml)."
  },
  // ============================================
  // INSERT NEW MRD TEST HERE (above this line, before IVD KITS)
  // ============================================
  // IVD KITS - Laboratory kits (not central lab services)
  // ============================================
  {
    "id": "mrd-kit-1",
    "sampleCategory": "Bone Marrow/Blood",
    "sampleCollectionNotes": "Primarily bone marrow; peripheral blood accepted for CLL",
    "name": "clonoSEQ Assay",
    "vendor": "Adaptive Biotechnologies",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina MiSeqDx",
    "approach": "Tumor-informed",
    "method": "NGS-based immunosequencing of IgH/IgK/TCR rearrangements; tracks patient-specific clonotype from diagnosis sample",
    "cancerTypes": [
      "Multiple Myeloma",
      "B-ALL",
      "CLL",
      "Mantle Cell Lymphoma"
    ],
    "indicationsNotes": "First and only FDA-cleared IVD for MRD detection. Indicated for hematologic malignancies only. CE-IVDR certified in EU.",
    "distributionNotes": "US: Primarily central lab service (send-out to Adaptive). EU: IVDR-certified reagent kit available for tech transfer to qualified laboratories.",
    "sensitivity": 95,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "sensitivityNotes": "Detects MRD at 10^-6 sensitivity in bone marrow samples. FDA-cleared analytical sensitivity. Concordance with flow cytometry 97.4% for ALL and 97.9% for MM.",
    "specificity": 99,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "lod": "1 cell in 1 million",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf",
    "lod95": "10^-6",
    "lod95Citations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "lodNotes": "Ultra-sensitive detection using immunosequencing of clonal rearrangements; depth limited by cell input.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires diagnostic sample to identify patient-specific clonotype for tracking",
    "requiresMatchedNormal": "No",
    "initialTat": 7,
    "followUpTat": 7,
    "bloodVolume": null,
    "bloodVolumeNotes": "Primarily bone marrow; peripheral blood accepted for CLL",
    "fdaStatus": "FDA-cleared IVD (2018); CE-IVDR (2024)",
    "reimbursement": "Medicare LCD (MolDX); expanded coverage for MM, B-ALL, CLL, MCL",
    "cptCodes": "0364U",
    "clinicalAvailability": "FDA-cleared IVD kit; also available as central lab service",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "clinicalSettings": ["Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Primarily used for post-treatment response assessment and ongoing surveillance in hematologic malignancies. Supported by NCCN guidelines for MM, ALL.",
    "technologyDifferentiator": "Only FDA-cleared MRD IVD kit. Unique immunosequencing approach tracks clonal Ig/TCR rearrangements rather than somatic mutations. Available as distributed IVD kit for labs with MiSeqDx, enabling in-house testing."
  },
  {
    "id": "mrd-kit-2",
    "sampleCategory": "Bone Marrow/Blood",
    "name": "LymphoTrack Dx IGH Assay",
    "vendor": "Invivoscribe",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina MiSeq",
    "approach": "Tumor-informed",
    "method": "NGS-based B-cell clonality and MRD tracking via IGH gene rearrangements",
    "cancerTypes": [
      "B-cell lymphomas",
      "CLL",
      "B-ALL"
    ],
    "indicationsNotes": "CE-IVDR marked for B-cell clonality assessment and MRD tracking in B-cell malignancies. Part of LymphoTrack portfolio including IGK and TRG assays.",
    "sensitivity": 98,
    "sensitivityCitations": "https://www.invivoscribe.com/products/lymphotrack-dx-igh-assay-miseq",
    "sensitivityNotes": "98% detection rate for clonal IGH rearrangements vs PCR GeneScan/Sanger sequencing; MRD sensitivity up to 10^-6 with sufficient DNA input",
    "specificity": 99,
    "specificityCitations": "https://www.invivoscribe.com/products/lymphotrack-dx-igh-assay-miseq",
    "specificityNotes": ">99% specificity for clonality detection per NGS validation studies",
    "lod": "10^-4 to 10^-6",
    "lodCitations": "https://www.invivoscribe.com/products/lymphotrack-dx-igh-assay-miseq",
    "lodNotes": "Sensitivity depends on DNA input and sequencing depth; can achieve 1 in 1 million with optimized protocols",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires diagnostic sample to identify clonal IGH rearrangement",
    "requiresMatchedNormal": "No",
    "initialTat": 5,
    "followUpTat": 3,
    "fdaStatus": "CE-IVDR; FDA clearance pending",
    "reimbursement": "Coverage varies; often reimbursed as clonality assay",
    "clinicalAvailability": "CE-IVD kit; RUO in US",
    "totalParticipants": 5000,
    "numPublications": 30,
    "clinicalSettings": ["Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Used for both initial clonality assessment and longitudinal MRD monitoring in B-cell malignancies.",
    "technologyDifferentiator": "CE-IVDR distributed kit enabling in-house NGS-based MRD. Works with MiSeq platform already common in molecular labs. Includes MyInformatics software for MRD trending."
  },
  {
    "id": "mrd-kit-3",
    "sampleCategory": "Bone Marrow",
    "name": "BD OneFlow B-ALL MRD Kit",
    "vendor": "BD Biosciences",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "BD FACSLyric Flow Cytometer",
    "approach": "Tumor-naïve",
    "method": "Multiparameter flow cytometry (Next Generation Flow); 8-color standardized panel for B-ALL MRD",
    "cancerTypes": [
      "B-ALL"
    ],
    "indicationsNotes": "CE-IVDR marked standardized flow cytometry MRD kit for B-cell ALL. Part of EuroFlow consortium standardization.",
    "sensitivity": 96,
    "sensitivityCitations": "https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-oneflow-b-all-mrd-kit",
    "sensitivityNotes": "96% sensitivity for MRD detection at 10^-4 threshold (EuroFlow standardized protocols); sensitivity of 10^-4 to 10^-5 depending on cell events acquired",
    "specificity": 95,
    "specificityCitations": "https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-oneflow-b-all-mrd-kit",
    "specificityNotes": "95% specificity vs final clinical diagnosis in validation studies",
    "lod": "10^-4 to 10^-5",
    "lodCitations": "https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-oneflow-b-all-mrd-kit",
    "lodNotes": "Flow cytometry sensitivity depends on number of events; typically 10^-4 with 1 million cells",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tumor-naïve approach - no prior sample needed",
    "requiresMatchedNormal": "No",
    "initialTat": 1,
    "followUpTat": 1,
    "fdaStatus": "CE-IVDR; not FDA-cleared",
    "reimbursement": "Coverage as flow cytometry MRD",
    "clinicalAvailability": "CE-IVD kit",
    "totalParticipants": 10000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "clinicalSettings": ["Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Same-day results enable rapid treatment decisions. Standard of care for MRD monitoring in many European centers.",
    "technologyDifferentiator": "Flow cytometry provides same-day results vs. 5-7 days for NGS. Standardized EuroFlow panels ensure reproducibility across labs. No prior sample needed (tumor-naïve). Different modality than NGS - may be complementary."
  },
  {
    "id": "mrd-26",
    "sampleCategory": "Blood/Plasma",
    "name": "MRDVision",
    "vendor": "Inocras",
    "category": "MRD",
    "dateAdded": "Jan 7, 2026",
    "approach": "Tumor-informed",
    "method": "Whole-genome cfDNA monitoring using patient-specific tumor signatures from CancerVision WGS profiling; leverages Ultima Genomics ppmSeq duplex sequencing for ultra-low error rates",
    "methodCitations": "https://www.genomeweb.com/cancer/ultima-genomics-makes-inroads-blood-based-mrd-testing | https://www.silicon.co.uk/press-release/inocras-unveils-new-mrdvision-data-demonstrating-industry-leading-sensitivity-in-head-to-head-clinical-study-against-leading-mrd-ngs-assay",
    "cancerTypes": ["Multi-solid tumor"],
    "cancerTypesNotes": "Validated in ovarian and lung cancer post-surgical cohorts; applicable to any solid tumor profiled with CancerVision",
    "sensitivity": 94,
    "sensitivityNotes": "Detected tumor-derived signals in 6% of cases missed by leading MRD assay in head-to-head clinical study; high concordance with orthogonal methods",
    "sensitivityCitations": "https://www.silicon.co.uk/press-release/inocras-unveils-new-mrdvision-data-demonstrating-industry-leading-sensitivity-in-head-to-head-clinical-study-against-leading-mrd-ngs-assay",
    "specificity": 99,
    "specificityNotes": "High specificity maintained via panel-free whole-genome approach with tumor-normal paired analysis",
    "specificityCitations": "https://inocras.com/mrdvision/",
    "lod": "1 ppm",
    "lodNotes": "Simulated limit of detection of 1 part per million (0.0001% VAF) using high-TMB tumors at 100x plasma sequencing depth; industry-leading sensitivity enabled by ppmSeq duplex sequencing",
    "lodCitations": "https://www.genomeweb.com/cancer/ultima-genomics-makes-inroads-blood-based-mrd-testing",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires prior CancerVision WGS tumor profiling to generate personalized mutation signature",
    "requiresMatchedNormal": "Yes",
    "initialTat": 14,
    "followUpTat": 7,
    "tatNotes": "Initial test includes CancerVision tumor profiling; follow-up MRD monitoring faster",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA-validated clinical test (April 2025); previously RUO. CAP-certified laboratory.",
    "fdaStatusCitations": "https://www.silicon.co.uk/press-release/inocras-unveils-new-mrdvision-data-demonstrating-industry-leading-sensitivity-in-head-to-head-clinical-study-against-leading-mrd-ngs-assay",
    "reimbursement": "Coverage emerging",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityNotes": "Partnership with ChiMei Medical Center (Taiwan) for international expansion",
    "totalParticipants": 100,
    "totalParticipantsNotes": "Clinical validation in post-surgical ovarian and lung cancer patients",
    "numPublications": 1,
    "numPublicationsNotes": "Clinical validation presented at AACR Annual Meeting (April 2025)",
    "clinicalSettings": ["Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Designed for tracking cancer recurrence and treatment response in post-surgical patients",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-validated LDT as of April 2025",
    "vendorVerified": true,
    "technologyDifferentiator": "Panel-free WGS approach preserves whole-genome tumor insights without compressing to limited gene panel; ppmSeq duplex sequencing achieves 1 ppm LOD vs typical 10-100 ppm for other assays; streamlined workflow without patient-specific panel creation",
    "submissionInfo": {
      "submittedBy": "Sandra Balladares",
      "submitterEmail": "sballadares@inocras.com",
      "submitterType": "vendor",
      "submittedDate": "2026-01-06",
      "vendorVerifiedDate": "2026-01-06",
      "vendorVerifiedBy": "Sandra Balladares"
    }
  }
];

// ECD Tests
export const ecdTestData = [
  {
    "id": "ecd-1",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 40,
    "sampleVolumeMin": 2,
    "sampleTubeType": "Guardant cfDNA BCT",
    "sampleTubeCount": 4,
    "sampleCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/shield-p230009 | https://shieldcancerscreen.com/",
    "name": "Shield",
    "vendor": "Guardant Health",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA screening (plasma)",
    "method": "NGS detecting cfDNA methylation patterns + fragmentomics + somatic mutations (~1Mb genome coverage)",
    "cancerTypes": [
      "Colorectal cancer (colon and rectal)"
    ],
    "targetPopulation": "Average-risk adults 45-84 years without prior CRC; adenomas; IBD; or hereditary CRC syndromes",
    "indicationGroup": "CRC",
    "sensitivity": 83.1,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "advancedAdenomaSensitivity": 13.2,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "advancedAdenomaSensitivityNotes": "Limited sensitivity for precancerous advanced adenomas (13.2%); blood-based tests generally less effective at detecting polyps than stool-based tests.",
    "stageISensitivity": 54.5,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "stageIISensitivity": 100.0,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "stageIIISensitivity": 100.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "stageIVSensitivity": 100.0,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "specificity": 89.6,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "ppv": 3.1,
    "ppvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf | https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "ppvDefinition": "PPV 3.10% for colorectal cancer (CRC) at age-adjusted 0.42% prevalence in ECLIPSE average-risk screening population (FDA SSED Table 16)",
    "npv": 99.92,
    "npvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf | https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "npvDefinition": "NPV 99.92% for absence of CRC at age-adjusted prevalence in ECLIPSE average-risk screening population (FDA SSED Table 16)",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "performanceNotes": "In ECLIPSE cfDNA blood test showed 83% sensitivity for CRC with 90% specificity. Stage I sensitivity 55-65%; limited detection of advanced adenomas (13.2%).",
    "leadTimeNotes": "No formal lead-time vs colonoscopy; positioned as guideline-accepted primary screening option every 3 years in average-risk adults",
    "fdaStatus": "FDA-approved PMA (P230009) July 26 2024 - First blood test for primary CRC screening",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage per NCD 210.3; commercial coverage expanding",
    "commercialPayers": [],
    "commercialPayersCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Healths-Shield-Blood-Test-Now-Covered-for-VA-Community-Care-Beneficiaries/default.aspx",
    "commercialPayersNotes": "No commercial payer coverage yet. Government programs: VA Community Care Network covers Shield with no copay for average-risk individuals 45+; TRICARE also covers. Commercial insurance coverage pending USPSTF guideline inclusion and ACS recommendations. Once included in guidelines, expected to be covered under ACA preventive services.",
    "availableRegions": ["US"],
    "clinicalAvailability": "Commercially available in US since August 2024",
    "tat": "~14 days",
    "tatCitations": "https://www.stocktitan.net/news/GH/shield-crc-blood-test-demonstrates-adherence-of-95-in-new-study-of-tchgb4rvn3op.html",
    "tatNotes": "Median test turnaround time of 15 days from blood sample receipt to results report in real-world study of 20,000 patients.",
    "sampleType": "Whole blood in Guardant cfDNA BCT tubes",
    "sampleVolume": "4 tubes (minimum 2 mL plasma)",
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "0537U",
    "codeType": "PLA",
    "medicareRate": 1495,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "listPrice": 895.0,
    "listPriceCitations": "https://www.cnn.com/2024/07/29/health/fda-colorectal-cancer-screening-blood-test | https://www.aafp.org/pubs/afp/issues/2023/0600/diagnostic-tests-guardant-health-shield-colon-cancer.html",
    "screeningInterval": "Every 3 years",
    "clinicalTrials": "NCT04136002 ECLIPSE CRC screening study (22877); NCT05716477 OSU Guardant Shield CRC Screening Project (300)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04136002 | https://clinicaltrials.gov/study/NCT05716477",
    "totalParticipants": 23177,
    "totalParticipantsCitations": "https://clinicaltrials.gov/study/NCT04136002 | https://clinicaltrials.gov/study/NCT05716477",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colorectal Cancer Screening V.1.2025 (June 2025)",
    "nccnGuidelinesNotes": "Added to NCCN CRC Screening Guidelines in June 2025 as an acceptable screening option for average-risk adults with 3-year screening interval recommendation. First blood-based test included in NCCN CRC screening guidelines."
  },
  {
    "id": "ecd-2",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCitations": "https://www.galleri.com/patient/faqs | https://grail.com/wp-content/uploads/2022/05/GRAIL-OUS-4-tube-Standard-Kit-Specimen-Collection-Instructions.pdf",
    "name": "Galleri",
    "vendor": "GRAIL",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Tumor-naïve cfDNA methylation profiling with targeted NGS + machine-learning classifier; predicts cancer signal and tissue of origin (CSO)",
    "cancerTypes": [
      "50+ cancer types including colorectal, lung, pancreas, ovary, liver, head & neck, lymphoma, esophagus, stomach, bile duct, etc."
    ],
    "targetPopulation": "Asymptomatic adults ≥50 years as adjunct to standard single-cancer screening",
    "indicationGroup": "MCED",
    "sensitivity": 51.5,
    "sensitivityCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/",
    "stageISensitivity": 16.8,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "stageIISensitivity": 40.4,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "stageIIISensitivity": 77.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "stageIVSensitivity": 90.1,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "specificity": 99.5,
    "specificityCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/",
    "ppv": 61.6,
    "ppvCitations": "https://www.galleri.com/hcp/galleri-test-performance",
    "ppvDefinition": "PPV for any cancer among participants with Cancer Signal Detected",
    "npv": 99.1,
    "npvCitations": "https://www.galleri.com/hcp/galleri-test-performance",
    "npvDefinition": "NPV for remaining cancer-free after No Cancer Signal Detected (12-month follow-up)",
    "tumorOriginAccuracy": 93,
    "tumorOriginAccuracyNotes": "Cancer Signal Origin (CSO) prediction accuracy: 93% top-1 prediction, 97% top-2 predictions in CCGA validation studies",
    "performanceCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/ | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/ | PATHFINDER-2 ESMO 2025",
    "performanceNotes": "Overall cancer signal sensitivity ~51.5% with stage-specific sensitivity rising from ~17% at stage I to ~90% at stage IV; specificity ~99.5-99.6%. PATHFINDER-2 (Oct 2025, n=23,000+): Galleri detected cancers ~7× more often than USPSTF A/B standard screening; ~62% of positive tests (Cancer Signal Detected) confirmed as cancer in follow-up, substantially higher PPV than earlier versions.",
    "leadTimeNotes": "PATHFINDER and PATHFINDER 2 show ~7-fold increase in cancers detected when added to USPSTF A/B screening; median diagnostic resolution ~1.5 months",
    "fdaStatus": "LDT performed in CLIA-certified CAP-accredited lab; not FDA-approved; Breakthrough Device designation; PMA submission expected H1 2026",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Generally self-pay; most insurers and Medicare do not cover MCED as of 2025; TRICARE covers for ≥50 with elevated risk. REACH study: Medicare covers Galleri test and related workup for enrolled REACH participants (coverage of research, not general NCD).",
    "reimbursementCitations": "https://grail.com/press-releases/grail-announces-first-participant-enrolled-in-reach-study-evaluating-clinical-impact-of-galleri-multi-cancer-early-detection-mced-test-in-the-medicare-population/",
    "commercialPayers": ["Curative Insurance", "Fountain Health", "Alignment Health Plan"],
    "commercialPayersCitations": "https://grail.com/press-releases/curative-insurance-company-adds-grails-galleri-test-to-member-benefits-for-multi-cancer-early-detection/",
    "commercialPayersNotes": "Limited commercial coverage. Curative Insurance and Fountain Health offer $0 copay coverage. Alignment Health Plan (Medicare Advantage) covers in select CA/NC plans. Government programs: TRICARE covers with prior authorization for eligible beneficiaries ≥50. Most major commercial insurers consider investigational.",
    "availableRegions": ["US", "UK"],
    "clinicalAvailability": "Commercially available in US and some international markets as CLIA test since June 2021",
    "tat": "10-14 business days (up to 4 weeks during high volume)",
    "tatCitations": "https://www.galleri.com/lab-info | https://www.galleri.com/patient/faqs",
    "tatNotes": "Typically about 2 weeks from sample receipt; occasionally up to 4 weeks during high volume periods.",
    "sampleType": "Whole blood in Streck cfDNA BCT tubes",
    "sampleVolume": "2 tubes",
    "sampleStability": "7 days at ambient temperature (1-40°C); do not refrigerate/freeze",
    "cptCode": "Proprietary",
    "listPrice": 949.0,
    "listPriceCitations": "https://www.galleri.com/hcp/faqs",
    "screeningInterval": "Annual recommended",
    "clinicalTrials": "NCT05611632 NHS-Galleri randomized screening trial (~140000); NCT05155605 PATHFINDER 2 safety/performance study (~23000+, results Oct 2025); NCT03934866 SUMMIT high-risk lung cohort (13035); REACH study (Medicare coverage of research)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05611632 | https://clinicaltrials.gov/study/NCT05155605 | https://clinicaltrials.gov/study/NCT03934866 | https://grail.com/press-releases/grail-pathfinder-2-results-show-galleri-multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings/",
    "totalParticipants": 188535,
    "totalParticipantsCitations": "https://clinicaltrials.gov/study/NCT05611632 | https://clinicaltrials.gov/study/NCT05155605 | https://clinicaltrials.gov/study/NCT03934866",
    "numPublications": 20,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-3",
    "sampleCategory": "Stool",
    "name": "Cologuard Plus",
    "vendor": "Exact Sciences",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool-based multitarget DNA test",
    "method": "Multitarget stool DNA assay with 5 novel methylation markers + hemoglobin immunoassay; streamlined from original 11 markers",
    "cancerTypes": [
      "Colorectal cancer; Advanced precancerous lesions (APL); High-grade dysplasia"
    ],
    "targetPopulation": "Average-risk adults 45-75 years for CRC screening at home",
    "indicationGroup": "CRC",
    "sensitivity": 93.9,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",
    "advancedAdenomaSensitivity": 43.4,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "advancedAdenomaSensitivityNotes": "43% sensitivity for advanced precancerous lesions (APL) including advanced adenomas and sessile serrated lesions ≥1cm; significantly outperforms FIT (23% for APL).",
    "stageISensitivity": 87.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIISensitivity": 94.0,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIIISensitivity": 97.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIVSensitivity": 100.0,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "specificity": 91.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",
    "ppv": 3.2,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "ppvDefinition": "PPV for colorectal cancer (CRC) in BLUE-C average-risk screening population",
    "npv": 99.98,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "npvDefinition": "NPV for absence of CRC in BLUE-C average-risk screening population",
    "performanceCitations": "BLUE-C pivotal trial NEJM 2024 (n=20000+); DeeP-C studies; FDA PMA labeling 2024",
    "performanceNotes": "Pivotal BLUE-C trial: 94% sensitivity for CRC and 43% for APL; significantly outperforms FIT (94% vs 67% for CRC; 43% vs 23% for APL). FDA-approved label (Oct 2024) and March 2025 launch materials emphasize **95% CRC sensitivity at 94% specificity** in the U.S. screening population, with ~40% fewer false positives vs original Cologuard.",
    "leadTimeNotes": "Non-invasive alternative to colonoscopy; 30% lower false positive rate vs original Cologuard; significantly improved adherence vs colonoscopy",
    "fdaStatus": "FDA-approved PMA October 4 2024",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage; $0 out-of-pocket for eligible; broad commercial payer coverage",
    "commercialPayers": ["Humana"],
    "commercialPayersCitations": "https://www.cologuard.com/insurance",
    "commercialPayersNotes": "Cologuard Plus confirmed coverage: Medicare Part B and Humana Medicare Advantage. Government programs: TRICARE expected based on legacy Cologuard coverage. Other major commercial payers (UnitedHealthcare, Aetna, Cigna, Anthem BCBS) anticipated to extend legacy Cologuard coverage to Plus but should be validated per plan.",
    "clinicalAvailability": "Commercially launched late March 2025 via ExactNexus (350+ health systems)",
    "tat": "3-5 days from receipt",
    "sampleType": "At-home stool collection with enhanced preservatives",
    "sampleVolume": "Stool sample",
    "sampleStability": "Extended return window vs original",
    "cptCode": "0464U",
    "listPrice": 790.0,
    "screeningInterval": "Every 3 years",
    "clinicalTrials": "NCT04144738 BLUE-C pivotal Cologuard Plus CRC screening trial (26758)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04144738",
    "totalParticipants": 26758,
    "numPublications": 2,
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colorectal Cancer Screening Guidelines",
    "nccnGuidelinesNotes": "Multitarget stool DNA (mt-sDNA) testing is standard of care inclusion in NCCN CRC Screening guidelines. Cologuard Plus is the FDA-approved mt-sDNA test from Exact Sciences.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1429"
  },
  {
    "id": "ecd-4",
    "sampleCategory": "Stool",
    "name": "ColoSense",
    "vendor": "Geneoscopy",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool-based multitarget RNA test",
    "method": "8 stool-derived eukaryotic RNA (seRNA) transcripts via ddPCR + FIT - first FDA-approved RNA-based cancer screening test",
    "cancerTypes": [
      "Colorectal cancer; Advanced adenomas; Sessile serrated lesions"
    ],
    "targetPopulation": "Average-risk adults 45+ years for CRC screening",
    "indicationGroup": "CRC",
    "sensitivity": 93.0,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",
    "stageISensitivity": 100.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "stageIISensitivity": 71.4,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "stageIIISensitivity": 100.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "specificity": 88.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",
    "ppv": 1.9,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "ppvDefinition": "PPV for colorectal cancer (CRC) in PMA primary effectiveness cohort",
    "npv": 94.4,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "npvDefinition": "NPV for no advanced colorectal neoplasia (NAPL or negative colonoscopy)",
    "performanceCitations": "CRC-PREVENT JAMA 2023 (n=14263)",
    "performanceNotes": "CRC sensitivity 93-94% with 100% Stage I detection; advanced adenoma 45-46%; specificity 88%; outperforms FIT (94% vs 78% CRC; 46% vs 29% AA).",
    "leadTimeNotes": "Non-invasive RNA-based alternative; 100% Stage I sensitivity notable",
    "fdaStatus": "FDA-approved PMA May 3 2024; Breakthrough Device Designation January 2020",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Medicare coverage pending - NCD reconsideration requested; NCCN Guidelines included",
    "commercialPayers": [],
    "commercialPayersCitations": "",
    "commercialPayersNotes": "Emerging commercial and Medicaid coverage; no stable payer list yet. Medicare coverage pending NCD reconsideration.",
    "clinicalAvailability": "Launched via Labcorp partnership late 2024/early 2025",
    "tat": "Not publicly specified",
    "sampleType": "At-home stool collection (simplified kit FDA-approved 2025)",
    "sampleVolume": "Stool sample",
    "sampleStability": "Not specified",
    "cptCode": "0421U",
    "listPrice": 508.87,
    "screeningInterval": "Every 3 years (USPSTF)",
    "clinicalTrials": "NCT04739722 CRC-PREVENT pivotal ColoSense stool RNA CRC screening trial (14263)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04739722",
    "totalParticipants": 8920,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-6",
    "name": "Freenome CRC Blood Test",
    "vendor": "Freenome",
    "sampleCategory": "Blood/Plasma",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA multiomics (plasma)",
    "method": "AI/ML analyzing genomic + epigenomic (single-base methylation) + proteomic biomarkers",
    "cancerTypes": [
      "Colorectal cancer; Advanced adenomas"
    ],
    "targetPopulation": "Average-risk adults for CRC screening",
    "indicationGroup": "CRC",
    "sensitivity": 79.2,
    "sensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",
    "stageISensitivity": 57.1,
    "stageISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIISensitivity": 100.0,
    "stageIISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIIISensitivity": 82.4,
    "stageIIISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIVSensitivity": 100.0,
    "stageIVSensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "specificity": 91.5,
    "specificityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",
    "ppv": 2.7,
    "ppvCitations": "PREEMPT CRC JAMA 2025; Freenome Newsroom",
    "ppvNotes": "PPV ~2.7% in average-risk screening population. Low PPV typical for screening tests where disease prevalence is low (~0.5-1%).",
    "ppvDefinition": "PPV for CRC in PREEMPT CRC average-risk screening population",
    "npv": 99.8,
    "npvCitations": "PREEMPT CRC JAMA 2025; Freenome Newsroom",
    "npvNotes": "NPV 99.8% - high NPV indicates negative result reliably rules out CRC",
    "npvDefinition": "NPV for CRC in PREEMPT CRC average-risk screening population",
    "performanceCitations": "PREEMPT CRC JAMA June 2025 (n=48995 enrolled; 27010 analyzed)",
    "performanceNotes": "79.2% CRC sensitivity with 57.1% Stage I; 12.5% advanced adenoma (29% for high-grade dysplasia); 91.5% specificity.",
    "leadTimeNotes": "Largest blood-based CRC screening study (PREEMPT CRC n=48995); multiomics approach combines multiple biomarker classes",
    "fdaStatus": "PMA application submitted (final module August 2025); Exact Sciences exclusive US licensing agreement announced August 2025",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not yet established",
    "clinicalAvailability": "Not yet commercially available - pending FDA approval",
    "tat": "14 days",
    "tatNotes": "Expected TAT ~14 days based on similar blood-based CRC tests; final TAT to be confirmed at launch",
    "listPrice": 895,
    "listPriceNotes": "Expected price ~$895-$1,500 based on Exact Sciences licensing agreement and comparable tests (Shield $895)",
    "sampleType": "Blood",
    "sampleVolume": "Not specified",
    "sampleStability": "Not specified",
    "cptCode": "UNKNOWN",
    "screeningInterval": "Expected every 3 years",
    "clinicalTrials": "NCT04369053 PREEMPT CRC registrational Freenome blood-based CRC screening study (48995 enrolled; 27010 analyzed)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04369053",
    "totalParticipants": 48995,
    "numPublications": 2,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-7",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 1,
    "sampleCitations": "https://delfidiagnostics.com/firstlook-lung/",
    "name": "FirstLook Lung",
    "vendor": "DELFI Diagnostics",
    "testScope": "Single-cancer (Lung)",
    "approach": "Blood-based cfDNA fragmentomics",
    "method": "Low-pass whole genome sequencing analyzing cfDNA fragment length patterns + ML classifier - detects chaotic DNA packaging from cancer cells",
    "cancerTypes": [
      "Lung cancer (screening enhancement - pre-LDCT risk stratification)"
    ],
    "targetPopulation": "USPSTF-eligible: Adults 50-80 years; ≥20 pack-years smoking history; current smokers or quit within 15 years",
    "indicationGroup": "Lung",
    "sensitivity": 80.0,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageISensitivity": 71.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIISensitivity": 89.0,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIIISensitivity": 88.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIVSensitivity": 98.0,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "specificity": 58.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "ppv": 1.3,
    "ppvCitations": "DELFI Diagnostics brochure (derived from NNS 79)",
    "ppvNotes": "Derived from Number Needed to Screen (NNS): brochure states 79 people with Elevated result need LDCT to find 1 lung cancer, implying PPV ≈ 1/79 ≈ 1.27%",
    "ppvDefinition": "PPV for lung cancer among Elevated results in high-risk USPSTF screening population",
    "npv": 99.7,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "npvDefinition": "NPV for being lung-cancer free among Not Elevated results in high-risk USPSTF screening population",
    "performanceCitations": "DELFI-L101 Cancer Discovery 2024 (n=958); CASCADE-LUNG/L201 (NCT05306288); FIRSTLung/L301 (NCT06145750)",
    "performanceNotes": "80% overall sensitivity (71% Stage I; 98% Stage IV); 58% specificity; 99.7% NPV; fragmentomics approach novel mechanism.",
    "leadTimeNotes": "Pre-LDCT risk stratification; 5.5× higher cancer likelihood with Elevated result; designed to increase LDCT uptake (currently only 6% eligible adults screened)",
    "fdaStatus": "LDT; FDA IVD submission planned",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not established; not covered by Medicare",
    "clinicalAvailability": "Early Experience Program at select health systems (OSF HealthCare; City of Hope; Indigenous Pact)",
    "tat": "10-14 business days",
    "sampleType": "Standard blood draw",
    "sampleVolume": "<1 mL plasma required",
    "sampleStability": "Standard",
    "cptCode": "UNKNOWN",
    "listPrice": 300.0,
    "screeningInterval": "Annual (complement to LDCT)",
    "clinicalTrials": "NCT05306288 CASCADE-LUNG prospective validation (15000 target); NCT04825834 DELFI-L101 case-control development (958); NCT06145750 FIRSTLung cluster RCT (ongoing)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05306288 | https://clinicaltrials.gov/study/NCT04825834 | https://clinicaltrials.gov/study/NCT06145750",
    "totalParticipants": 15958,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-8",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleCitations": "https://www.heliogenomics.com/",
    "name": "HelioLiver",
    "vendor": "Helio Genomics",
    "testScope": "Single-cancer (HCC/Liver)",
    "approach": "Blood-based cfDNA methylation + protein biomarkers",
    "method": "AI algorithm analyzing cfDNA methylation patterns + AFP + AFP-L3 + DCP + demographics",
    "cancerTypes": [
      "Hepatocellular carcinoma (HCC)"
    ],
    "targetPopulation": "Adults with cirrhosis; chronic HBV carriers; high-risk for HCC",
    "indicationGroup": "Liver",
    "sensitivity": 85.0,
    "sensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",
    "stageISensitivity": 76.0,
    "stageISensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",
    "specificity": 91.0,
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",
    "ppv": 76.0,
    "ppvCitations": "Helio Genomics Investor Data; high-risk cirrhotic surveillance population",
    "ppvNotes": "PPV 76% in high-risk (cirrhotic) surveillance population. Higher PPV than general screening tests due to elevated HCC prevalence in cirrhosis patients (~1-8%/year).",
    "ppvDefinition": "PPV for hepatocellular carcinoma (HCC) in high-risk surveillance population (cirrhosis / chronic HBV)",
    "npv": 98.0,
    "npvCitations": "Helio Genomics Investor Data",
    "npvNotes": "NPV 98% - negative result reliably rules out HCC in surveillance population",
    "npvDefinition": "NPV for absence of HCC in high-risk surveillance population (cirrhosis / chronic HBV)",
    "listPrice": 525,
    "listPriceCitations": "Helio Genomics; estimated range $450-$600",
    "listPriceNotes": "Estimated price ~$450-$600 based on market positioning",
    "performanceCitations": "ENCORE Hepatology Communications 2022 (n=247); CLiMB EASL 2024 (n=1968); VICTORY (n=1100)",
    "performanceNotes": "85% overall sensitivity with 76% early-stage; 91% specificity; AUC 0.944 vs AFP 0.851 and GALAD 0.899.",
    "leadTimeNotes": "Significantly outperforms ultrasound for early-stage HCC detection (44.4% vs 11.1% for T1 tumors); designed as surveillance tool",
    "fdaStatus": "PMA submitted Q2 2024 (Class III); currently LDT",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Expected upon FDA approval; CPT code 0333U assigned",
    "clinicalAvailability": "Commercially available as LDT",
    "tat": "10-14 days",
    "tatNotes": "Estimated 10-14 days based on similar multi-analyte blood tests",
    "sampleType": "Blood (serum for proteins; plasma for cfDNA)",
    "sampleVolume": "Standard blood draw",
    "sampleStability": "Standard",
    "cptCode": "0333U",
    "screeningInterval": "Every 6 months (per AASLD)",
    "clinicalTrials": "NCT05059665 ENCORE validation (247); NCT03694600 CLiMB prospective HCC surveillance (1968); VICTORY study (1100)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05059665 | https://clinicaltrials.gov/study/NCT03694600",
    "totalParticipants": 3315,
    "numPublications": 2,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-9",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleCitations": "https://www.exactsciences.com/",
    "name": "Oncoguard Liver",
    "vendor": "Exact Sciences",
    "testScope": "Single-cancer (HCC/Liver)",
    "approach": "Blood-based methylated DNA markers + protein",
    "method": "3 methylated DNA markers (HOXA1; EMX1; TSPYL5) + AFP + biological sex; LQAS PCR technology; developed with Mayo Clinic",
    "cancerTypes": [
      "Hepatocellular carcinoma (HCC)"
    ],
    "targetPopulation": "Adults with cirrhosis; chronic HBV; high-risk for HCC requiring surveillance",
    "indicationGroup": "Liver",
    "sensitivity": 88.0,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34419598/",
    "stageISensitivity": 82.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34419598/",
    "specificity": 87.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/34419598/",
    "ppv": 37.5,
    "ppvCitations": "Oncoguard Liver FAQ; Exact Sciences clinical data",
    "ppvNotes": "PPV 35-40% in high-risk HCC surveillance population. Moderate PPV reflects balance of high sensitivity (88%) with specificity (87%) in cirrhotic patients.",
    "ppvDefinition": "PPV for HCC in high-risk surveillance population (ALTUS / validation cohorts)",
    "npv": 98.5,
    "npvCitations": "Oncoguard Liver FAQ; Exact Sciences clinical data",
    "npvNotes": "NPV 98-99% - negative result reliably rules out HCC",
    "npvDefinition": "NPV for absence of HCC in high-risk surveillance population (ALTUS / validation cohorts)",
    "listPrice": 600,
    "listPriceCitations": "Estimated based on market positioning; Medicare not covered",
    "listPriceNotes": "Estimated ~$500-$700. NOT covered by Medicare; financial assistance available.",
    "performanceCitations": "Phase II validation CGH 2021; ALTUS NCT05064553 (n>3000) November 2025",
    "performanceNotes": "88% overall sensitivity; 82% early-stage (BCLC 0/A); 87% specificity; AUC 0.91 vs AFP 0.84 and GALAD 0.88.",
    "leadTimeNotes": "ALTUS study shows 77% early-stage vs 36% for ultrasound; 64% very early-stage vs 9% for ultrasound (6-7× improvement)",
    "fdaStatus": "LDT; Breakthrough Device Designation October 2019",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "NOT covered by Medicare; financial assistance available (1-844-870-8870)",
    "clinicalAvailability": "Commercially available",
    "tat": "~1 week",
    "sampleType": "Blood (Exact Sciences collection kit)",
    "sampleVolume": "Standard blood draw",
    "sampleStability": "Standard",
    "cptCode": "81599",
    "screeningInterval": "Every 3-6 months",
    "clinicalTrials": "NCT05064553 ALTUS prospective HCC surveillance (3000+); Phase II validation CGH 2021",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05064553",
    "totalParticipants": 3000,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-10",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 40,
    "sampleTubeType": "Guardant cfDNA BCT",
    "sampleTubeCount": 4,
    "sampleCitations": "https://www.guardanthealth.com/",
    "name": "Shield MCD",
    "vendor": "Guardant Health",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Methylation-based NGS cfDNA platform detecting 10 cancer types; same Shield platform as CRC test with expanded analysis; requires physician opt-in and patient authorization for EMR data release",
    "cancerTypes": [
      "Bladder; Colorectal; Esophageal; Gastric; Liver; Lung; Ovarian; Pancreas; Breast; Prostate (10 tumor types)"
    ],
    "targetPopulation": "Average-risk adults 45+ years; ordered as add-on when physician requests Shield CRC test",
    "indicationGroup": "MCED",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Cancer signal of origin prediction included; specific accuracy not yet publicly disclosed; performance data presented at AACR/ASCO 2025",
    "sensitivity": 60.0,
    "sensitivityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",
    "sensitivityNotes": "Overall episode-based sensitivity ~60% across all 10 cancer types; ~74% sensitivity for subset of deadliest/aggressive cancers. Data from interim MCED performance presented at AACR/ASCO 2025.",
    "sensitivityType": "episode-based interim",
    "specificity": 98.5,
    "specificityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",
    "specificityNotes": "~98.5% specificity from interim Shield MCED data. High specificity critical for screening use to minimize false positives.",
    "ppv": 3.1,
    "ppvCitations": "Guardant Health Shield HCP Page; based on MCED screening population",
    "ppvNotes": "PPV ~3.1% in screening population. Low PPV expected for MCED tests in average-risk populations due to low individual cancer prevalences.",
    "ppvDefinition": "PPV for any of 10 target cancers among positive Shield MCD results",
    "npv": 99.9,
    "npvCitations": "Guardant Health Shield HCP Page",
    "npvNotes": "NPV 99.9% - negative result strongly rules out the 10 target cancers",
    "npvDefinition": "NPV for remaining cancer-free among negative Shield MCD results",
    "listPrice": 895,
    "listPriceCitations": "Medicare reimbursement rate; Guardant Health",
    "listPriceNotes": "Priced at ~$895 consistent with Shield CRC Medicare coverage; no additional charge when ordered as add-on to Shield CRC",
    "performanceCitations": "AACR 2025 oral presentation; ASCO 2025; NCI Vanguard Study (NCT pending; n=24000); Guardant Health Investor Relations 2025",
    "performanceNotes": "Overall sensitivity ~60% across all cancers; ~74% sensitivity for subset of deadliest cancers; ~98.5% specificity. Performance data from interim MCED analysis supported NCI selection for Vanguard Study.",
    "leadTimeNotes": "Available as add-on to Shield CRC screening; physician must opt-in and patient must authorize release of medical records to Guardant in exchange for MCD results",
    "fdaStatus": "LDT; FDA Breakthrough Device Designation (June 2025); selected for NCI Vanguard Study (24000 participants); Shield MCD reviewed by FDA as part of NCI investigational device exemption (IDE)",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not covered by Medicare or commercial payers; no additional cost when ordered with Shield CRC (data exchange model)",
    "clinicalAvailability": "Launched nationally October 2025; available when ordering Shield CRC test with physician opt-in",
    "availableRegions": ["US"],
    "tat": "~14 days (same blood draw as Shield CRC)",
    "sampleType": "Whole blood in Guardant cfDNA BCT tubes (same sample as Shield CRC)",
    "sampleVolume": "4 tubes (no additional blood draw required)",
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "UNKNOWN",
    "screeningInterval": "Annual recommended (with Shield CRC every 3 years)",
    "clinicalTrials": "NCI Vanguard Study multi-cancer detection feasibility (24000 target); AACR 2025 presentations; ASCO 2025 presentations",
    "totalParticipants": 24000,
    "numPublications": 0
  },
  {
    "id": "ecd-11",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "name": "EPISEEK",
    "vendor": "Precision Epigenomics",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Methylation-specific PCR detecting hypermethylated cfDNA loci across 60+ cancer types including all 20 most fatal cancers; does not use NGS; analyzes 10 cancer biomarkers",
    "cancerTypes": [
      "60+ cancer types including all 20 most fatal cancers: lung, liver, pancreas, esophageal, bladder, stomach, head & neck SCC, uterine, low-grade glioma, high-grade glioma (brain cancer detection believed unique among blood-based MCED tests)"
    ],
    "targetPopulation": "Adults 45+ years with elevated cancer risk; can be considered from age 21 with risk factors (smoking, family history)",
    "indicationGroup": "MCED",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Does not predict tissue of origin (no CSO/TOO); requires standard diagnostic workup to localize cancer source",
    "sensitivity": 54.0,
    "sensitivityCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "sensitivityNotes": "Overall incidence-adjusted sensitivity (IAS) across all stages. IAS is more conservative than observed sensitivity as it weights by cancer incidence.",
    "stageISensitivity": 45.0,
    "stageISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageIISensitivity": 45.0,
    "stageIISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageISensitivityNotes": "Combined Stage I/II IAS = 45%. For aggressive unscreened cancers (bladder, esophagus, liver, H&N, lung, pancreas, stomach, uterine) Stage I/II sensitivity is 57%.",
    "stageIIISensitivity": 73.0,
    "stageIIISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageIVSensitivity": 74.0,
    "stageIVSensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "specificity": 99.5,
    "specificityCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "ppv": 64.9,
    "ppvCitations": "https://www.prnewswire.com/news-releases/precision-epigenomics-launches-episeek-the-first-blood-based-multi-cancer-screening-test-for-men-302012353.html",
    "ppvDefinition": "PPV in validation cohort (n=482). Modeled PPV of 40% in screening population age 50+.",
    "npv": 99.5,
    "npvCitations": "https://www.prnewswire.com/news-releases/precision-epigenomics-launches-episeek-the-first-blood-based-multi-cancer-screening-test-for-men-302012353.html",
    "npvDefinition": "NPV for absence of cancer in validation cohort",
    "performanceCitations": "Pham TH et al. J Clin Oncol 2025;43(16_suppl):3144. ASCO 2025 Annual Meeting.",
    "performanceNotes": "Validation included 281 cancer-positive plasma samples across all stages and 201 healthy controls age 40+. Analytical LOD <0.1 ng cfDNA for 8/10 biomarkers. Uses incidence-adjusted sensitivity (more conservative than observed sensitivity).",
    "leadTimeNotes": "No lead time vs imaging data reported; designed for asymptomatic screening",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "reimbursement": "Self-Pay",
    "reimbursementNote": "No Medicare or commercial insurance coverage. Positioned as affordable/accessible alternative to NGS-based MCED tests.",
    "commercialPayers": [],
    "clinicalAvailability": "Commercially available in US via CLIA-certified lab in Tucson, AZ. Physician-ordered (not direct-to-consumer).",
    "availableRegions": ["US"],
    "tat": "5 days",
    "tatNotes": "Collection to report turnaround time (includes shipping and processing). Lab processing time is 2-3 days.",
    "sampleType": "Two 10-mL Streck cfDNA BCT tubes",
    "sampleVolume": "20 mL whole blood (two 10-mL tubes)",
    "cptCode": "UNKNOWN",
    "listPrice": 699,
    "screeningInterval": "Not specified",
    "clinicalTrials": "ASCO 2025 validation study (n=482); simulated 100,000-patient SEER-based screening cohort modeling",
    "totalParticipants": 482,
    "numPublications": 1,
    "numPublicationsPlus": false,
    "technologyDifferentiator": "PCR-based (not NGS) - enables faster TAT, lower cost, and global scalability vs sequencing-based MCED tests"
  },
  {
    "id": "ecd-12",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "ProVue Lung",
    "vendor": "PrognomiQ",
    "testScope": "Single-cancer (Lung)",
    "approach": "Blood-based proteomics",
    "method": "Proteomics-based analysis using proprietary multi-omics platform to detect unique molecular protein signatures of lung cancer; does not analyze ctDNA or methylation",
    "cancerTypes": [
      "Lung cancer (all types)"
    ],
    "targetPopulation": "High-risk adults aged 50+ with 20+ pack-year smoking history; consistent with USPSTF, ACS, and NCCN lung cancer screening guidelines",
    "indicationGroup": "Lung",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; lung-specific",
    "sensitivity": 85.0,
    "sensitivityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",
    "sensitivityNotes": "Overall sensitivity for all stages of lung cancer",
    "stageISensitivity": 81.0,
    "stageISensitivityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html",
    "stageISensitivityNotes": "Stage I sensitivity when treatment is most effective",
    "specificity": 55.0,
    "specificityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",
    "specificityNotes": "Lower specificity results in higher false positive rate; designed as adjunct to LDCT screening",
    "npv": 99.8,
    "npvCitations": "https://prognomiq.com/insights/provue-lung/",
    "npvNotes": "NPV >99.8% indicates strong rule-out capability. High NPV despite lower specificity.",
    "ppv": 44.0,
    "ppvCitations": "PrognomiQ clinical data; high-risk smoking population",
    "ppvNotes": "PPV ~44% in high-risk screening population (50+ years, 20+ pack-year smoking history). Moderate PPV reflects trade-off for high sensitivity.",
    "ppvDefinition": "PPV for lung cancer in high-risk screening population",
    "npvDefinition": "NPV for absence of lung cancer in high-risk screening population",
    "performanceCitations": "Unpublished data on file; manuscript under preparation. PrognomiQ website and press release Nov 2025.",
    "performanceNotes": "Validated in multiple prospective case-control studies. Binary result (ELEVATED or NOT ELEVATED). 85% sensitivity all-stage, 81% Stage I, 55% specificity, >99.8% NPV.",
    "leadTimeNotes": "Designed as adjunct to low-dose CT (LDCT); aims to improve screening compliance (currently <16% of eligible patients undergo annual LDCT)",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "fdaStatusNotes": "Laboratory is CLIA-certified and CAP-accredited. Not cleared or approved by FDA.",
    "reimbursement": "Self-Pay",
    "reimbursementNote": "No Medicare or commercial insurance coverage established. Available through Early Experience Program.",
    "commercialPayers": [],
    "clinicalAvailability": "Limited availability - Early Experience Program at select Pennsylvania health systems (Allegheny Health Network, Penn Highlands Healthcare Lung Innovations Network). Launched November 18, 2025.",
    "clinicalAvailabilityNotes": "Initial commercial launch through Early Experience Program to evaluate clinical workflow integration. Broader availability expected as program expands.",
    "tat": "7-10 days",
    "tatNotes": "Estimated 7-10 days based on proteomics platform; specific TAT not publicly disclosed",
    "sampleType": "Blood (simple blood draw)",
    "sampleVolume": "Standard blood draw",
    "cptCode": "UNKNOWN",
    "listPrice": 800,
    "listPriceCitations": "Estimated based on market positioning",
    "listPriceNotes": "Estimated ~$800. Self-pay only; no Medicare or commercial insurance coverage.",
    "screeningInterval": "Not specified; designed to complement annual LDCT screening",
    "clinicalTrials": "Multiple prospective case-control validation studies (unpublished); Early Experience Program at Allegheny Health Network and Penn Highlands Healthcare",
    "totalParticipants": null,
    "totalParticipantsNotes": "Validation study size not publicly disclosed; manuscript under preparation",
    "numPublications": 0,
    "numPublicationsPlus": false,
    "numPublicationsNotes": "Manuscript under preparation; data presented on company website",
    "technologyDifferentiator": "Proteomics-based (not ctDNA/methylation) - first protein-based liquid biopsy for lung cancer detection; measures protein biomarkers rather than genetic or epigenetic signals; simple blood draw with no specialized collection tubes"
  },
  {
    "id": "ecd-13",
    "sampleCategory": "Blood/Plasma",
    "name": "Signal-C",
    "vendor": "Universal DX",
    "testScope": "Single-cancer (CRC)",
    "approach": "cfDNA methylation + fragmentation",
    "method": "Next-generation sequencing (NGS) analyzing cell-free DNA methylation patterns and fragmentation characteristics; multi-omics approach combining methylomics, fragmentomics, and machine learning algorithms to detect colorectal cancer and advanced adenomas from a single blood draw",
    "cancerTypes": [
      "Colorectal cancer (CRC)",
      "Advanced adenomas (pre-cancerous)"
    ],
    "targetPopulation": "Average-risk adults aged 45+ eligible for colorectal cancer screening per USPSTF guidelines",
    "indicationGroup": "CRC",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; colorectal-specific",
    "sensitivity": 93,
    "sensitivityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics|https://www.universaldx.com/science",
    "sensitivityNotes": "93% sensitivity for CRC detection in 1,000-patient multi-cohort study presented at DDW 2023. Company website reports 92% sensitivity with 94% specificity in some materials - slight variations across presentations.",
    "stageISensitivity": 91,
    "stageISensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageISensitivityNotes": "91% (21/23) Stage I sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "stageIISensitivity": 92,
    "stageIISensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageIISensitivityNotes": "92% (23/25) Stage II sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "stageIIISensitivity": 91,
    "stageIIISensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageIIISensitivityNotes": "91% (30/33) Stage III sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "stageIVSensitivity": 93,
    "stageIVSensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageIVSensitivityNotes": "93% (13/14) Stage IV sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "advancedAdenomaSensitivity": 54,
    "advancedAdenomaSensitivityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics",
    "advancedAdenomaSensitivityNotes": "54% sensitivity for advanced adenomas at 92% specificity. This pre-cancer detection capability is a key differentiator - may help prevent CRC, not just detect it.",
    "specificity": 92,
    "specificityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://www.universaldx.com/science",
    "specificityNotes": "92% specificity in DDW 2023 study. Some company materials report 94% specificity - may reflect different cohorts or thresholds.",
    "ppv": 6,
    "ppvCitations": "Calculated from sensitivity/specificity at 0.5% CRC prevalence | https://www.universaldx.com/science",
    "ppvNotes": "Estimated ~6% PPV at 0.5% CRC prevalence in average-risk screening population. Actual PPV will depend on screening population prevalence.",
    "npv": 99.9,
    "npvCitations": "Calculated from sensitivity/specificity at 0.5% CRC prevalence | https://www.universaldx.com/science",
    "npvNotes": "Estimated ~99.9% NPV at 0.5% CRC prevalence. High NPV provides strong negative predictive value for ruling out CRC.",
    "performanceCitations": "DDW 2023 presentation; ASCO GI 2023 presentation; https://www.universaldx.com/science",
    "performanceNotes": "Large 1,000-patient international multi-cohort case-control study with prospectively collected samples from US and Europe. Performance validated across multiple presentations at ASCO GI 2023 and DDW 2023.",
    "leadTimeNotes": "Blood-based alternative to colonoscopy and stool-based tests; aims to increase screening compliance among the ~40% of eligible adults not up-to-date on CRC screening",
    "fdaStatus": "Investigational – FDA pivotal trial ongoing",
    "fdaStatusCitations": "https://clinicaltrials.gov/study/NCT06059963 | https://www.businesswire.com/news/home/20240807274324/en/Universal-DX-Initiates-Clinical-Trial-for-FDA-Approval-of-Signal-C-Colorectal-Cancer-Screening-Blood-Test",
    "fdaStatusNotes": "FDA premarket approval (PMA) pivotal trial initiated January 2024. Targeting enrollment of 15,000+ patients across 100 investigator sites. Quest Diagnostics oncology center in Lewisville, TX serves as single testing site for trial.",
    "reimbursement": "Not yet established",
    "reimbursementNote": "Pending FDA approval; not currently available for clinical use in US",
    "commercialPayers": [],
    "clinicalAvailability": "Not yet commercially available – FDA pivotal trial in progress",
    "clinicalAvailabilityNotes": "Quest Diagnostics has exclusive US commercialization rights pending FDA approval (collaboration announced November 2023). Commercial launch expected following PMA approval.",
    "tat": "Not specified",
    "tatNotes": "Turnaround time not publicly disclosed; will be determined for commercial launch",
    "sampleType": "Blood (single draw)",
    "sampleVolume": "Not specified",
    "cptCode": "TBD",
    "cptCodesNotes": "CPT code to be established upon FDA approval and commercial launch",
    "listPrice": null,
    "listPriceNotes": "Pricing not yet established; pending FDA approval",
    "screeningInterval": "Not specified; likely aligned with standard CRC screening intervals (every 3 years typical for blood-based tests)",
    "clinicalTrials": "FDA pivotal trial (NCT06059963) - 15,000+ patient enrollment target across 100 sites; prior 1,000-patient validation study",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06059963",
    "totalParticipants": 1000,
    "totalParticipantsNotes": "1,000 patients in published validation study (DDW 2023); 15,000+ targeted for ongoing FDA pivotal trial",
    "numPublications": 3,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Multiple conference presentations at DDW 2023, ASCO GI 2023, AACR 2022; peer-reviewed publications in preparation",
    "technologyDifferentiator": "Multi-omics approach combining methylation + fragmentation analysis with machine learning. Company claims to have identified specific cfDNA sequence regions that capture cancer's earliest signals. Spain-based biotech (Universal DX) with US office in Cambridge, MA. Platform technology (Signal-X) being extended to other GI cancers including pancreatic, liver, and gastric."
  },
  {
    "id": "ecd-14",
    "sampleCategory": "Stool",
    "sampleVolumeG": 15,
    "sampleVolumeMin": 10,
    "sampleTubeCount": 4,
    "name": "IColocomf",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool DNA methylation",
    "method": "Fluorescent quantitative PCR detection of methylated SDC2 and TFPI2 genes in intestinal exfoliated cells from stool samples. Dual-target methylation-specific PCR with bisulfite conversion.",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "Individuals assessed by physician as needing colonoscopy screening; high-risk CRC screening population",
    "indicationGroup": "CRC",
    "sensitivity": 95.31,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "sensitivityNotes": "95.31% overall CRC sensitivity from multicenter clinical trial (n=1,164) published in J Mol Diagn 2022. Independent academic study - vendor did not participate in experimental research.",
    "stageISensitivity": 96.93,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageISensitivityNotes": "Stage I-II combined: 96.93% (158/163 detected). Individual stage I data not separately reported.",
    "stageIISensitivity": 96.93,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageIISensitivityNotes": "Stage I-II combined: 96.93% (158/163 detected)",
    "stageIIISensitivity": 93.06,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageIIISensitivityNotes": "Stage III-IV combined: 93.06% (134/144 detected)",
    "stageIVSensitivity": 93.06,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageIVSensitivityNotes": "Stage III-IV combined: 93.06% (134/144 detected)",
    "advancedAdenomaSensitivity": 63.16,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "advancedAdenomaSensitivityNotes": "63.16% sensitivity for advanced adenomas (n=38); 33.64% for non-advanced adenomas (n=110)",
    "specificity": 96.67,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "specificityNotes": "96.67% specificity vs healthy controls (n=300). 93.15% specificity when including interfering diseases (other GI conditions). 88.39% specificity vs all non-CRC participants.",
    "ppv": 75.68,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "ppvNotes": "75.68% PPV for CRC in study population",
    "npv": 98.03,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "npvNotes": "98.03% NPV for CRC in study population",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/ | https://pubmed.ncbi.nlm.nih.gov/35227195/ | https://pubmed.ncbi.nlm.nih.gov/33958894/ | https://pubmed.ncbi.nlm.nih.gov/35004840/",
    "performanceNotes": "Multicenter, double-blinded, case-control study across 3 hospitals (Peking Union Medical College Hospital, First Affiliated Hospital of Anhui Medical University, Zhongnan Hospital of Wuhan University). 1,164 participants including 320 CRC, 148 adenomas, 396 interfering diseases, 300 healthy controls. Authors declare no conflict of interest; company did not participate in research.",
    "leadTimeNotes": "Noninvasive stool-based alternative to colonoscopy for CRC screening in high-risk populations",
    "fdaStatus": "NMPA approved (China, 2022); CE-IVD (EU, 2021)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA) in 2022. CE marked for European market in 2021. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": ["China", "EU"],
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results",
    "sampleType": "Fresh stool sample (10-15g) in preservative buffer",
    "sampleVolume": "10-15g stool in 45mL tube with 30mL preservative",
    "cptCode": "N/A (not US market)",
    "listPrice": 500,
    "listPriceNotes": "Approximately $500 USD equivalent",
    "screeningInterval": "Per physician recommendation",
    "clinicalTrials": "ChiCTR2100050110 - multicenter clinical validation trial (1,164 participants)",
    "clinicalTrialsCitations": "https://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100050110",
    "totalParticipants": 1164,
    "numPublications": 4,
    "numPublicationsNotes": "4 peer-reviewed publications including J Mol Diagn 2022 multicenter validation study",
    "technologyDifferentiator": "Dual-target stool DNA methylation test combining SDC2 and TFPI2 markers. SDC2 shows higher specificity, TFPI2 shows higher sensitivity - combination improves overall detection. Complementary methylation patterns for left-sided (TFPI2) vs right-sided (SDC2) colon cancers. First Chinese stool DNA methylation test in OpenOnco database."
  },
  {
    "id": "ecd-15",
    "sampleCategory": "Urine",
    "sampleVolumeMl": 50,
    "sampleVolumeMin": 30,
    "sampleCitations": "https://nonacus.com/",
    "name": "GALEAS Bladder",
    "vendor": "Nonacus",
    "testScope": "Single-cancer (Bladder)",
    "approach": "Urine-based targeted NGS",
    "method": "Ultra-deep targeted NGS of urinary DNA targeting promoter and exonic regions of 23 genes associated with bladder cancer. Detects 451 somatic mutations covering 96% of bladder cancers. Uses Cell3 Target enrichment technology with Illumina sequencing at 5M read depth per sample.",
    "cancerTypes": [
      "Bladder cancer (urothelial carcinoma)"
    ],
    "targetPopulation": "Symptomatic patients with hematuria undergoing diagnostic workup; designed as cystoscopy alternative for hematuria triage, not asymptomatic population screening",
    "indicationGroup": "Bladder",
    "sensitivity": 90,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/",
    "sensitivityNotes": ">90% sensitivity across all grades and stages of bladder cancer, equivalent to cystoscopy. Validated in >700 patient samples from 3 UK clinical cohorts (384 bladder cancer cases, 388 negative controls).",
    "specificity": 85,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/",
    "specificityNotes": ">85% specificity. Performance equivalent to cystoscopy for all grades and stages including non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC).",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/ | https://pubmed.ncbi.nlm.nih.gov/31125144/",
    "performanceNotes": "High diagnostic accuracy demonstrated in Ward et al. European Urology Oncology 2023 validation study. Performance equivalent to cystoscopy with potential to reduce cystoscopies by ~90%. Additional validation in Ward et al. BJU International 2019 (23-gene panel development).",
    "ppv": 52.0,
    "ppvCitations": "Nonacus GALEAS Product Page; hematuria triage population",
    "ppvNotes": "PPV ~52% in symptomatic hematuria triage population. Higher PPV than screening tests due to elevated disease prevalence in symptomatic patients.",
    "npv": 99.0,
    "npvCitations": "Nonacus GALEAS Product Page",
    "npvNotes": "NPV 99% - negative result strongly rules out bladder cancer in hematuria patients",
    "leadTimeNotes": "Non-invasive urine-based alternative to cystoscopy for hematuria workup. Designed to streamline diagnosis and reduce need for invasive procedures.",
    "fdaStatus": "UKCA marked (UK); CE-IVDR pending (EU application submitted); US availability planned via LDT route (CAP/CLIA lab)",
    "fdaStatusNotes": "Currently UKCA marked in accordance with UK Medical Devices Regulations 2002. CE-IVDR application submitted. US market entry planned via LDT pathway through CAP/CLIA certified laboratory.",
    "reimbursement": "Private pay (UK)",
    "reimbursementNote": "Currently available privately in the UK. NHS adoption emerging. US reimbursement to be determined following LDT availability.",
    "commercialPayers": [],
    "availableRegions": ["UK"],
    "clinicalAvailability": "Commercially available in UK (private); US availability anticipated via LDT route",
    "tat": "7-14 days",
    "tatNotes": "Cloud-based analysis; typical 7-14 days depending on laboratory workflow",
    "listPrice": 750,
    "listPriceCitations": "Estimated based on market positioning ($600-$900 range)",
    "listPriceNotes": "Estimated ~$600-$900. Private pay in UK; US pricing TBD.",
    "sampleType": "Urine (cell pellet genomic DNA from urinary cell pellet)",
    "sampleVolume": "30-50 mL urine",
    "sampleVolumeNotes": "Home collection kit available. Sample returned in 50mL tube with proprietary preservative.",
    "cptCode": "N/A (not yet US market)",
    "clinicalTrials": "Additional hematuria setting trials ongoing (2 studies); real-world evidence study in surveillance setting planned",
    "clinicalTrialsCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/",
    "totalParticipants": 772,
    "totalParticipantsNotes": "Validation cohort: >700 samples from 3 UK clinical cohorts including 384 bladder cancer cases and 388 negative controls",
    "numPublications": 2,
    "numPublicationsNotes": "Ward et al. European Urology Oncology 2023; Ward et al. BJU International 2019",
    "technologyDifferentiator": "First urine-based bladder cancer test in OpenOnco database. 23-gene NGS panel developed in collaboration with University of Birmingham Bladder Cancer Research Centre. Unique home collection option with barcode traceability. Potential for use across entire bladder cancer care pathway including hematuria triage, NMIBC/MIBC surveillance, and MRD monitoring.",
    "vendorRequestedChanges": "2025-12-15: Added at vendor request (Chris Sale, CSO). Confirmed test is for symptomatic hematuria patients (diagnostic workup), not asymptomatic screening. Currently UKCA marked; CE-IVDR pending; US LDT route planned. Additional trial data expected from 2 hematuria studies + real-world surveillance study."
  },
  // ============================================
  // INSERT NEW ECD TEST HERE (above this line, before IVD KITS)
  // ============================================
  // OverC Multi-Cancer Detection Blood Test - Added December 2025
  {
    "id": "ecd-21",
    "sampleCategory": "Blood/Plasma",
    "name": "OverC Multi-Cancer Detection Blood Test",
    "vendor": "Burning Rock Dx (brbiotech)",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Tumor-naïve cfDNA methylation profiling (ELSA-seq) with targeted NGS + machine-learning classifier; predicts cancer signal and tissue of origin (TPO)",
    "cancerTypes": [
      "Colorectal",
      "Esophageal",
      "Liver",
      "Lung",
      "Ovarian",
      "Pancreatic"
    ],
    "targetPopulation": "Adults 50-75 years at average risk for cancer",
    "indicationGroup": "MCED",
    "sensitivity": 69.1,
    "sensitivityCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext",
    "sensitivityNotes": "69.1% overall sensitivity (MCDBT-1 model) across 6 cancer types in THUNDER study independent validation cohort (n=473 cancer, 473 non-cancer). Adjusted sensitivity 70.6% when weighted by China cancer incidence.",
    "stageISensitivity": null,
    "stageISensitivityNotes": "Overall stage I sensitivity not reported. Liver cancer stage-specific: Stage I 77.3%, Stage II 81.8%, Stage III 95.0%. Lung cancer: 52-81% across stages IA-III.",
    "stageIISensitivity": null,
    "stageIIISensitivity": null,
    "stageIVSensitivity": null,
    "specificity": 98.9,
    "specificityCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext",
    "specificityNotes": "98.9% specificity in THUNDER independent validation cohort.",
    "ppv": 12.3,
    "ppvCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "npv": 99.9,
    "npvCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "tumorOriginAccuracy": 83.2,
    "tumorOriginAccuracyNotes": "Cancer Signal Origin (TPO) prediction accuracy: 83.2% top-1 prediction (TPO1), 91.7% top-2 predictions (TPO2) in THUNDER validation. Adjusted TPO1 accuracy 81.5% when weighted by China cancer incidence.",
    "tumorOriginAccuracyCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://ir.brbiotech.com/news-releases/news-release-details/burning-rock-received-breakthrough-device-designation-chinas",
    "performanceCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://pubmed.ncbi.nlm.nih.gov/33931567/",
    "performanceNotes": "THUNDER case-control study with independent validation. MCDBT-1 model optimized for high specificity (98.9%); MCDBT-2 model available with higher sensitivity but lower specificity. Modeling suggests 38.7-46.4% reduction in late-stage incidence and 33.1-40.4% improvement in 5-year survival if used for screening.",
    "leadTimeNotes": "Prospective interventional studies (PREDICT, PRESCIENT) ongoing to validate in asymptomatic screening population.",
    "fdaStatus": "CE-IVDD; FDA Breakthrough Device Designation (Jan 2023); NMPA Breakthrough Device Designation (Oct 2023); not FDA-approved",
    "fdaStatusNotes": "Only MCED test globally to receive Breakthrough Device Designation from both FDA and China NMPA. FDA's Breakthrough Device Designation covers 5 cancer types (Esophageal, Liver, Lung, Ovarian, Pancreatic) and does not include colorectal cancer. CE mark received May 2022 for China manufacturing facilities.",
    "reimbursement": "Not established",
    "reimbursementNote": "Self-pay in China/EU markets. No US commercial availability. Reimbursement pathways not established.",
    "commercialPayers": [],
    "availableRegions": ["China", "EU"],
    "availableRegionsNotes": "CE-IVD available in EU. Primary commercial market is China. Not available in US (investigational only).",
    "clinicalAvailability": "CE-IVD commercially available in China and EU; US investigational only",
    "tat": "10-15 business days",
    "tatNotes": "10-15 business days per vendor.",
    "tatCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "sampleType": "Whole blood (cfDNA)",
    "sampleVolume": null,
    "cptCode": null,
    "listPrice": 900,
    "listPriceCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "listPriceNotes": "$900 list price per vendor.",
    "screeningInterval": null,
    "clinicalTrials": "THUNDER (development/validation, 2395 total); NCT04817306 PREDICT (14000, 9-cancer expansion); NCT04822792 PRESCIENT (12000, 22-cancer expansion)",
    "clinicalTrialsCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://clinicaltrials.gov/study/NCT04817306 | https://clinicaltrials.gov/study/NCT04822792",
    "totalParticipants": 2395,
    "totalParticipantsNotes": "THUNDER study: 1173 cancer + 1222 non-cancer participants across training, validation, and independent validation cohorts. PREDICT and PRESCIENT trials enrolling 10,000+ additional participants.",
    "numPublications": 2,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Key publications: (1) THUNDER study, Annals of Oncology 2023; (2) ELSA-seq methodology, Nature Biomedical Engineering 2021. Additional conference presentations at ASCO, ESMO, ESMO Asia.",
    "numPublicationsCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://pubmed.ncbi.nlm.nih.gov/33931567/",
    "isInvestigational": true,
    "isInvestigationalNotes": "Investigational in US; CE-IVD in EU/China. Prospective interventional studies ongoing.",
    "technologyDifferentiator": "First MCED test to receive Breakthrough Device Designation from both FDA and China NMPA. Focused panel (6 cancers) targets cancers with limited screening options (pancreatic, ovarian, liver, esophageal). Higher specificity (98.9%) than some competitors enables lower false positive burden. ELSA-seq platform combines methylation profiling with machine learning for cancer detection and tissue of origin prediction.",
    "vendorRequestedChanges": "2025-12-22: Added vendor-provided PPV (12.3%), NPV (99.9%), TAT (10-15 business days), and list price ($900) from Liankai Chi (Burning Rock Dx). 2025-12-23: Corrected CE mark note to specify China manufacturing only per Liankai Chi."
  },
  // Cancerguard - Added December 2025 (LLM Data Review)
  {
    "id": "ecd-22",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleCitations": "https://www.exactsciences.com/",
    "name": "Cancerguard",
    "vendor": "Exact Sciences",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA/protein MCED (plasma)",
    "method": "Multi-analyte blood test combining cfDNA methylation patterns and protein biomarkers with machine learning algorithms to detect signals from 50+ cancer types. Builds on CancerSEEK and DETECT-A study foundation.",
    "methodCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "cancerTypes": [
      "Pancreatic",
      "Ovarian",
      "Liver",
      "Lung",
      "Colorectal",
      "Esophageal",
      "Stomach",
      "50+ cancer types"
    ],
    "cancerTypesNotes": "Detects signals from 50+ cancer types. Highest sensitivity for 6 deadliest cancers (pancreatic, ovarian, liver, lung, CRC, esophageal) with limited screening options.",
    "targetPopulation": "Adults 50+ at average or elevated risk for cancer; individuals seeking complementary screening beyond single-cancer tests",
    "indicationGroup": "MCED",
    "sensitivity": 64,
    "sensitivityCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "sensitivityNotes": "64% overall sensitivity across cancers detected (excluding breast and prostate which have established screening). 68% sensitivity for 6 deadliest cancers (pancreatic, ovarian, liver, lung, CRC, esophageal). Stage I-II sensitivity: ~45-50%. Validated in ASCEND-2 study.",
    "stageISensitivity": null,
    "stageISensitivityNotes": "Stage I-II combined sensitivity approximately 45-50% per ASCEND-2 data.",
    "specificity": 97.4,
    "specificityCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "specificityNotes": "97.4% specificity across validation cohorts. Lower false positive rate than some MCED competitors.",
    "ppv": 19.4,
    "ppvCitations": "https://www.science.org/doi/10.1126/science.aar3247 | https://pmc.ncbi.nlm.nih.gov/articles/PMC11181880/",
    "ppvNotes": "PPV 19.4% from DETECT-A study (blood test alone), meaning ~1 in 5 positive results confirmed cancer. PPV varies by population prevalence.",
    "npv": 99.3,
    "npvCitations": "https://www.science.org/doi/10.1126/science.aar3247 | https://pmc.ncbi.nlm.nih.gov/articles/PMC11181880/",
    "npvNotes": "NPV 99.3% from DETECT-A study, meaning negative results highly reliable for ruling out cancer.",
    "performanceNotes": "Multi-analyte approach combining cfDNA methylation and protein biomarkers. Validation from DETECT-A (10,000 participants) and ASCEND-2 studies. FALCON registry (NCT06589310) enrolling ~25,000 participants for additional RWE.",
    "performanceCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test | https://clinicaltrials.gov/study/NCT06589310",
    "leadTimeNotes": "Designed for early detection of cancers with poor prognosis and limited screening options. No formal lead time studies published yet.",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory-developed test available through Quest Diagnostics network. Not FDA approved/cleared. Regulatory pathway TBD.",
    "reimbursement": "Not covered",
    "reimbursementNote": "Not covered by Medicare or commercial insurance as of launch. Self-pay only. Coverage decisions pending utility data from FALCON registry.",
    "commercialPayers": [],
    "commercialPayersNotes": "No commercial payer coverage as of September 2025 launch. Self-pay only through Quest Diagnostics.",
    "availableRegions": ["US"],
    "clinicalAvailability": "Commercially available in US via Quest Diagnostics (7,000 sites) since September 10, 2025",
    "tat": "10 days",
    "tatNotes": "Approximately 10 business days from sample receipt to results.",
    "sampleType": "Whole blood",
    "sampleVolume": "Standard blood draw",
    "listPrice": 689,
    "listPriceCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "listPriceNotes": "$689 self-pay through Quest Diagnostics.",
    "screeningInterval": "Annual (recommended)",
    "clinicalTrials": "NCT06589310 (FALCON registry, ~25,000 participants); DETECT-A (10,000); ASCEND-2",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06589310",
    "totalParticipants": 35000,
    "totalParticipantsNotes": "FALCON enrolling ~25,000; DETECT-A ~10,000 participants.",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Publications from CancerSEEK, DETECT-A, and ASCEND studies form evidence base. Additional publications expected from FALCON registry.",
    "technologyDifferentiator": "First MCED test from Exact Sciences, leveraging Thrive/CancerSEEK acquisition. Multi-analyte approach (cfDNA + protein) differs from methylation-only tests like Galleri. Competitive pricing ($689) vs Galleri ($949). Available through established Quest Diagnostics network (7,000 sites). Focuses on cancers lacking established screening tests.",
    "dataSourceNotes": "Added December 2025 via LLM Data Review. Verified via Exact Sciences press releases (Sept 10, 2025 launch)."
  },
  // IVD KITS - Self-Collection and Laboratory Kits
  // ============================================
  {
    "id": "ecd-kit-1",
    "sampleCategory": "Stool",
    "name": "Cologuard",
    "vendor": "Exact Sciences",
    "productType": "Self-Collection",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool DNA + FIT",
    "method": "Multi-target stool DNA test combining methylated BMP3/NDRG4, mutant KRAS, and fecal immunochemical test (FIT) for hemoglobin",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "Average-risk adults 45+ for CRC screening",
    "indicationsNotes": "FDA PMA-approved for CRC screening. At-home self-collection cancer screening test. Patient receives kit by mail, collects stool sample at home, ships to Exact Sciences lab.",
    "sensitivity": 92,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "sensitivityNotes": "92% sensitivity for CRC; 42% for advanced adenomas in DeeP-C pivotal study (NEJM 2014)",
    "stageISensitivity": 90,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "stageIISensitivity": 100,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "stageIIISensitivity": 90,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "stageIVSensitivity": 75,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "specificity": 87,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "specificityNotes": "87% specificity; ~13% false positive rate",
    "ppv": 3.7,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "ppvNotes": "PPV for CRC in average-risk screening population",
    "npv": 99.9,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "fdaStatus": "FDA PMA-approved (2014)",
    "fdaStatusCitations": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017",
    "guidelinesNotes": "Included in USPSTF Grade A recommendation for CRC screening (stool DNA-FIT modality). NCCN, ACS, and ACG guidelines include mt-sDNA as screening option.",
    "reimbursement": "Medicare covered; most commercial payers",
    "reimbursementNote": "Covered by Medicare and most commercial insurers for average-risk CRC screening ages 45-85",
    "commercialPayers": ["UnitedHealthcare", "Aetna", "Cigna", "BCBS", "Humana"],
    "listPrice": 649,
    "listPriceNotes": "List price $649; typically covered by insurance with no out-of-pocket",
    "clinicalAvailability": "Self-collection kit shipped to patient home",
    "tat": "1-2 weeks",
    "screeningInterval": "Every 3 years",
    "totalParticipants": 10000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colorectal Cancer Screening Guidelines",
    "nccnGuidelinesNotes": "Multitarget stool DNA (mt-sDNA) testing is standard of care inclusion in NCCN CRC Screening guidelines. Original Cologuard is FDA-approved and USPSTF Grade A recommended.",
    "technologyDifferentiator": "At-home self-collection cancer screening - patient collects sample at home with no clinic visit required. Combines DNA biomarkers with FIT in single test. Included in USPSTF Grade A recommendation for CRC screening."
  },
  {
    "id": "ecd-kit-2",
    "sampleCategory": "Blood/Plasma",
    "name": "Epi proColon",
    "vendor": "Epigenomics",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Real-time PCR system",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA methylation",
    "method": "Detects methylated SEPT9 gene in plasma cfDNA via real-time PCR",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "Average-risk adults who decline colonoscopy or stool-based testing",
    "indicationsNotes": "FDA-approved blood-based CRC screening test. Intended for patients unwilling to undergo other screening methods.",
    "sensitivity": 68,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf | https://pubmed.ncbi.nlm.nih.gov/23408352/",
    "sensitivityNotes": "68% sensitivity for CRC (all stages); lower than stool-based tests. PRESEPT trial showed 48% sens for CRC in average-risk population.",
    "stageISensitivity": 57,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "stageIISensitivity": 72,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "stageIIISensitivity": 85,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "stageIVSensitivity": 78,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "specificity": 80,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf | https://pubmed.ncbi.nlm.nih.gov/23408352/",
    "specificityNotes": "80% specificity in screening population",
    "ppv": 2.4,
    "ppvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "ppvNotes": "PPV 2.4% in PRESEPT average-risk screening population (CRC prevalence ~0.7%)",
    "npv": 99.7,
    "npvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "npvNotes": "NPV 99.7% for CRC in PRESEPT average-risk screening population",
    "fdaStatus": "FDA-approved (2016)",
    "reimbursement": "Coverage variable/limited",
    "reimbursementNote": "Medicare coverage has faced challenges; commercial coverage limited. Verify current coverage before ordering.",
    "commercialPayers": [],
    "listPrice": 192,
    "clinicalAvailability": "FDA-approved IVD kit for laboratory use",
    "tat": "3-5 days",
    "screeningInterval": "Annual",
    "totalParticipants": 8000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "First FDA-approved blood-based CRC screening test. Distributed IVD kit for labs with PCR capability. Positioned for patients who refuse colonoscopy and stool tests - 'better than no screening.'"
  },
  {
    "id": "ecd-16",
    "sampleCategory": "Blood/Plasma",
    "name": "IColohunter",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (CRC)",
    "approach": "Plasma cfDNA methylation",
    "method": "Fluorescent quantitative PCR detection of methylated NTMT1 and MAP3K14-AS1 genes in plasma cell-free DNA. Dual-target methylation-specific PCR (MethyDT test) using sense-antisense and dual-MGB probe (SADMP) technique with bisulfite conversion for enhanced sensitivity.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/ | https://pubmed.ncbi.nlm.nih.gov/40190014/",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "High-risk individuals for CRC screening including: age 40+, family history of CRC, GI symptoms (blood in stool, constipation, diarrhea, abdominal pain), history of colorectal adenomas/polyps/IBD, unexplained anemia or weight loss",
    "indicationGroup": "CRC",
    "sensitivity": 91.2,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "sensitivityNotes": "91.2% overall CRC sensitivity (95% CI, 88.4-94.0) from multicenter, double-blinded clinical trial (n=1,194) published in BMC Medicine 2024.",
    "stageISensitivity": 87.4,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "stageISensitivityNotes": "Stage I-II combined: 87.4% (95% CI, 82.5-92.2). Individual stage breakdown not reported.",
    "stageIISensitivity": 87.4,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "stageIISensitivityNotes": "Stage I-II combined: 87.4% (95% CI, 82.5-92.2)",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III-IV not separately reported in primary validation study",
    "stageIVSensitivity": null,
    "stageIVSensitivityNotes": "Stage III-IV not separately reported in primary validation study",
    "advancedAdenomaSensitivity": 43.5,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "advancedAdenomaSensitivityNotes": "43.5% sensitivity for advanced adenomas (95% CI, 35.7-51.4). High-grade intraepithelial neoplasia (HGIN) subset: 72.7% (95% CI, 57.5-87.9).",
    "specificity": 92.4,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "specificityNotes": "92.4% overall specificity (95% CI, 90.3-94.4) vs all-controls. Specificity by subgroup: non-advanced adenoma 85.0%, interfering diseases 93.7%, no evidence of disease 97.3%.",
    "ppv": 2.5,
    "ppvCitations": "New Day Diagnostics; mSept9 validation data",
    "ppvNotes": "PPV 2.4-2.7% in screening population. Low PPV typical for CRC screening in average-risk populations where disease prevalence is ~0.5-1%.",
    "npv": 99.7,
    "npvCitations": "New Day Diagnostics; mSept9 validation data",
    "npvNotes": "NPV 99.7-99.8% - negative result reliably rules out CRC",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/ | https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03662-y",
    "performanceNotes": "Multicenter, double-blinded, cross-sectional study at five class A tertiary hospitals in China (Nov 2022-Jul 2023). 1,194 participants. Methylation accuracy validated by Sanger sequencing on 320 samples. Significantly outperformed CEA and CA19-9 tumor markers in paired analysis.",
    "leadTimeNotes": "Non-invasive blood-based alternative to colonoscopy for CRC screening in high-risk populations. Complements stool-based IColocomf test from same vendor.",
    "fdaStatus": "NMPA approved (China); CE-IVD (EU)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). CE marked for European market. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": ["China", "EU"],
    "availableRegionsCitations": "https://www.whaltglobal.com/icolohunter/",
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results. In-lab processing time ~4.5 hours.",
    "sampleType": "Plasma from peripheral blood",
    "sampleVolume": "Blood draw for plasma isolation",
    "cptCode": "N/A (not US market)",
    "listPrice": 275,
    "listPriceNotes": "Approximately $200-$350 USD equivalent based on regional pricing",
    "screeningInterval": "Per physician recommendation",
    "clinicalTrials": "NCT05508503 - multicenter clinical validation trial (1,194 participants across 5 hospitals)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05508503 | https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "totalParticipants": 1194,
    "numPublications": 2,
    "numPublicationsNotes": "2 peer-reviewed publications: BMC Medicine 2024 (multicenter validation, PMID 39379942), Chinese Medical Journal 2025 (SADMP technique development, PMID 40190014)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/ | https://pubmed.ncbi.nlm.nih.gov/40190014/",
    "technologyDifferentiator": "Blood-based (plasma) cfDNA methylation test using dual NTMT1 + MAP3K14-AS1 markers. Novel SADMP (sense-antisense dual-MGB probe) technique provides ~2-fold signal enhancement vs single-strand approaches. Complements vendor's stool-based IColocomf test (SDC2/TFPI2 markers). Blood draw offers higher patient compliance than stool collection. Second Chinese plasma methylation CRC test in OpenOnco database."
  },
  {
    "id": "ecd-17",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "IEsohunter",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (Esophageal)",
    "approach": "Plasma cfDNA methylation",
    "method": "Multiplex quantitative PCR detection of methylated OTOP2 and KCNA3 genes in plasma cell-free DNA. Algorithm-free interpretation strategy using bisulfite conversion and fluorescent quantitative PCR. Proprietary Methylation Navigation Technology (DMLT) and Methylation PCR Sensitization Technology (SEM-PCR).",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/ | https://pubmed.ncbi.nlm.nih.gov/37650127/",
    "cancerTypes": [
      "Esophageal cancer (ESCC and EAC)"
    ],
    "targetPopulation": "High-risk individuals for esophageal cancer screening including: age ≥40, residents of high-incidence areas, history of head/neck cancer, precancerous esophageal lesions, lifestyle risk factors (smoking, alcohol, hot foods), first-degree relatives with esophageal cancer history",
    "indicationGroup": "Esophageal",
    "sensitivity": 87.4,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "sensitivityNotes": "87.4% overall EC sensitivity (95% CI 83.4-90.6) from prospective, double-blinded, multicenter clinical trial (n=1,116) published in J Hematol Oncol 2024.",
    "stageISensitivity": 78.5,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageISensitivityNotes": "Stage I: 78.5% (95% CI 69.1-85.6)",
    "stageIISensitivity": 87.3,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageIISensitivityNotes": "Stage II: 87.3% (95% CI 79.4-92.4)",
    "stageIIISensitivity": 92.5,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageIIISensitivityNotes": "Stage III: 92.5% (95% CI 85.9-96.2)",
    "stageIVSensitivity": 96.9,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageIVSensitivityNotes": "Stage IV: 96.9% (95% CI 84.3-99.8)",
    "hginSensitivity": 52.1,
    "hginSensitivityNotes": "High-grade intraepithelial neoplasia (HGIN): ~52% sensitivity. AUC for HGIN detection: 0.727 (95% CI 0.653-0.801).",
    "specificity": 93.3,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "specificityNotes": "93.3% overall specificity (95% CI 91.2-94.9) vs all controls including healthy controls, benign GI lesions, and other malignancies.",
    "ppv": 18.0,
    "ppvCitations": "Calculated from clinical trial data; high-risk screening population",
    "ppvNotes": "PPV ~18% in high-risk screening population. Lower PPV reflects relatively lower prevalence of esophageal cancer even in high-risk populations.",
    "npv": 98.0,
    "npvCitations": "Clinical trial data; high-risk screening population",
    "npvNotes": "NPV 98% - negative result reliably rules out esophageal cancer",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/ | https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01565-2",
    "performanceNotes": "Prospective, double-blinded, multicenter study at 5 tertiary referral centers across China (Sep 2022-Oct 2023). 1,116 participants: 334 EC, 71 HGIN, 711 controls. AUC for EC detection: 0.903 (95% CI 0.880-0.927). Post-surgical clearance: 100% (47/47) turned negative after EC resection, demonstrating potential for surveillance.",
    "leadTimeNotes": "Non-invasive blood-based alternative to endoscopy for esophageal cancer screening in high-risk populations. First commercially available plasma methylation test for esophageal cancer detection.",
    "fdaStatus": "NMPA approved (China); CE-IVD (EU)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). CE marked for European market. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": ["China", "EU"],
    "availableRegionsCitations": "https://www.whaltglobal.com/iesohunter/",
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results. In-lab processing time ~4.5 hours.",
    "sampleType": "Plasma from peripheral blood",
    "sampleVolume": "10 mL blood",
    "cptCode": "N/A (not US market)",
    "listPrice": 500,
    "listPriceNotes": "Approximately $500 USD equivalent",
    "screeningInterval": "Per physician recommendation",
    "clinicalTrials": "NCT05680077 - prospective multicenter clinical validation trial (1,116 participants across 5 centers)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05680077 | https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "totalParticipants": 1116,
    "numPublications": 2,
    "numPublicationsNotes": "2 verified peer-reviewed publications: J Hematol Oncol 2024 (multicenter prospective validation, PMID 38890756), Chinese Medical Journal 2023 (marker discovery, PMID 37650127)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/ | https://pubmed.ncbi.nlm.nih.gov/37650127/",
    "technologyDifferentiator": "First commercially available plasma cfDNA methylation test for esophageal cancer detection. Dual OTOP2 + KCNA3 markers identified through whole-genome bisulfite sequencing. Algorithm-free interpretation eliminates complex scoring - either marker positive = positive result. Detects both ESCC (predominant in Asia) and EAC (predominant in Western countries). Post-surgical clearance demonstrated (100% negative after resection) suggests utility for recurrence monitoring. Third test from Wuhan Ammunition Life Technology in OpenOnco database (alongside IColocomf and IColohunter)."
  },
  {
    "id": "ecd-18",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "IHepcomf",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (Liver)",
    "approach": "Plasma cfDNA methylation",
    "method": "Triplex quantitative methylation-specific PCR (qMSP) detection of methylated GNB4 and Riplet (RNF135) genes in plasma cell-free DNA. Bisulfite conversion followed by fluorescent quantitative PCR with dual-target interpretation.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/38154055/",
    "cancerTypes": [
      "Primary liver cancer (HCC, ICC, cHCC-ICC)"
    ],
    "targetPopulation": "High-risk individuals for liver cancer screening including: (1) individuals with diabetes, (2) individuals with liver cirrhosis, (3) individuals with chronic hepatitis, (4) individuals with chronic alcohol consumption, (5) individuals with family history of liver cancer, (6) individuals with non-alcoholic fatty liver disease (NAFLD)",
    "indicationGroup": "Liver",
    "sensitivity": 92.3,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/",
    "sensitivityNotes": "92.3% overall PLC sensitivity (95% CI 89.4-94.7) from multicenter, double-blind, cross-sectional study (n=1,182) published in Clinical Epigenetics 2025. HCC-specific sensitivity: 91.9% (95% CI 87.6-95.0). ICC sensitivity: 93.3% (95% CI 85.9-97.5).",
    "stageISensitivity": 84.4,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/39324668/",
    "stageISensitivityNotes": "Stage I HCC: 84.4% per vendor data. Early-stage (TNM I-II combined) PLC: 88.7% (95% CI 83.9-92.5) per primary validation study.",
    "stageIISensitivity": 88.7,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/39324668/",
    "stageIISensitivityNotes": "Early-stage (TNM I-II) PLC: 88.7% (95% CI 83.9-92.5). Stage I HCC: 81.7% per analytical validation study (PMID 39324668).",
    "specificity": 93.4,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/",
    "specificityNotes": "93.4% overall specificity (95% CI 91.3-95.0) vs controls with benign liver disease (BLD) or non-liver primary malignancies (NLPM). Excellent specificity for other cancers: 91.5%, with 100% specificity for breast, lung, and bladder cancer.",
    "ppv": 38.0,
    "ppvCitations": "Clinical trial data; high-risk liver cancer surveillance population",
    "ppvNotes": "PPV ~38% in high-risk surveillance population (cirrhosis, chronic hepatitis, diabetes, NAFLD).",
    "npv": 97.0,
    "npvCitations": "Clinical trial data",
    "npvNotes": "NPV 97% - negative result reliably rules out primary liver cancer",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-025-01920-1",
    "performanceNotes": "Multicenter, double-blind, cross-sectional study at 3 Grade A tertiary hospitals in China (Sep 2022-Aug 2024). 1,182 participants: 430 PLC (including HCC, ICC, cHCC-ICC) and 752 controls. AUC significantly superior to AFP alone. Kappa values >0.99 vs Sanger sequencing confirming analytical accuracy. Post-surgical recurrence detection: 95.8% sensitivity, 100% specificity.",
    "leadTimeNotes": "Non-invasive blood-based alternative to ultrasound + AFP for liver cancer surveillance in high-risk populations. Superior sensitivity to AFP alone, particularly for early-stage detection.",
    "fdaStatus": "NMPA approved (China); CE-IVD (EU)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). CE marked for European market. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": ["China", "EU"],
    "availableRegionsCitations": "https://www.whaltglobal.com/ihepcomf/",
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results.",
    "sampleType": "Plasma from peripheral blood",
    "sampleVolume": "10 mL blood",
    "cptCode": "N/A (not US market)",
    "listPrice": 400,
    "listPriceNotes": "Approximately $400 USD equivalent",
    "screeningInterval": "Per physician recommendation, typically every 6 months for high-risk populations per HCC surveillance guidelines",
    "clinicalTrials": "NCT05668793 - multicenter, double-blind, cross-sectional clinical validation trial (1,182 participants across 3 hospitals)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05668793 | https://pubmed.ncbi.nlm.nih.gov/40624654/",
    "totalParticipants": 1182,
    "numPublications": 4,
    "numPublicationsNotes": "4 verified peer-reviewed publications: Clin Epigenetics 2025 (multicenter validation, PMID 40624654), Cancer Reports 2024 (analytical validation, PMID 39324668), Epigenetics 2024 (marker discovery, PMID 38154055), Front Genet 2022 (CTC combination, PMID 36479252)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/39324668/ | https://pubmed.ncbi.nlm.nih.gov/38154055/ | https://pubmed.ncbi.nlm.nih.gov/36479252/",
    "technologyDifferentiator": "First plasma cfDNA methylation test for primary liver cancer (PLC) in OpenOnco database. Dual GNB4 + Riplet markers detect both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Superior to AFP alone for early-stage detection. Post-surgical recurrence monitoring capability demonstrated (95.8% sensitivity). Fourth test from Wuhan Ammunition Life Technology (alongside IColocomf, IColohunter, and IEsohunter)."
  },
  {
    "id": "ecd-19",
    "sampleCategory": "Urine",
    "sampleVolumeMl": 1.8,
    "name": "IUrisure",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (Urothelial)",
    "approach": "Urine DNA methylation",
    "method": "Methylation-specific PCR (MSP) detection of methylated AL021918.2 and VIM (Vimentin) genes in urine DNA. Requires only 1.8 mL of full-voided urine. Bisulfite conversion followed by fluorescent quantitative PCR with dual-target interpretation.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "cancerTypes": [
      "Urothelial carcinoma (bladder, ureter, renal pelvis)"
    ],
    "targetPopulation": "High-risk individuals for urothelial carcinoma screening including: (1) individuals with gross or microscopic hematuria, (2) long-term smokers, (3) individuals with prolonged exposure to industrial chemicals or aristolochic acid, (4) those with first-degree relatives with family history of urothelial cancer",
    "indicationGroup": "Bladder/Urothelial",
    "sensitivity": 93.94,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "sensitivityNotes": "93.94% overall UC sensitivity from clinical validation study (n=477) published in Chinese Medical Journal 2024. Study conducted at Peking University First Hospital / National Urological Cancer Center.",
    "stageISensitivity": 94.44,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "stageISensitivityNotes": "Ta stage (non-invasive papillary): 94.44% sensitivity. High sensitivity for early-stage non-muscle-invasive bladder cancer.",
    "specificity": 92.02,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "specificityNotes": "92.02% specificity vs controls including other urological carcinomas (renal cell, prostate) and benign diseases.",
    "ppv": 31.0,
    "ppvCitations": "Clinical trial data; hematuria/high-risk population",
    "ppvNotes": "PPV ~31% in high-risk urothelial cancer screening population (hematuria, smokers, chemical exposure).",
    "npv": 99.0,
    "npvCitations": "Clinical trial data",
    "npvNotes": "NPV 99% - negative result strongly rules out urothelial carcinoma",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/ | https://journals.lww.com/cmj/fulltext/2024/01200/an_accurate_diagnostic_approach_for_urothelial.12.aspx",
    "performanceNotes": "Clinical validation at Peking University First Hospital with 477 urine samples: 264 urothelial carcinoma (199 bladder, 39 renal pelvis, 26 ureter) and 213 controls (other urological cancers and benign diseases). Tested across all grades (PUNLMP, low-grade, high-grade) and stages. Novel AL021918.2 marker combined with established VIM biomarker. Small-volume requirement (1.8 mL) enables convenient sample collection.",
    "leadTimeNotes": "Non-invasive urine-based alternative to cystoscopy for urothelial cancer detection. Particularly useful for hematuria workup and bladder cancer surveillance.",
    "fdaStatus": "NMPA approved (China)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). Not CE-IVD marked or FDA approved.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. Not available outside China.",
    "commercialPayers": [],
    "availableRegions": ["China"],
    "availableRegionsCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "clinicalAvailability": "Commercially available in China",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results.",
    "sampleType": "Voided urine",
    "sampleVolume": "1.8 mL urine (minimum)",
    "cptCode": "N/A (not US market)",
    "listPrice": 450,
    "listPriceNotes": "Approximately $450 USD equivalent",
    "screeningInterval": "Per physician recommendation; for surveillance, typically aligned with cystoscopy intervals",
    "clinicalTrials": "ChiCTR2200066864 - clinical validation trial (477 participants) at Peking University First Hospital",
    "clinicalTrialsCitations": "http://www.chictr.org.cn/searchprojen.aspx?btngo=btn&regno=ChiCTR2200066864 | https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "totalParticipants": 477,
    "numPublications": 1,
    "numPublicationsNotes": "1 peer-reviewed publication: Chinese Medical Journal 2024 (clinical validation, PMID 37455255)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "technologyDifferentiator": "First urine-based DNA methylation test for urothelial carcinoma in OpenOnco database. Novel dual-target combination: AL021918.2 (novel marker identified through TCGA/GEO analysis) + VIM (established bladder cancer biomarker). Requires minimal urine volume (1.8 mL) for small-volume convenience. Detects bladder cancer and upper tract urothelial carcinoma (ureter, renal pelvis). Non-invasive alternative to cystoscopy for hematuria workup and surveillance. Fifth test from Wuhan Ammunition Life Technology."
  },
  {
    "id": "ecd-20",
    "sampleCategory": "Blood/Plasma",
    "name": "Avantect Pancreatic Cancer Test",
    "vendor": "ClearNote Health",
    "testScope": "Single-cancer (Pancreatic)",
    "approach": "cfDNA 5-hydroxymethylcytosine (5hmC) profiling",
    "method": "Epigenomic profiling of 5-hydroxymethylcytosine (5hmC) signatures in cell-free DNA using targeted enrichment and next-generation sequencing, combined with machine learning algorithm integrating genomic features for pancreatic cancer signal detection.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/39230538/ | https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "cancerTypes": [
      "Pancreatic cancer (pancreatic ductal adenocarcinoma)"
    ],
    "targetPopulation": "High-risk adults: (1) Age 50+ with new-onset type 2 diabetes diagnosed within 36 months, (2) Genetic predisposition to pancreatic cancer, (3) Family history of pancreatic cancer",
    "indicationGroup": "Pancreatic",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; pancreatic-specific",
    "sensitivity": 68.3,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "sensitivityNotes": "68.3% sensitivity for early-stage (stage I/II) pancreatic cancer (95% CI: 51.9%-81.9%) in blinded validation cohort. Overall sensitivity across all stages not separately reported.",
    "stageISensitivity": 68.3,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "stageISensitivityNotes": "Stage I/II combined: 68.3% (95% CI: 51.9%-81.9%). Individual stage I data not separately reported.",
    "stageIISensitivity": 68.3,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "stageIISensitivityNotes": "Stage I/II combined: 68.3% (95% CI: 51.9%-81.9%)",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Late-stage (III/IV) sensitivity not separately reported in validation study",
    "stageIVSensitivity": null,
    "stageIVSensitivityNotes": "Late-stage (III/IV) sensitivity not separately reported in validation study",
    "specificity": 96.9,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "specificityNotes": "96.9% overall specificity (95% CI: 96.1%-97.7%) vs non-cancer controls and non-pancreatic cancers combined in blinded validation cohort.",
    "ppv": 25.0,
    "ppvCitations": "ClinicalTrials.gov NCT06803771; Avantect Official Site; based on high-risk (new-onset diabetic) population",
    "ppvNotes": "PPV ~25% in high-risk population (new-onset diabetics). Higher PPV than general screening due to elevated pancreatic cancer prevalence in this risk group.",
    "npv": 99.0,
    "npvCitations": "ClearNote Health clinical data; high-risk screening population",
    "npvNotes": "NPV 99% - negative result strongly rules out pancreatic cancer in high-risk population",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/ | https://pubmed.ncbi.nlm.nih.gov/39230538/",
    "performanceNotes": "Blinded validation cohort: 3,674 participants (102 pancreatic cancer, 2,048 non-cancer, 1,524 non-pancreatic cancers). Analytical validation showed 100% precision concordance in biological replicates, sample stability up to 7 days post-collection, and >95% concordance with EM-Seq method. LOD studies showed equal performance between early- and late-stage samples.",
    "leadTimeNotes": "Designed for early detection in high-risk populations before clinical presentation. Pancreatic cancer diagnosed at stage I has >80% five-year survival vs <10% at stage IV.",
    "fdaStatus": "LDT (CLIA #05D2249973, CAP #9219174); NYSDOH approved; not FDA cleared",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare $1,160 (CPT 0410U, effective Jan 2024); commercial coverage expanding via Claritev/PHCS/MultiPlan networks",
    "commercialPayers": [],
    "commercialPayersCitations": "https://www.clearnotehealth.com/press-release/avantect-pancreatic-cancer-test-receives-cpt-code-and-preliminary-payment-determination-from-the-centers-for-medicare-and-medicaid-services/",
    "commercialPayersNotes": "ClearNote Health accepts all insurance and bills payers directly. Claritev (formerly MultiPlan) national PPO network agreement provides access for health plan members. Financial assistance program available with self-pay rates $0-495 based on financial need.",
    "availableRegions": ["US", "International"],
    "clinicalAvailability": "Commercially available in US; international distribution agreements covering 50+ countries; Quest Diagnostics phlebotomy partnership",
    "tat": "Results typically within 2 weeks",
    "sampleType": "Whole blood",
    "sampleVolume": null,
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "0410U",
    "codeType": "PLA",
    "medicareRate": 1160,
    "medicareStatus": "Priced",
    "medicareEffective": "2024-01-01",
    "adltStatus": false,
    "listPrice": 495,
    "listPriceNotes": "Self-pay/financial assistance rate $0-495; Medicare rate $1,160",
    "screeningInterval": "Not specified; clinical judgment based on risk factors",
    "clinicalTrials": "Selected for NCI Vanguard Multicancer Detection study; PRECEDE Consortium member",
    "clinicalTrialsCitations": "https://www.clearnotehealth.com/about-us/",
    "totalParticipants": 3674,
    "totalParticipantsNotes": "Blinded validation cohort: 102 PaC + 2,048 non-cancer + 1,524 non-PaC cancers. Training cohort: 132 PaC + 528 non-cancer.",
    "numPublications": 2,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/ | https://pubmed.ncbi.nlm.nih.gov/39230538/",
    "numPublicationsNotes": "2 peer-reviewed publications: Clin Gastroenterol Hepatol 2023 (clinical validation, PMID 36967102), J Mol Diagn 2024 (analytical validation, PMID 39230538). Both authored by ClearNote Health employees.",
    "technologyDifferentiator": "First commercially available single-cancer ECD test for pancreatic cancer in OpenOnco database. Uses 5-hydroxymethylcytosine (5hmC) profiling rather than standard 5-methylcytosine (5mC) methylation—5hmC is an oxidized derivative of 5mC with distinct tissue-specific patterns. Targets defined high-risk population (new-onset T2DM, genetic predisposition, family history) rather than general population screening. Strong specificity (96.9%) critical for screening context where false positives lead to unnecessary workup.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-16: Initial submission by Adrian Vilalta (ClearNote Health). 2026-01-07: Vendor verified data accuracy - no changes requested."
  },
  {
    "id": "ecd-25",
    "sampleCategory": "Saliva",
    "name": "CancerDetect Oral & Throat",
    "vendor": "Viome",
    "testScope": "Single-cancer (Oral/Throat)",
    "approach": "Saliva-based metatranscriptomic screening",
    "method": "RNA-based metatranscriptomic profiling of host and microbial gene expression in saliva, analyzed via machine-learning classifier to detect molecular signatures associated with OSCC and OPSCC",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://www.nature.com/articles/s41525-021-00257-x",
    "cancerTypes": [
      "Oral squamous cell carcinoma (OSCC)",
      "Oropharyngeal squamous cell carcinoma (OPSCC)"
    ],
    "cancerTypesNotes": "Detects molecular features in saliva associated with oral cavity and throat cancers; similar sensitivity for early and late-stage cancers",
    "targetPopulation": "Adults ≥50 years OR adults ≥18 with tobacco use history (current or past)",
    "indicationGroup": "Oral/Throat Cancer",
    "sensitivity": 90,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://cancerdetect.viome.com/",
    "sensitivityNotes": "90% sensitivity for OSCC; 84.2-90% for OPSCC depending on source. Similar performance across early (Stage I/II) and late (Stage III/IV) stages per validation study.",
    "specificity": 95,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://cancerdetect.viome.com/",
    "specificityNotes": "94-95% specificity across validation cohorts; 97.9% observed in larger technical validation (n=282)",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://www.nature.com/articles/s41525-021-00257-x",
    "performanceNotes": "Validation cohort of 230 samples (20 OSCC, 76 OPSCC, 134 controls). Earlier Nature study (n=433) showed ROC AUC 0.87 for high-risk population, 0.9+ for OC-only cohort.",
    "fdaStatus": "LDT - FDA Breakthrough Device Designation",
    "fdaStatusNotes": "Lab-developed test performed in CLIA-certified laboratory (Bothell, WA). Received FDA Breakthrough Device designation for accelerated review. Not FDA-approved/cleared.",
    "reimbursement": "Self-pay",
    "reimbursementNote": "Direct-to-consumer test; no insurance coverage. Available via healthcare providers through ViomePRO.",
    "availableRegions": ["US"],
    "clinicalAvailability": "Commercially available in US (not available in NY due to state regulations)",
    "tat": "~28 days",
    "tatNotes": "Expect results within 4 weeks per vendor",
    "sampleType": "Saliva rinse (at-home collection)",
    "sampleVolume": "Saliva rinse kit provided",
    "listPrice": 599,
    "listPriceNotes": "$599 list price; promotional pricing available ($299 with DETECT code). Includes healthcare provider consultation if positive result.",
    "numPublications": 2,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://www.nature.com/articles/s41525-021-00257-x",
    "numPublicationsNotes": "Banavar et al. Oral Oncology 2023 (validation study, n=1,175); Banavar et al. npj Genomic Medicine 2021 (discovery study, n=433). Both from Viome Research Institute.",
    "totalParticipants": 1175,
    "validationCohortSize": 230,
    "validationCohortStudy": "Prospective validation on 230 samples (20 OSCC, 76 OPSCC, 134 negatives including 14 pre-malignant) from high-risk population ≥50 years or with tobacco history",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-certified LDT with FDA Breakthrough Device designation; not FDA-approved",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-01-01: Initial submission by Momchilo Vuyisich (Viome) with peer-reviewed publications. Vendor verified via email momo@viome.com."
  },
  {
    "id": "ecd-26",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "Trucheck Intelli",
    "vendor": "Datar Cancer Genetics",
    "category": "ECD",
    "dateAdded": "Jan 7, 2026",
    "testScope": "Multi-cancer (70+ types)",
    "approach": "Circulating tumor cell (CTC) analysis",
    "method": "Analyzes circulating tumor cells from peripheral blood using epigenetically activated medium for cell stabilization, followed by fluorophore-conjugated antibody characterization against multiple immunocytochemistry markers; quantitative fluorescence imaging on high-content screening platform",
    "methodCitations": "https://uk.datarpgx.com/trucheck-non-invasive-blood-tests | https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22366",
    "cancerTypes": [
      "Adenocarcinoma (21 sites)",
      "Adenosquamous Carcinoma",
      "CNS Malignancies",
      "Gastrointestinal Stromal Tumors",
      "Melanomas",
      "Mesothelioma",
      "Neuroendocrine Tumors",
      "Squamous Cell Carcinoma (20 sites)",
      "Transitional Cell Carcinoma"
    ],
    "cancerTypesNotes": "70+ cancer types across major histological subtypes including AD (bile duct, breast, colon, lung, ovary, pancreas, prostate, etc.), SCC (oral, lung, cervix, skin, etc.), NET, GIST, melanoma, mesothelioma, CNS tumors, and TCC",
    "targetPopulation": "Asymptomatic individuals",
    "indicationGroup": "Multi-Cancer Early Detection",
    "sensitivity": 88.2,
    "sensitivityCitations": "https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22366",
    "sensitivityNotes": "88.24% sensitivity in multi-cancer validation study; based on detection of circulating tumor-associated cell clusters",
    "specificity": 96.3,
    "specificityCitations": "https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22366",
    "specificityNotes": "96.3% specificity in clinical validation",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/31743438/ | https://pubmed.ncbi.nlm.nih.gov/33029899/ | https://pubmed.ncbi.nlm.nih.gov/32898291/",
    "performanceNotes": "Validated across multiple peer-reviewed publications; hallmark CTC clusters signify 230x higher one-year cancer risk",
    "fdaStatus": "CE-IVD",
    "fdaStatusNotes": "CE-IVD marked in Europe; not FDA-cleared in US",
    "reimbursement": "Self-pay / varies by region",
    "reimbursementNote": "Coverage varies by country; primarily self-pay",
    "availableRegions": ["EU", "UK", "International"],
    "clinicalAvailability": "Commercially available (CE-IVD)",
    "tat": "Up to 14 working days",
    "tatNotes": "14 working days from sample receipt",
    "sampleType": "Venous blood (EDTA)",
    "sampleVolume": "10ml",
    "listPrice": null,
    "listPriceNotes": "Contact vendor for pricing",
    "numPublications": 3,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/31743438/ | https://pubmed.ncbi.nlm.nih.gov/33029899/ | https://pubmed.ncbi.nlm.nih.gov/32898291/",
    "numPublicationsNotes": "Akolkar et al. Int J Cancer 2019 (circulating tumor-associated cell ensembles); Gaya et al. Cancer Cytopathol 2020 (pan-cancer diagnostic triaging); Ranade et al. Cancer Prev Res 2021 (230x one-year cancer risk)",
    "totalParticipants": 40000,
    "totalParticipantsPlus": true,
    "validationCohortSize": 1000,
    "validationCohortStudy": "Multi-center validation across >40,000 participants per vendor; peer-reviewed studies include diagnostic triaging cohort",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "CE-IVD marked; uses CTC approach distinct from ctDNA-based MCED tests",
    "vendorVerified": false,
    "technologyDifferentiator": "CTC-based approach (not ctDNA) - analyzes intact circulating tumor cells rather than fragmented DNA; enables detection of tumor-associated cell clusters which correlate with higher cancer risk; 70+ cancer type coverage using immunocytochemistry markers",
    "submissionInfo": {
      "submittedBy": "Jigar Pandya",
      "submitterEmail": "jigar.pandya@datarpgx.org",
      "submitterType": "expert",
      "submittedDate": "2026-01-07"
    }
  },
  {
    "id": "ecd-27",
    "sampleCategory": "Blood/Plasma",
    "name": "OncoXPLORE+",
    "vendor": "OncoDNA",
    "category": "ECD",
    "dateAdded": "Jan 8, 2026",
    "testScope": "Multi-cancer",
    "approach": "Multi-modal (mutations + CNV + fragmentomics)",
    "method": "Integrates three parallel analytical tracks from a single blood sample: (1) 441-gene targeted panel covering 1.5 Mb including all exonic regions and 20bp flanking regions for SNVs, Indels, fusions, and splicing variants; (2) genome-wide Copy Number Alteration (CNA) profiling via LP-WGS; (3) GIPXplore fragmentomics module using proprietary ML pipeline analyzing genome-wide cfDNA fragmentation signatures for cancer detection and Tissue-of-Origin inference. Built on 15+ years of KU Leuven research.",
    "methodCitations": "https://www.nature.com/articles/s41467-024-46435-0 | https://oncngs.eu | https://oncodna.com",
    "cancerTypes": [
      "Multi-solid tumors",
      "Hematological malignancies"
    ],
    "cancerTypesNotes": "Pan-cancer detection capability; fragmentomics module can infer Tissue-of-Origin for localization. Specific validation data for colorectal cancer, breast cancer, and multiple myeloma.",
    "cancerTypesCitations": "https://www.nature.com/articles/s41467-024-46435-0",
    "targetPopulation": "High-risk asymptomatic individuals, NSAS triage, therapy selection when tissue unavailable",
    "indicationGroup": "Multi-Cancer Early Detection",
    "sensitivity": 53.5,
    "sensitivityCitations": "https://www.nature.com/articles/s41467-024-46435-0 | Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "sensitivityNotes": "~53.5% sensitivity for early-stage cancers at ~99% specificity in asymptomatic screening context. GIPXplore classifier achieved 81.62% overall accuracy with 95% specificity for pan-cancer detection. Cancer-specific AUCs from Nature Comms study: Multiple Myeloma 95.0%, Early-Stage Breast Cancer 90.1%, Colorectal Cancer 84.7%.",
    "specificity": 99,
    "specificityCitations": "https://www.nature.com/articles/s41467-024-46435-0 | Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "specificityNotes": "~99% specificity in early-stage screening context. 95% specificity for pan-cancer GIPXplore classifier. Near 100% specificity for all variant types on targeted panel.",
    "tissueOfOrigin": true,
    "tissueOfOriginAccuracy": 88.7,
    "tissueOfOriginNotes": "88.7% TOO accuracy for true positives using fragmentomics-based cell type deconvolution. Leverages cell-type-specific epigenetic patterns; can identify contributions from 490+ cell types.",
    "tissueOfOriginCitations": "https://www.nature.com/articles/s41467-024-46435-0",
    "lod": "0.3% VAF",
    "lodNotes": "Analytical LoD near 0.3% VAF for targeted 441-gene panel. Technical sensitivity: 88.6% at 0.5% VAF, >93% at 1% VAF, >93% at 2% VAF.",
    "lodCitations": "Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "genesAnalyzed": 441,
    "genesAnalyzedNotes": "441-gene targeted panel covering 1.5 Mb content. Detects SNVs, Indels, fusions, and unusual splicing. Complemented by genome-wide LP-WGS for CNA profiling.",
    "genesAnalyzedCitations": "https://oncodna.com | Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "fdaStatus": "RUO (CE-IVDR planned)",
    "fdaStatusNotes": "Currently Research Use Only (RUO) kit for collaborative projects. CE-IVDR technical file submission planned for end of 2026. One of only 2 finalists in EU OncNGS Pre-Commercial Procurement project.",
    "reimbursement": "Not applicable (investigational)",
    "reimbursementNote": "RUO product; no reimbursement pathway currently",
    "availableRegions": ["EU (RUO)"],
    "clinicalAvailability": "RUO kit for collaborative projects; Phase 3 OncNGS clinical validation ongoing through March 2026",
    "clinicalTrials": "OncNGS Phase 3 clinical validation at 7 European pilot hospitals including Institut Curie (France), Ludwig Maximilians University (Germany), Institut Jules Bordet (Belgium)",
    "clinicalTrialsCitations": "https://oncngs.eu/index.php/phase3/",
    "totalParticipants": null,
    "validationCohortSize": 744,
    "validationCohortStudy": "Nature Communications 2024 study: 744 healthy individuals and patients (Stanley et al.)",
    "numPublications": 2,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/38472221/ | https://academic.oup.com/bioinformatics/article/40/9/btae522/7739698",
    "numPublicationsNotes": "Stanley/Vermeesch et al., Nature Communications 2024 (cell type signatures in cfDNA fragmentation); Passemiers/Vermeesch et al., Bioinformatics 2024 (MetDecode methylation-based deconvolution). Additional OncNGS consortium publications in progress.",
    "isRUO": true,
    "isInvestigational": true,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "RUO product in OncNGS Phase 3 clinical validation (through March 2026). CE-IVDR submission planned end of 2026. Integrated into OncoKDM platform (registered medical device, GDPR compliant).",
    "technologyDifferentiator": "Multi-modal liquid biopsy combining mutations + CNV + fragmentomics in single workflow. GIPXplore fragmentomics leverages cell-type-specific epigenetic patterns to detect cancer signals even when specific mutations are unknown or at very low concentrations. Tumor-naïve approach - no prior tissue biopsy required. Built on 15+ years of KU Leuven research. One of only 2 finalists in EU OncNGS Pre-Commercial Procurement.",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Initial submission by Christophe Van Huffel (OncoDNA) with detailed vendor responses to clarification questions. Performance data from Nature Communications 2024 and internal validation cohorts.",
    "submissionInfo": {
      "submittedBy": "Christophe Van Huffel",
      "submitterEmail": "c.vanhuffel@oncodna.com",
      "submitterType": "vendor",
      "submittedDate": "2025-12-09",
      "clarificationDate": "2026-01-08"
    }
  }
];

// TRM Tests
export const trmTestData = [
  {
    "id": "trm-1",
    "sampleCategory": "Blood/Plasma",
    "name": "Guardant360 Response",
    "vendor": "Guardant Health",
    "approach": "Tumor-agnostic",
    "method": "Hybrid-capture NGS ctDNA panel (Guardant360) with algorithmic quantitation of variant allele fraction changes over time",
    "cancerTypes": [
      "Advanced solid tumors (NSCLC, bladder, breast, GI, others)"
    ],
    "targetPopulation": "Patients with measurable or evaluable advanced solid tumors starting systemic therapy",
    "responseDefinition": "≥50% decrease in ctDNA level from baseline to first on-treatment time point; increase from baseline defines molecular non-response",
    "leadTimeVsImaging": 56.0,
    "leadTimeVsImagingNotes": "Guardant Response can predict treatment response approximately 8 weeks (~56 days) earlier than standard imaging assessments.",
    "leadTimeVsImagingCitations": "https://guardanthealth.com/products-services/guardant-response/ | Guardant Health Response product page",
    "lod": "~0.1–0.2% VAF",
    "lodNotes": "Analytical validation demonstrates detection sensitivity down to ~0.1% MAF (mutant allele fraction) with high accuracy. Detection range 0.1%–0.8% VAF depending on variant type and sample characteristics.",
    "lodCitations": "https://pubmed.ncbi.nlm.nih.gov/26474073/ | Lanman RB et al. PLoS One 2015;10(10):e0140712; https://guardanthealth.com/ | Guardant360 CDx technical specifications",
    "fdaStatus": "DISCONTINUED - CLIA LDT no longer available",
    "tat": "7-14 days",
    "tatNotes": "When available, TAT was 7-14 days based on Guardant360 platform turnaround time.",
    "reimbursement": "N/A - Discontinued",
    "reimbursementNote": "Product sun-setted December 2025. Guardant has consolidated to Reveal MRD (early-stage) and Reveal TRM (advanced/metastatic) for monitoring applications.",
    "clinicalTrials": "SERENA-6 Phase III ESR1-mutant advanced breast cancer (866); clinical validation supported by 40+ studies using Guardant360 platform for ctDNA response assessment",
    "totalParticipants": 866,
    "numPublications": 40,
    "numPublicationsPlus": true,
    "isDiscontinued": true,
    "discontinuedDate": "December 2024",
    "discontinuedReason": "Product consolidated into Reveal TRM for therapy response monitoring"
  },
  {
    "id": "trm-2",
    "sampleCategory": "Blood/Plasma",
    "name": "Signatera (IO Monitoring)",
    "vendor": "Natera",
    "approach": "Tumor-informed",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Tumor-informed; needs primary tumor tissue.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Matched normal blood required.",
    "method": "Personalized amplicon-based NGS panels targeting 16+ patient-specific variants identified from tumor/normal sequencing",
    "cancerTypes": [
      "Any solid tumor on ICI therapy"
    ],
    "targetPopulation": "Patients with advanced or metastatic solid tumors starting ICI monotherapy or ICI-based combinations",
    "responseDefinition": "Change in personalized ctDNA level from baseline to beginning of cycle 3 (~6 weeks); increase vs decrease vs clearance",
    "lod": "~0.01% VAF",
    "lodNotes": "Analytical validation demonstrates LoD ~0.01% VAF (2 mutant haploid genomes among 20,000 normals), with ≥95% sensitivity and ~99–99.7% specificity at this level. Detection rule requires 2 of 16 tracked variants to call positive.",
    "lodCitations": "https://www.natera.com/oncology/signatera-mrd-test/clinical-evidence/ | Natera Signatera clinical evidence",
    "fdaStatus": "LDT in CLIA/CAP lab; covered by Medicare for ICI treatment response monitoring",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare-covered under LCD L38779 for colorectal, breast, bladder, ovarian, and lung cancers, including ovarian cancer in adjuvant/surveillance settings, neoadjuvant and adjuvant breast cancer, and stage I–III NSCLC surveillance, as well as pan-cancer immunotherapy response monitoring. As of June 2025, the genome-based Signatera Genome assay has matching Medicare coverage for these indications.",
    "commercialPayers": ["UnitedHealthcare", "Cigna", "Anthem BCBS", "BCBS Louisiana", "Blue Shield of California"],
    "commercialPayersCitations": "https://www.natera.com/oncology/billing/",
    "commercialPayersNotes": "Natera is in-network with most major health plans including Cigna, UnitedHealthcare, and Blue Shield of California. BCBS Louisiana provides explicit coverage. Note: Aetna lists Signatera codes as in-network but current policies show non-covered; verify with plan.",
    "clinicalTrials": "NCT04660344 IMvigor011 Phase III bladder cancer (760); NCT05987241 MODERN (Alliance A032103) Phase 2/3 bladder cancer (~400 target); BESPOKE IO prospective observational study (multi-center)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04660344 | https://clinicaltrials.gov/study/NCT05987241",
    "totalParticipants": 1160,
    "tat": "7-10 days",
    "tatNotes": "Subsequent blood draws have 7-10 day turnaround. Initial test design takes 3-4 weeks.",
    "tatCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/",
    "numPublications": 125,
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Merkel Cell Carcinoma V.2.2025",
    "nccnGuidelinesNotes": "NCCN includes positive recommendation for ctDNA monitoring in surveillance for MCC (where ICI is standard therapy), citing Signatera data.",
    "nccnGuidelinesCitations": "https://www.natera.com/company/news/nccn-strengthens-guidance-on-ctdna-in-colon-cancer-rectal-cancer-and-merkel-cell-carcinoma/"
  },
  {
    "id": "trm-3",
    "sampleCategory": "Blood/Plasma",
    "name": "NeXT Personal",
    "vendor": "Personalis",
    "approach": "Tumor-informed",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires WGS of tumor tissue to design personalized panel.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Matched normal blood required for germline filtering.",
    "method": "Whole-genome sequencing of tumor and matched normal with design of personalized panels targeting up to ~1,800 variants; deep sequencing of plasma cfDNA",
    "cancerTypes": [
      "Multiple solid tumors (breast, colorectal, NSCLC, melanoma, renal, others)"
    ],
    "targetPopulation": "Patients with solid tumors after curative-intent therapy (MRD) and those on systemic therapy",
    "responseDefinition": "Quantitative change in ctDNA signal (PPM) over time; molecular response often defined as deep decrease or clearance below limit of detection",
    "lod": "~3.45 ppm (≈0.000345% VAF)",
    "lodNotes": "3.45 ppm is the LoD95 (limit of detection at 95% confidence). Detection threshold is ~1.67 ppm. WGS-based tumor-informed tracking with up to 1,800 variants provides high sensitivity for low-burden disease.",
    "lodCitations": "https://www.personalis.com/next-personal-assay-performance/ | Personalis NeXT Personal analytical validation",
    "fdaStatus": "High-complexity LDT in CLIA/CAP lab; not FDA-approved",
    "reimbursement": "Medicare coverage for select solid tumor indications including stage II-III breast cancer surveillance",
    "reimbursementNote": "Co-commercialized with Tempus AI as xM (NeXT Personal Dx), with Tempus serving as the exclusive commercial diagnostic partner for tumor-informed MRD in breast, lung, colorectal cancers and solid-tumor immunotherapy monitoring. Clinically launched within Tempus’ MRD portfolio and covered by Medicare for select solid tumor indications (for example, stage II–III breast cancer surveillance).",
    "clinicalTrials": "NCT06230185 B-STRONGER I TNBC MRD/monitoring study (422); VICTORI resectable colorectal cancer MRD study (~71, interim cohort)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06230185",
    "totalParticipants": 493,
    "tat": "7-10 days",
    "tatNotes": "Subsequent monitoring blood draws typically 7-10 days. Initial WGS and panel design ~3-4 weeks.",
    "numPublications": 5,
    "numPublicationsPlus": true
  },
  {
    "id": "trm-4",
    "sampleCategory": "Blood/Plasma",
    "name": "Tempus xM for TRM",
    "vendor": "Tempus",
    "approach": "Tumor-naïve",
    "method": "Algorithmic estimation of ctDNA tumor fraction from Tempus xF/xF+ liquid biopsy data using diverse genomic events and germline-informed modeling",
    "cancerTypes": [
      "Advanced solid tumors on ICI"
    ],
    "targetPopulation": "Patients with advanced cancers receiving ICI-based therapy",
    "responseDefinition": "≥50% reduction in ctDNA tumor fraction from baseline to early on-treatment time point (e.g., post-cycle 1)",
    "lod": "~0.1% VAF",
    "lodNotes": "LoD inferred from Tempus xF/xF+ platform specifications and general hybrid-capture ctDNA literature. Not explicitly validated for the TRM-specific application; most published data are for MRD (GALAXY/CIRCULATE-Japan analyses).",
    "lodCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/ | Tempus xF/xM technical documentation",
    "fdaStatus": "Research-use-only biomarker and clinical-development tool",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Currently available for research use only, with clinical availability expected later in 2025 per Tempus’ June 2025 xM for TRM announcement; used mainly in research and biopharma collaborations and not yet a standard reimbursed clinical assay.",
    "numPublications": 3,
    "tat": "5-7 days",
    "tatNotes": "TAT similar to Tempus xF/xF+ liquid biopsy platform (5-7 days from sample receipt).",
    "numPublicationsPlus": true
  },
  {
    "id": "trm-5",
    "sampleCategory": "Blood/Plasma",
    "name": "RaDaR",
    "vendor": "NeoGenomics",
    "approach": "Tumor-informed",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Tumor-informed (WES of tumor); personalized panel designed from tumor variants.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Buffy coat matched normal used for germline filtering.",
    "method": "Personalized amplicon-based NGS panels (up to ~48 variants) designed from WES of tumor and matched normal; deep ctDNA sequencing",
    "cancerTypes": [
      "Multiple solid tumors (breast, melanoma, colorectal, head & neck, lung, others)"
    ],
    "targetPopulation": "High-risk early-stage and advanced solid-tumor patients followed longitudinally after treatment or on systemic therapy",
    "responseDefinition": "Track ctDNA levels over serial time points; response often defined as rapid fall or clearance vs persistent or rising ctDNA",
    "lod": "0.001% VAF",
    "lodNotes": "Analytical LoD ~0.001% VAF (~10 ppm), consistent with RaDaR ST MRD assay specifications. Earlier claims of 10⁻⁵–10⁻⁶ were not supported by peer-reviewed validation data.",
    "lodCitations": "https://neogenomics.com/test-menu/radar | NeoGenomics RaDaR product specifications",
    "fdaStatus": "LDT in NeoGenomics CLIA/CAP lab; not FDA-approved",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Used in clinical research and select clinical programs; payer coverage still emerging. NeoGenomics has also introduced a WES-based RaDaR ST assay, currently positioned for biopharma partners and interventional trials.",
    "commercialPayers": ["Blue Shield of California"],
    "commercialPayersCitations": "https://www.decibio.com/",
    "commercialPayersNotes": "Blue Shield of California covers RaDaR. Coverage is still emerging for TRM applications.",
    "clinicalTrials": "ISLB 2025 bridging study (166; 15 solid tumor types; 97% concordance RaDaR ST vs RaDaR 1.0); c-TRAK TN TNBC study (161); TRACER breast cancer MRD study (~100); CHiRP breast cancer study (~100); NABUCCO bladder cancer study (54); LUCID NSCLC study (88); CLEAR-Me melanoma study (66)",
    "totalParticipants": 735,
    "tat": "7 days",
    "tatNotes": "RaDaR plasma cfDNA analysis: 7 days. Initial panel design and development: 4 weeks.",
    "tatCitations": "https://neogenomics.com/test-menu/radarr",
    "numPublications": 15,
    "numPublicationsPlus": true
  },
  {
    "id": "trm-6",
    "sampleCategory": "Blood/Plasma",
    "name": "FoundationOne Tracker (TRM)",
    "vendor": "Foundation Medicine / Natera",
    "approach": "Tumor-informed",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires prior or concurrent tumor CGP by FoundationOne CDx to identify patient-specific somatic variants for personalized panel design.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Germline and CHIP filtering performed computationally without mandatory matched-normal sequencing.",
    "method": "Personalized ctDNA assay derived from FoundationOne CDx tumor sequencing; multiplex PCR–based plasma assay quantifies mean tumor molecules per mL (MTM/mL) over time to track treatment response in patients with advanced solid tumors.",
    "cancerTypes": [
      "Advanced solid tumors (all solid tumors)"
    ],
    "targetPopulation": "Patients with advanced solid tumors receiving systemic therapy, particularly immune checkpoint inhibitor (ICI) therapy. Medicare coverage specifically for ICI response monitoring.",
    "responseDefinition": "Continuous change in ctDNA level (MTM/mL) from baseline to early on-treatment timepoints; molecular response (ctDNA decline or clearance) correlates with improved PFS and OS.",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "Studies in NSCLC (IMpower131) showed ctDNA clearance preceded imaging response; in OMICO-MoST study, ctDNA clearance preceded scan response with median lead time of 11.5 months in complete responders.",
    "lod": "≥5 mean tumor molecules/mL",
    "lodCitations": "https://assets.ctfassets.net/w98cd481qyp0/McnwKHMvPB5gG1RIlUlPT/f2c1465e602b97a37d989f71c2c1ac88/FoundationOne_Tracker_Technical_Specifications.pdf",
    "fdaStatus": "CLIA clinical LDT for treatment response monitoring – NOT separately FDA cleared/approved",
    "fdaStatusCitations": "Foundation Medicine press release October 2023.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via Palmetto GBA MolDX, effective June 17, 2023, for monitoring response to immune checkpoint inhibitor (ICI) therapy in all solid tumors. Also approved through New York CLEP. Commercial payer coverage varies.",
    "reimbursementCitations": "Foundation Medicine/Natera press release October 10, 2023.",
    "cptCodesNotes": "Billing via MolDX program; specific PLA code TBD.",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "US: Medicare covered for ICI monitoring. International: Available via Roche global network.",
    "clinicalAvailability": "Broadly available to all U.S. physicians since October 2023 for treatment response monitoring; available internationally via Roche affiliates.",
    "clinicalTrials": "IMpower131 (NSCLC, Kasi et al. Clin Cancer Res 2023); OMICO-MoST (pan-cancer immunotherapy); multiple interventional studies.",
    "clinicalTrialsCitations": "Kasi PM et al. Clin Cancer Res 2023; OMICO-MoST (Mol Oncol 2023).",
    "totalParticipants": null,
    "tat": "7-10 days",
    "tatNotes": "Subsequent monitoring blood draws 7-10 days TAT. Initial panel design from FoundationOne CDx results.",
    "numPublications": 4,
    "numPublicationsPlus": true,
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Clinical LDT with Medicare coverage for TRM of ICI therapy. Broad clinical launch October 2023. MolDX coverage effective June 17, 2023. Uses the same personalized ctDNA technology as the MRD application but is commercially available for TRM while MRD remains investigational."
  },
  {
    "id": "trm-7",
    "sampleCategory": "Blood/Plasma",
    "name": "FoundationOne Monitor",
    "vendor": "Foundation Medicine",
    "approach": "Tumor-naïve",
    "method": "324-gene hybrid-capture ctDNA NGS assay built on the FoundationOne Liquid CDx platform; reports ctDNA tumor fraction (%) and percent change over time while detecting SNVs, indels, CNAs, rearrangements, and complex biomarkers (bTMB, MSI).",
    "cancerTypes": [
      "Advanced solid tumors"
    ],
    "targetPopulation": "Patients with advanced or metastatic solid tumors enrolled in clinical trials where longitudinal ctDNA tumor fraction and emerging resistance mutations are monitored.",
    "responseDefinition": "Percentage change in ctDNA tumor fraction between baseline and early on-treatment timepoints; incorporates multi-omic information (aneuploidy, VAFs, CNVs, fragment length) with CHIP filtering.",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "In mCRPC study (IMbassador250), ctDNA tumor fraction detected treatment response earlier than radiographic progression.",
    "lod": "≥5 mean tumor molecules/mL (MTM/mL)",
    "lodNotes": "5 MTM/mL is the validated LoD threshold. This is sample-level mean tumor molecules, not VAF. Analytical sensitivity varies by sample input, tumor characteristics, and variant type.",
    "lodCitations": "https://pubmed.ncbi.nlm.nih.gov/32976510/ | Woodhouse R et al. PLoS One 2020;15:e0237802; https://www.foundationmedicine.com/ | Foundation Medicine technical documentation",
    "fdaStatus": "Clinical LDT – built on FDA-approved FoundationOne Liquid CDx platform; not separately FDA approved",
    "fdaStatusCitations": "Foundation Medicine press release June 2023; Foundation Medicine monitoring portfolio.",
    "reimbursement": "No specific coverage",
    "reimbursementNote": "Clinical LDT without dedicated reimbursement pathway; coverage may depend on institution and context.",
    "cptCodesNotes": "No specific CPT codes; may be billed under general CGP codes.",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "Available via Foundation Medicine and Roche global network.",
    "clinicalAvailability": "Available as clinical LDT in US and internationally via Roche. Initially launched June 2023 for biopharma partners; now available for clinical use.",
    "clinicalTrials": "IMbassador250 (mCRPC, enzalutamide ± atezolizumab); multiple biopharma-sponsored early-phase and response-adaptive studies.",
    "clinicalTrialsCitations": "Sweeney CJ et al. Clin Cancer Res 2024;30:4115-4122.",
    "totalParticipants": null,
    "tat": "10-14 days",
    "tatNotes": "Standard liquid biopsy TAT similar to FoundationOne Liquid CDx platform.",
    "numPublications": 3,
    "numPublicationsPlus": true,
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Tissue-naïve ctDNA tumor-fraction assay for TRM and resistance detection. Available as clinical LDT built on FDA-approved FoundationOne Liquid CDx platform. No dedicated payer coverage pathway yet. Positioned as option when tumor tissue is not available."
  },
  {
    "id": "trm-8",
    "sampleCategory": "Blood/Plasma",
    "name": "Northstar Response",
    "vendor": "BillionToOne",
    "approach": "Tumor-naïve",
    "method": "Single-molecule NGS (smNGS) with patented Quantitative Counting Templates (QCT) technology; measures >2200 cancer-specific methylated genomic loci (v2, expanded from >500 in v1); provides absolute quantification of methylated ctDNA molecules with WBC noise filtering via buffy coat sequencing.",
    "cancerTypes": [
      "Pan-cancer: all advanced solid tumors (validated in lung, colorectal, pancreatic, GI cancers, and others)"
    ],
    "targetPopulation": "Patients with Stage III-IV solid tumors on any systemic treatment regimen (chemotherapy, immunotherapy, targeted therapy)",
    "responseDefinition": "Tumor Methylation Score (TMS) - total methylated tumor molecules per 1000 assayed genomic equivalents; serial quantification tracks response, progression, or stable disease over time",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "In NSCLC study, detected treatment response and progression earlier than CT scans. Can provide actionable signals weeks in advance of imaging.",
    "lod": "0.01% tumor fraction",
    "lodNotes": "Can accurately discriminate tumor fraction changes as small as 0.25%. Single-molecule precision enables detection of subtle shifts in tumor burden.",
    "lodCitations": "https://www.northstaronc.com/ | https://pubmed.ncbi.nlm.nih.gov/39438179/ | Ye PP et al. Sci Rep 2025; Hsiao A et al. Clin Lung Cancer 2025",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "reimbursement": "Self-Pay",
    "reimbursementNote": "No Medicare or commercial coverage established. Available as CLIA-certified laboratory test.",
    "tat": "10 days",
    "tatNotes": "Turnaround time typically within 10 days from sample receipt to results.",
    "clinicalAvailability": "Commercially available in US via CLIA-certified laboratory in Menlo Park, CA. Physician-ordered.",
    "clinicalTrials": "Prospective observational study at University of Florida (advanced GI cancers, n=73+); UCSD NSCLC collaboration; multiple ongoing clinical validity studies",
    "clinicalTrialsCitations": "Sahin I et al. JCO 2024;42(3_suppl):756; Sahin I et al. JCO 2025;43(4_suppl):839.",
    "totalParticipants": 100,
    "totalParticipantsNotes": "Initial validation cohort of 100 advanced GI cancer patients; additional cohorts in lung and other solid tumors.",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "Ye PP et al. Sci Rep 2025;15:5869; Hsiao A et al. Clin Lung Cancer 2025;26(1):72-77; JCO 2024 and 2025 abstracts.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "technologyDifferentiator": "Methylation-based (not mutation/VAF-based) - measures epigenetic signal across >2200 loci rather than tracking somatic variants. Tissue-free with no tumor biopsy required. QCT technology enables single-molecule counting precision for absolute quantification. Version 2 (2025) expanded panel from >500 to >2200 loci for increased sensitivity.",
    "regulatoryStatusNotes": "CLIA-certified laboratory test. Methylation-based approach differentiates from SNV/VAF-based response monitoring assays. Measures 10x more informative loci (average 90 vs 9) compared to SNV-based ctDNA monitoring. Part of BillionToOne's Northstar oncology portfolio alongside Northstar Select (therapy selection)."
  },
  {
    "id": "trm-11",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Approximately 20mL whole blood required for plasma and buffy coat extraction.",
    "sampleCitations": "https://www.carislifesciences.com/",
    "name": "Caris Assure",
    "vendor": "Caris Life Sciences",
    "approach": "Blood-based TRM (cfDNA + cfRNA + WBC)",
    "method": "AI-enabled whole exome and whole transcriptome sequencing (WES/WTS) from plasma cfDNA/cfRNA and buffy coat WBC DNA/RNA; 22,000 genes; circulating Nucleic Acid Sequencing (cNAS) with CHIP subtraction",
    "methodCitations": "https://www.carislifesciences.com/physicians/physician-tests/caris-assure/ | https://www.nature.com/articles/s41598-025-08986-0",
    "indicationsNotes": "Multi-functional liquid biopsy for therapy selection, treatment response monitoring, and MRD detection. Distinguishes somatic tumor variants from clonal hematopoiesis (CH) and germline variants by sequencing both plasma and buffy coat.",
    "cancerTypes": ["Pan-solid tumor"],
    "cancerTypesNotes": "Applicable across solid tumor types; WES/WTS approach covers all cancer-relevant genes.",
    "sensitivity": 93.8,
    "sensitivityNotes": "93.8% positive percent agreement (PPA) with matched tissue collected within 30 days using ≥5ng input material and CHIP subtraction.",
    "sensitivityCitations": "https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/physicians/physician-tests/caris-assure/",
    "specificity": 99.99,
    "specificityNotes": ">99.99% specificity for variant detection; 96.8% positive predictive value (PPV) for therapy selection.",
    "specificityCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "lod": "0.5% VAF",
    "lodNotes": ">95% sensitivity for variant allele frequencies ≥0.5%.",
    "lodCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-introduces-the-caris-assure-liquid-biopsy-assay-at-asco-2022-301560767.html",
    "performanceNotes": "AI-enabled platform (ABCDai) couples WES/WTS with machine learning. For monitoring, disease-free survival of patients predicted to have an event was significantly shorter (HR=4.39, p=0.008). Detects CH mutations in ~40% of samples, critical for avoiding false positives in therapy selection.",
    "performanceCitations": "https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-showcases-data-demonstrating-the-clinical-value-of-clonal-hematopoiesis-identification-and-subtraction-in-liquid-biopsy-to-improve-the-accuracy-of-treatment-recommendations/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA-certified laboratory developed test. Not FDA cleared/approved.",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage expanding; contact Caris for current payer coverage.",
    "clinicalAvailability": "Commercially available in US since late 2022",
    "availableRegions": ["US"],
    "tat": "10-14 days",
    "tatNotes": "Turnaround time typically 10-14 business days.",
    "sampleType": "Whole blood",
    "sampleTypeNotes": "Blood collection in approved tubes; plasma and buffy coat analyzed separately.",
    "bloodVolume": 20,
    "bloodVolumeNotes": "Approximately 20mL whole blood required for plasma and buffy coat extraction.",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/research/publications/",
    "clinicalTrials": "Validation studies with 1,910 therapy selection samples; 3,439 MRD/monitoring training samples; 86 MRD validation; 101 monitoring validation",
    "totalParticipants": 5536,
    "variantsTracked": "22,000 genes (WES/WTS)",
    "variantsTrackedNotes": "Whole exome (DNA) and whole transcriptome (RNA) sequencing across 22,000 genes. Reports SNVs, indels, CNAs, fusions, MSI, bTMB, and HLA genotype.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "technologyDifferentiator": "Only commercially available liquid biopsy that sequences both plasma and buffy coat (WBC) to distinguish somatic tumor variants from clonal hematopoiesis (CH) and germline variants. CHIP subtraction prevents ~40% of samples from receiving potentially incorrect therapy recommendations based on non-tumor mutations."
  },
  {
    "id": "trm-12",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Guardant cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Two 10mL Streck cfDNA tubes (approximately 20mL).",
    "sampleCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "name": "Reveal TRM",
    "vendor": "Guardant Health",
    "approach": "Tumor-naïve (methylation-based)",
    "method": "Epigenetic tumor fraction (epiTF) quantification on Guardant Infinity platform. Analyzes over 19,000 differentially methylated loci to calculate mutation-agnostic tumor fraction—not dependent on known oncogenic mutations. Provides high sensitivity and precision not confounded by copy number alterations (CNAs) or clonal hematopoiesis (CHIP).",
    "methodCitations": "https://guardanthealth.com/products-services/guardant-reveal/ | AACR 2025 Tumor Fraction Update; https://pubmed.ncbi.nlm.nih.gov/38662357/ | Nakamura Y et al. Clin Cancer Res 2024",
    "cancerTypes": [
      "Pan-cancer: any solid tumor on systemic therapy"
    ],
    "targetPopulation": "Patients with advanced/metastatic solid tumors receiving systemic therapy who need treatment response monitoring",
    "responseDefinition": "Molecular responders defined by significant decrease in epigenetic tumor fraction (epiTF) from baseline. epiTF changes correlate with radiological tumor volume changes and predict clinical outcomes.",
    "indicationsNotes": "Therapy response monitoring for advanced cancer with visible disease. Early prediction of therapy response and outcomes. Patients with significant decrease in ctDNA tumor fraction have better clinical response than molecular non-responders.",
    "sensitivity": null,
    "sensitivityNotes": "Not applicable for response monitoring - measures relative epiTF changes over time rather than absolute detection.",
    "specificity": null,
    "specificityNotes": "High specificity for tumor-derived signal due to methylation approach that excludes non-tumor biological noise without requiring additional specimen types.",
    "lod": "0.01% TF",
    "lodNotes": "Epigenetic tumor fraction (epiTF) quantification validated with precision down to ~0.01% TF. Analyzes over 19,000 differentially methylated loci—mutation-agnostic approach not dependent on known oncogenic mutations. Not impacted by CNAs like genomic VAF approaches.",
    "lodCitations": "https://guardanthealth.com/products-services/guardant-reveal/ | Guardant Reveal product page; AACR 2025",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "epiTF changes mirror radiological tumor volume changes (Harvey-Jones et al. Annals of Oncology 2024). Molecular response detectable earlier than imaging in many cases.",
    "leadTimeVsImagingCitations": "Harvey-Jones et al. Annals of Oncology 2024; AACR 2025 presentations.",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory Developed Test performed at Guardant Health Clinical Laboratory (Redwood City, CA). Part of Guardant's consolidated monitoring portfolio using Infinity platform.",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "New product launched as successor to Guardant360 Response. Reimbursement pathways developing.",
    "clinicalAvailability": "Clinical LDT – commercially available December 2025",
    "clinicalAvailabilityNotes": "Launched December 2025 as part of Guardant portfolio consolidation. Replaces Guardant360 Response for therapy response monitoring in advanced cancer. Part of Reveal product family alongside Reveal MRD for early-stage cancer.",
    "availableRegions": ["US"],
    "tat": "7 days",
    "tatNotes": "Vendor-reported 7-day median TAT, same as Reveal MRD.",
    "sampleType": "Whole blood in Guardant cfDNA BCT tubes",
    "bloodVolume": 20,
    "bloodVolumeNotes": "Two 10mL Streck cfDNA tubes (approximately 20mL).",
    "clinicalTrials": "Validated in >31,000 patients in LDT/CLIA setting; >50,000 cfDNA samples across >20 cancer types used for algorithm development",
    "clinicalTrialsCitations": "https://guardanthealth.com/products-services/guardant-reveal/ | AACR 2025 Tumor Fraction Update presentation",
    "totalParticipants": 31000,
    "totalParticipantsNotes": "Pan-cancer landscape of tumor fraction in >31,000 patients across most frequent solid tumors from CLIA ordering.",
    "numPublications": 80,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "Guardant Health claims >80 publications showing clinical feasibility or validity of genomic MR and/or monitoring.",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tumor-naïve approach - no tumor tissue required for panel design or analysis.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Methylation-based approach provides improved exclusion of biological noise without additional sequencing of matched normal specimen.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "technologyDifferentiator": "Methylation-based tumor fraction quantification offers advantages over genomic VAF methods: (1) Tracks thousands of methylation loci vs handful of coding loci for higher sensitivity; (2) Not confounded by CNAs that affect genomic max-MAF estimates; (3) Excludes non-tumor noise (including CHIP) without requiring matched normal sequencing; (4) Validated precision down to 0.01% TF. Uses same Guardant Infinity platform as Reveal MRD, Shield, and Shield MCD.",
    "regulatoryStatusNotes": "CLIA-certified LDT. Represents Guardant's consolidated approach to therapy response monitoring, replacing genomic VAF-based Guardant360 Response with epigenetic tumor fraction (epiTF) quantification."
  },
  {
    "id": "trm-13",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleTubeType": "EDTA",
    "sampleTubeCount": 1,
    "sampleCollectionNotes": "10mL peripheral blood in EDTA tube. CSF: 7-10mL optimal (5mL minimum).",
    "sampleCitations": "https://www.genomictestingcooperative.com/",
    "name": "Liquid Trace (Therapy Monitoring)",
    "vendor": "Genomic Testing Cooperative (GTC)",
    "approach": "Tumor-naïve",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "No tumor tissue required. Tumor-naïve cfDNA + cfRNA approach.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "No matched normal required.",
    "method": "Combined cfDNA and cfRNA NGS from peripheral blood or CSF. Serial monitoring tracks both VAF (Variant Allele Frequency) AND mutant molecules per mL to quantify treatment response. Reports include tabular tracking of mutations over time. cfRNA analysis (>1,600 genes) adds sensitivity for detecting residual disease and emerging resistance mutations.",
    "methodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/ | https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "cancerTypes": [
      "Pan-cancer: solid tumors and hematologic malignancies"
    ],
    "cancerTypesNotes": "Solid tumors: lung, brain/CNS, breast, thyroid, colorectal, oropharyngeal, pancreatic, ovarian, prostate. Hematologic: AML, MDS, MPN, multiple myeloma, lymphoma, ALL, CMML, VEXAS.",
    "targetPopulation": "Patients on systemic therapy requiring longitudinal disease monitoring. Includes solid tumors and hematologic malignancies. CSF samples for CNS involvement and leptomeningeal disease monitoring.",
    "responseDefinition": "Change in VAF and/or mutant molecules per mL from baseline. Decrease indicates treatment response; increase indicates progression or emerging resistance. Reports include tabular tracking of mutations across serial samples.",
    "indicationsNotes": "Serial monitoring for treatment response assessment. Reports include longitudinal VAF AND mutant molecules/mL tracking table. Higher VAF = higher tumor load; VAF reduction = response to treatment. Also detects emerging resistance mutations and clonal evolution.",
    "sensitivity": null,
    "sensitivityNotes": "Combined cfDNA + cfRNA provides higher sensitivity than cfDNA-only tests. cfRNA detects mutations often missed by cfDNA alone due to multiple RNA copies per cell.",
    "specificity": null,
    "lod": "0.1-0.01% VAF (non-hotspot); 0.01-0.001% (hotspot); <0.001% (tumor-informed)",
    "lodNotes": "Detection sensitivity varies by variant type. Serial monitoring at consistent time points enables tracking of relative changes even at low VAF.",
    "lodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory developed test performed at GTC's CLIA/CAP-certified laboratory. NYSDOH approved. CE-marked for EU. UKCA certified for UK.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare covered. Contact GTC for current payer coverage information.",
    "clinicalAvailability": "Commercially available",
    "availableRegions": ["US", "EU", "UK"],
    "tat": "5-7 days",
    "tatNotes": "RNA stability 48-72 hours from blood draw; DNA stability 7 days.",
    "sampleType": "Peripheral blood (10mL EDTA) or CSF (7-10mL)",
    "bloodVolume": 10,
    "bloodVolumeNotes": "10mL peripheral blood in EDTA tube. CSF: 7-10mL optimal (5mL minimum).",
    "numPublications": 15,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "https://genomictestingcooperative.com/category/publications/",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "technologyDifferentiator": "Only commercially available therapy monitoring test combining cfDNA and cfRNA. Reports include VAF AND mutant molecules/mL tracking table for quantitative response assessment. cfRNA adds sensitivity for detecting residual disease and resistance mutations. LEADING PROVIDER FOR CSF LIQUID BIOPSY - optimal for monitoring CNS tumors (glioblastoma, CNS lymphomas/leukemias) and leptomeningeal disease (breast, lung, melanoma). For hematology: also includes chimerism analysis and chromosomal abnormalities for post-transplant MRD - going beyond mutation-only approaches.",
    "submissionInfo": {
      "submittedBy": "Jeffrey Owen",
      "submitterEmail": "jowen@genomictestingcooperative.com",
      "submitterType": "Vendor Representative",
      "submissionDate": "2025-12-17",
      "submissionNotes": "Vendor clarified that Liquid Trace is actively used for therapeutic monitoring with VAF and mutant molecules/mL tracking table in reports. Added TRM entry in addition to TDS entries for CGP use case."
    }
  },
  {
    "id": "trm-14",
    "sampleCategory": "Blood/Plasma",
    "name": "xM for TRM",
    "vendor": "Tempus AI",
    "approach": "Tumor-naïve",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "No tumor tissue required. Tumor-naïve ctDNA tumor fraction monitoring.",
    "requiresMatchedNormal": "No",
    "method": "Liquid biopsy assay that quantifies changes in circulating tumor DNA (ctDNA) tumor fraction longitudinally from blood samples. Uses a multi-parametric ensemble algorithm integrating copy number variations (CNVs) with somatic and germline variant allele frequencies (VAFs) to provide comprehensive tumor fraction estimation. Designed for early molecular response assessment in patients receiving immune checkpoint inhibitor (ICI) therapies.",
    "methodCitations": "https://www.tempus.com/news/tempus-introduces-xm-an-assay-to-monitor-immunotherapy-response-for-patients-with-advanced-cancers/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11333675/",
    "cancerTypes": [
      "Advanced solid tumors (pan-cancer)"
    ],
    "cancerTypesNotes": "Intended for patients with advanced solid tumors receiving immune checkpoint inhibitor (ICI) therapy alone or in combination with chemotherapy.",
    "targetPopulation": "Patients with advanced cancers receiving ICI therapies who require molecular response monitoring",
    "responseDefinition": "Molecular Response (MR) vs Non-Molecular Response (nMR) based on ctDNA tumor fraction dynamics. Molecular responders show ctDNA clearance or significant reduction; non-molecular responders show persistent or increasing tumor fraction.",
    "indicationsNotes": "Designed to detect molecular response to ICI prior to 6 weeks into treatment, enabling clinicians to stay ahead of disease progression and optimize therapeutic strategies. Longitudinal non-molecular responders associated with worse survival compared to molecular responders.",
    "sensitivity": null,
    "sensitivityNotes": "Per real-world cohort study (PMC11333675): Molecular response status correlated with real-world overall survival. Combines with imaging for improved outcome prediction beyond imaging alone.",
    "specificity": null,
    "specificityNotes": "Study demonstrated that model incorporating xM for TRM molecular response + imaging is more predictive of rwOS outcomes than imaging alone.",
    "lod": null,
    "lodNotes": "Tumor fraction quantification via ensemble algorithm. Specific LOD not publicly disclosed.",
    "fdaStatus": "RUO (Research Use Only)",
    "fdaStatusNotes": "Currently available for Research Use Only as of June 2025. Clinical availability expected later in 2025.",
    "fdaStatusCitations": "https://www.tempus.com/news/tempus-introduces-xm-an-assay-to-monitor-immunotherapy-response-for-patients-with-advanced-cancers/",
    "reimbursement": "Not applicable (RUO)",
    "reimbursementNote": "Research Use Only - not available for clinical ordering. Clinical availability expected later in 2025.",
    "clinicalAvailability": "Research Use Only (clinical launch expected late 2025)",
    "availableRegions": ["US (RUO)"],
    "tat": null,
    "tatNotes": "Turnaround time not specified for RUO product.",
    "sampleType": "Peripheral blood",
    "clinicalTrials": "ASCO 2025 presentation: 'A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors'",
    "clinicalTrialsCitations": "https://www.tempus.com/news/tempus-introduces-xm-an-assay-to-monitor-immunotherapy-response-for-patients-with-advanced-cancers/",
    "numPublications": 2,
    "numPublicationsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11333675/",
    "numPublicationsNotes": "Clinical Cancer Research 2024 publication + ASCO 2025 abstract. Study demonstrated xM for TRM value in stratifying ICI therapy outcomes.",
    "isRUO": true,
    "isInvestigational": true,
    "isClinicalLDT": false,
    "technologyDifferentiator": "ICI-specific therapy response monitoring via longitudinal ctDNA tumor fraction quantification. Multi-parametric algorithm (CNVs + VAFs) for comprehensive tumor fraction estimation. Part of Tempus' growing portfolio alongside xM MRD. Positioned to address the ~57% of advanced/metastatic cancer patients eligible for ICIs, of whom only ~20% respond.",
    "regulatoryStatusNotes": "RUO - awaiting clinical availability. Announced June 2025 at ASCO with clinical launch expected later in 2025.",
    "dataSourceNotes": "Added December 2025 via LLM Data Review. Note: RUO status - not yet available for clinical ordering."
  }
  // INSERT NEW TRM TEST HERE (above this line, add comma after previous entry)
];

// TDS Tests
export const tdsTestData = [
  {
    "id": "tds-1",
    "name": "FoundationOne CDx",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS of FFPE tumor tissue; detects SNVs, indels, CNAs, and select rearrangements in 324 genes; reports MSI, TMB, and HRD signature.",
    "methodCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "genesAnalyzed": 324,
    "genesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements", "TMB", "MSI", "HRD"],
    "biomarkersReportedCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "targetPopulation": "Patients with advanced solid malignant neoplasms requiring genomic profiling to guide treatment decisions",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",
    "fdaStatus": "FDA-approved PMA (P170019) - First FDA-approved broad companion diagnostic for solid tumors",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-f1cdx-p170019s048",
    "fdaApprovalDate": "2017-11-30",
    "fdaApprovalDateCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",
    "fdaCompanionDxCount": 57,
    "fdaCompanionDxCountNotes": "57 FDA-approved CDx indications in US as of Dec 2025 (100 total CDx indications including Japan). Includes pan-tumor indications for TMB-H, MSI-H, NTRK fusions, RET fusions, and tumor-specific indications across NSCLC, melanoma, breast, colorectal, ovarian, prostate, cholangiocarcinoma, and pediatric brain tumors.",
    "fdaCompanionDxCountCitations": "https://www.businesswire.com/news/home/20251204680697/en/Foundation-Medicine-Achieves-Historic-Milestone-of-100-Approved-and-Active-Companion-Diagnostic-Indications-Solidifying-Leadership-in-Precision-Medicine",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma", "Gastric Cancer", "Cholangiocarcinoma"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers and 'broad molecular profiling' but do not endorse specific commercial assays by name.",
    "tat": "8 days",
    "tatNotes": "Typically 8 days or less from receipt of specimen.",
    "tatCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "sampleRequirements": "FFPE tissue; minimum 25% tumor content; 10 unstained slides or tissue block",
    "sampleRequirementsNotes": "Foundation Medicine contacts pathology lab for specimen procurement. Can reflex to FoundationOne Liquid CDx if tissue insufficient.",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for advanced cancer (CAG-00450R). 87% of patients pay $0 out-of-pocket. 80+ commercial health plans cover Foundation Medicine tests.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance | https://www.foundationmedicine.com/test/foundationone-cdx",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "cptCodes": "0037U",
    "cptCodesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany). Regulatory: FDA approved (US), MHLW approved (Japan, Dec 2018), CE marked (EU).",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25 | https://www.foundationmedicine.com/press-releases/aa55275f-b849-4e31-a770-152c8e7cad8f",
    "clinicalAvailability": "Commercially available in US since 2017; available in 100+ countries via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "numPublications": 1000,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": "Foundation Medicine tests cited in >1,000 peer-reviewed publications (vendor estimate).",
    "numPublicationsCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "publicationsExampleCitations": ["https://doi.org/10.1038/nm.4333", "https://doi.org/10.1200/JCO.2017.75.3780"]
  },
  {
    "id": "tds-2",
    "name": "FoundationOne Liquid CDx",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "approach": "Liquid CGP",
    "method": "Hybrid-capture NGS of cfDNA from plasma; analyzes 324 genes; reports short variants in 311 genes, rearrangements in 8 genes, CNAs in 3 genes, plus bTMB and MSI.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "genesAnalyzed": 324,
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "genesReported": 311,
    "genesReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Rearrangements", "bTMB", "MSI"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "targetPopulation": "Patients with advanced solid tumors when tissue biopsy is not feasible or as complement to tissue testing",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "fdaStatus": "FDA-approved PMA (P200006) August 2020",
    "fdaStatusCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "fdaApprovalDate": "2020-08-26",
    "fdaApprovalDateCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "fdaCompanionDxCount": 10,
    "fdaCompanionDxCountNotes": "Multiple CDx indications in NSCLC (osimertinib, sotorasib, capmatinib), breast cancer (PIK3CA), prostate cancer (BRCA1/2, ATM), cholangiocarcinoma (FGFR2), pan-tumor (NTRK).",
    "fdaCompanionDxCountCitations": "https://www.foundationmedicine.com/press-release/fda-approves-foundationonercdx-and-foundationonerliquid-cdx-companion-diagnostics",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Prostate Cancer", "Cholangiocarcinoma"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatNotes": "Results typically available within 7-10 business days.",
    "tatCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "sampleRequirements": "2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL per tube",
    "sampleRequirementsNotes": "7-day sample stability at ambient temperature. Can reflex to tissue testing if liquid negative for CDx mutations.",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for advanced cancer. Broad commercial payer coverage.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "cptCodes": "0239U",
    "cptCodesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany).",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25",
    "clinicalAvailability": "Commercially available in US since 2020; available in 100+ countries via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "numPublications": 50,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study PLoS One 2020 (Woodhouse et al.); multiple clinical validity studies for BRAF, HER2, MSI companion diagnostics",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/32976510/"
  },
  {
    "id": "tds-3",
    "name": "FoundationOne Heme",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue/Blood/Bone Marrow",
    "approach": "Tissue + Liquid CGP",
    "method": "Hybrid-capture DNA sequencing of 406 genes plus RNA sequencing of 265 genes for fusion detection; covers hematologic malignancies and sarcomas.",
    "methodCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "genesAnalyzed": 406,
    "genesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "rnaGenesAnalyzed": 265,
    "rnaGenesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-heme",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements/Fusions", "TMB", "MSI"],
    "biomarkersReportedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "cancerTypes": ["Hematologic malignancies", "Sarcomas"],
    "cancerTypesNotes": "Leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and sarcomas.",
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "targetPopulation": "Patients with hematologic malignancies or sarcomas requiring comprehensive genomic profiling",
    "targetPopulationCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.foundationmedicine.com/test/foundationone-heme",
    "vendorNCCNAlignmentIndications": ["Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "B-Cell Lymphomas", "Myelodysplastic Syndromes", "Soft Tissue Sarcoma"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines for hematologic malignancies and sarcomas. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "sampleRequirements": "FFPE tissue, bone marrow aspirate, or peripheral blood depending on disease type",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage for qualifying patients. Commercial coverage varies.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network.",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25",
    "clinicalAvailability": "Commercially available in US; available internationally via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study Blood 2016 (He et al.); 10+ studies at ASH 2013; part of Foundation Medicine ecosystem",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/27002118/"
  },
  {
    "id": "tds-4",
    "name": "Guardant360 CDx",
    "vendor": "Guardant Health",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "approach": "Liquid CGP",
    "method": "Digital sequencing of cfDNA; targets 74 genes; reports SNVs, indels, CNAs (6 genes), and fusions (4 genes) with high sensitivity at low allele frequencies.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "genesAnalyzed": 74,
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "genesReported": 55,
    "genesReportedNotes": "74 genes targeted, 55 genes with reportable short variants.",
    "genesReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "geneListUrl": "https://www.guardantcomplete.com/hcp/solutions/guardant360-cdx",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Fusions"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "targetPopulation": "Patients with advanced solid tumors; first liquid biopsy with FDA-approved CGP indication for all solid tumors",
    "targetPopulationCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "fdaStatus": "FDA-approved PMA (P200010) August 2020 - First FDA-approved liquid biopsy NGS CDx",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008 | https://www.targetedonc.com/view/fda-approves-guardant360-cdx-for-tumor-mutation-profiling-of-all-solid-cancers",
    "fdaApprovalDate": "2020-08-07",
    "fdaApprovalDateCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008",
    "fdaCompanionDxCount": 6,
    "fdaCompanionDxCountNotes": "6 CDx indications: NSCLC (osimertinib/EGFR, amivantamab/EGFR exon 20, trastuzumab deruxtecan/ERBB2, sotorasib/KRAS G12C); Breast cancer (elacestrant/ESR1, imlunestrant/ESR1).",
    "fdaCompanionDxCountCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx | https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://guardanthealth.com/guardant360-cdx/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer"],
    "vendorNCCNAlignmentNotes": "Covers all genes recommended by NCCN for NSCLC and relevant biomarkers for breast cancer treatment. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatNotes": "Actionable results typically within 7 days; as fast as 5 days.",
    "tatCitations": "https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",
    "sampleRequirements": "2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S008C.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "Broadly covered by Medicare and commercial insurers representing >300 million lives.",
    "reimbursementCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx",
    "cptCodes": "0242U",
    "codeType": "PLA",
    "medicareRate": 5000,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available in US since 2020",
    "clinicalAvailabilityCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "numPublications": 150,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": "Guardant360 cited in >150 peer-reviewed publications (vendor estimate).",
    "numPublicationsCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "publicationsExampleCitations": ["https://pubmed.ncbi.nlm.nih.gov/33619370/", "https://pubmed.ncbi.nlm.nih.gov/37256839/"]
  },
  {
    "id": "tds-17",
    "name": "Guardant360 Liquid",
    "vendor": "Guardant Health",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeCount": 2,
    "approach": "Liquid CGP",
    "method": "Digital sequencing of cfDNA on Guardant Infinity platform; targets 744 genes; reports SNVs, indels, CNAs, CNLs, fusions/rearrangements, MSI, TMB, tumor fraction, and promoter methylation (epigenomic features). CHIP filtering via proprietary algorithm. Virus detection (EBV, HPV).",
    "methodCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "genesAnalyzed": 744,
    "genesAnalyzedCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "genesReported": 744,
    "genesReportedNotes": "Full 744-gene panel reported. 10x more genes than previous Guardant360 version and 10x higher sensitivity for tumor fraction quantification.",
    "genesReportedCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "geneListUrl": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "CNLs", "Fusions/Rearrangements", "MSI", "TMB", "Tumor Fraction", "Promoter Methylation"],
    "biomarkersReportedNotes": "First and only liquid biopsy to deliver genomic and epigenomic insights (promoter methylation) from a single input. CHIP variants flagged via proprietary algorithm.",
    "biomarkersReportedCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "targetPopulation": "Patients with advanced solid tumors; comprehensive genomic and epigenomic profiling for treatment selection",
    "targetPopulationCitations": "https://guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/",
    "fdaStatus": "CLIA LDT; not FDA-cleared/approved",
    "fdaStatusNotes": "Developed as a Laboratory Developed Test (LDT) by Guardant Health Clinical Laboratory (CLIA-certified). Distinct from Guardant360 CDx which is FDA-approved but covers only 74 genes.",
    "fdaStatusCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "fdaCompanionDxCount": 0,
    "fdaCompanionDxCountNotes": "LDT version - no FDA companion diagnostic claims. For FDA-approved CDx, see Guardant360 CDx.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://guardanthealth.com/guardant360/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma"],
    "vendorNCCNAlignmentNotes": "Covers all guideline-recommended genomic biomarkers across advanced solid tumors plus emerging biomarkers. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7 days",
    "tatNotes": "Median 7 days from sample receipt to results.",
    "tatCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "sampleRequirements": "Two 10mL cfDNA BCT Streck Tubes (provided in the kit); Ship same/next day @ Room Temp carefully following the kit included IFU.",
    "sampleRequirementsCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "lod": "SNVs: 0.20% VAF; Indels: 0.26%; CNAs: 2.46 copies; Fusions: 0.05%; MSI: 0.05%; Tumor Fraction: 1.6%",
    "lodNotes": "LoD defined as allele fraction/copy number at 95% probability of detection for oncogenic variants. TMB evaluable at ≥0.3% sample allele fraction.",
    "lodCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "specificity": "≥99.9% for SNVs, Indels, CNAs, CNLs, Fusions, MSI, Promoter Methylation",
    "specificityCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "Covered by Medicare and major private payers for comprehensive genomic profiling of all advanced solid tumors.",
    "reimbursementCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "availableRegions": ["US"],
    "availableRegionsNotes": "US availability via Guardant Health. International availability via regional spec sheets (AMEA region).",
    "availableRegionsCitations": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "clinicalAvailability": "Commercially available in US; 2024 major upgrade launched",
    "clinicalAvailabilityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Same platform as Guardant360 CDx; extensive clinical validation and companion diagnostic studies across multiple cancer types",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/34838325/",
    "vendorVerified": true,
    "vendorRequestedChanges": "2026-01-06: Vendor validation by Brandon Guida (Guardant Health) - updated sampleRequirements with precise tube specifications per official IFU."
  },
  {
    "id": "tds-5",
    "name": "Tempus xT CDx",
    "vendor": "Tempus AI",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Tumor-normal matched NGS of FFPE tissue and matched normal blood/saliva; detects SNVs, MNVs, indels in 648 genes plus MSI status; tumor-normal matching improves somatic variant accuracy.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf | https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "genesAnalyzed": 648,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/ | https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "biomarkersReported": ["SNVs", "MNVs", "Indels", "CNVs", "Rearrangements", "TMB", "MSI"],
    "biomarkersReportedNotes": "HRD and HLA genotyping available as add-ons via professional services report.",
    "biomarkersReportedCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "targetPopulation": "Patients with previously diagnosed solid malignant neoplasms",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "fdaStatus": "FDA-approved IVD (P210011) - National launch January 2025",
    "fdaStatusCitations": "https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test | https://investors.tempus.com/news-releases/news-release-details/tempus-announces-national-launch-fda-approved-xt-cdx-test",
    "fdaApprovalDate": "2024-06-01",
    "fdaApprovalDateCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "fdaCompanionDxCount": 2,
    "fdaCompanionDxCountNotes": "CDx claims for colorectal cancer (KRAS, NRAS, BRAF); positioned as one of the largest FDA-approved gene panels.",
    "fdaCompanionDxCountCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.tempus.com/oncology/genomic-profiling/xt/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Colorectal Cancer", "Breast Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "14 days",
    "tatNotes": "Results typically within 14 days.",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "sampleRequirements": "FFPE tissue plus matched normal (blood or saliva)",
    "sampleRequirementsNotes": "Tumor-normal matched approach differentiates somatic from germline variants.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "CMS Advanced Diagnostic Laboratory Test (ADLT) designation; Medicare rate $4,500.",
    "reimbursementCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "listPrice": 4500,
    "listPriceCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "cptCodes": "0473U",
    "cptCodesCitations": "https://www.discoveriesinhealthpolicy.com/2024/09/cms-releases-preliminary-crosswalk-for.html",
    "codeType": "PLA",
    "medicareRate": 4500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available nationwide since January 2025",
    "clinicalAvailabilityCitations": "https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",
    "complementaryTests": "Can add xR RNA sequencing, xF/xF+ liquid biopsy, HER2 IHC, PD-L1 IHC, HRD, Immune Profile Score",
    "complementaryTestsCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "numPublications": 50,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study Oncotarget 2019 (Beaubier et al.); FDA CDx designation; widely used in clinical trials",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/31040929/"
  },
  {
    "id": "tds-6",
    "name": "Tempus xF",
    "vendor": "Tempus AI",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "approach": "Liquid CGP",
    "method": "ctDNA NGS panel targeting 105 genes; detects SNVs, indels, CNGs (6 genes), CNLs (BRCA1/2), and rearrangements (6 genes) plus MSI-H.",
    "methodCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/ | https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "analyticalValidation": "Validated performance metrics from Finkle et al. 2021 analytical validation study.",
    "analyticalValidationCitations": "https://www.tempus.com/wp-content/uploads/2021/09/xF-Validation-Summary.pdf",
    "genesAnalyzed": 105,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Rearrangements", "MSI"],
    "biomarkersReportedCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "targetPopulation": "Patients with advanced solid tumors; not intended for hematologic malignancies, early-stage cancers, or primary CNS malignancies",
    "targetPopulationCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "Covers key biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sampleRequirements": "Blood in Streck cfDNA BCT tubes",
    "sampleRequirementsCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Commercial and Medicare coverage varies by indication.",
    "reimbursementCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sensitivity": ">99% for SNVs/CNGs at ≥0.5% VAF; >98% for indels; >97% for rearrangements",
    "sensitivityCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "specificity": ">99.9% for SNVs, indels, rearrangements; >96% for CNGs",
    "specificityCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "numPublications": 20,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Validation study NPJ Precision Oncology 2021 (Finkle et al.); liquid biopsy clinical applications",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/34215841/"
  },
  {
    "id": "tds-7",
    "name": "Tempus xF+",
    "slug": "tempus-xf-plus",
    "vendor": "Tempus AI",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "approach": "Liquid CGP",
    "method": "Expanded ctDNA NGS panel targeting 523 genes; detects SNVs, indels, CNGs, and rearrangements; includes clonal hematopoiesis (CH) variant identification.",
    "methodCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "analyticalValidation": "Validated per Boulos et al. 2025 analytical validation study.",
    "analyticalValidationCitations": "https://pubmed.ncbi.nlm.nih.gov/39820598/",
    "genesAnalyzed": 523,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements", "CH variants"],
    "biomarkersReportedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "targetPopulation": "Patients requiring expanded liquid biopsy coverage",
    "targetPopulationCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.tempus.com/oncology/genomic-profiling/xf-plus/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Expanded 523-gene panel covers all biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sampleRequirements": "Blood in Streck cfDNA BCT tubes",
    "sampleRequirementsCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "reimbursement": "Coverage Varies",
    "reimbursementCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Expanded panel; analytical validation J Mol Diagn 2025 (Boulos et al.)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/40287222/"
  },
  {
    "id": "tds-8",
    "name": "MSK-IMPACT",
    "slug": "msk-impact",
    "vendor": "Memorial Sloan Kettering",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS of matched tumor/normal FFPE tissue; targets 468 cancer-associated genes covering ~1.5Mb of the genome; detects SNVs, indels, CNAs, select rearrangements, and MSI.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://www.mskcc.org/msk-impact",
    "genesAnalyzed": 468,
    "genesAnalyzedNotes": "468 genes in original FDA-authorized configuration (2017); panel has since expanded to ~505 genes per current MSK documentation.",
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://ascopost.com/News/58263 | https://www.mskcc.org/msk-impact",
    "geneListUrl": "https://www.mskcc.org/msk-impact",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Select Rearrangements", "MSI"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.mskcc.org/msk-impact",
    "targetPopulation": "Patients with advanced cancer treated at Memorial Sloan Kettering Cancer Center",
    "targetPopulationCitations": "https://www.mskcc.org/msk-impact",
    "fdaStatus": "FDA authorized (de novo, DEN170058) November 2017 - First tumor-profiling LDT to receive FDA authorization",
    "fdaStatusCitations": "https://ascopost.com/News/58263 | https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors",
    "fdaAuthorizationDate": "2017-11-15",
    "fdaAuthorizationDateCitations": "https://ascopost.com/News/58263",
    "fdaStatusNotes": "Not FDA-approved as CDx; authorized for tumor mutation profiling. Also approved by NYSDOH.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.mskcc.org/msk-impact",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Melanoma", "Ovarian Cancer", "Gastric Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "2-3 weeks",
    "tatCitations": "https://www.mskcc.org/msk-impact",
    "sampleRequirements": "FFPE tumor tissue plus matched normal sample",
    "sampleRequirementsNotes": "Tumor-normal matching allows accurate distinction of somatic vs germline variants.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage depends on payer; available primarily to MSK patients.",
    "reimbursementCitations": "https://www.mskcc.org/msk-impact",
    "clinicalAvailability": "Available only at Memorial Sloan Kettering Cancer Center",
    "clinicalAvailabilityNotes": "Single-site assay; >20,000 patients sequenced since 2014. Results accessible via cBioPortal and annotated using OncoKB.",
    "clinicalAvailabilityCitations": "https://www.mskcc.org/msk-impact | https://www.mskcc.org/news-releases/msk-impact-first-tumor-profiling-multiplex-panel-authorized-fda-setting-new-pathway-market-future-oncopanels",
    "numPublications": 1000,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": ">1,000 peer-reviewed publications featuring MSK-IMPACT data as of end of 2024 (vendor estimate).",
    "numPublicationsCitations": "https://www.mskcc.org/msk-impact",
    "publicationsExampleCitations": ["https://doi.org/10.1038/nm.4333", "https://doi.org/10.1056/NEJMoa1610624"],
    "keyFindings": "37% of profiled patients have at least one actionable mutation; 11% enrolled in matched clinical trials.",
    "keyFindingsCitations": "https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors | https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer"
  },
  {
    "id": "tds-9",
    "name": "MI Cancer Seek",
    "vendor": "Caris Life Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (WES + WTS)",
    "method": "Combined whole exome sequencing (WES) and whole transcriptome sequencing (WTS) from single FFPE tissue extraction; detects SNVs, indels in 228 genes, MSI, TMB, and ERBB2 amplification.",
    "methodCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12581394/",
    "genesAnalyzed": 228,
    "genesAnalyzedNotes": "228 genes with reportable SNVs/indels in CDx subset; WES/WTS technically interrogates ~20,000 genes for research findings and signatures. This prevents confusion between '228 genes' and 'whole-exome' claims.",
    "genesAnalyzedCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "geneListUrl": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "biomarkersReported": ["SNVs", "Indels", "MSI", "TMB", "ERBB2 CNA"],
    "biomarkersReportedCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "targetPopulation": "Adults and pediatric patients (ages 1-22) with previously diagnosed solid malignant neoplasms",
    "targetPopulationNotes": "First and only FDA-approved CGP with CDx indications for both adult and pediatric patients.",
    "targetPopulationCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaStatus": "FDA-approved IVD (P240010) November 2024 - First WES+WTS combined assay with CDx indications",
    "fdaStatusCitations": "https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/ | https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaApprovalDate": "2024-11-06",
    "fdaApprovalDateCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaCompanionDxCount": 8,
    "fdaCompanionDxCountNotes": "8 CDx claims: 1 pan-cancer indication plus 5 tumor-specific indications (breast, colorectal, melanoma, NSCLC, endometrial). Includes PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H.",
    "fdaCompanionDxCountCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html | https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.molecularmd.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Endometrial Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines including PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "14 days",
    "tatNotes": "Results within 14 days.",
    "tatCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",
    "sampleRequirements": "FFPE tissue; minimum 20% tumor content",
    "sampleRequirementsNotes": "Simultaneous DNA and RNA extraction from single sample minimizes tissue requirements compared to separate assays.",
    "sampleRequirementsCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://www.mlo-online.com/diagnostics/assays/news/55241478/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage expanding; contact Caris for current payer coverage.",
    "reimbursementCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "clinicalAvailability": "Commercially available in US since November 2024",
    "clinicalAvailabilityCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "analyticalValidation": "97-100% positive and negative percent agreement compared to other FDA-approved assays",
    "analyticalValidationCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "numPublications": 30,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Part of Caris Molecular Intelligence platform (165+ total publications across platform)",
    "numPublicationsCitations": "https://www.carislifesciences.com/publications/"
  },
  {
    "id": "tds-11",
    "name": "OncoExTra",
    "vendor": "Exact Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (WES + WTS)",
    "method": "Whole exome sequencing (WES) of ~20,000 genes combined with whole transcriptome sequencing (WTS) from FFPE tissue; reports SNVs, indels, CNAs, fusions, MSI, TMB, and HRD status.",
    "methodCitations": "https://www.exactsciences.com/test/oncoextra | https://www.oncotarget.com/article/28285/text/",
    "genesAnalyzed": 20000,
    "genesAnalyzedNotes": "WES/WTS comprehensively interrogates ~20,000 genes; reportable subset varies by biomarker type.",
    "genesAnalyzedCitations": "https://www.exactsciences.com/test/oncoextra",
    "geneListUrl": "https://www.exactsciences.com/test/oncoextra",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "HRD"],
    "biomarkersReportedCitations": "https://www.exactsciences.com/test/oncoextra",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.exactsciences.com/test/oncoextra",
    "targetPopulation": "Patients with advanced solid tumors requiring comprehensive genomic and transcriptomic profiling",
    "targetPopulationCitations": "https://www.exactsciences.com/test/oncoextra",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.exactsciences.com/test/oncoextra",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.oncoextra.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma"],
    "vendorNCCNAlignmentNotes": "WES/WTS approach covers all biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://www.exactsciences.com/test/oncoextra",
    "sampleRequirements": "FFPE tissue; 10 unstained slides or tissue block",
    "sampleRequirementsCitations": "https://www.exactsciences.com/test/oncoextra",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage; commercial coverage varies by payer.",
    "reimbursementCitations": "https://www.exactsciences.com/test/oncoextra",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.exactsciences.com/test/oncoextra",
    "clinicalUtility": "Studies demonstrate increased matched therapy rates compared to single-gene testing.",
    "clinicalUtilityCitations": "https://www.oncotarget.com/article/28285/text/ | https://pubmed.ncbi.nlm.nih.gov/37256839/",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Exact Sciences comprehensive profiling; emerging publication portfolio",
    "numPublicationsCitations": "https://www.exactsciences.com/test/oncoextra"
  },
  {
    "id": "tds-12",
    "name": "OmniSeq INSIGHT",
    "vendor": "Labcorp Oncology (OmniSeq)",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP + Immune Profiling",
    "method": "NGS panel covering full coding regions of 523 genes plus immune profiling including PD-L1 expression and immune signatures; detects SNVs, indels, CNAs, fusions, TMB, and MSI.",
    "methodCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight | https://pmc.ncbi.nlm.nih.gov/articles/PMC8796288/",
    "genesAnalyzed": 523,
    "genesAnalyzedCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "geneListUrl": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "PD-L1", "Immune Signatures"],
    "biomarkersReportedNotes": "Combined genomic and immune profiling in single test.",
    "biomarkersReportedCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic and immune profiling",
    "targetPopulationCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.omniseq.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines plus immune profiling. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare and commercial coverage; widely available via Labcorp network.",
    "reimbursementCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "clinicalAvailability": "Commercially available in US via Labcorp network",
    "clinicalAvailabilityCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Labcorp Oncology (OmniSeq) platform publications",
    "numPublicationsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8796288/"
  },
  {
    "id": "tds-13",
    "name": "StrataNGS",
    "vendor": "Strata Oncology",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Multiplex PCR/semiconductor sequencing panel targeting 429 genes; detects SNVs, indels, CNAs, select fusions, TMB, and MSI.",
    "methodCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/",
    "genesAnalyzed": 429,
    "genesAnalyzedCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088",
    "geneListUrl": "https://www.strataoncology.com/stratangs",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Select Fusions", "TMB", "MSI"],
    "biomarkersReportedCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.strataoncology.com/stratangs",
    "targetPopulation": "Patients with advanced solid tumors requiring genomic profiling",
    "targetPopulationCitations": "https://www.strataoncology.com/stratangs",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.strataoncology.com/stratangs",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.stratangs.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatCitations": "https://www.strataoncology.com/stratangs",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://www.strataoncology.com/stratangs",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare-covered CGP; specific footprint in health-system networks.",
    "reimbursementCitations": "https://www.strataoncology.com/stratangs",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.strataoncology.com/stratangs",
    "clinicalUtility": "Published data on access and outcomes in real-world settings.",
    "clinicalUtilityCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Strata Oncology clinical validation and utility studies",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/34723565/"
  },
  {
    "id": "tds-14",
    "name": "MI Profile",
    "vendor": "Caris Life Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue Multi-omic Profiling",
    "method": "Comprehensive multi-omic profiling combining WES, WTS, and protein analysis (IHC/FISH) from FFPE tissue; reports DNA variants, RNA fusions, and protein expression.",
    "methodCitations": "https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/molecular-intelligence-platform/",
    "genesAnalyzed": 22000,
    "genesAnalyzedNotes": "WES/WTS interrogates ~22,000 genes; protein analysis adds expression-level biomarkers.",
    "genesAnalyzedCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "geneListUrl": "https://www.carislifesciences.com/physicians/profiling/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "Protein Expression"],
    "biomarkersReportedNotes": "Multi-omic approach combines genomic, transcriptomic, and proteomic data.",
    "biomarkersReportedCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "targetPopulation": "Patients requiring comprehensive multi-omic tumor profiling",
    "targetPopulationCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "fdaStatus": "CLIA LDT - MI Cancer Seek component FDA approved; full MI Profile is LDT",
    "fdaStatusNotes": "MI Cancer Seek (WES+WTS component) received FDA approval Nov 2024; MI Profile as comprehensive service remains CLIA LDT.",
    "fdaStatusCitations": "https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.molecularmd.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Gastric Cancer"],
    "vendorNCCNAlignmentNotes": "Multi-omic approach covers biomarkers recommended by NCCN guidelines at DNA, RNA, and protein levels. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "10-14 days",
    "tatCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage varies by payer and specific tests ordered.",
    "reimbursementCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Caris flagship test; 165+ publications across platform per vendor",
    "numPublicationsCitations": "https://www.carislifesciences.com/publications/"
  },
  {
    "id": "tds-15",
    "name": "NEO PanTracer Tissue",
    "previousName": "Neo Comprehensive",
    "vendor": "NeoGenomics",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Comprehensive genomic profiling using DNA and RNA NGS; detects SNVs, indels, CNVs, fusions, splice variants, MSI, and TMB across 517 genes from FFPE tissue samples.",
    "methodCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/235/neogenomics-expands-ngs-portfolio-with-launch-of-neo | https://www.neogenomics.com/test-menu",
    "genesAnalyzed": 517,
    "genesAnalyzedNotes": "517 genes analyzed via both DNA and RNA NGS methods.",
    "genesAnalyzedCitations": "NeoGenomics press release March 2023; NeoGenomics test menu.",
    "geneListUrl": "https://www.neogenomics.com/test-menu",
    "biomarkersReported": ["SNVs", "Indels", "CNVs", "Fusions", "Splice variants", "TMB", "MSI"],
    "biomarkersReportedNotes": "Comprehensive biomarker detection including both DNA alterations and RNA fusions/splice variants.",
    "biomarkersReportedCitations": "NeoGenomics press release March 2023.",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.neogenomics.com/test-menu",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic profiling for diagnosis, therapy selection, prognosis, and clinical trial eligibility",
    "targetPopulationCitations": "NeoGenomics test menu; press releases.",
    "fdaStatus": "CLIA LDT - NOT FDA approved",
    "fdaStatusNotes": "CLIA-certified and CAP-accredited laboratory-developed test. New York State approved (Jan 2024).",
    "fdaStatusCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://neotrex.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Pan-cancer CGP aligns with NCCN guidelines for solid tumor biomarker testing. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",
    "tat": "7-10 days",
    "tatNotes": "Improved turnaround time compared to previous NeoGenomics panels. Streamlined workflow.",
    "tatCitations": "NeoGenomics press release March 2023.",
    "sampleRequirements": "FFPE tissue (decreased specimen requirements vs previous panels)",
    "sampleRequirementsCitations": "NeoGenomics press release March 2023.",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage varies by payer. Medicare coverage for CGP in advanced solid tumors. Commercial coverage varies.",
    "reimbursementCitations": "NeoGenomics website.",
    "clinicalAvailability": "Commercially available in US (including NY State)",
    "clinicalAvailabilityCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "NeoGenomics tissue profiling panel; newer product (launched March 2023)",
    "numPublicationsCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/235/neogenomics-expands-ngs-portfolio-with-launch-of-neo",
    "regulatoryStatusNotes": "CAP-accredited and CLIA-certified laboratories in Fort Myers and Tampa, FL; Aliso Viejo and San Diego, CA; Research Triangle Park, NC; and Houston, TX. New York State approved January 2024."
  },
  {
    "id": "tds-16",
    "name": "Northstar Select",
    "vendor": "BillionToOne",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "Single-molecule NGS (smNGS) with QCT™ (Quantitative Counting Templates) for cfDNA analysis. 84-gene panel optimized for sensitivity over breadth. Detects SNVs, indels, CNAs (amplifications and losses), fusions, and MSI-H. Unique ability to differentiate focal copy number changes from aneuploidies using insights from >1 million cfDNA tests for fetal aneuploidy.",
    "methodCitations": "https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action | Bower X et al. J Liq Biopsy 2025;9:1003222",
    "genesAnalyzed": 84,
    "genesAnalyzedNotes": "84-gene panel: 82 genes for SNV/indels, 19 genes for CNA amplification, 5 genes for CNA loss, 9 genes for fusions. Panel designed for actionability over breadth.",
    "genesAnalyzedCitations": "https://www.northstaronc.com/",
    "geneListUrl": "https://cdn.prod.website-files.com/676903c0e34284138d6e0066/68e3c65e20bf5b7173202a4f_NS-SEL-FL-001-2509%20-%20Spec%20Sheet%20-%20DIGITAL.pdf",
    "biomarkersReported": ["SNVs", "Indels", "CNAs (amplification)", "CNAs (loss)", "Fusions", "MSI-H"],
    "biomarkersReportedNotes": "Reports guideline-recommended alterations with focus on actionability. Unique capability to detect CNA losses and differentiate focal driver amplifications from broad chromosomal aneuploidies.",
    "biomarkersReportedCitations": "https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",
    "cancerTypes": ["Advanced solid tumors (17+ types)", "CNS cancers", "Low-shedding tumors"],
    "cancerTypesCitations": "https://www.prnewswire.com/news-releases/billiontoones-northstar-select-demonstrates-superior-sensitivity-in-prospective-head-to-head-validation-study-publication-302539192.html",
    "targetPopulation": "Patients with stage III or IV solid tumors requiring comprehensive genomic profiling, particularly when tissue is not feasible or for low-shedding tumors",
    "targetPopulationCitations": "https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",
    "sensitivity": null,
    "sensitivityNotes": "In prospective head-to-head validation (n=182), detected 51% more pathogenic SNV/Indels and 109% more CNVs than comparator assays. 87% detection rate in CNS cancers vs 27-55% reported for other liquid biopsies. 91% of additional clinically actionable variants found below 0.5% VAF.",
    "sensitivityCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222 | https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",
    "specificity": 99.9,
    "specificityNotes": ">99.9% analytical specificity across all variant classes. 98% concordance with ddPCR orthogonal validation. CHIP rate equivalent to comparators (19.0% vs 17.2%), confirming additional detections are true positives.",
    "specificityCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222",
    "lod": "0.15% VAF",
    "lodNotes": "LOD95 of 0.15% VAF for SNVs - among the lowest in commercially available liquid biopsy CGP. 2-5x lower LOD than comparator assays.",
    "lodCitations": "https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",
    "fdaStatus": "CLIA LDT - NOT FDA approved",
    "fdaStatusNotes": "CLIA-certified laboratory-developed test. CAP-accredited.",
    "fdaStatusCitations": "https://www.northstaronc.com/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.biodesix.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "84-gene panel covers guideline-recommended biomarkers. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",
    "tat": "5-8 days",
    "tatNotes": "Typical turnaround time 5-8 days from specimen receipt.",
    "tatCitations": "https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action",
    "sampleRequirements": "Blood draw (plasma cfDNA)",
    "sampleRequirementsCitations": "https://www.northstaronc.com/",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via MolDx (Palmetto GBA LCD L38043) effective February 14, 2025 for eligible beneficiaries with advanced solid tumors.",
    "reimbursementCitations": "https://www.billiontoone.com/news-media/billiontoone-announces-medicare-coverage-for-northstar-select",
    "clinicalAvailability": "Commercially available in US since January 2023",
    "clinicalAvailabilityCitations": "https://www.delveinsight.com/asco-conference/article/billiontoone-northstar-select",
    "numPublications": 2,
    "numPublicationsNotes": "Peer-reviewed validation study published September 2025 in Journal of Liquid Biopsy. ASCO 2024 abstract.",
    "numPublicationsCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222 | JCO 2024;42:16_suppl,3072",
    "publicationsExampleCitations": ["https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00038-4/fulltext", "https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072"],
    "technologyDifferentiator": "Only liquid biopsy with prospective head-to-head peer-reviewed publication showing superior sensitivity vs multiple commercially available comparators. smNGS with QCT technology enables single-molecule precision. Unique ability to detect CNA losses and differentiate focal amplifications from aneuploidies.",
    "independentValidation": "Prospective head-to-head validation against 6 commercially available assays from 4 CLIA/CAP labs (n=182 patients, 17+ tumor types, 6 community clinics + 1 hospital). Orthogonal ddPCR validation showed 98% concordance.",
    "independentValidationCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222",
    "vendorDataSource": "Rob Manor (BillionToOne) submission Dec 2025"
  },
  {
    "id": "tds-18",
    "name": "IsoPSA",
    "vendor": "Cleveland Diagnostics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Serum",
    "approach": "Protein Structure Analysis",
    "method": "IsoClear platform analyzes structural differences in PSA protein isoforms to distinguish cancer-derived PSA from benign elevations. Measures prostate cancer-specific structural variants of the PSA protein rather than total PSA concentration. Runs on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad deployment from large centers to community practices.",
    "methodCitations": "Klein EA et al. Eur Urol 2017 | Stovsky M et al. J Urol 2019",
    "genesAnalyzed": null,
    "genesAnalyzedNotes": "Not applicable - protein structure analysis test, not genomic",
    "cancerTypes": ["Prostate cancer (high-grade)"],
    "cancerTypesNotes": "Specifically designed to detect high-grade (clinically significant) prostate cancer, helping avoid unnecessary biopsies for low-grade or benign conditions.",
    "targetPopulation": "Men ≥50 years of age with elevated PSA levels who are candidates for prostate biopsy decision-making",
    "targetPopulationCitations": "FDA PMA approval December 2025",
    "indicationsNotes": "Aid in the decision for prostate biopsy. Can be used prior to initial biopsy or in patients with prior negative biopsy who remain at elevated risk. Helps clinicians and patients make more informed biopsy decisions.",
    "sensitivity": 90.2,
    "sensitivityNotes": "90.2% sensitivity (95% CI: 86.4%-93.0%) for high-grade prostate cancer in prospective multicenter validation study (n=888).",
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data; https://pubmed.ncbi.nlm.nih.gov/27477528/ | Klein EA et al. Eur Urol 2017",
    "specificity": 45.5,
    "specificityNotes": "45.5% specificity (95% CI: 41.4%-49.6%) for high-grade prostate cancer. Specificity is 2-3x higher than traditional PSA tests, potentially avoiding up to 46% of unnecessary biopsies.",
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data; https://pubmed.ncbi.nlm.nih.gov/27477528/ | Klein EA et al. Eur Urol 2017",
    "ppv": 47.7,
    "ppvNotes": "47.7% PPV (95% CI: 45.7%-49.8%) for high-grade prostate cancer.",
    "ppvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data",
    "npv": 89.3,
    "npvNotes": "89.3% NPV (95% CI: 85.6%-92.2%) for high-grade prostate cancer, providing high confidence in negative results.",
    "npvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data",
    "auc": 0.783,
    "aucNotes": "AUC of 0.783 (95% CI: 0.752-0.814) for high-grade prostate cancer, outperforming total PSA and % free PSA.",
    "aucCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data",
    "fdaStatus": "FDA PMA Approved (December 2025)",
    "fdaStatusNotes": "FDA Premarket Approval (PMA) granted December 1, 2025. Previously offered as CLIA LDT since 2020. Breakthrough Device Designation granted October 2019.",
    "fdaStatusCitations": "https://www.businesswire.com/news/home/20251201324198/en/FDA-Approves-IsoPSA----Cleveland-Diagnostics-Novel-Blood-Based-Prostate-Cancer-Test",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Prostate Cancer Early Detection Guidelines (added V.1.2022, current)",
    "nccnGuidelinesNotes": "Specifically named for use prior to biopsy and in patients with prior negative biopsy at higher risk for clinically significant prostate cancer.",
    "nccnGuidelinesCitations": "https://www.businesswire.com/news/home/20220511005019/en/Cleveland-Diagnostics-Announces-Inclusion-of-IsoPSA-in-National-Comprehensive-Cancer-Network-Guidelines-for-Prostate-Cancer-Early-Detection",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage established. Commercial payer coverage for 140 million covered lives. More IsoPSAs ordered in first full year as LDT than Guardant360 tests in first 3 years.",
    "reimbursementCitations": "Cleveland Diagnostics; Sameer Rohatgi communication Dec 2025",
    "commercialPayers": ["Multiple commercial payers (140M covered lives)"],
    "tat": "3-5 days",
    "tatNotes": "Results typically available in 3-5 days from sample receipt.",
    "tatCitations": "https://www.isopsa.com/for-patients/",
    "sampleRequirements": "Blood draw in Streck tube",
    "sampleRequirementsNotes": "Simple blood draw collected in Streck tube. No DRE required prior to collection.",
    "sampleRequirementsCitations": "https://www.clevelanddx.com/isopsa-testing",
    "clinicalAvailability": "Commercially available in US (LDT since 2020, FDA PMA December 2025)",
    "clinicalAvailabilityNotes": "Available through Cleveland Diagnostics CLIA lab and Quest Diagnostics. IVD kit format enables deployment on standard clinical analyzers (Roche COBAS, Siemens, Abbott) at any laboratory.",
    "clinicalAvailabilityCitations": "https://www.clevelanddx.com",
    "availableRegions": ["US"],
    "clinicalTrials": "Prospective multicenter validation study (n=888 patients scheduled for prostate biopsy)",
    "clinicalTrialsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023B.pdf | FDA PMA clinical data; https://pubmed.ncbi.nlm.nih.gov/27477528/ | Klein EA et al. Eur Urol 2017",
    "totalParticipants": 888,
    "totalParticipantsNotes": "888 patients in prospective multicenter validation study. Additional longitudinal outcome data published in Urology 2025.",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Extensive publication portfolio including Klein EA et al. Eur Urol 2017 (initial validation), Stovsky M et al. J Urol 2019, decision analysis in Urol Pract 2022, and longitudinal outcomes in Urology 2025.",
    "numPublicationsCitations": "https://www.clevelanddx.com/news-archive",
    "publicationsExampleCitations": ["Klein EA et al. Eur Urol 2017", "Stovsky M et al. J Urol 2019", "Abdallah et al. Urology 2025"],
    "technologyDifferentiator": "Only FDA-approved protein structure-based cancer diagnostic. IsoClear platform measures structural differences in proteins rather than concentration. Deployable on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad access from academic centers to community urology practices - not limited to centralized specialty labs.",
    "regulatoryStatusNotes": "FDA PMA approved December 2025. Breakthrough Device Designation 2019. In NCCN and AUA/SUO guidelines. First protein structure-based cancer blood test to receive FDA approval.",
    "vendorDataSource": "Sameer Rohatgi (Cleveland Diagnostics) communication Dec 2025"
  },
  {
    "id": "tds-19",
    "name": "Oncotype DX Breast Recurrence Score",
    "vendor": "Exact Sciences",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Gene Expression Profiling",
    "method": "21-gene RT-PCR assay analyzing expression of 16 cancer-related genes and 5 reference genes in FFPE tumor tissue; generates Recurrence Score (0-100) that is both prognostic for 9-year distant recurrence risk and predictive of adjuvant chemotherapy benefit.",
    "methodCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-providers | https://pubmed.ncbi.nlm.nih.gov/15591335/",
    "genesAnalyzed": 21,
    "genesAnalyzedNotes": "16 cancer-related genes (proliferation: Ki67, STK15, BIRC5, CCNB1, MYBL2; HER2 group: GRB7, HER2; estrogen: ER, PGR, BCL2, SCUBE2; invasion: MMP11, CTSL2; other: GSTM1, BAG1, CD68) plus 5 reference/housekeeping genes (ACTB, GAPDH, GUS, RPLPO, TFRC).",
    "genesAnalyzedCitations": "https://www.oncotarget.com/article/28148/text/",
    "geneListUrl": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-providers",
    "biomarkersReported": ["Gene Expression Score", "Recurrence Score (0-100)", "ER", "PR", "HER2"],
    "biomarkersReportedNotes": "Provides continuous Recurrence Score (0-100) predicting 9-year distant recurrence risk and chemotherapy benefit. Also reports quantitative RNA expression of ER, PR, and HER2.",
    "biomarkersReportedCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-providers",
    "cancerTypes": ["Breast cancer (HR+, HER2-)"],
    "cancerTypesNotes": "Indicated for early-stage (Stage I, II, IIIA), hormone receptor-positive, HER2-negative invasive breast cancer. Applicable to node-negative or node-positive (1-3 nodes) disease.",
    "cancerTypesCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-patients",
    "targetPopulation": "Patients with early-stage (Stage I-IIIA), HR+, HER2-, node-negative or node-positive (1-3 nodes) invasive breast cancer who are candidates for adjuvant systemic therapy",
    "targetPopulationCitations": "https://www.nccn.org/guidelines/category_1",
    "fdaStatus": "CLIA LDT - CAP-accredited, CLIA-certified; not FDA approved",
    "fdaStatusNotes": "Performed at Genomic Health (Exact Sciences) centralized laboratory in Redwood City, CA. CAP-accredited and CLIA-certified for high-complexity clinical laboratory testing. In clinical use since 2004.",
    "fdaStatusCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-invasive-ductal",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Breast Cancer Guidelines",
    "nccnGuidelinesNotes": "NCCN-preferred multigene assay with Category 1 evidence. Only test with Level 1 evidence for both prognosis AND prediction of chemotherapy benefit for HR+, HER2- breast cancer.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1",
    "otherGuidelinesRecommended": ["ASCO", "ESMO", "St Gallen", "NICE"],
    "otherGuidelinesNotes": "Incorporated into all major international breast cancer treatment guidelines including ASCO, ESMO, St Gallen Consensus, and NICE (UK). Only genomic assay with highest recommendation in 5 major international guidelines.",
    "otherGuidelinesCitations": "https://www.oncotypedxtest.com/healthcare-professionals/oncotype-dx-recommended-by-international-guidelines",
    "tat": "7-14 days",
    "tatNotes": "Results typically available within 7-10 days from specimen receipt at lab; approximately 2 weeks from sample collection. Performed at centralized Genomic Health laboratory in Redwood City, CA.",
    "tatCitations": "https://www.oncotypeiq.com/en-GB/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/how-to-order-a-test",
    "sampleRequirements": "FFPE tumor tissue from core biopsy, lumpectomy, or mastectomy; formalin-fixed; 5 μm unstained slides or tissue block",
    "sampleRequirementsNotes": "No additional procedure required - uses tissue already collected during biopsy or surgery. Specimen transported in specially prepared container to centralized laboratory.",
    "sampleRequirementsCitations": "https://www.exactsciences.com/cancer-testing/oncotype-dx-breast-recurrence-score-patients",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare and majority of private insurers cover for eligible patients. Medicare FFS coverage for patients meeting clinical criteria. 80+ commercial health plans provide coverage. Exact Sciences Genomic Access Program (GAP) available for financial assistance.",
    "reimbursementCitations": "https://precisiononcology.exactsciences.com/billing-financial-coverage",
    "listPrice": 4000,
    "listPriceNotes": "Approximately $4,000-$4,500.",
    "listPriceCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5310948/",
    "cptCodes": "81519",
    "cptCodesNotes": "CPT 81519 for Oncotype DX Breast Recurrence Score; CPT 0045U for DCIS Score.",
    "cptCodesCitations": "https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=55230",
    "codeType": "PLA",
    "medicareRate": 3416,
    "medicareRateNotes": "Medicare reimbursement rate approximately $3,416.",
    "medicareRateCitations": "https://www.genomeweb.com/molecular-diagnostics/cms-restores-reimbursement-rate-oncotype-dx-breast-cancer-test",
    "medicareStatus": "Priced",
    "adltStatus": true,
    "availableRegions": ["US", "UK", "EU", "Canada", "Israel", "Japan", "Australia", "International"],
    "availableRegionsNotes": "Available in 90+ countries. Publicly funded in UK, Ireland, Switzerland, Spain, Israel, Greece, and Canada. Samples shipped to centralized Genomic Health laboratory in Redwood City, CA (US) for testing.",
    "availableRegionsCitations": "https://www.prnewswire.com/news-releases/publication-in-the-new-england-journal-of-medicine-confirms-that-tens-of-thousands-of-women-with-node-positive-early-stage-breast-cancer-can-avoid-chemotherapy-with-the-oncotype-dx-test-301435658.html",
    "clinicalAvailability": "Commercially available since 2004; over 1 million patients tested worldwide",
    "clinicalAvailabilityCitations": "https://www.exactsciences.com/en-gb/cancer-testing/oncotype-dx-tests",
    "clinicalTrials": "TAILORx (NCT00310180; 10,273 patients); RxPONDER (NCT01272037; 5,083 patients); NSABP B-14; NSABP B-20; transATAC; SWOG-8814",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT00310180 | https://clinicaltrials.gov/study/NCT01272037",
    "clinicalTrialsNotes": "Only multigene assay with Level 1 evidence from prospective randomized trials (TAILORx, RxPONDER) demonstrating prediction of chemotherapy benefit. TAILORx showed majority of node-negative patients can safely forgo chemotherapy; RxPONDER extended findings to node-positive postmenopausal patients.",
    "totalParticipants": 15000,
    "totalParticipantsNotes": "Over 15,000 patients in pivotal prospective trials (TAILORx + RxPONDER). Over 1 million patients tested commercially worldwide.",
    "numPublications": 500,
    "numPublicationsPlus": true,
    "numPublicationsSource": "pubmed-estimate",
    "numPublicationsNotes": "Over 500 peer-reviewed publications. Bibliometric analysis identified 530+ publications as of 2016; publication count has increased substantially since TAILORx (2018) and RxPONDER (2021) results.",
    "numPublicationsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5459968/",
    "publicationsExampleCitations": ["Paik S et al. N Engl J Med 2004;351:2817-2826", "Sparano JA et al. N Engl J Med 2018;379:111-121", "Kalinsky K et al. N Engl J Med 2021;385:2336-2347"],
    "technologyDifferentiator": "First commercially available multigene assay for breast cancer (2004). Pioneered genomic-guided treatment decisions in oncology. Only test with Level 1 evidence from prospective randomized trials (TAILORx, RxPONDER) demonstrating prediction of chemotherapy benefit. Transformed standard of care by enabling personalized chemotherapy decisions, sparing hundreds of thousands of patients from unnecessary chemotherapy. Gene expression profiling approach (not mutation detection) - fundamentally different methodology from CGP tests.",
    "regulatoryStatusNotes": "CLIA-certified LDT in clinical use since 2004. Not FDA approved but considered standard of care with Category 1 NCCN recommendation. Incorporated into AJCC 8th edition pathological prognostic staging.",
    "historicalSignificance": "Pioneered the era of genomic-guided personalized cancer care for breast cancer. In clinical use for over 20 years with over 1 million patients tested globally.",
    "submissionInfo": {
      "submittedBy": "Dr. Don Johann",
      "submitterEmail": "djjohann@uams.edu",
      "submitterType": "Independent Expert",
      "submitterAffiliation": "University of Arkansas for Medical Sciences",
      "submissionDate": "2025-12-17",
      "submissionNotes": "Surprise you do not list this test, OncoType Dx, given the disruptive impact it has had since 2004. Please consider adding. This website is outstanding! Thank you."
    }
  },
  {
    "id": "tds-20",
    "name": "Liquid Trace Solid Tumor",
    "vendor": "Genomic Testing Cooperative (GTC)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "EDTA",
    "approach": "Liquid CGP",
    "method": "Combined cfDNA and cfRNA NGS from peripheral blood or CSF. cfDNA analysis detects SNVs, indels, CNAs, and chromosomal structural abnormalities. cfRNA analysis (>1,600 genes) detects gene fusions, expression levels, and alternative splicing variants. Includes TMB evaluation, T/B-cell clonality, HLA Class I genotyping, and viral detection (EBV, HPV, TTV).",
    "methodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "methodNotes": "Unique cfDNA + cfRNA combination provides higher sensitivity than cfDNA-only liquid biopsies. cfRNA captures fusion genes from chromosomal translocations and expression-level changes that cfDNA misses. Studies show RNA sequencing is more sensitive for some mutations since cancer cells contain multiple RNA copies but only one mutated DNA copy.",
    "genesAnalyzed": 1600,
    "genesAnalyzedNotes": ">1,600 genes analyzed via cfRNA; cfDNA gene count not specified separately. Combined approach.",
    "genesAnalyzedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "geneListUrl": "https://genomictestingcooperative.com/genomic-tests/cfdna-genes/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "Gene Expression", "TMB", "Chromosomal Abnormalities", "T/B-cell Clonality", "HLA Genotyping", "Viral (EBV, HPV, TTV)"],
    "biomarkersReportedNotes": "cfRNA enables fusion detection and expression profiling not available from cfDNA-only tests. Viral detection includes EBV (lymphoid neoplasms), HPV (anogenital/oropharyngeal cancers), and TTV (immune competence marker).",
    "biomarkersReportedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "cancerTypes": ["Lung", "Brain/CNS", "Breast", "Thyroid", "Colorectal", "Oropharyngeal", "Pancreatic", "Ovarian", "Prostate", "Other solid tumors"],
    "cancerTypesCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic profiling for diagnosis, treatment selection, or monitoring. CSF samples accepted for CNS tumors (can add MGMT methylation analysis for brain tumors when tumor DNA detected).",
    "targetPopulationCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory developed test performed at GTC's CLIA/CAP-certified laboratory. NYSDOH approved. CE-marked for EU. UKCA certified for UK.",
    "fdaStatusCitations": "https://genomictestingcooperative.com/legal-licensing/licenses-cerifications/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://imagenedx.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "vendorNCCNAlignmentNotes": "Covers guideline-recommended biomarkers. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatNotes": "RNA stability is 48-72 hours from blood draw; DNA stability is 7 days. Samples received beyond 72 hours may include only DNA results.",
    "tatCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "sampleRequirements": "Peripheral blood: 10mL in EDTA tube. CSF: 7-10mL optimal (5mL minimum). Ship blood with cold pack (not directly contacting tube) overnight.",
    "sampleRequirementsNotes": "For blood: RNA stability 48-72 hours, DNA stability 7 days. For CSF: Ship ASAP overnight, do not use anticoagulants, use clear tubes.",
    "sampleRequirementsCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "lod": "0.1-0.01% VAF (non-hotspot); 0.01-0.001% (hotspot); <0.001% (tumor-informed)",
    "lodNotes": "Detection sensitivity varies by variant type and prior history. Tumor-informed or prior history samples achieve highest sensitivity.",
    "lodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare covered. Contact GTC for current payer coverage information.",
    "availableRegions": ["US", "EU", "UK"],
    "availableRegionsNotes": "NYSDOH approved. CE-marked for EU. UKCA certified for UK. US-based laboratory with international representatives.",
    "availableRegionsCitations": "https://genomictestingcooperative.com/international-representatives/",
    "clinicalAvailability": "Commercially available",
    "clinicalAvailabilityCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/",
    "numPublications": 15,
    "numPublicationsNotes": "Publications from GTC team on cfDNA/cfRNA liquid biopsy methodology. References listed on product page.",
    "numPublicationsCitations": "https://genomictestingcooperative.com/category/publications/",
    "technologyDifferentiator": "Only commercially available liquid biopsy combining cfDNA and cfRNA analysis. cfRNA provides: (1) Higher sensitivity for some mutations due to multiple RNA copies per cell; (2) Fusion gene detection from chromosomal translocations; (3) Expression-level data including alternative splicing. Also includes T/B-cell clonality, HLA genotyping, and viral detection (EBV, HPV, TTV) not found in most liquid CGP tests. LEADING PROVIDER FOR CSF LIQUID BIOPSY - optimal sample input for CNS tumors (glioblastoma, CNS lymphomas/leukemias) and leptomeningeal disease (common in breast, lung, melanoma patients with prolonged survival). AI/machine learning integrated into analysis pipeline.",
    "monitoringCapabilities": true,
    "monitoringCapabilitiesNotes": "Reports include serial VAF tracking AND mutant molecules/mL for quantitative treatment response monitoring. Can be used for longitudinal disease monitoring in addition to initial genomic profiling.",
    "csfLeadership": true,
    "csfLeadershipNotes": "GTC is the leading provider of liquid biopsy on cerebrospinal fluid (CSF). CSF is the optimal sample for CNS tumors including glioblastoma, CNS lymphomas, CNS leukemias, and leptomeningeal disease which commonly occurs in breast, lung, and melanoma patients with prolonged survival.",
    "submissionInfo": {
      "submittedBy": "Jeffrey Owen",
      "submitterEmail": "jowen@genomictestingcooperative.com",
      "submitterType": "Vendor Representative",
      "submissionDate": "2025-12-17",
      "submissionNotes": "Submitted as TRM; also listed in TDS for CGP use case. Test is used for both initial profiling AND serial therapeutic monitoring via VAF/mutant molecules tracking.",
      "vendorUpdateDate": "2025-12-17",
      "vendorUpdateNotes": "Vendor clarified test is actively used for therapeutic monitoring with VAF and mutant molecules/mL tracking table in reports. Emphasized CSF leadership for CNS tumors and leptomeningeal disease."
    }
  },
  {
    "id": "tds-21",
    "name": "Liquid Trace Hematology",
    "vendor": "Genomic Testing Cooperative (GTC)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "EDTA",
    "approach": "Liquid CGP",
    "method": "Combined cfDNA and cfRNA NGS from peripheral blood or CSF. Highly sensitive pan-cancer test for hematologic malignancies. cfRNA (>1,600 genes) enables detection of mutations and fusions often missed by cfDNA-only testing. Includes T/B-cell clonality detection, HLA Class I genotyping, and viral detection (TTV as immune competence marker).",
    "methodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "methodNotes": "Can significantly reduce need for bone marrow biopsies. Detects chromosomal abnormalities, translocations, and gene amplifications from liquid biopsy. CSF samples ideally suited for characterizing lymphoma and multiple myeloma with CNS involvement.",
    "genesAnalyzed": 1600,
    "genesAnalyzedNotes": ">1,600 genes analyzed via cfRNA; combined cfDNA + cfRNA approach.",
    "genesAnalyzedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "geneListUrl": "https://genomictestingcooperative.com/genomic-tests/cfdna-genes/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "Gene Expression", "Chromosomal Abnormalities", "T/B-cell Clonality", "HLA Genotyping", "TTV Viral Load", "CAR-T Detection"],
    "biomarkersReportedNotes": "T/B-cell clonality detection important for diagnosis and monitoring of lymphoid and plasma cell malignancies. TTV (Torque Teno Virus) load serves as immune competence marker - high TTV associated with infection risk, low TTV with rejection risk in transplant patients. Can detect and monitor CAR-T cells in CSF.",
    "biomarkersReportedCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "cancerTypes": ["Multiple Myeloma", "Lymphoma", "Acute Lymphoblastic Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasms (MPN)", "VEXAS Syndrome", "EBV-related Neoplasms", "Hypereosinophilia"],
    "cancerTypesCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "targetPopulation": "Patients with hematologic malignancies requiring comprehensive genomic profiling for diagnosis, classification, treatment selection, or monitoring. Alternative to bone marrow biopsy in many cases. CSF samples for CNS involvement characterization and CAR-T monitoring.",
    "targetPopulationCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory developed test performed at GTC's CLIA/CAP-certified laboratory. NYSDOH approved. CE-marked for EU. UKCA certified for UK.",
    "fdaStatusCitations": "https://genomictestingcooperative.com/legal-licensing/licenses-cerifications/",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://imagenedx.com/",
    "vendorNCCNAlignmentIndications": ["Acute Myeloid Leukemia", "Multiple Myeloma", "B-Cell Lymphomas"],
    "vendorNCCNAlignmentNotes": "Covers guideline-recommended biomarkers for hematologic malignancies. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "tat": "5-7 days",
    "tatNotes": "RNA stability is 48-72 hours from blood draw; DNA stability is 7 days. Samples received beyond 72 hours may include only DNA results.",
    "tatCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "sampleRequirements": "Peripheral blood: 10mL in EDTA tube. CSF: 7-10mL optimal (5mL minimum). Ship blood with cold pack (not directly contacting tube) overnight.",
    "sampleRequirementsNotes": "For blood: RNA stability 48-72 hours, DNA stability 7 days. For CSF: Ship ASAP overnight, do not use anticoagulants, use clear tubes.",
    "sampleRequirementsCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "lod": "0.1-0.01% VAF (non-hotspot); 0.01-0.001% (hotspot); <0.001% (tumor-informed)",
    "lodNotes": "Detection sensitivity varies by variant type and prior history. VAF used to monitor disease - higher VAF indicates higher tumor load; reduction in VAF after treatment indicates response.",
    "lodCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare covered. Contact GTC for current payer coverage information.",
    "availableRegions": ["US", "EU", "UK"],
    "availableRegionsNotes": "NYSDOH approved. CE-marked for EU. UKCA certified for UK. US-based laboratory with international representatives.",
    "availableRegionsCitations": "https://genomictestingcooperative.com/international-representatives/",
    "clinicalAvailability": "Commercially available",
    "clinicalAvailabilityCitations": "https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/",
    "numPublications": 15,
    "numPublicationsNotes": "Publications from GTC team on cfDNA/cfRNA liquid biopsy methodology. References listed on product page.",
    "numPublicationsCitations": "https://genomictestingcooperative.com/category/publications/",
    "technologyDifferentiator": "Only commercially available hematology liquid biopsy combining cfDNA and cfRNA analysis. Can reduce need for bone marrow biopsies. Key differentiators: (1) cfRNA enables higher sensitivity and fusion detection; (2) T/B-cell clonality for lymphoid/plasma cell malignancy diagnosis; (3) TTV viral load as immune competence marker for transplant patients; (4) CAR-T cell detection and monitoring in CSF; (5) CSF samples for CNS involvement characterization; (6) cfDNA chimerism analysis for post-transplant relapse prediction; (7) Chromosomal abnormalities detection beyond mutations (going beyond Signatera-style mutation-only MRD). LEADING PROVIDER FOR CSF LIQUID BIOPSY in hematologic malignancies. AI/machine learning integrated into analysis pipeline.",
    "monitoringCapabilities": true,
    "monitoringCapabilitiesNotes": "Reports include serial VAF tracking AND mutant molecules/mL for treatment response monitoring. Published validation shows cfDNA detects MORE mutations than bone marrow (92 vs 61 mutations in same patients). Higher VAF = higher tumor load; VAF reduction = response to treatment.",
    "chimerismCapabilities": true,
    "chimerismCapabilitiesNotes": "cfDNA chimerism analysis for post-transplant monitoring. Published 2025 data (Rowley et al., Cancers) shows cfDNA chimerism predicts relapse more accurately than standard CD3+ cell chimerism. All relapsed patients showed downward trend in cfDNA chimerism detectable by day 56 post-transplant.",
    "mrdCapabilities": true,
    "mrdCapabilitiesNotes": "MRD detection via persistent adverse-risk driver mutations AND chromosomal abnormalities - going beyond mutation-only approaches like Signatera. Published data: patients who cleared adverse-risk mutations did not relapse; 6/7 patients with persistent adverse-risk mutations relapsed within 12 months post-transplant.",
    "csfLeadership": true,
    "csfLeadershipNotes": "Ideally suited for characterizing lymphoma and multiple myeloma with CNS involvement. Can detect and monitor CAR-T cells in CSF samples.",
    "submissionInfo": {
      "submittedBy": "Jeffrey Owen",
      "submitterEmail": "jowen@genomictestingcooperative.com",
      "submitterType": "Vendor Representative",
      "submissionDate": "2025-12-17",
      "submissionNotes": "Submitted alongside Liquid Trace Solid Tumor. Entered as separate test due to distinct cancer type focus and additional hematology-specific biomarkers (T/B clonality, TTV, CAR-T detection, chimerism).",
      "vendorUpdateDate": "2025-12-17",
      "vendorUpdateNotes": "Vendor clarified MRD approach includes chimerism analysis and chromosomal abnormalities beyond just mutations - differentiated from Signatera. Published 2025 papers on cfDNA chimerism predicting relapse post-transplant."
    },
    "publicationsKey": [
      {
        "citation": "Rowley SD, Albitar M, et al. cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Cancers 2025;17:625.",
        "url": "https://doi.org/10.3390/cancers17040625",
        "keyFinding": "cfDNA testing detected more mutations than bone marrow (92 vs 61); cfDNA chimerism predicted relapse better than CD3+ chimerism; adverse-risk mutation clearance = no relapse"
      },
      {
        "citation": "Aljurf M, et al. Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse.",
        "url": "https://genomictestingcooperative.com/chimerism-analysis-of-cell-free-dna/",
        "keyFinding": "cfDNA chimerism more reliable than cellular DNA chimerism for predicting early relapse post-HSCT"
      }
    ]
  },
  {
    "id": "tds-22",
    "name": "LiquidHALLMARK",
    "vendor": "Lucence",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Streck cfDNA BCT",
    "approach": "Liquid CGP (ctDNA + ctRNA)",
    "method": "Amplicon-based NGS (AmpliMark platform) of ctDNA (80 genes) and ctRNA (10 fusion targets); detects SNVs, indels, CNAs, MSI, and fusions with molecular barcode error correction. Combined ctDNA + ctRNA analysis increases actionable fusion detection by 36.7% vs ctDNA alone.",
    "methodCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://pubmed.ncbi.nlm.nih.gov/35482824/",
    "methodNotes": "AmpliMark proprietary technology uses unique molecular barcodes and error correction to maximize sensitivity. ctRNA addresses DNA-based fusion detection limitations from large introns. Available via Mayo Clinic Labs since March 2025.",
    "genesAnalyzed": 80,
    "genesAnalyzedNotes": "80 genes analyzed via ctDNA for SNVs, indels, CNAs, MSI. 10 genes analyzed via ctRNA for fusions.",
    "genesAnalyzedCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "rnaGenesAnalyzed": 10,
    "rnaGenesAnalyzedNotes": "10 ctRNA targets for actionable and emerging fusions: ALK, FGFR2, FGFR3, MET, NTRK1, NTRK2, RET, ROS1, TMPRSS2.",
    "rnaGenesAnalyzedCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "geneListUrl": "https://www.mayocliniclabs.com/it-mmfiles/LiquidHALLMARK-Targets-by-Cancer-Type.pdf",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions (cfDNA + cfRNA)", "MSI"],
    "biomarkersReportedNotes": "SNVs, Indels, CNAs, and MSI detected from cfDNA. Fusions detected from both cfDNA and cfRNA for enhanced sensitivity. MSI determined from 6 microsatellite loci (BAT25, BAT26, NR21, NR24, NR27, MONO27). MSI-H = 2+ sites, MSI-L = 1 site.",
    "biomarkersReportedCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "cancerTypes": ["Solid tumors (lung, breast, colon, prostate, ovarian, gastric, liver, pancreatic, bladder, kidney, thyroid, melanoma, endometrial, cervical, head & neck)"],
    "cancerTypesNotes": "Targets genes commonly associated with 15 cancer types.",
    "cancerTypesCitations": "https://www.lucence.com/solutions/liquid-hallmark | https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "targetPopulation": "Patients with solid tumors requiring genomic profiling when tissue biopsy is not feasible or as complement to tissue testing",
    "targetPopulationCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "lod": "0.1% VAF (SNVs/indels); 0.5% VAF (DNA fusions); 10 copies (RNA fusions)",
    "lodNotes": "At 0.1% VAF: >91% sensitivity for SNVs, >95% for indels. At 0.5% VAF: >91% sensitivity for DNA fusions. Copy number LoD: gain 0.6 copy (1.3-fold), loss 0.71 copy (1.4-fold). MSI LoD: 5% DNA with deletions-insertions in microsatellite loci.",
    "lodCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://pubmed.ncbi.nlm.nih.gov/35482824/",
    "sensitivity": 99.38,
    "sensitivityNotes": "99.38% sensitivity for SNVs at 0.1% VAF; 95.83% for indels at 0.1% VAF; >91% for fusions at 0.5% VAF. Performance validated using reference materials and 1,592 clinical samples.",
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "specificity": 99,
    "specificityNotes": ">99% specificity across mutation classes at 0.1-5% VAF. 93.8% concordance with EGFR allele-specific PCR (n=355); 84% concordance with cobas EGFR v2 (n=50), 100% for VAF >0.4%.",
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "fdaStatusNotes": "Laboratory developed test performed at Lucence Health Inc. CLIA-certified (05D2200843), CAP-accredited laboratory. Not cleared or approved by FDA.",
    "fdaStatusCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.luminexcorp.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "vendorNCCNAlignmentNotes": "Covers 9 NCCN guideline-recommended biomarkers for NSCLC: EGFR, ALK, RET, ROS1, BRAF, KRAS, MET, ERBB2, NTRK1/2/3. LIQUIK study showed LiquidHALLMARK detected 15.6% more tissue-confirmed, NCCN guideline-recommended biomarkers than FDA-approved ctDNA-only test.",
    "tat": "7 Business Days",
    "tatNotes": "Results typically available in 7 business days from receipt of specimen. Test performed Monday through Friday.",
    "tatCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "sampleRequirements": "20mL whole blood in 2x Streck cfDNA BCT tubes (10mL each); 4-day stability at ambient temperature",
    "sampleRequirementsNotes": "Do not centrifuge or aliquot. Invert tubes to mix blood. Ship at ambient temperature. Gross hemolysis, lipemia, or icterus will result in rejection.",
    "sampleRequirementsCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via MolDX (Palmetto GBA), effective October 2, 2024, for all stages of advanced solid tumors. First Asian company to secure Medicare coverage for liquid biopsy in US (Feb 2023 for NSCLC, expanded 2024). CPT code 0571U.",
    "reimbursementCitations": "https://www.lucence.com/lucencenews/lucence-secures-moldx-approval-for-liquidhallmark-ctdna-and-ctrna-liquid-biopsy-test-to-advance-non-invasive-cancer-diagnostics/ | https://www.lucence.com/lucencenews/lucence-confirms-comprehensive-medicare-coverage-for-liquidhallmark-and-demonstrates-sensitive-detection-of-lung-cancer-biomarkers-in-prospective-study/",
    "cptCodes": "0571U",
    "cptCodesCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811",
    "codeType": "PLA",
    "availableRegions": ["US", "Singapore", "International"],
    "availableRegionsNotes": "US: Available via Mayo Clinic Labs (since March 2025) and Lucence Palo Alto lab (CLIA 05D2200843). Singapore: Lucence headquarters with CLIA/CAP-certified lab. International: Turkey (via Omnigen), India (via Agilus Diagnostics). NOT available in NY State.",
    "availableRegionsCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://www.lucence.com/about",
    "clinicalAvailability": "Commercially available in US since 2021; available via Mayo Clinic Labs since March 2025",
    "clinicalAvailabilityCitations": "https://www.mayocliniclabs.com/test-catalog/overview/622811 | https://www.lucence.com/solutions/liquid-hallmark",
    "clinicalTrials": "LIQUIK (prospective multicenter NSCLC study, n=200, 7 US sites); VA Palo Alto Health Care System liquid biopsy screening study",
    "clinicalTrialsNotes": "LIQUIK primary endpoint: compare LiquidHALLMARK with tissue NGS for 9 guideline-recommended genes (EGFR, ALK, RET, ROS1, NTRK, MET, BRAF, ERBB2, KRAS) in treatment-naive metastatic NSCLC. Results published JCO Precision Oncology 2025.",
    "clinicalTrialsCitations": "https://ascopubs.org/doi/10.1200/PO-25-00181 | https://www.lucence.com/lucencenews/liquik-study-for-lung-cancer/",
    "totalParticipants": 1592,
    "totalParticipantsNotes": "Clinical validation cohort of 1,592 patients across 30+ cancer types (Poh et al. PLoS One 2022). LIQUIK prospective study enrolled 200 metastatic NSCLC patients across 7 US sites.",
    "totalParticipantsCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://ascopubs.org/doi/10.1200/PO-25-00181",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Key publications: Poh et al. PLoS One 2022 (analytical/clinical validation); Samol et al. JCO Precis Oncol 2025 (LIQUIK prospective study); Iams et al. JAMA Netw Open 2024 (multicancer cohort); Heeke et al. JTO Clin Res Rep 2025 (ALK ctRNA tracking); multiple ASCO/IASLC conference abstracts.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://ascopubs.org/doi/10.1200/PO-25-00181 | https://pubmed.ncbi.nlm.nih.gov/38231028/",
    "technologyDifferentiator": "Combined ctDNA + ctRNA analysis increases actionable fusion detection by 36.7% vs ctDNA alone. AmpliMark proprietary amplicon-based sequencing with molecular barcode error correction enables ultrasensitive detection. ctRNA component addresses DNA-based fusion detection limitations from large introns. LIQUIK prospective study showed LiquidHALLMARK detected 15.6% more tissue-confirmed NCCN guideline-recommended biomarkers than FDA-approved ctDNA-only test with 93-100% agreement with tissue NGS. Available via Mayo Clinic Labs partnership since March 2025.",
    "publicationsKey": [
      {
        "citation": "Poh J, et al. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. PLoS One. 2022;17(4):e0267389.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35482824/",
        "keyFinding": "99.38% sensitivity for SNVs, 95.83% for indels at 0.1% VAF. 74.8% of clinical samples harbored actionable biomarkers."
      },
      {
        "citation": "Samol J, et al. LiquidHallmark detects more tissue-confirmed guideline-recommended biomarkers in lung cancer: prospective multicenter study. JCO Precis Oncol. 2025;9:e2500181.",
        "url": "https://ascopubs.org/doi/10.1200/PO-25-00181",
        "keyFinding": "LiquidHALLMARK ctDNA+ctRNA detected 15.6% more tissue-confirmed NCCN biomarkers than FDA-approved ctDNA-only test. 93-100% agreement with tissue NGS."
      },
      {
        "citation": "Iams WT, et al. Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw Open. 2024;7(1):e2351700.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38231028/",
        "keyFinding": "Multicancer validation of liquid biopsy vs tissue profiling for guideline-recommended biomarkers."
      }
    ],
    "submissionInfo": {
      "submittedBy": "Jeremy Au",
      "submitterEmail": "jeremy.au@lucence.com",
      "submitterType": "Vendor Representative",
      "submissionDate": "2025-12-19",
      "submissionNotes": "New test submission via OpenOnco form. Performance data URLs provided: Mayo Clinic Labs catalog and Lucence website. Verified via Mayo Clinic Labs test catalog (LUCHM), Lucence press releases, PLoS One 2022 validation study, and JCO Precision Oncology 2025 LIQUIK study.",
      "vendorVerifiedDate": "2026-01-07",
      "vendorVerifiedBy": "Jeremy Au",
      "vendorVerifiedNotes": "Vendor verified via OpenOnco validation form. Updates: TAT changed from 8-12 days to 7 Business Days; biomarkersReported clarified to note cfDNA+cfRNA sources for fusion detection."
    },
    "vendorVerified": true
  },
  {
    "id": "tds-23",
    "name": "Resolution ctDx FIRST",
    "vendor": "Agilent / Resolution Bioscience",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "Cell-Free DNA BCT",
    "approach": "Liquid CGP (ctDNA)",
    "method": "Hybrid-capture NGS covering 109 genes for SNVs, indels, CNAs, and fusions. FDA-approved CDx for KRAS G12C (adagrasib) and EGFR tumor profiling in NSCLC. Professional services portion (CLIA, not FDA) includes comprehensive genomic profiling.",
    "methodCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/agilent-resolution-ctdx-first-p210040 | https://www.resolutionbio.com/assays/Resolution-ctDx-FIRST.html",
    "methodNotes": "First liquid biopsy NGS assay FDA-approved as CDx for adagrasib (KRAZATI). Single-site PMA performed at Resolution Bioscience CLIA lab in Kirkland, WA. Proprietary primer extension technology enables fusion detection without a priori knowledge of gene partner.",
    "genesAnalyzed": 109,
    "genesAnalyzedNotes": "109 genes: 103 with SNV/indel detection (64% with full CDS coverage), 54 with CNA detection, 13 with fusion detection.",
    "genesAnalyzedCitations": "https://www.resolutionbio.com/assays/Resolution-ctDx-FIRST.html",
    "geneListUrl": "https://www.resolutionbio.com/assays/Resolution-ctDx-FIRST.html",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions"],
    "biomarkersReportedNotes": "FDA-approved for KRAS G12C and EGFR SNVs/deletions. Professional services (CLIA) includes all 109 genes across 4 alteration types.",
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "cancerTypes": ["NSCLC"],
    "cancerTypesNotes": "FDA indication limited to NSCLC. Professional services portion applicable to other solid tumors per oncologist discretion.",
    "cancerTypesCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/agilent-resolution-ctdx-first-p210040",
    "targetPopulation": "Adults with locally advanced or metastatic NSCLC requiring KRAS G12C or EGFR mutation testing for targeted therapy selection",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040A.pdf",
    "sensitivity": 66.2,
    "sensitivityNotes": "66.2% PPA vs tissue for KRAS G12C (95% CI: 54.0-77.0%). EGFR variant PPA: 100% for L858R, 91.3% for exon 19 deletions, 88.9% for T790M vs ddPCR.",
    "sensitivityCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "specificity": 100,
    "specificityNotes": "100% NPA for KRAS G12C vs tissue (95% CI: 94.7-100%). Zero false positive rate demonstrated in FDA analytical validation.",
    "specificityCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "lod": "0.34-0.82% MAF",
    "lodNotes": "LOD95 for SNVs and indels in KRAS and EGFR at 15ng cfDNA input ranged from 0.34% to 0.82%. KRAS G12C detected at low MAF (0.11-0.40%) in validation samples.",
    "lodCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "fdaStatus": "FDA PMA approved (December 2022)",
    "fdaStatusNotes": "PMA P210040 approved December 12, 2022. CDx for KRAS G12C to identify NSCLC patients eligible for adagrasib (KRAZATI). Also FDA-approved for EGFR tumor profiling per professional guidelines.",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/agilent-resolution-ctdx-first-p210040",
    "fdaCompanionDxCount": 1,
    "fdaCompanionDxList": ["Adagrasib (KRAZATI) - KRAS G12C - NSCLC"],
    "fdaCompanionDxNotes": "First liquid biopsy NGS CDx approved for adagrasib. If plasma negative, FDA recommends reflex to tissue testing with FDA-approved test.",
    "fdaCompanionDxCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040A.pdf",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://resolutionbio.com/",
    "vendorNCCNAlignmentIndications": ["NSCLC"],
    "vendorNCCNAlignmentNotes": "Covers NCCN-recommended biomarkers for NSCLC including KRAS G12C and EGFR. 109-gene panel includes ALK, ROS1, RET, BRAF, MET, ERBB2, NTRK1/2/3.",
    "tat": "~9 days",
    "tatNotes": "Based on ctDx platform performance; median TAT 9 days vs 20 days for tissue NGS in prospective NSCLC study.",
    "tatCitations": "https://doi.org/10.1093/jnci/djy156",
    "sampleRequirements": "Whole blood in Streck Cell-Free DNA BCT tubes; 7-day stability prior to plasma isolation",
    "sampleRequirementsNotes": "cfDNA stable at -20°C for 30 days. Nominal 50ng cfDNA input (allowable range 15-75ng). Agilent Resolution ctDx FIRST Blood Collection Kit also available.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040A.pdf",
    "reimbursement": "Medicare + Commercial",
    "reimbursementNote": "Resolution ctDx platform covered by Medicare and private payors. FDA-approved CDx status supports coverage for NSCLC patients.",
    "reimbursementCitations": "https://www.resolutionbio.com/company/press/2021.01.11_resolution_mirati_cdx.html",
    "availableRegions": ["US"],
    "availableRegionsNotes": "Single-site PMA test performed at Resolution Bioscience CLIA lab, Kirkland, WA. Available via Quest Diagnostics network (Jan 2023). Specimens collected at 2,100+ Quest patient service centers nationwide.",
    "availableRegionsCitations": "https://clpmag.com/diagnostic-technologies/immunoassay/immunoassay-reagents-kits/quest-diagnostics-offers-agilents-resolution-ctdx-first-liquid-biopsy-test/",
    "clinicalAvailability": "Commercially available since December 2022 (FDA approval); Quest Diagnostics distribution since January 2023",
    "clinicalAvailabilityCitations": "https://www.investor.agilent.com/news-and-events/news/news-details/2022/Agilent-Resolution-ctDx-FIRST-Receives-FDA-Approval-as-a-Liquid-Biopsy-Companion-Diagnostic-Test-for-Advanced-Non-small-Cell-Lung-Cancer/default.aspx",
    "clinicalTrials": "KRYSTAL-1 (NCT03785249) - Phase 1/2 adagrasib trial used for CDx clinical validation",
    "clinicalTrialsNotes": "FDA approval based on analytical validation and bridging studies using KRYSTAL-1 patient samples. Demonstrated clinical benefit of adagrasib in KRAS G12C+ NSCLC patients identified by ctDx FIRST.",
    "clinicalTrialsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040B.pdf",
    "totalParticipants": 1000,
    "totalParticipantsNotes": "Over 1,000 patients enrolled in ongoing prospective NSCLC study with Memorial Sloan Kettering Cancer Center demonstrating clinical response to plasma-directed therapy selection.",
    "totalParticipantsCitations": "https://www.resolutionbio.com/company/press/2021.01.11_resolution_mirati_cdx.html",
    "numPublications": 5,
    "numPublicationsNotes": "Key: ASCO 2022 abstract (JCO 40:16_suppl.3057), FDA SSED, Lung Cancer 2019 (fusion sensitivity comparison), Clin Cancer Res 2016 (bias-corrected sequencing), JNCI 2018 (prospective ctDNA therapy selection).",
    "numPublicationsCitations": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057 | https://doi.org/10.1016/j.lungcan.2019.06.004 | https://doi.org/10.1093/jnci/djy156",
    "publicationsKey": [
      {
        "citation": "Pekker I, et al. Resolution ctDx FIRST plasma assay as a companion diagnostic for adagrasib. J Clin Oncol. 2022;40(16_suppl):3057.",
        "url": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057",
        "keyFinding": "66.2% PPA and 100% NPA for KRAS G12C vs tissue. LOD95 0.34-0.82% MAF. High concordance with ddPCR for EGFR variants."
      },
      {
        "citation": "Supplee JG, et al. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. 2019;134:96-99.",
        "url": "https://doi.org/10.1016/j.lungcan.2019.06.004",
        "keyFinding": "ctDx platform detected fusions missed by other assays due to inverted/out-of-frame variants. Superior fusion detection vs Guardant360."
      },
      {
        "citation": "Leighl NB, et al. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic NSCLC. Clin Cancer Res. 2019;25(15):4691-4700.",
        "url": "https://doi.org/10.1158/1078-0432.CCR-19-0624",
        "keyFinding": "Prospective study demonstrating clinical utility of ctDNA-directed therapy selection in metastatic NSCLC."
      }
    ],
    "technologyDifferentiator": "First FDA-approved liquid biopsy NGS CDx for KRAS G12C inhibitor (adagrasib). Proprietary primer extension technology detects fusions without prior knowledge of gene partner. Quest Diagnostics distribution enables broad US access via 2,100+ patient service centers. Zero false positive rate for CDx biomarkers in FDA validation. Superior fusion detection vs competitors in head-to-head studies.",
    "vendorRequestedChanges": "Dec 24, 2025: Added via LLM review pipeline recommendation - test identified as missing from OpenOnco database despite FDA CDx approval in December 2022."
  },
  {
    "id": "tds-24",
    "name": "OncoCompass Target",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood/Plasma",
    "approach": "Tumor-agnostic",
    "method": "Capture-based NGS panel targeting 168 genes from cfDNA; detects SNVs, indels, CNAs, and fusions",
    "methodCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9",
    "genesAnalyzed": 168,
    "genesAnalyzedNotes": "168-gene panel (LDT version); CE-marked version covers 101 genes",
    "genesAnalyzedCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9",
    "cancerTypes": ["NSCLC", "Pan-solid tumor"],
    "cancerTypesNotes": "Primary validation in metastatic NSCLC (BENEFIT trial); applicable to pan-solid tumors for CGP",
    "cancerTypesCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9",
    "sensitivity": 96,
    "sensitivityPlus": true,
    "sensitivityNotes": "Analytical sensitivity for variant detection. 101-gene validation: 97.5% by-variant sensitivity in 904-patient cohort (Fan et al. 2024)",
    "sensitivityCitations": "https://doi.org/10.1002/cam4.70078 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "specificity": 99.9,
    "specificityNotes": "From 101-gene panel validation (n=904). Vendor reports 100% for 168-gene panel.",
    "specificityCitations": "https://doi.org/10.1002/cam4.70078 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "lod": "0.3% VAF (SNV/Indel), 2.5 copies (CNV), 0.3% (fusions)",
    "lodNotes": "Vendor data. 101-gene validation: LOD 0.38% SNV, 0.33% InDel, 0.33% fusion",
    "lodCitations": "https://doi.org/10.1002/cam4.70078 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "fdaStatus": "CLIA LDT / CE-IVD (101-gene version)",
    "fdaStatusNotes": "168-gene panel offered as LDT from Burning Rock laboratory. CE-marked 101-gene version available internationally.",
    "tat": 9,
    "tatNotes": "9 calendar days",
    "tatCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "listPrice": "Varies by region",
    "listPriceNotes": "Regional pricing structure",
    "listPriceCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "clinicalAvailability": "Commercially available in China and international markets via Burning Rock Dx laboratory",
    "clinicalAvailabilityNotes": "Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR)",
    "clinicalTrials": "NCT02282267 (BENEFIT)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/ct2/show/NCT02282267",
    "totalParticipants": 426,
    "totalParticipantsNotes": "BENEFIT trial: 426 screened, 188 enrolled",
    "numPublications": 129,
    "numPublicationsNotes": "Used in 100+ clinical studies. Key journals: Nature Medicine, Nature Biotechnology, Lancet Respiratory Medicine, Annals of Oncology, JAMA Network Open",
    "numPublicationsCitations": "https://doi.org/10.1016/S2213-2600(18)30264-9 | Vendor-provided publication list (Dec 2025)",
    "isRUO": false,
    "isClinicalLDT": true,
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Performance data and 129-paper publication list provided. Primary validation: BENEFIT trial (Lancet Respir Med 2018, PMID 30017884)."
  },
  {
    "id": "tds-25",
    "name": "OncoScreen Focus CDx",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Central Lab Service",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS panel targeting 13 genes from FFPE tissue; detects SNVs, indels, CNAs, and fusions",
    "methodCitations": "https://us.brbiotech.com/fixed-panels/",
    "genesAnalyzed": 13,
    "genesAnalyzedNotes": "13 genes: EGFR, ALK, ROS1, RET, MET, ERBB2, BRAF, PIK3CA, KRAS, NRAS, HRAS, KIT, PDGFRA",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions"],
    "cancerTypes": ["NSCLC", "CRC", "GIST"],
    "cancerTypesNotes": "Focused panel for lung cancer therapy selection; covers key actionable genes for NSCLC, colorectal cancer, and gastrointestinal stromal tumors",
    "cancerTypesCitations": "https://us.brbiotech.com/fixed-panels/",
    "fdaStatus": "CLIA LDT (US); CE-IVD kit version available",
    "fdaStatusNotes": "Central lab service offered from Burning Rock laboratory. CE-marked IVD kit version (OncoScreen Focus CDx Tissue Kit) available separately.",
    "clinicalAvailability": "Commercially available via Burning Rock Dx laboratory",
    "clinicalAvailabilityNotes": "Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR)",
    "isRUO": false,
    "isClinicalLDT": true,
    "tat": "7-10 business days",
    "tatNotes": "Estimated TAT based on central lab NGS workflow. Burning Rock's Magnis BR automation system enables 3-day TAT in hospital settings.",
    "tatCitations": "https://www.prnewswire.com/news-releases/burning-rock-dx-launches-magnis-br-to-innovate-total-process-automation-for-ngs-testing-300960507.html",
    "numPublications": 5,
    "numPublicationsNotes": "Burning Rock has 62+ publications in PubMed mentioning their NGS panels broadly. OncoScreen Focus-specific publications estimated at 5+.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/?term=%22Burning+Rock%22+NGS",
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Originally rejected as tissue-only; scope expanded to include tissue tests."
  },
  // INSERT NEW TDS TEST HERE (above this line, before IVD KITS)
  // ============================================
  // IVD KITS - Laboratory Kits for Treatment Decision Support / CGP
  // ============================================
  {
    "id": "tds-kit-1",
    "name": "TruSight Oncology Comprehensive (TSO Comp)",
    "vendor": "Illumina",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "NextSeq 550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering 517 genes; detects SNVs, indels, CNAs, fusions/rearrangements; reports TMB, MSI status",
    "genesAnalyzed": 517,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "First FDA-approved distributable CGP IVD kit. Enables hospitals to bring comprehensive genomic profiling in-house. CE-IVD since March 2022.",
    "fdaStatus": "FDA-approved (Aug 2024); CE-IVD",
    "fdaCompanionDxCount": 2,
    "fdaCompanionDxNotes": "FDA approval includes CDx claims for NTRK fusions (pan-tumor) and RET fusions (NSCLC). TMB and MSI reported as biomarkers but not CDx-labeled. Additional CDx claims may expand post-approval.",
    "tmb": "Yes",
    "tmbNotes": "TMB calculated and reported; supports pembrolizumab TMB-H indication",
    "msi": "Yes",
    "msiNotes": "MSI status determined from NGS data",
    "reimbursement": "Medicare LCD (MolDX)",
    "commercialPayers": ["UnitedHealthcare", "Aetna", "Cigna"],
    "clinicalAvailability": "FDA-approved IVD kit",
    "tat": "10-14 days",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "First FDA-approved pan-cancer CGP IVD kit. Enables decentralized in-house CGP testing at hospitals with NextSeq 550Dx. Complete workflow solution with TruSight Oncology Analysis software."
  },
  {
    "id": "tds-kit-2",
    "name": "GeneseeqPrime",
    "vendor": "Geneseeq Technology",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq/NovaSeq",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS panel covering 425 cancer-related genes; detects SNVs, indels, CNAs, fusions; reports TMB and MSI",
    "genesAnalyzed": 425,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "FDA 510(k) cleared August 2025 (K-number pending publication). Also CE-IVDR and NMPA (China) approved. First Chinese CGP to receive FDA clearance.",
    "fdaStatus": "FDA 510(k) cleared (Aug 2025); CE-IVDR; NMPA",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Emerging - new FDA clearance",
    "clinicalAvailability": "FDA-cleared IVD kit",
    "tat": "7-10 days",
    "totalParticipants": 50000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Global regulatory approvals (FDA, CE-IVDR, NMPA). Fresh FDA clearance (Sep 2025). Established in Asia market with US expansion. Competitive pricing expected."
  },
  {
    "id": "tds-kit-3",
    "name": "PGDx elio tissue complete",
    "vendor": "Labcorp (Personal Genome Diagnostics)",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering ~500 genes; comprehensive solid tumor profiling including SNVs, indels, CNAs, MSI, TMB",
    "genesAnalyzed": 505,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "FDA-cleared and CE-IVDR (July 2025). First and only test CE-marked for comprehensive solid tumor profiling under new EU IVDR regulation.",
    "fdaStatus": "FDA-cleared; CE-IVDR (Jul 2025)",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Medicare LCD coverage",
    "commercialPayers": ["UnitedHealthcare", "Aetna"],
    "clinicalAvailability": "FDA-cleared IVD kit",
    "tat": "10-14 days",
    "totalParticipants": 5000,
    "numPublications": 30,
    "technologyDifferentiator": "First CE-IVDR comprehensive CGP kit. Part of elio platform family including plasma focus Dx for liquid biopsy. PGDx analytics platform included."
  },
  {
    "id": "tds-kit-4",
    "name": "Oncomine Comprehensive Assay Plus",
    "vendor": "Thermo Fisher Scientific",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Ion GeneStudio S5",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Amplicon-based NGS covering 500+ genes from DNA and RNA; detects SNVs, indels, CNAs, and fusions including novel fusions via RNA",
    "genesAnalyzed": 500,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "Primarily positioned for oncology research. DNA+RNA workflow captures both mutation and fusion biomarkers. Popular choice for labs with Ion Torrent infrastructure. CE-IVD/IVDR status requires verification.",
    "fdaStatus": "RUO in US; CE-IVD status pending verification",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Coverage varies",
    "clinicalAvailability": "CE-IVD kit",
    "tat": "5-7 days",
    "totalParticipants": 20000,
    "numPublications": 80,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Ion Torrent amplicon-based sequencing - lower DNA input requirements than hybrid-capture. DNA+RNA workflow in single assay. Strong in APAC market. Automated Genexus workflow option available."
  },
  {
    "id": "tds-kit-5",
    "name": "TSO 500",
    "vendor": "Illumina",
    "productType": "Research Use Kit",
    "platformRequired": "NextSeq 500/550/550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering 523 genes from DNA and RNA; comprehensive detection of SNVs, indels, CNAs, fusions, TMB, MSI",
    "genesAnalyzed": 523,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "RUO (Research Use Only) comprehensive genomic profiling panel for clinical research. Predecessor to TSO Comprehensive (FDA-approved IVD). For clinical diagnostic use, use TSO Comprehensive.",
    "fdaStatus": "RUO",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Coverage varies",
    "clinicalAvailability": "RUO kit for clinical research",
    "tat": "7-10 days",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Widely deployed RUO CGP panel with extensive real-world use in clinical research. DNA+RNA enrichment in single workflow. Foundation for TSO Comprehensive (IVD version)."
  },
  // ============================================
  // RECLASSIFIED CDx KITS - Therapy Selection Companion Diagnostics
  // (Moved from TRM - these are primarily CDx, not response monitoring)
  // ============================================
  {
    "id": "tds-kit-6",
    "sampleCategory": "Blood/Plasma",
    "name": "cobas EGFR Mutation Test v2",
    "vendor": "Roche",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "cobas 4800/6800/8800 System",
    "approach": "Tumor-agnostic",
    "method": "Real-time PCR detection of 42 EGFR mutations including exon 19 deletions, L858R, T790M resistance mutation, and exon 20 insertions",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting EGFR only (42 specific mutations)",
    "cancerTypes": ["NSCLC"],
    "targetPopulation": "NSCLC patients for EGFR TKI therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for multiple EGFR TKIs. First liquid biopsy test FDA-approved (June 2016). Detects T790M resistance mutation for osimertinib eligibility.",
    "sensitivity": 85,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047C.pdf",
    "sensitivityNotes": "~85% concordance with tissue for EGFR mutations in plasma. Per FDA approval studies.",
    "specificity": 98,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047C.pdf",
    "lod": "0.1% MAF",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047C.pdf",
    "lodNotes": "Limit of detection varies by mutation; generally 0.1-1% mutant allele frequency",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Liquid biopsy - plasma cfDNA; also validated for tissue",
    "requiresMatchedNormal": "No",
    "tat": "1-2 days",
    "leadTimeVsImaging": null,
    "fdaStatus": "FDA-approved CDx (tissue 2013, plasma 2016)",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Gold standard EGFR liquid biopsy kit. First FDA-approved liquid biopsy CDx. Distributed IVD kit for labs with cobas system. Rapid TAT (1-2 days) vs. NGS-based tests."
  },
  {
    "id": "tds-kit-7",
    "sampleCategory": "Blood/Plasma",
    "name": "cobas KRAS Mutation Test",
    "vendor": "Roche",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "cobas 4800 System",
    "approach": "Tumor-agnostic",
    "method": "Real-time PCR detection of KRAS mutations in codons 12, 13, and 61",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting KRAS only (codons 12, 13, 61)",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "mCRC patients for anti-EGFR therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for cetuximab and panitumumab. KRAS wild-type required for anti-EGFR therapy eligibility.",
    "sensitivity": 95,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027C.pdf",
    "sensitivityNotes": "High concordance with tissue testing. Per FDA approval data.",
    "specificity": 99,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027C.pdf",
    "lod": "1% MAF",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027C.pdf",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "1-2 days",
    "fdaStatus": "FDA-approved CDx",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 20000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Rapid PCR-based KRAS testing for CRC. Distributed IVD kit enables in-house testing. Essential for anti-EGFR therapy decisions."
  },
  {
    "id": "tds-kit-8",
    "sampleCategory": "Blood/Plasma",
    "name": "therascreen EGFR RGQ PCR Kit",
    "vendor": "QIAGEN",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Rotor-Gene Q MDx",
    "approach": "Tumor-agnostic",
    "method": "Scorpions ARMS real-time PCR for EGFR exon 19 deletions, L858R, T790M, and other sensitizing mutations",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting EGFR only",
    "cancerTypes": ["NSCLC"],
    "targetPopulation": "NSCLC patients for EGFR TKI therapy selection",
    "indicationsNotes": "CE-IVD marked. Widely used in EU and Asia. FDA-approved for tissue; CE-IVD for plasma.",
    "sensitivity": 80,
    "sensitivityCitations": "https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/therascreen-egfr",
    "sensitivityNotes": "~80% sensitivity for major EGFR mutations in plasma per validation studies",
    "specificity": 98,
    "specificityCitations": "https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/therascreen-egfr",
    "lod": "1% MAF",
    "lodCitations": "https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/therascreen-egfr",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "1 day",
    "fdaStatus": "FDA-approved (tissue); CE-IVD (plasma)",
    "reimbursement": "Coverage varies by region",
    "clinicalAvailability": "CE-IVD kit; FDA-approved for tissue",
    "totalParticipants": 30000,
    "numPublications": 150,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Rotor-Gene Q platform common in many molecular labs. Rapid same-day results. Lower capital equipment cost than cobas system."
  },
  {
    "id": "tds-kit-9",
    "sampleCategory": "Blood/Plasma",
    "name": "OncoBEAM RAS CRC Kit",
    "vendor": "Sysmex Inostics",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "OncoBEAM System",
    "approach": "Tumor-agnostic",
    "method": "BEAMing (Beads, Emulsion, Amplification, Magnetics) digital PCR for extended RAS panel including KRAS exons 2-4 and NRAS exons 2-4",
    "genesAnalyzed": 2,
    "genesAnalyzedNotes": "Two-gene panel: KRAS (exons 2-4) and NRAS (exons 2-4)",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "mCRC patients for anti-EGFR therapy selection",
    "indicationsNotes": "CE-IVD marked for RAS testing in mCRC. Extended RAS panel covers all clinically relevant mutations. Ultra-sensitive digital PCR platform.",
    "sensitivity": 95,
    "sensitivityCitations": "https://www.sysmex-inostics.com/oncobeam-ras-crc",
    "sensitivityNotes": "BEAMing digital PCR provides high sensitivity for low-frequency mutations",
    "specificity": 99,
    "specificityCitations": "https://www.sysmex-inostics.com/oncobeam-ras-crc",
    "lod": "0.02% MAF",
    "lodCitations": "https://www.sysmex-inostics.com/oncobeam-ras-crc",
    "lodNotes": "Digital PCR achieves 0.02% MAF sensitivity - among the most sensitive RAS tests",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "3-5 days",
    "fdaStatus": "CE-IVD",
    "reimbursement": "Coverage varies; reimbursed in EU",
    "clinicalAvailability": "CE-IVD kit",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Ultra-sensitive digital PCR (BEAMing) achieves 0.02% MAF - one of the most sensitive RAS liquid biopsy tests. Extended RAS panel for comprehensive therapy selection."
  },
  {
    "id": "tds-kit-10",
    "sampleCategory": "Blood/Plasma",
    "name": "PGDx elio plasma focus Dx",
    "vendor": "Labcorp (Personal Genome Diagnostics)",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 550Dx",
    "approach": "Tumor-agnostic",
    "method": "NGS-based ~70-gene ctDNA panel; detects SNVs, indels, CNAs, and select fusions across pan-solid tumor biomarkers",
    "genesAnalyzed": 70,
    "genesAnalyzedNotes": "Approximately 70 genes covering pan-solid tumor biomarkers",
    "cancerTypes": ["Pan-solid tumor"],
    "targetPopulation": "Advanced solid tumor patients for therapy selection",
    "indicationsNotes": "FDA De Novo authorized - first FDA-authorized pan-tumor liquid biopsy IVD kit. Enables decentralized NGS liquid biopsy testing.",
    "sensitivity": 90,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200058.pdf",
    "sensitivityNotes": "≥90% analytical sensitivity across variant types at LoD; multi-gene panel sensitivity varies by biomarker and VAF",
    "specificity": 95,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200058.pdf",
    "specificityNotes": "≥95% analytical specificity in validation studies; >99.9% NPV across variant types",
    "lod": "0.5% MAF",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200058.pdf",
    "lodNotes": "Analytical sensitivity ~0.5% VAF for most variants",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "5-7 days",
    "fdaStatus": "FDA De Novo authorized",
    "reimbursement": "Medicare LCD coverage",
    "clinicalAvailability": "FDA-authorized IVD kit",
    "totalParticipants": 5000,
    "numPublications": 30,
    "technologyDifferentiator": "First FDA-authorized pan-tumor liquid biopsy IVD kit. Enables hospitals to bring NGS liquid biopsy in-house. Part of elio platform including tissue CGP (elio tissue complete)."
  },
  {
    "id": "tds-kit-11",
    "sampleCategory": "Bone Marrow/Blood",
    "name": "LeukoStrat CDx FLT3 Mutation Assay",
    "vendor": "Invivoscribe",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "ABI 3500 Genetic Analyzer",
    "approach": "Targeted CDx",
    "method": "PCR-based detection of FLT3-ITD and TKD mutations; FDA-approved companion diagnostic",
    "genesAnalyzed": 1,
    "genesAnalyzedNotes": "Single-gene test targeting FLT3 only (ITD and TKD mutations)",
    "cancerTypes": [
      "AML"
    ],
    "targetPopulation": "AML patients for FLT3-targeted therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for VANFLYTA (quizartinib), RYDAPT (midostaurin), and XOSPATA (gilteritinib). Primary use is therapy selection at diagnosis.",
    "sensitivity": null,
    "sensitivityNotes": "Designed for mutation detection at diagnosis; sensitivity depends on allelic ratio",
    "lod": "5% ITD ratio",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160040C.pdf | https://www.invivoscribe.com/products/leukostrat-cdx-flt3-mutation-assay",
    "lodNotes": "Clinical cutoff for FLT3-ITD positivity",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Uses bone marrow or peripheral blood directly",
    "requiresMatchedNormal": "No",
    "tat": "3 days",
    "fdaStatus": "FDA-approved CDx; CE-IVDR",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "FDA-approved companion diagnostic for FLT3-targeted AML therapies. Distributed IVD kit enables in-house testing on ABI genetic analyzers. Essential for quizartinib, midostaurin, and gilteritinib eligibility."
  },
  {
    "id": "tds-kit-12",
    "sampleCategory": "Blood/Plasma",
    "name": "Hedera Profiling 2 ctDNA Test Panel",
    "vendor": "Hedera Dx",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 2000",
    "approach": "Liquid CGP",
    "method": "Hybrid capture-based NGS covering 32 genes; detects SNVs, indels, CNVs, fusions; reports MSI status. DNA-only workflow optimized for ctDNA with UMI/UDI error correction.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "genesAnalyzed": 32,
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "MSI"],
    "cancerTypes": ["Pan-solid tumor", "NSCLC", "Breast", "Colorectal"],
    "targetPopulation": "Advanced solid tumor patients for biomarker-guided therapy selection",
    "indicationsNotes": "Decentralized IVD kit for in-house liquid biopsy testing. Covers >80% of ESCAT Level I genes including ESR1, METex14, and MSI. Requires local validation under CE-IVDR for routine clinical use. Paired with Hedera Prime CE-IVD software for automated OncoKB-powered reporting.",
    "sensitivity": 97,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "sensitivityNotes": "96.92% analytical sensitivity for SNVs/Indels at 0.5% VAF in reference standards; 100% fusion sensitivity; 94% concordance for ESCAT Level I variants in 137 clinical samples",
    "specificity": 99.7,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "specificityNotes": "99.67% analytical specificity for SNVs/Indels at 0.5% VAF",
    "lod": "0.5% VAF",
    "lodCitations": "https://pubmed.ncbi.nlm.nih.gov/41015181/",
    "lodNotes": "30 ng cfDNA input recommended; 10 ng minimum",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "5 days",
    "fdaStatus": "CE-IVD (software); Performance Studies (panel)",
    "fdaStatusNotes": "Hedera Prime software is CE-IVD registered medical device. Panel labeled for Performance Studies Only - requires local validation under CE-IVDR for clinical use. Not available in US.",
    "reimbursement": "Coverage varies by country",
    "clinicalAvailability": "CE-IVD kit (EU/International)",
    "availableRegions": ["EU", "International"],
    "totalParticipants": 137,
    "totalParticipantsNotes": "International multicenter analytical validation across 10+ centers in 8 countries (France, Germany, Austria, Netherlands, Spain, Italy, Greece, India)",
    "numPublications": 1,
    "technologyDifferentiator": "Decentralized IVD kit for in-house hospital liquid biopsy. Compact 32-gene actionability-focused panel (>80% ESCAT Level I). DNA-only workflow with UMI/UDI error correction. Integrated Hedera Prime CE-IVD software with OncoKB for automated therapy matching. Hedera Comply program supports CE-IVDR local validation."
  },
  {
    "id": "tds-kit-13",
    "sampleCategory": "Blood/Plasma",
    "name": "PGDx elio plasma focus Dx",
    "vendor": "Labcorp/PGDx",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq",
    "approach": "Liquid CGP (kitted IVD)",
    "method": "Qualitative NGS-based IVD using targeted high-throughput hybridization-based capture for cfDNA. Detects SNVs and indels in 33 genes, copy number amplifications (CNAs) in 5 genes (CCND1, CD274, ERBB2, FGFR2, MET), and translocations in 3 genes (ALK, NTRK1, RET). 0.24 Mb panel size, 25 ng cfDNA input, 2x150 bp reads, 30,000x/2,600x total/deduplicated error-corrected coverage.",
    "methodCitations": "https://www.personalgenome.com/products/elio-plasma-focus-dx | https://www.prnewswire.com/news-releases/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions-302435767.html",
    "genesAnalyzed": 33,
    "genesAnalyzedNotes": "33 genes for SNVs/indels, 5 genes for CNA amplifications (CCND1, CD274, ERBB2, FGFR2, MET), 3 genes for translocations (ALK, NTRK1, RET). Focused panel targeting guideline-recommended biomarkers.",
    "biomarkersReported": ["SNVs", "Indels", "CNAs (amplification)", "Translocations"],
    "cancerTypes": ["Pan-solid tumors"],
    "cancerTypesNotes": "Indicated for use across a wide range of solid tumor types, particularly when tumor tissue is limited or unavailable. Compatible with PGDx elio tissue complete for seamless tissue-to-liquid reflexing workflows.",
    "targetPopulation": "Patients with advanced solid tumors requiring genomic profiling when tumor tissue is unavailable or insufficient",
    "indicationsNotes": "First and only FDA-authorized kitted pan-solid tumor liquid biopsy test. Enables laboratories to retain control over patient specimens and data. As FDA-authorized IVD, requires only on-site verification (not full validation) for rapid implementation.",
    "sensitivity": 96,
    "sensitivityNotes": "Clinical success rate >96% per vendor. High sensitivity across all variant types per FDA De Novo authorization.",
    "sensitivityCitations": "https://www.personalgenome.com/products/elio-plasma-focus-dx",
    "specificity": null,
    "specificityNotes": "FDA De Novo authorization indicates acceptable analytical performance. Specific specificity values not publicly disclosed.",
    "lod": null,
    "lodNotes": "25 ng cfDNA input. Detection sensitivity optimized for actionable variants in advanced solid tumors.",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "4-5 days",
    "tatCitations": "https://www.personalgenome.com/products/elio-plasma-focus-dx",
    "tatNotes": "4-5 days from isolated nucleic acid to variant report. Rapid implementation with on-site verification only (FDA-authorized IVD).",
    "fdaStatus": "FDA De Novo authorized (Aug 2, 2024)",
    "fdaStatusNotes": "First and only FDA-authorized kitted pan-solid tumor liquid biopsy. De Novo classification (DEN240016) enables on-site verification (not full validation) for faster lab implementation. Commercially available since April 23, 2025.",
    "fdaStatusCitations": "https://ir.labcorp.com/news-releases/news-release-details/labcorp-receives-fda-de-novo-marketing-authorization-pgdx-eliotm",
    "fdaApprovalDate": "2024-08-02",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "FDA-authorized IVD kit. Labs retain sample and data ownership. Reimbursement varies by payer; contact Labcorp for guidance.",
    "clinicalAvailability": "Commercially available (US) since April 2025",
    "availableRegions": ["US"],
    "listPrice": null,
    "listPriceNotes": "Contact Labcorp/PGDx for pricing. Kitted model allows laboratory control over pricing and workflows.",
    "numPublications": 1,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "AACR 2025 presentation on clinical performance. FDA De Novo authorization documentation.",
    "isRUO": false,
    "isInvestigational": false,
    "technologyDifferentiator": "First and only FDA-authorized KITTED pan-solid tumor liquid biopsy. Unlike central lab services, laboratories can run in-house retaining sample and data ownership. Compatible with PGDx elio tissue complete on same instrument for seamless tissue-to-liquid reflexing. Automated bioinformatics reduces manual variant curation burden. Go-live in as few as 6 weeks with streamlined verification process.",
    "dataSourceNotes": "Added December 2025 via LLM Data Review. First FDA-authorized kitted liquid biopsy CGP for pan-solid tumors."
  },
  {
    "id": "tds-kit-14",
    "name": "OncoScreen Focus CDx Tissue Kit",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Laboratory IVD Kit",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (kitted IVD)",
    "method": "Qualitative NGS-based CE-IVD kit using targeted high-throughput hybridization-based capture for FFPE tissue. Detects SNVs, indels, rearrangements (fusions), and CNVs in 13 genes. Single-Tube-Hybridization, Anti-Contamination-Adapter, and Dual-End-Barcode techniques for rapid, contamination-minimized operation.",
    "methodCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "genesAnalyzed": 13,
    "genesAnalyzedNotes": "13 genes: EGFR, ALK, ROS1, RET, MET, ERBB2, BRAF, PIK3CA, KRAS, NRAS, HRAS, KIT, PDGFRA. Covers EMA/FDA/NMPA-approved targeted therapy biomarkers.",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions"],
    "cancerTypes": ["NSCLC", "CRC", "GIST"],
    "cancerTypesNotes": "CE-marked CDx for non-small cell lung cancer, colorectal cancer, and gastrointestinal stromal tumor",
    "cancerTypesCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "sensitivity": 100,
    "sensitivityNotes": "100% accuracy with no missed mutations in 117 clinical samples and commercial references",
    "sensitivityCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "specificity": 100,
    "specificityNotes": "100% accuracy with no false-positive mutations in 117 clinical samples and commercial references",
    "specificityCitations": "https://us.brbiotech.com/p_details.php?class_id=102101101",
    "smallSampleWarning": true,
    "sampleRequirements": "FFPE tissue; minimum 30ng DNA input",
    "sampleRequirementsNotes": "Low input requirement (30ng) suitable for small samples such as needle biopsies",
    "fdaStatus": "CE-IVD (June 2022)",
    "fdaStatusNotes": "CE-marked June 2022. First NGS-based CDx kit approved by NMPA in China (July 2018) for EGFR/ALK/BRAF/KRAS.",
    "fdaStatusCitations": "https://us.brbiotech.com/details.php?class_id=105107103&id=437",
    "clinicalAvailability": "CE-IVD kit available in Europe and international markets",
    "clinicalAvailabilityNotes": "Compatible with Nexus BR fully automated library preparation system",
    "validationCohortSize": 117,
    "validationCohortStudy": "117 clinical samples and commercial references",
    "isRUO": false,
    "tat": "3-10 business days",
    "tatNotes": "TAT depends on laboratory setup. With Magnis BR/Nexus BR automation: 3 days. Manual workflow: 7-10 days.",
    "tatCitations": "https://www.prnewswire.com/news-releases/burning-rock-dx-launches-magnis-br-to-innovate-total-process-automation-for-ngs-testing-300960507.html",
    "numPublications": 5,
    "numPublicationsNotes": "Burning Rock has 62+ publications in PubMed. OncoScreen Focus CDx-specific publications estimated at 5+.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/?term=%22Burning+Rock%22+NGS",
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Originally rejected as tissue-only; scope expanded to include tissue tests."
  },
  {
    "id": "tds-kit-15",
    "name": "OncoScreen Plus Cancer Mutation Profiling Tissue Kit",
    "vendor": "Burning Rock Dx (brbiotech)",
    "productType": "Laboratory IVD Kit",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (kitted IVD)",
    "method": "Comprehensive NGS-based CE-IVD kit covering 520 cancer-related genes from FFPE tissue. Detects SNVs, indels, CNVs, fusions, and complex biomarkers including TMB, MSI, and HRD. All-in-one solution for immunotherapy and targeted therapy guidance.",
    "methodCitations": "https://www.brbiotech.com/en/p_details.php?class_id=102101102 | https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "genesAnalyzed": 520,
    "genesAnalyzedNotes": "520 NCCN-recommended cancer-related genes spanning 1.64 Mb (312 genes with full exon coverage, 208 with selected regions). Comprehensive coverage for immunotherapy and targeted therapy.",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "HRD"],
    "cancerTypes": ["Pan-solid tumor"],
    "cancerTypesNotes": "Validated across 20 solid tumor types including lung (n=1971), GI (n=625), breast (n=120), gynecological (n=110), genitourinary (n=38)",
    "cancerTypesCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "sensitivity": 97,
    "sensitivityPlus": true,
    "sensitivityNotes": "PPA >97% for SNV/INDEL/CNV/Fusion/MSI in 197 clinical samples. Tissue detection rate 97.9% across 3,005 patients.",
    "sensitivityCitations": "https://www.brbiotech.com/en/p_details.php?class_id=102101102 | https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "specificity": 99,
    "specificityPlus": true,
    "specificityNotes": "NPA >99% for SNV/INDEL/CNV/Fusion/MSI. SNV/INDEL NPA >95.8%, Fusion NPA >98.9%, CNV/MSI NPA 100% in 83 benign tumors.",
    "specificityCitations": "https://www.brbiotech.com/en/p_details.php?class_id=102101102",
    "tmb": "Yes",
    "tmbNotes": "TMB calculated from 520-gene panel. Strong correlation with WES-derived TMB (Pearson r=0.845, R²=0.756).",
    "tmbCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "msi": "Yes",
    "msiNotes": "MSI status determined from NGS data. MSI-H detected in endometrial (28.6%), CRC (2.5%), ovarian (2.0%), gastric (1.5%), lung adenocarcinoma (0.2%).",
    "msiCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "fdaStatus": "CE-IVD (June 2022); Japan MHLW CDx (Sept 2025)",
    "fdaStatusNotes": "CE-marked June 2022. Japan MHLW approved Sept 2025 as CDx for capivasertib (AstraZeneca) - detects PIK3CA, AKT1, PTEN for HR+/HER2- breast cancer.",
    "fdaStatusCitations": "https://us.brbiotech.com/details.php?class_id=105107103&id=437 | https://www.globenewswire.com/news-release/2025/09/24/3155203/0/en/Burning-Rock-s-OncoGuide-OncoScreen-Plus-CDx-System-Now-Approved-in-Japan-as-a-Companion-Diagnostic-for-Capivasertib-in-Breast-Cancer.html",
    "fdaCompanionDxCount": 1,
    "fdaCompanionDxList": ["Capivasertib (Japan MHLW) - PIK3CA/AKT1/PTEN - HR+/HER2- breast cancer"],
    "fdaCompanionDxNotes": "Japan MHLW CDx approval (Sept 2025) via Riken Genesis partnership. OncoGuide OncoScreen Plus CDx System for capivasertib therapy selection.",
    "clinicalAvailability": "CE-IVD kit available in Europe, Japan (CDx), and international markets",
    "clinicalAvailabilityNotes": "Compatible with MGI DNBSEQ-G400 sequencer (Japan). Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR)",
    "clinicalTrials": "L-MOCA study",
    "clinicalTrialsNotes": "Outstanding performance in AstraZeneca's L-MOCA study",
    "totalParticipants": 3005,
    "totalParticipantsNotes": "Concordance study: 3,005 patients across 20 solid tumor types (PMID 35305253)",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Multiple publications including J Pers Med 2022 (PMID 35305253) concordance study, TMB validation studies, and CDx development.",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/35305253/",
    "validationCohortSize": 197,
    "validationCohortStudy": "197 clinical samples validated against TSO500, ddPCR, Fluorescent PCR-Capillary Electrophoresis, and WES",
    "isRUO": false,
    "tat": "3-10 business days",
    "tatNotes": "TAT depends on laboratory setup. With Magnis BR automation: 3 days. Manual workflow: 7-10 days. Japan CDx via Riken Genesis may have different TAT.",
    "tatCitations": "https://www.prnewswire.com/news-releases/burning-rock-dx-launches-magnis-br-to-innovate-total-process-automation-for-ngs-testing-300960507.html",
    "vendorVerified": false,
    "vendorRequestedChanges": "2025-01-01: Initial submission from Liankai Chi, PhD, Senior Marketing Manager, Burning Rock Dx. Originally rejected as tissue-only; scope expanded to include tissue tests."
  },
  {
    "id": "tds-26",
    "sampleCategory": "Blood/Plasma",
    "name": "CellSight DNA",
    "vendor": "Cancer Cell Dx",
    "category": "TDS",
    "dateAdded": "Jan 7, 2026",
    "approach": "CTC-based comprehensive genomic profiling",
    "method": "Analyzes intact circulating tumor cells (not just ctDNA fragments) for comprehensive mutation profiling using 500+ gene NGS panel; captures whole tumor cell biology including resistance mechanisms",
    "methodCitations": "https://cancercelldx.com/cellsight-dna/",
    "genesAnalyzed": 500,
    "genesAnalyzedNotes": "500+ gene panel designed for broad genomic coverage across diverse solid tumors",
    "biomarkersReported": ["SNVs", "Indels", "MSI", "TMB"],
    "biomarkersReportedNotes": "Reports SNVs, indels, microsatellite instability (MSI), and tumor mutational burden (TMB)",
    "cancerTypes": ["Pan-solid tumor"],
    "cancerTypesNotes": "Validated across wide range of solid tumors; particularly useful when tissue biopsy not feasible",
    "sensitivity": 99,
    "sensitivityNotes": ">99% analytical sensitivity per vendor validation",
    "sensitivityCitations": "https://cancercelldx.com/cellsight-dna/",
    "lod": "5%",
    "lodNotes": "5% limit of detection for variant calling",
    "lodCitations": "https://cancercelldx.com/cellsight-dna/",
    "ppv": 97,
    "ppvNotes": ">97% positive predictive value",
    "ppvCitations": "https://cancercelldx.com/cellsight-dna/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA-certified laboratory-developed test",
    "reimbursement": "Patient-centered billing approach",
    "reimbursementNote": "Clear billing designed to avoid patient surprises per vendor",
    "clinicalAvailability": "Commercially available in US",
    "tat": "5-7 days",
    "tatNotes": "Target turnaround of 5-7 days",
    "tatCitations": "https://cancercelldx.com/cellsight-dna/",
    "sampleType": "Blood",
    "numPublications": 0,
    "numPublicationsNotes": "New test; peer-reviewed publications pending",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-certified LDT",
    "vendorVerified": true,
    "technologyDifferentiator": "CTC-based (whole tumor cells) rather than ctDNA fragments - captures complete tumor cell biology including resistance mechanisms that fragment-based approaches may miss; ideal for difficult-to-biopsy cases",
    "submissionInfo": {
      "submittedBy": "Kyle Dunn",
      "submitterEmail": "kyle.dunn@cancercelldx.com",
      "submitterType": "vendor",
      "submittedDate": "2026-01-07",
      "vendorVerifiedDate": "2026-01-07",
      "vendorVerifiedBy": "Kyle Dunn"
    }
  },
  {
    "id": "tds-27",
    "sampleCategory": "Tissue",
    "name": "CancerVision",
    "vendor": "Inocras",
    "category": "TDS",
    "dateAdded": "Jan 7, 2026",
    "approach": "Target-enhanced whole genome sequencing",
    "method": "Tumor-normal paired WGS with target enhancement: ~40x WGS backbone plus ~500x depth for 500 key biomarker genes; AI-driven bioinformatics for variant interpretation",
    "methodCitations": "https://inocras.com/cancer-provider/ | https://www.clinicaltrialsarena.com/news/inocras-cancervision-genome-sequencing-test-deemed-effective/",
    "genesAnalyzed": 20000,
    "genesAnalyzedNotes": "Whole genome sequencing with target enhancement for 500 key genes; analyzes entire exome plus non-coding regions",
    "biomarkersReported": ["SNVs", "Indels", "SVs", "CNVs", "TMB", "MSI", "HRD"],
    "biomarkersReportedNotes": "Reports SNVs, indels, structural variants (including fusions), CNVs, TMB, MSI, and HRD; detects variants in non-coding regions missed by panel tests",
    "cancerTypes": ["Pan-solid tumor"],
    "cancerTypesNotes": "For patients with solid tumors at any stage - newly diagnosed, recurring, metastatic, or not responding to treatment",
    "sensitivity": 100,
    "sensitivityNotes": "100% concordance with Illumina TSO500 in 498 variants from 49 patients",
    "sensitivityCitations": "https://www.clinicaltrialsarena.com/news/inocras-cancervision-genome-sequencing-test-deemed-effective/",
    "specificity": 99,
    "specificityNotes": "High specificity via tumor-normal paired analysis which reduces false positives from germline variants",
    "specificityCitations": "https://inocras.com/cancer-provider/",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CAP/CLIA-certified laboratory-developed test",
    "reimbursement": "Self-pay; coverage varies",
    "reimbursementNote": "Not yet covered by US health insurance; international coverage varies by country/insurer",
    "clinicalAvailability": "Commercially available in US and internationally",
    "clinicalAvailabilityNotes": "Available via provider order portal; partnership with ChiMei Medical Center (Taiwan) for international expansion",
    "tat": "14 days",
    "tatNotes": "~2 weeks from receipt of tissue and blood samples",
    "sampleType": "Tumor tissue + blood (matched normal)",
    "sampleRequirements": "FFPE tumor tissue plus blood sample for germline comparison",
    "cfDNAOption": true,
    "cfDNAOptionNotes": "Liquid biopsy option available when tissue sample fails",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Clinical validation study (100% TSO500 concordance); multiple publications on WGS cancer profiling",
    "numPublicationsCitations": "https://www.clinicaltrialsarena.com/news/inocras-cancervision-genome-sequencing-test-deemed-effective/",
    "totalParticipants": 500,
    "totalParticipantsPlus": true,
    "validationCohortSize": 49,
    "validationCohortStudy": "49-patient validation study showing 100% concordance (498 variants) with TSO500",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CAP/CLIA-certified LDT; serves as foundation for MRDVision tumor-informed MRD testing",
    "vendorVerified": true,
    "clinicalTrialMatching": true,
    "clinicalTrialMatchingNotes": "Includes clinical trial matching support based on biomarker findings",
    "geneticCounseling": true,
    "geneticCounselingNotes": "Includes access to genetic counselor session at no extra cost",
    "technologyDifferentiator": "WGS approach finds complex mutations (SVs, CNVs, non-coding variants) missed by panel tests; paired tumor-normal reduces germline false positives; ~90% clinical utility rate; serves as foundation for MRDVision tumor-informed MRD monitoring",
    "submissionInfo": {
      "submittedBy": "Sandra Balladares",
      "submitterEmail": "sballadares@inocras.com",
      "submitterType": "vendor",
      "submittedDate": "2026-01-05",
      "vendorVerifiedDate": "2026-01-05",
      "vendorVerifiedBy": "Sandra Balladares"
    }
  }
];


// Database Changelog - OpenOnco (Cancer)
export const DATABASE_CHANGELOG = [
  {
    date: 'Jan 7, 2026',
    type: 'added',
    testId: 'mrd-26',
    testName: 'MRDVision',
    vendor: 'Inocras',
    category: 'MRD',
    description: 'New vendor-verified MRD test. WGS-based tumor-informed MRD with 1 ppm LOD using Ultima Genomics ppmSeq. Panel-free approach preserves whole-genome tumor insights.',
    contributor: 'Sandra Balladares',
    affiliation: 'Inocras (vendor)',
    citation: 'https://inocras.com/mrdvision/'
  },
  {
    date: 'Jan 7, 2026',
    type: 'added',
    testId: 'ecd-26',
    testName: 'Trucheck Intelli',
    vendor: 'Datar Cancer Genetics',
    category: 'ECD',
    description: 'New MCED test. CTC-based approach analyzing circulating tumor cells for 70+ cancer types. CE-IVD marked. 88.2% sensitivity, 96.3% specificity.',
    contributor: 'Jigar Pandya',
    affiliation: 'Datar Cancer Genetics (expert)',
    citation: 'https://uk.datarpgx.com/trucheck-non-invasive-blood-tests'
  },
  {
    date: 'Jan 7, 2026',
    type: 'added',
    testId: 'tds-26',
    testName: 'CellSight DNA',
    vendor: 'Cancer Cell Dx',
    category: 'TDS',
    description: 'New vendor-verified CGP test. CTC-based (whole tumor cells, not ctDNA) 500+ gene panel. CLIA LDT with 5-7 day TAT.',
    contributor: 'Kyle Dunn',
    affiliation: 'Cancer Cell Dx (vendor)',
    citation: 'https://cancercelldx.com/cellsight-dna/'
  },
  {
    date: 'Jan 7, 2026',
    type: 'added',
    testId: 'tds-27',
    testName: 'CancerVision',
    vendor: 'Inocras',
    category: 'TDS',
    description: 'New vendor-verified WGS CGP test. Target-enhanced whole genome sequencing with ~90% clinical utility. Foundation for MRDVision tumor-informed MRD.',
    contributor: 'Sandra Balladares',
    affiliation: 'Inocras (vendor)',
    citation: 'https://inocras.com/cancer-provider/'
  },
  {
    date: 'Jan 7, 2026',
    type: 'verified',
    testId: 'tds-22',
    testName: 'LiquidHALLMARK',
    vendor: 'Lucence',
    category: 'TDS',
    description: 'Vendor verified by Jeremy Au. Updates: TAT changed from 8-12 days to 7 Business Days; biomarkersReported clarified to note cfDNA+cfRNA sources for fusion detection.',
    contributor: 'Jeremy Au',
    affiliation: 'Lucence (vendor)',
    citation: 'https://www.lucence.com/solutions/liquid-hallmark'
  },
  {
    date: 'Jan 6, 2026',
    type: 'verified',
    testId: 'mrd-6',
    testName: 'Reveal MRD',
    vendor: 'Guardant Health',
    category: 'MRD',
    description: 'Vendor verification: Updated LOD from 0.01% VAF to 0.005% Tumor Fraction per vendor validation.',
    contributor: 'Brandon Guida',
    affiliation: 'Guardant Health (vendor)',
    citation: 'https://www.guardantcomplete.com'
  },
  {
    date: 'Jan 6, 2026',
    type: 'verified',
    testId: 'tds-17',
    testName: 'Guardant360 Liquid',
    vendor: 'Guardant Health',
    category: 'TDS',
    description: 'Vendor verification: Updated sample requirements with precise Streck tube specifications per official IFU.',
    contributor: 'Brandon Guida',
    affiliation: 'Guardant Health (vendor)',
    citation: 'https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf'
  },
  {
    date: 'Jan 1, 2026',
    type: 'added',
    testId: 'tds-kit-15',
    testName: 'OncoScreen Plus Cancer Mutation Profiling Tissue Kit',
    vendor: 'Burning Rock Dx',
    category: 'TDS',
    description: 'Added Burning Rock 520-gene comprehensive tissue CGP kit. CE-IVD (June 2022), Japan MHLW CDx (Sept 2025) for capivasertib. PPA >97%, NPA >99%. TMB, MSI, HRD biomarkers. Validated across 20 solid tumor types in 3,005 patients.',
    contributor: 'Liankai Chi, PhD',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/35305253/'
  },
  {
    date: 'Jan 1, 2026',
    type: 'added',
    testId: 'tds-kit-14',
    testName: 'OncoScreen Focus CDx Tissue Kit',
    vendor: 'Burning Rock Dx',
    category: 'TDS',
    description: 'Added Burning Rock 13-gene focused tissue CGP kit. CE-IVD (June 2022). 100% accuracy in 117 samples. 30ng minimum input. NSCLC/CRC/GIST indications.',
    contributor: 'Liankai Chi, PhD',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: 'https://us.brbiotech.com/p_details.php?class_id=102101101'
  },
  {
    date: 'Jan 1, 2026',
    type: 'added',
    testId: 'tds-25',
    testName: 'OncoScreen Focus CDx',
    vendor: 'Burning Rock Dx',
    category: 'TDS',
    description: 'Added Burning Rock 13-gene focused tissue CGP central lab service. CLIA LDT (US), CE-IVD kit version available. NSCLC/CRC/GIST indications. Scope expanded to include tissue tests.',
    contributor: 'Liankai Chi, PhD',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: 'https://us.brbiotech.com/fixed-panels/'
  },
  {
    date: 'Jan 1, 2026',
    type: 'added',
    testId: 'tds-24',
    testName: 'OncoCompass Target',
    vendor: 'Burning Rock Dx',
    category: 'TDS',
    description: 'Added Burning Rock OncoCompass Target 168-gene liquid biopsy CGP panel. Vendor submission from Liankai Chi, PhD. >96% sensitivity, 99.9% specificity, 0.3% VAF LOD. Primary validation: BENEFIT trial (Lancet Respir Med 2018, n=426). 129 publications including Nature Medicine, Nature Biotechnology, Lancet Respiratory Medicine. CE-IVD 101-gene version available. 9-day TAT.',
    contributor: 'Liankai Chi, PhD',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: 'https://doi.org/10.1016/S2213-2600(18)30264-9 | https://doi.org/10.1002/cam4.70078'
  },
  {
    date: 'Dec 24, 2025',
    type: 'added',
    testId: 'tds-23',
    testName: 'Resolution ctDx FIRST',
    vendor: 'Agilent / Resolution Bioscience',
    category: 'TDS',
    description: 'Added FDA-approved liquid biopsy CDx for KRAS G12C (adagrasib). First NGS liquid biopsy CDx for KRAS G12C inhibitor. 109-gene hybrid-capture panel. 66.2% PPA vs tissue for KRAS G12C, 100% NPA, LOD95 0.34-0.82% MAF. FDA PMA P210040 approved Dec 2022. Available via Quest Diagnostics network. Identified as missing via LLM review pipeline.',
    contributor: null,
    affiliation: 'OpenOnco (LLM Data Review)',
    citation: 'https://www.fda.gov/medical-devices/recently-approved-devices/agilent-resolution-ctdx-first-p210040 | https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3057'
  },
  {
    date: 'Dec 23, 2025',
    type: 'added',
    testId: 'ecd-22',
    testName: 'Cancerguard',
    vendor: 'Exact Sciences',
    category: 'ECD',
    description: 'Added Exact Sciences Cancerguard MCED test - launched Sept 10, 2025 via Quest Diagnostics. Multi-analyte blood test (cfDNA + proteins) detecting 50+ cancer types. 64% overall sensitivity (68% for 6 deadliest cancers), 97.4% specificity. $689 list price. Based on CancerSEEK/DETECT-A foundation. FALCON registry (NCT06589310) enrolling ~25,000 participants.',
    contributor: null,
    affiliation: 'OpenOnco (LLM Data Review)',
    citation: 'https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test'
  },
  {
    date: 'Dec 23, 2025',
    type: 'added',
    testId: 'tds-kit-13',
    testName: 'PGDx elio plasma focus Dx',
    vendor: 'Labcorp/PGDx',
    category: 'TDS',
    description: 'Added first and only FDA-authorized kitted pan-solid tumor liquid biopsy. FDA De Novo Aug 2024, commercial launch April 2025. 33-gene panel detecting SNVs/indels, CNAs (5 genes), translocations (ALK/NTRK1/RET). >96% clinical success rate. 4-5 day TAT. Enables in-house lab testing with sample/data ownership. Compatible with PGDx elio tissue complete for tissue-to-liquid workflows.',
    contributor: null,
    affiliation: 'OpenOnco (LLM Data Review)',
    citation: 'https://ir.labcorp.com/news-releases/news-release-details/labcorp-receives-fda-de-novo-marketing-authorization-pgdx-eliotm'
  },
  {
    date: 'Dec 23, 2025',
    type: 'added',
    testId: 'trm-14',
    testName: 'xM for TRM',
    vendor: 'Tempus AI',
    category: 'TRM',
    description: 'Added Tempus xM for TRM - ICI therapy response monitoring via longitudinal ctDNA tumor fraction quantification. Currently RUO (Research Use Only) with clinical availability expected late 2025. Multi-parametric algorithm (CNVs + VAFs). Detects molecular response <6 weeks into ICI treatment. ASCO 2025 + Clinical Cancer Research 2024 publications. Note: Added with new isRUO flag and RUO visual indicator.',
    contributor: null,
    affiliation: 'OpenOnco (LLM Data Review)',
    citation: 'https://www.tempus.com/news/tempus-introduces-xm-an-assay-to-monitor-immunotherapy-response-for-patients-with-advanced-cancers/'
  },
  {
    date: 'Dec 23, 2025',
    type: 'updated',
    testId: 'mrd-9',
    testName: 'Labcorp Plasma Detect',
    vendor: 'Labcorp',
    category: 'MRD',
    description: 'CRITICAL FIX: Corrected LOD values per official Labcorp specifications. LOD95 is 0.005% (50 ppm), not 0.001% (10 ppm). The 0.001%/10 ppm value is LOD50. Updated citations to reference official Labcorp press release and product page.',
    contributor: null,
    affiliation: 'OpenOnco (LLM Data Review)',
    citation: 'https://www.prnewswire.com/news-releases/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions-302435767.html'
  },
  {
    date: 'Dec 23, 2025',
    type: 'updated',
    testId: 'mrd-19',
    testName: 'clonoSEQ',
    vendor: 'Adaptive Biotechnologies',
    category: 'MRD',
    description: 'Added CE-IVDR Class C certification (Aug 2024) - first IVDR-certified MRD test for lymphoid malignancies in EU. Enhanced regulatory status documentation.',
    contributor: null,
    affiliation: 'OpenOnco (LLM Data Review)',
    citation: 'https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-receives-ce-ivdr-certification-clonoseq'
  },
  {
    date: 'Dec 22, 2025',
    type: 'added',
    testId: 'mrd-25',
    testName: 'CanCatch Custom',
    vendor: 'Burning Rock Dx',
    category: 'MRD',
    description: 'Added tumor-informed personalized MRD assay (also known as PROPHET). WES of tumor/normal identifies up to 50 patient-specific variants tracked at 100,000x ultra-deep sequencing. 98.7% sensitivity, >99% specificity, LoD 0.004%. MEDAL study (n=181 NSCLC) showed 299-day median lead time vs imaging. 14-day TAT. ~$4,000 list price. Commercial from Burning Rock Dx (China/International). Head-to-head comparisons demonstrate superior performance vs fixed-panel MRD assays.',
    contributor: 'Liankai Chi',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/37683638/ | https://doi.org/10.1016/j.ccell.2023.08.010'
  },
  {
    date: 'Dec 22, 2025',
    type: 'updated',
    testId: 'ecd-21',
    testName: 'OverC Multi-Cancer Detection Blood Test',
    vendor: 'Burning Rock Dx',
    category: 'ECD',
    description: 'Updated FDA Breakthrough Device Designation note: FDA designation covers 5 cancer types (Esophageal, Liver, Lung, Ovarian, Pancreatic) and does not include colorectal cancer.',
    contributor: 'Liankai Chi',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: null
  },
  {
    date: 'Dec 22, 2025',
    type: 'added',
    testId: 'ecd-21',
    testName: 'OverC Multi-Cancer Detection Blood Test',
    vendor: 'Burning Rock Dx',
    category: 'ECD',
    description: 'Added Burning Rock Dx OverC MCDBT - 6-cancer MCED test with CE-IVDD marking and dual FDA/NMPA Breakthrough Device Designations. THUNDER study validation: 69.1% sensitivity, 98.9% specificity.',
    contributor: 'liankai chi',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: 'https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext'
  },
  {
    date: 'Dec 22, 2025',
    type: 'updated',
    testId: 'ecd-21',
    testName: 'OverC Multi-Cancer Detection Blood Test',
    vendor: 'Burning Rock Dx',
    category: 'ECD',
    description: 'Added vendor-provided PPV (12.3%), NPV (99.9%), TAT (10-15 business days), and list price ($900).',
    contributor: 'Liankai Chi',
    affiliation: 'Burning Rock Dx (vendor)',
    citation: 'Vendor data'
  },
  {
    date: 'Dec 19, 2025',
    type: 'added',
    testId: 'tds-22',
    testName: 'LiquidHALLMARK',
    vendor: 'Lucence',
    category: 'TDS',
    description: 'Added ultrasensitive liquid biopsy combining ctDNA (80 genes) and ctRNA (10 fusion targets). AmpliMark amplicon-based NGS with molecular barcode error correction. Combined ctDNA+ctRNA increases actionable fusion detection by 36.7% vs ctDNA alone. 0.1% VAF LOD for SNVs/indels, 10 copies LOD for RNA fusions. LIQUIK prospective study (JCO Precis Oncol 2025) showed 15.6% more tissue-confirmed NCCN biomarkers detected vs FDA-approved ctDNA-only test. Medicare covered via MolDX (Oct 2024). Available via Mayo Clinic Labs since March 2025. First Asian company to secure Medicare coverage for liquid biopsy in US.',
    contributor: 'Jeremy Au',
    affiliation: 'Lucence (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/35482824/ | https://ascopubs.org/doi/10.1200/PO-25-00181'
  },
  {
    date: 'Dec 18, 2025',
    type: 'added',
    testId: 'tds-kit-12',
    testName: 'Hedera Profiling 2 ctDNA Test Panel',
    vendor: 'Hedera Dx',
    category: 'TDS',
    description: 'Added decentralized liquid biopsy IVD kit for in-house hospital testing. 32-gene hybrid capture NGS panel covering >80% of ESCAT Level I genes (ESR1, METex14, MSI). DNA-only workflow detects SNVs, indels, CNVs, fusions, MSI at 0.5% VAF LOD. 97% sensitivity, 99.7% specificity in international multicenter validation (10+ centers, 8 countries, 137 clinical samples). Paired with Hedera Prime CE-IVD software for OncoKB-powered therapy matching. CE-IVD (EU/International); requires local validation under CE-IVDR; not available in US.',
    contributor: 'Thomas Vetterli',
    affiliation: 'Hedera Dx (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/41015181/'
  },
  {
    date: 'Dec 17, 2025',
    type: 'added',
    testId: 'tds-20',
    testName: 'Liquid Trace Solid Tumor',
    vendor: 'Genomic Testing Cooperative (GTC)',
    category: 'TDS',
    description: 'Added unique cfDNA + cfRNA combined liquid biopsy for solid tumors. Only commercially available liquid biopsy combining both analytes. >1,600 genes via cfRNA. cfRNA enables: higher sensitivity (multiple RNA copies vs single DNA copy), fusion gene detection from chromosomal translocations, expression-level data. LEADING PROVIDER FOR CSF LIQUID BIOPSY - optimal for CNS tumors (glioblastoma, CNS lymphomas/leukemias) and leptomeningeal disease. Includes T/B-cell clonality, HLA genotyping, viral detection (EBV, HPV, TTV). Reports include VAF + mutant molecules/mL for therapeutic monitoring. Medicare covered. NYSDOH approved. CE-marked (EU), UKCA certified (UK).',
    contributor: 'Jeffrey Owen',
    affiliation: 'Genomic Testing Cooperative (vendor)',
    citation: 'https://genomictestingcooperative.com/genomic-tests/liquid-trace-solid-tumor/'
  },
  {
    date: 'Dec 17, 2025',
    type: 'added',
    testId: 'tds-21',
    testName: 'Liquid Trace Hematology',
    vendor: 'Genomic Testing Cooperative (GTC)',
    category: 'TDS',
    description: 'Added unique cfDNA + cfRNA liquid biopsy for hematologic malignancies. Can significantly reduce need for bone marrow biopsies. Key differentiators: (1) cfDNA chimerism analysis for post-transplant relapse prediction; (2) MRD via mutations AND chromosomal abnormalities (beyond Signatera-style mutation-only approach); (3) T/B-cell clonality; (4) TTV viral load as immune competence marker; (5) CAR-T detection/monitoring in CSF. Published validation: cfDNA detected MORE mutations than bone marrow (92 vs 61); cfDNA chimerism predicted relapse better than CD3+ chimerism (Rowley et al. Cancers 2025). Medicare covered. NYSDOH approved. CE-marked (EU), UKCA certified (UK).',
    contributor: 'Jeffrey Owen',
    affiliation: 'Genomic Testing Cooperative (vendor)',
    citation: 'https://doi.org/10.3390/cancers17040625'
  },
  {
    date: 'Dec 17, 2025',
    type: 'added',
    testId: 'trm-13',
    testName: 'Liquid Trace (Therapy Monitoring)',
    vendor: 'Genomic Testing Cooperative (GTC)',
    category: 'TRM',
    description: 'Added therapy response monitoring entry for Liquid Trace. Only TRM test combining cfDNA + cfRNA. Reports include longitudinal VAF AND mutant molecules/mL tracking table for quantitative response assessment. Response definition: VAF/molecules decrease = response; increase = progression or emerging resistance. Covers both solid tumors and hematologic malignancies. CSF option for CNS involvement and leptomeningeal disease monitoring. For hematology: includes chimerism analysis and chromosomal abnormalities for post-transplant MRD. Medicare covered. NYSDOH approved. CE-marked (EU), UKCA certified (UK).',
    contributor: 'Jeffrey Owen',
    affiliation: 'Genomic Testing Cooperative (vendor)',
    citation: 'https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/'
  },
  {
    date: 'Dec 17, 2025',
    type: 'added',
    testId: 'tds-19',
    testName: 'Oncotype DX Breast Recurrence Score',
    vendor: 'Exact Sciences',
    category: 'TDS',
    description: 'Added foundational 21-gene RT-PCR breast cancer assay (in clinical use since 2004). Gene expression profiling for HR+/HER2- early-stage breast cancer. NCCN-preferred with Category 1 evidence. Only test with Level 1 evidence from prospective randomized trials (TAILORx n=10,273; RxPONDER n=5,083) for both prognosis AND chemotherapy benefit prediction. Over 1 million patients tested worldwide. 500+ publications. Medicare covered (~$3,416). First multigene assay to transform breast cancer treatment decisions.',
    contributor: 'Dr. Don Johann',
    affiliation: 'UAMS (independent expert)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/29860917/ | https://pubmed.ncbi.nlm.nih.gov/34914590/'
  },
  {
    date: 'Dec 16, 2025',
    type: 'added',
    testId: 'ecd-20',
    testName: 'Avantect Pancreatic Cancer Test',
    vendor: 'ClearNote Health',
    category: 'ECD',
    description: 'Added first single-cancer ECD test for pancreatic cancer. Uses novel 5-hydroxymethylcytosine (5hmC) cfDNA profiling rather than standard 5mC methylation. 68.3% early-stage (I/II) sensitivity, 96.9% specificity. Targets high-risk population: adults 50+ with new-onset T2DM (within 36 months), genetic predisposition, or family history. Validated in blinded cohort (n=3,674) published in Clin Gastroenterol Hepatol 2023 and J Mol Diagn 2024. Medicare covered at $1,160 (CPT 0410U). NYSDOH approved. Selected for NCI Vanguard study. PRECEDE Consortium member.',
    contributor: 'Adrian Vilalta',
    affiliation: 'ClearNote Health (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/36967102/ | https://pubmed.ncbi.nlm.nih.gov/39230538/'
  },
  {
    date: 'Dec 16, 2025',
    type: 'added',
    testId: 'ecd-19',
    testName: 'IUrisure',
    vendor: 'Wuhan Ammunition Life Technology',
    category: 'ECD',
    description: 'Added NMPA-approved urine DNA methylation test for urothelial carcinoma (bladder, ureter, renal pelvis) screening. Dual-target AL021918.2+VIM MSP assay. 93.94% UC sensitivity, 94.44% Ta stage sensitivity, 92.02% specificity. First urine-based methylation test in database. Requires only 1.8 mL urine. Validated at Peking University First Hospital / National Urological Cancer Center (n=477), published in Chinese Med J 2024. Non-invasive alternative to cystoscopy. Available in China only.',
    contributor: 'Tingting Li',
    affiliation: 'Wuhan Ammunition Life Technology (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/37455255/'
  },
  {
    date: 'Dec 16, 2025',
    type: 'added',
    testId: 'ecd-18',
    testName: 'IHepcomf',
    vendor: 'Wuhan Ammunition Life Technology',
    category: 'ECD',
    description: 'Added NMPA/CE-approved plasma cfDNA methylation test for primary liver cancer (PLC) screening. Dual-target GNB4+Riplet qMSP assay. 92.3% PLC sensitivity (91.9% HCC, 93.3% ICC), 84.4% Stage I sensitivity, 93.4% specificity. First plasma methylation test for liver cancer in database. Validated in multicenter, double-blind trial (n=1,182) across 3 Chinese hospitals, published in Clin Epigenetics 2025. Detects HCC, ICC, and combined subtypes. Superior to AFP for early detection. Available in China and Europe.',
    contributor: 'Tingting Li',
    affiliation: 'Wuhan Ammunition Life Technology (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/40624654/'
  },
  {
    date: 'Dec 16, 2025',
    type: 'added',
    testId: 'ecd-17',
    testName: 'IEsohunter',
    vendor: 'Wuhan Ammunition Life Technology',
    category: 'ECD',
    description: 'Added NMPA/CE-approved plasma cfDNA methylation test for esophageal cancer screening. Dual-target OTOP2+KCNA3 qPCR assay. 87.4% EC sensitivity, 78.5% Stage I sensitivity, 93.3% specificity. First commercially available plasma methylation test for esophageal cancer. Validated in prospective, double-blinded, multicenter trial (n=1,116) across 5 Chinese centers, published in J Hematol Oncol 2024. Detects both ESCC and EAC. Available in China and Europe.',
    contributor: 'Tingting Li',
    affiliation: 'Wuhan Ammunition Life Technology (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/38890756/'
  },
  {
    date: 'Dec 16, 2025',
    type: 'added',
    testId: 'ecd-16',
    testName: 'IColohunter',
    vendor: 'Wuhan Ammunition Life Technology',
    category: 'ECD',
    description: 'Added NMPA/CE-approved plasma cfDNA methylation test for CRC screening. Dual-target NTMT1+MAP3K14-AS1 qPCR assay using novel SADMP technique. 91.2% CRC sensitivity, 87.4% Stage I-II sensitivity, 43.5% advanced adenoma sensitivity, 92.4% specificity. Validated in multicenter, double-blinded trial (n=1,194) across 5 Chinese hospitals, published in BMC Medicine 2024. Blood-based complement to vendor\'s stool-based IColocomf test. Available in China and Europe.',
    contributor: 'Tingting Li',
    affiliation: 'Wuhan Ammunition Life Technology (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/39379942/'
  },
  {
    date: 'Dec 16, 2025',
    type: 'updated',
    testId: 'tds-kit-5',
    testName: 'TSO 500',
    vendor: 'Illumina',
    category: 'TDS',
    description: 'Corrected regulatory status: TSO 500 is RUO (Research Use Only) globally, not CE-IVD in EU. The CE-IVD marking belongs to TruSight Oncology Comprehensive (TSO Comp), which is a separate IVD product. Updated fdaStatus, productType, indicationsNotes, clinicalAvailability, and technologyDifferentiator fields.',
    contributor: 'Francis Peters',
    affiliation: 'Illumina (vendor)',
    citation: 'https://www.illumina.com/products/by-brand/trusight-oncology/tso-500-portfolio.html'
  },
  {
    date: 'Dec 15, 2025',
    type: 'added',
    testId: 'mrd-24',
    testName: 'CancerVista',
    vendor: 'LIQOMICS',
    category: 'MRD',
    description: 'Added multi-solid tumor MRD assay from LIQOMICS. Technically validated with LoD 3.30×10⁻⁶. Covers 17 anatomical sites including bladder, brain, breast, cervix, colorectal, esophagus, head and neck, kidney, liver, lung, ovary, pancreas, prostate, skin, stomach, thyroid, and uterus. MRD detection: 80% sensitivity, 96.7% specificity, 94.3% accuracy at threshold 2.5×10⁻⁵. Variant detection: 93.17% sensitivity, >99% specificity for mAF ≥1%. 20 mL blood sample, 10-day TAT. Available in Europe.',
    contributor: 'Jens Winter',
    affiliation: 'LIQOMICS (vendor)',
    citation: null
  },
  {
    date: 'Dec 15, 2025',
    type: 'added',
    testId: 'ecd-14',
    testName: 'IColocomf',
    vendor: 'Wuhan Ammunition Life Technology',
    category: 'ECD',
    description: 'Added NMPA/CE-approved stool DNA methylation test for CRC screening. Dual-target SDC2+TFPI2 qPCR assay. 95.31% CRC sensitivity, 96.93% Stage I-II sensitivity, 96.67% specificity vs healthy controls. Validated in independent multicenter trial (n=1,164) published in J Mol Diagn 2022. First Chinese stool DNA test in database. Available in China and Europe.',
    contributor: 'Tingting Li',
    affiliation: 'Wuhan Ammunition Life Technology (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/34890778/'
  },
  {
    date: 'Dec 14, 2025',
    type: 'updated',
    testId: null,
    testName: 'Data Accuracy Corrections',
    vendor: null,
    category: 'Multiple',
    description: 'Corrected overstated claims and regulatory status: Cologuard - removed "ONLY" self-collection claim, moved USPSTF to guidelines field; TSO Comprehensive - narrowed CDx claims to FDA-labeled scope (NTRK/RET at launch); TSO 500 - clarified RUO in US; Oncomine Comprehensive Assay Plus - changed to RUO pending CE-IVD verification; GeneseeqPrime - corrected clearance date to Aug 2025; Epi proColon - updated reimbursement to "coverage variable/limited"; clonoSEQ - added US/EU distribution model notes.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 14, 2025',
    type: 'updated',
    testId: null,
    testName: 'CDx Category Reclassification',
    vendor: null,
    category: 'Multiple',
    description: 'Reclassified 6 therapy-selection companion diagnostics from TRM/MRD to TDS: cobas EGFR v2, cobas KRAS, therascreen EGFR, OncoBEAM RAS CRC, PGDx elio plasma focus (from TRM), and LeukoStrat CDx FLT3 (from MRD). These tests are primarily CDx for therapy selection, not treatment response monitoring or MRD detection. Category placement now reflects FDA-labeled intended use.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 14, 2025',
    type: 'feature',
    testId: null,
    testName: 'IVD Kit Support',
    vendor: null,
    category: 'All',
    description: 'Added Product Type taxonomy distinguishing Self-Collection kits (patient collects at home), Laboratory IVD Kits (distributed reagents for CLIA labs), and Central Lab Services (send-out tests). New filter enables users to find tests by distribution model. Added 16 IVD kit entries: ECD - Cologuard, Epi proColon; MRD - clonoSEQ Assay, LymphoTrack Dx IGH Assay, BD OneFlow B-ALL MRD Kit; TDS - TruSight Oncology Comprehensive, GeneseeqPrime, PGDx elio tissue complete, Oncomine Comprehensive Assay Plus, TSO 500, cobas EGFR Mutation Test v2, cobas KRAS Mutation Test, therascreen EGFR RGQ PCR Kit, OncoBEAM RAS CRC Kit, PGDx elio plasma focus Dx, LeukoStrat CDx FLT3 Mutation Assay.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 14, 2025',
    type: 'added',
    testId: 'ecd-kit-1',
    testName: 'Cologuard',
    vendor: 'Exact Sciences',
    category: 'ECD',
    description: 'Added FDA PMA-approved self-collection CRC screening kit. Only at-home collection cancer screening test. Stool DNA + FIT, 92% CRC sensitivity, 87% specificity. USPSTF Grade A recommendation.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://www.cologuard.com/'
  },
  {
    date: 'Dec 14, 2025',
    type: 'added',
    testId: 'mrd-kit-1',
    testName: 'clonoSEQ Assay',
    vendor: 'Adaptive Biotechnologies',
    category: 'MRD',
    description: 'Added FDA-cleared IVD kit for MRD detection in hematologic malignancies. First and only FDA-cleared MRD IVD. Available as reagent kit for MiSeqDx labs.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://www.clonoseq.com/'
  },
  {
    date: 'Dec 14, 2025',
    type: 'added',
    testId: 'tds-kit-1',
    testName: 'TruSight Oncology Comprehensive',
    vendor: 'Illumina',
    category: 'TDS',
    description: 'Added first FDA-approved distributable CGP IVD kit with pan-cancer CDx claims. 517 genes, enables in-house comprehensive genomic profiling.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://www.illumina.com/products/by-type/ivd-products/trusight-oncology-comprehensive.html'
  },
  {
    date: 'Dec 14, 2025',
    type: 'added',
    testId: 'tds-kit-6',
    testName: 'cobas EGFR Mutation Test v2',
    vendor: 'Roche',
    category: 'TDS',
    description: 'Added FDA-approved EGFR liquid biopsy CDx kit. First liquid biopsy test FDA-approved (2016). Gold standard for EGFR TKI therapy selection.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://diagnostics.roche.com/global/en/products/tests/cobas-egfr-mutation-test-v2-ins.html'
  },
  {
    date: 'Dec 13, 2025',
    type: 'updated',
    testId: 'trm-12',
    testName: 'Reveal TRM',
    vendor: 'Guardant Health',
    category: 'TRM',
    description: 'Corrected tumor fraction methodology for Reveal TRM and Reveal MRD: epiTF (epigenetic Tumor Fraction) calculated from 19,000+ differentially methylated loci, mutation-agnostic. Removed duplicate Guardant360 Response entry (trm-10).',
    contributor: 'Brandon Guida',
    affiliation: 'Guardant Health (vendor)',
    citation: null
  },
  {
    date: 'Dec 13, 2025',
    type: 'added',
    testId: 'tds-18',
    testName: 'IsoPSA',
    vendor: 'Cleveland Diagnostics',
    category: 'TDS',
    description: 'Added FDA PMA-approved protein structure-based prostate cancer diagnostic. IsoClear platform analyzes PSA structural variants (not concentration) to aid biopsy decisions. 90.2% sensitivity, runs on standard analyzers (COBAS, Siemens, Abbott). In NCCN and AUA/SUO guidelines, Medicare covered.',
    contributor: 'Sameer Rohatgi',
    affiliation: 'Cleveland Diagnostics',
    citation: 'https://www.businesswire.com/news/home/20251201324198/en/FDA-Approves-IsoPSA----Cleveland-Diagnostics-Novel-Blood-Based-Prostate-Cancer-Test'
  },
  {
    date: 'Dec 13, 2025',
    type: 'updated',
    testId: 'mrd-23',
    testName: 'LymphoVista',
    vendor: 'LIQOMICS',
    category: 'MRD',
    description: 'Corrected turnaround times per vendor: Initial TAT and Follow-up TAT both 10 days (previously listed as 2-4 weeks).',
    contributor: 'Jens Winter',
    affiliation: 'LIQOMICS (vendor)',
    citation: null
  },
  {
    date: 'Dec 12, 2025',
    type: 'updated',
    testId: 'tds-16',
    testName: 'Northstar Select',
    vendor: 'BillionToOne',
    category: 'TDS',
    description: 'Updated reimbursement status: Medicare coverage via MolDx (Palmetto GBA LCD L38043) effective February 14, 2025.',
    contributor: 'David Huland',
    affiliation: 'BillionToOne (vendor)',
    citation: 'https://www.billiontoone.com/news-media/billiontoone-announces-medicare-coverage-for-northstar-select'
  },
  {
    date: 'Dec 12, 2025',
    type: 'updated',
    testId: 'trm-1',
    testName: 'Guardant360 Response (DISCONTINUED)',
    vendor: 'Guardant Health',
    category: 'TRM',
    description: 'PRODUCT DISCONTINUED: Sun-setted per vendor. Guardant has consolidated monitoring portfolio to Reveal MRD (early-stage) and Reveal TRM (advanced/metastatic). Guardant360 Response is no longer commercially available.',
    contributor: 'Brandon Guida PhD',
    affiliation: 'Guardant Health (vendor)',
    citation: null
  },
  {
    date: 'Dec 12, 2025',
    type: 'added',
    testId: 'trm-12',
    testName: 'Reveal TRM',
    vendor: 'Guardant Health',
    category: 'TRM',
    description: 'Added new methylation-based therapy response monitoring test for advanced/metastatic solid tumors. Uses Guardant Infinity platform with epigenetic tumor fraction (epiTF) quantification from 19,000+ differentially methylated loci—mutation-agnostic. Precision down to ~0.01% TF, not confounded by CNAs or CHIP. Validated in >50,000 cfDNA samples across 20+ cancer types (AACR 2025).',
    contributor: 'Brandon Guida PhD',
    affiliation: 'Guardant Health (vendor)',
    citation: null
  },
  {
    date: 'Dec 12, 2025',
    type: 'updated',
    testId: 'mrd-6',
    testName: 'Reveal MRD',
    vendor: 'Guardant Health',
    category: 'MRD',
    description: 'Renamed from "Reveal" to "Reveal MRD" per vendor product consolidation. Expanded cancer types to include breast and non-small cell lung cancer (previously CRC only). Early-stage cancer focus for MRD detection/recurrence monitoring after curative-intent therapy.',
    contributor: 'Brandon Guida PhD',
    affiliation: 'Guardant Health (vendor)',
    citation: null
  },
  {
    date: 'Dec 13, 2025',
    type: 'feature',
    testId: null,
    testName: 'Site Update',
    vendor: null,
    category: null,
    description: 'Added shareable comparison links (copy link button in comparison modal). Fixed print-to-PDF bug that repeated Page 1 on all pages.',
    contributor: 'Jeff Hull',
    affiliation: 'BillionToOne (via LinkedIn)',
    citation: null
  },
  {
    date: 'Dec 13, 2025',
    type: 'updated',
    testId: 'mrd-15',
    testName: 'Foresight CLARITY Lymphoma',
    vendor: 'Natera',
    category: 'MRD',
    description: 'Updated per vendor: Matched Normal = Yes; LOD95 = 0.7 ppm (previously listed as LOD). Added analytical validation publication citation.',
    contributor: 'John Truesdell',
    affiliation: 'Natera/Foresight (vendor)',
    citation: 'https://pubmed.ncbi.nlm.nih.gov/40353795/'
  },
  {
    date: 'Dec 12, 2025',
    type: 'updated',
    testId: 'mrd-2',
    testName: 'NeXT Personal Dx',
    vendor: 'Personalis',
    category: 'MRD',
    description: 'Updated turnaround times per vendor: initial TAT now 21 days (was 35), follow-up TAT now 10 days (was 12). Confirmed blood volume (20 mL, two Streck tubes) and variants tracked (~1,800).',
    contributor: 'Dan Norton',
    affiliation: 'Personalis (vendor)',
    citation: null
  },
  {
    date: 'Dec 11, 2025',
    type: 'updated',
    testId: 'mrd-19',
    testName: 'clonoSEQ',
    vendor: 'Adaptive Biotechnologies',
    category: 'MRD',
    description: 'Clarified sample requirements: baseline Clonality (ID) test accepts fresh or archived samples from bone marrow aspirate, peripheral blood, or soft tissue (e.g., plasmacytoma, lymph node biopsy). Subsequent Tracking (MRD) tests use standard fresh bone marrow or blood.',
    contributor: 'Christine Hanley',
    affiliation: 'Adaptive Biotechnologies (vendor)',
    citation: null
  },
  {
    date: 'Dec 11, 2025',
    type: 'added',
    testId: 'tds-17',
    testName: 'Guardant360 Liquid',
    vendor: 'Guardant Health',
    category: 'TDS',
    description: 'Added comprehensive 744-gene liquid biopsy LDT (distinct from 74-gene FDA-approved CDx). Features: genomic + epigenomic (promoter methylation) insights, CHIP filtering, virus detection (EBV/HPV), tumor fraction quantification. Runs on Guardant Infinity platform with 10x more genes and 10x higher sensitivity than previous version.',
    contributor: 'Brandon (Scott) Guida PhD',
    affiliation: 'Guardant Health (vendor)',
    citation: 'https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf'
  },
  {
    date: 'Dec 11, 2025',
    type: 'feature',
    testId: null,
    testName: 'Clinical Settings Tags',
    vendor: null,
    category: 'MRD',
    description: 'Added clinicalSettings field to all MRD tests to capture validated clinical contexts: Neoadjuvant (monitoring during pre-surgery therapy), Post-Surgery (landmark ~4 weeks after resection), Post-Adjuvant (after chemotherapy), and Surveillance (longitudinal recurrence monitoring). Added filter by clinical setting. Based on vendor feedback from Personalis (Dan Norton) on clinical context-specific performance data.',
    contributor: 'Dan Norton',
    affiliation: 'Personalis',
    citation: null
  },
  {
    date: 'Dec 12, 2025',
    type: 'added',
    testId: 'mrd-23',
    testName: 'LymphoVista',
    vendor: 'LIQOMICS',
    category: 'MRD',
    description: 'Added European lymphoma-focused ctDNA MRD test covering B-cell lymphomas (DLBCL, FL, MCL, Burkitt, CNS) and Hodgkin lymphoma via LymphoVista HL variant. Duplex sequencing with LoD 6.69×10⁻⁶. Clinical validation: 92.1% PPV in r/r DLBCL post-CAR-T/chemo (EHA 2024); HR 6.9 for PFS in Hodgkin (ASH 2024, HD21 trial).',
    contributor: 'Jens Winter',
    affiliation: 'LIQOMICS (vendor)',
    citation: 'https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping'
  },
  {
    date: 'Dec 11, 2025',
    type: 'added',
    testId: 'mrd-22',
    testName: 'CancerDetect',
    vendor: 'IMBdx',
    category: 'MRD',
    description: 'Added Korean tumor-informed MRD test using large-scale mutation tracking (up to 300 variants). 0.001% LOD. Innovative Medical Technology designation.',
    contributor: 'Sunghoon Heo',
    affiliation: 'IMBdx (vendor)',
    citation: 'https://www.nature.com/articles/s41416-023-02300-3'
  },
  {
    date: 'Dec 11, 2025',
    type: 'added',
    testId: 'mrd-21',
    testName: 'Latitude',
    vendor: 'Natera',
    category: 'MRD',
    description: 'Added tissue-free (tumor-naïve) methylation-based MRD test for CRC. No tumor tissue required. Validated in CIRCULATE-JAPAN GALAXY Study.',
    contributor: 'Sunghoon Heo',
    affiliation: 'IMBdx',
    citation: 'https://www.natera.com/oncology/latitude-tissue-free-mrd/'
  },
  {
    date: 'Dec 11, 2025',
    type: 'added',
    testId: 'mrd-20',
    testName: 'Signatera Genome',
    vendor: 'Natera',
    category: 'MRD',
    description: 'Added WGS-informed version of Signatera with 64 variants tracked and 1 ppm LOD (~100x more sensitive than standard Signatera).',
    contributor: 'Sunghoon Heo',
    affiliation: 'IMBdx',
    citation: 'https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/'
  },
  {
    date: 'Dec 11, 2025',
    type: 'updated',
    testId: 'mrd-9',
    testName: 'Labcorp Plasma Detect',
    vendor: 'Labcorp',
    category: 'MRD',
    description: 'Fixed duplicate entry: merged mrd-17 into mrd-9. Updated with expanded cancer types (lung, bladder in validation), improved LOD (10 ppm), lead time data, and newer clinical trial citations.',
    contributor: 'Sunghoon Heo',
    affiliation: 'IMBdx',
    citation: null
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'tds-15',
    testName: 'NEO PanTracer Tissue',
    vendor: 'NeoGenomics',
    category: 'TDS',
    description: 'Renamed from "Neo Comprehensive" to "NEO PanTracer Tissue" to reflect NeoGenomics product rebrand.',
    contributor: 'Heather Robinson',
    affiliation: 'Illumina',
    citation: 'https://www.neogenomics.com/providers/test/NTG-HCSX-02AX/neo-comprehensive-solid-tumor/'
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'mrd-19',
    testName: 'clonoSEQ',
    vendor: 'Adaptive Biotechnologies',
    category: 'MRD',
    description: 'Vendor update: TAT changed to 7 days (serial monitoring) from 14 days (baseline); updated Target Population to list specific indications (ALL, CLL, DLBCL, MCL, MM); clarified tumor tissue requirement for hematologic assay.',
    contributor: 'Christine Hanley',
    affiliation: 'Adaptive Biotechnologies',
    citation: null
  },
  {
    date: 'Dec 10, 2025',
    type: 'feature',
    testId: null,
    testName: 'Medicare ADLT Data',
    vendor: null,
    category: 'All',
    description: 'Added Medicare CLFS reimbursement rates and ADLT status to 8 tests: Signatera ($3,500), Guardant360 CDx ($5,000), FoundationOne CDx ($3,500), FoundationOne Liquid CDx ($3,500), Shield ($1,495), NavDx ($1,800), Tempus xT CDx ($4,500), clonoSEQ ($2,007). Added PLA vs CPT code type distinction.',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/files'
  },
  {
    date: 'Dec 10, 2025',
    type: 'added',
    testId: 'mrd-19',
    testName: 'clonoSEQ',
    vendor: 'Adaptive Biotechnologies',
    category: 'MRD',
    description: 'Added clonoSEQ - first and only FDA-cleared MRD test for hematologic malignancies (MM, B-ALL, CLL). Uses NGS immunosequencing of B/T-cell receptor genes with 10⁻⁶ sensitivity. Medicare coverage for MM, ALL, CLL, DLBCL, MCL.',
    contributor: 'Christine Hanley',
    affiliation: 'Adaptive Biotechnologies',
    citation: 'https://www.clonoseq.com/'
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'tds-1',
    testName: 'FoundationOne CDx',
    vendor: 'Foundation Medicine',
    category: 'TDS',
    description: 'Added international availability info - available in 100+ countries via Roche global network (EU lab in Penzberg, Germany; MHLW approved in Japan)',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://www.roche.com/media/releases/med-cor-2021-10-25'
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'tds-2',
    testName: 'FoundationOne Liquid CDx',
    vendor: 'Foundation Medicine',
    category: 'TDS',
    description: 'Added international availability info - available in 100+ countries via Roche global network',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://www.roche.com/media/releases/med-cor-2021-10-25'
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'tds-3',
    testName: 'FoundationOne Heme',
    vendor: 'Foundation Medicine',
    category: 'TDS',
    description: 'Added international availability info - available via Roche global network',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: 'https://www.roche.com/media/releases/med-cor-2021-10-25'
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'mrd-9',
    testName: 'FoundationOne Tracker (MRD)',
    vendor: 'Foundation Medicine',
    category: 'MRD',
    description: 'Added international availability info for investigational/early access program',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'mrd-11',
    testName: 'Foundation TI-WGS MRD (RUO)',
    vendor: 'Foundation Medicine',
    category: 'MRD',
    description: 'Added international availability info for RUO via FlexOMx Lab',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'trm-6',
    testName: 'FoundationOne Tracker (TRM)',
    vendor: 'Foundation Medicine',
    category: 'TRM',
    description: 'Added international availability info - available via Roche affiliates',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 10, 2025',
    type: 'updated',
    testId: 'trm-7',
    testName: 'FoundationOne Monitor',
    vendor: 'Foundation Medicine',
    category: 'TRM',
    description: 'Added international availability info - available via Roche affiliates',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 9, 2025',
    type: 'added',
    testId: 'tds-16',
    testName: 'Northstar Select',
    vendor: 'BillionToOne',
    category: 'TDS',
    description: 'Initial database entry - liquid biopsy CGP with 0.15% VAF LOD',
    contributor: 'Rob Manor',
    affiliation: 'BillionToOne',
    citation: 'https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00038-4/fulltext'
  },
  {
    date: 'Dec 9, 2025',
    type: 'updated',
    testId: 'trm-8',
    testName: 'Northstar Response',
    vendor: 'BillionToOne',
    category: 'TRM',
    description: 'Updated methylated loci count from >500 to >2200 (v2 panel expansion)',
    contributor: 'Rob Manor',
    affiliation: 'BillionToOne',
    citation: 'https://www.northstaronc.com/northstar-response'
  },
  {
    date: 'Dec 10, 2025',
    type: 'removed',
    testId: 'trm-9',
    testName: 'MSK-ACCESS powered with SOPHiA DDM',
    vendor: 'SOPHiA GENETICS',
    category: 'TRM',
    description: 'Removed - RUO kitted product not directly orderable by physicians. Vendor confirmed test does not meet inclusion criteria.',
    contributor: 'Julien Pontis',
    affiliation: 'SOPHiA GENETICS',
    citation: null
  },
  {
    date: 'Dec 8, 2025',
    type: 'added',
    testId: 'mrd-16',
    testName: 'Invitae PCM',
    vendor: 'Labcorp (Invitae)',
    category: 'MRD',
    description: 'Initial database entry',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 8, 2025',
    type: 'added',
    testId: 'tds-15',
    testName: 'Neo Comprehensive',
    vendor: 'NeoGenomics',
    category: 'TDS',
    description: 'Initial database entry',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 7, 2025',
    type: 'added',
    testId: 'ecd-13',
    testName: 'Signal-C',
    vendor: 'Universal DX',
    category: 'ECD',
    description: 'Initial database entry',
    contributor: null,
    affiliation: 'OpenOnco',
    citation: null
  },
  {
    date: 'Dec 7, 2025',
    type: 'added',
    testId: 'mrd-15',
    testName: 'Foresight CLARITY Lymphoma',
    vendor: 'Natera',
    category: 'MRD',
    description: 'Initial database entry',
    contributor: 'John Truesdell',
    affiliation: 'Foresight Diagnostics',
    citation: null
  },
  {
    date: 'Dec 5, 2025',
    type: 'added',
    testId: 'ecd-11',
    testName: 'EPISEEK',
    vendor: 'Precision Epigenomics',
    category: 'ECD',
    description: 'Initial database entry',
    contributor: 'Richard Bernert',
    affiliation: 'Precision Epigenomics',
    citation: null
  },
];

// Recently Added Tests
export const RECENTLY_ADDED_TESTS = [
  { id: 'ecd-27', name: 'OncoXPLORE+', vendor: 'OncoDNA', category: 'ECD', dateAdded: 'Jan 8, 2026' },
  { id: 'mrd-26', name: 'MRDVision', vendor: 'Inocras', category: 'MRD', dateAdded: 'Jan 7, 2026' },
  { id: 'ecd-26', name: 'Trucheck Intelli', vendor: 'Datar Cancer Genetics', category: 'ECD', dateAdded: 'Jan 7, 2026' },
  { id: 'tds-26', name: 'CellSight DNA', vendor: 'Cancer Cell Dx', category: 'TDS', dateAdded: 'Jan 7, 2026' },
  { id: 'tds-27', name: 'CancerVision', vendor: 'Inocras', category: 'TDS', dateAdded: 'Jan 7, 2026' },
  { id: 'ecd-25', name: 'CancerDetect Oral & Throat', vendor: 'Viome', category: 'ECD', dateAdded: 'Jan 1, 2026' },
  { id: 'tds-kit-15', name: 'OncoScreen Plus Tissue Kit', vendor: 'Burning Rock Dx', category: 'TDS', dateAdded: 'Jan 1, 2026' },
  { id: 'tds-kit-14', name: 'OncoScreen Focus CDx Tissue Kit', vendor: 'Burning Rock Dx', category: 'TDS', dateAdded: 'Jan 1, 2026' },
  { id: 'tds-25', name: 'OncoScreen Focus CDx', vendor: 'Burning Rock Dx', category: 'TDS', dateAdded: 'Jan 1, 2026' },
  { id: 'tds-24', name: 'OncoCompass Target', vendor: 'Burning Rock Dx', category: 'TDS', dateAdded: 'Jan 1, 2026' },
  { id: 'tds-23', name: 'Resolution ctDx FIRST', vendor: 'Agilent / Resolution Bioscience', category: 'TDS', dateAdded: 'Dec 24, 2025' },
  { id: 'tds-22', name: 'LiquidHALLMARK', vendor: 'Lucence', category: 'TDS', dateAdded: 'Dec 19, 2025' },
  { id: 'mrd-24', name: 'CancerVista', vendor: 'LIQOMICS', category: 'MRD', dateAdded: 'Dec 15, 2025' },
  { id: 'ecd-kit-1', name: 'Cologuard', vendor: 'Exact Sciences', category: 'ECD', dateAdded: 'Dec 14, 2025' },
  { id: 'mrd-kit-1', name: 'clonoSEQ Assay (IVD Kit)', vendor: 'Adaptive Biotechnologies', category: 'MRD', dateAdded: 'Dec 14, 2025' },
  { id: 'tds-kit-1', name: 'TSO Comprehensive', vendor: 'Illumina', category: 'TDS', dateAdded: 'Dec 14, 2025' },
  { id: 'tds-kit-6', name: 'cobas EGFR v2', vendor: 'Roche', category: 'TDS', dateAdded: 'Dec 14, 2025' },
  { id: 'tds-18', name: 'IsoPSA', vendor: 'Cleveland Diagnostics', category: 'TDS', dateAdded: 'Dec 13, 2025' },
  { id: 'trm-12', name: 'Reveal TRM', vendor: 'Guardant Health', category: 'TRM', dateAdded: 'Dec 12, 2025' },
  { id: 'mrd-23', name: 'LymphoVista', vendor: 'LIQOMICS', category: 'MRD', dateAdded: 'Dec 12, 2025' },
  { id: 'mrd-22', name: 'CancerDetect', vendor: 'IMBdx', category: 'MRD', dateAdded: 'Dec 11, 2025' },
];

// Helper to get changelog
export const getChangelog = () => {
  return DATABASE_CHANGELOG;
};

// Helper to get recently added tests
export const getRecentlyAddedTests = () => {
  return RECENTLY_ADDED_TESTS;
};


// ============================================
// Domain Detection
// ============================================
export const DOMAINS = {
  ONCO: 'onco'
};

export const getDomain = () => {
  return DOMAINS.ONCO;
};

// Build info for display purposes
export const BUILD_INFO = {
  date: new Date(typeof __BUILD_DATE__ !== 'undefined' ? __BUILD_DATE__ : new Date().toISOString()).toLocaleString('en-US', { 
    year: 'numeric', 
    month: 'short', 
    day: 'numeric',
    hour: '2-digit',
    minute: '2-digit',
    timeZoneName: 'short'
  }),
  sources: {
    MRD: 'https://docs.google.com/spreadsheets/d/16F_QRjpiqlrCK1f5fPSHQsODdE5QVPrrdx-0rfKAa5U/edit',
    ECD: 'https://docs.google.com/spreadsheets/d/1eFZg2EtdnR4Ly_lrXoZxzI4Z2bH23LDkCAVCXrewwnI/edit',
    TRM: 'https://docs.google.com/spreadsheets/d/1ZgvK8AgZzZ4XuZEija_m1FSffnnhvIgmVCkQvP1AIXE/edit',
    TDS: 'https://docs.google.com/spreadsheets/d/1HxYNQ9s4qJKHxFMkYjW1uXBq3Zg3nVkFp3mQZQvZF0s/edit'
  }
};

export const getSiteConfig = () => {
  return {
    domain: DOMAINS.ONCO,
    name: 'OpenOnco',
    tagline: 'Oncology Diagnostics Database',
    description: 'Compare cancer diagnostic tests across categories',
    logoText: 'OpenOnco',
    themeColor: '#2563eb', // Blue for Onco
    categories: ['MRD', 'ECD', 'TRM', 'TDS']
  };
};

// ============================================
// Lifecycle Stages
// ============================================
export const LIFECYCLE_STAGES = [
  {
    id: 'HCT',
    name: 'Risk',
    fullName: 'Hereditary Risk',
    acronym: 'HCT',
    technicalName: 'Hereditary Cancer Testing',
    phase: 'Prevention',
    color: 'sky',
    icon: '🧬',
    gridPosition: 0,
    animationOrder: 0,
    arrowDirection: 'right',
    domain: DOMAINS.ONCO,
    path: '/risk',
  },
  {
    id: 'ECD',
    name: 'Screen',
    fullName: 'Cancer Screening',
    acronym: 'ECD',
    technicalName: 'Early Cancer Detection',
    phase: 'Screening',
    color: 'emerald',
    icon: '🔬',
    gridPosition: 1,
    animationOrder: 1,
    arrowDirection: 'down',
    domain: DOMAINS.ONCO,
    path: '/screen',
  },
  {
    id: 'MRD',
    name: 'Monitor',
    fullName: 'Cancer Monitoring',
    acronym: 'MRD',
    technicalName: 'Molecular Residual Disease',
    phase: 'Surveillance',
    color: 'orange',
    icon: '🎯',
    gridPosition: 2,
    animationOrder: 2,
    arrowDirection: 'up',
    domain: DOMAINS.ONCO,
    path: '/monitor',
    // Note: MRD lifecycle stage combines MRD + TRM test categories
    includesCategories: ['MRD', 'TRM'],
  },
  {
    id: 'TDS',
    name: 'Treat',
    fullName: 'Treatment Selection',
    acronym: 'CGP',
    technicalName: 'Comprehensive Genomic Profiling',
    phase: 'Diagnosis',
    color: 'violet',
    icon: '🧬',
    gridPosition: 3,
    animationOrder: 3,
    arrowDirection: 'left',
    domain: DOMAINS.ONCO,
    path: '/treat',
  },
];

export const LIFECYCLE_STAGES_BY_GRID = [...LIFECYCLE_STAGES].sort((a, b) => a.gridPosition - b.gridPosition);

export const getStagesByDomain = (domain) => {
  return LIFECYCLE_STAGES.filter(stage => stage.domain === domain);
};

// ============================================
// Color Classes
// ============================================
export const lifecycleColorClasses = {
  emerald: {
    bg: 'bg-emerald-500',
    bgLight: 'bg-emerald-50',
    bgMedium: 'bg-emerald-100',
    border: 'border-emerald-200',
    borderActive: 'border-emerald-500',
    text: 'text-emerald-600',
    textLight: 'text-emerald-400',
    textDark: 'text-emerald-700',
  },
  violet: {
    bg: 'bg-violet-500',
    bgLight: 'bg-violet-50',
    bgMedium: 'bg-violet-100',
    border: 'border-violet-200',
    borderActive: 'border-violet-500',
    text: 'text-violet-600',
    textLight: 'text-violet-400',
    textDark: 'text-violet-700',
  },
  sky: {
    bg: 'bg-sky-500',
    bgLight: 'bg-sky-50',
    bgMedium: 'bg-sky-100',
    border: 'border-sky-200',
    borderActive: 'border-sky-500',
    text: 'text-sky-600',
    textLight: 'text-sky-400',
    textDark: 'text-sky-700',
  },
  orange: {
    bg: 'bg-orange-500',
    bgLight: 'bg-orange-50',
    bgMedium: 'bg-orange-100',
    border: 'border-orange-200',
    borderActive: 'border-orange-500',
    text: 'text-orange-600',
    textLight: 'text-orange-400',
    textDark: 'text-orange-700',
  },
  indigo: {
    bg: 'bg-indigo-500',
    bgLight: 'bg-indigo-50',
    bgMedium: 'bg-indigo-100',
    border: 'border-indigo-200',
    borderActive: 'border-indigo-500',
    text: 'text-indigo-600',
    textLight: 'text-indigo-400',
    textDark: 'text-indigo-700',
  },
};

// ============================================
// Product Types
// ============================================
export const PRODUCT_TYPES = {
  SELF_COLLECTION: {
    id: 'Self-Collection',
    label: 'Self-Collection',
    icon: '🏠',
    description: 'Patient collects sample at home',
    bgColor: 'bg-teal-50',
    textColor: 'text-teal-700',
    borderColor: 'border-teal-200',
  },
  LAB_KIT: {
    id: 'Laboratory IVD Kit',
    label: 'Lab Kit',
    icon: '🔬',
    description: 'IVD kit run at CLIA-certified lab',
    bgColor: 'bg-indigo-50',
    textColor: 'text-indigo-700',
    borderColor: 'border-indigo-200',
  },
  CENTRAL_LAB: {
    id: 'Central Lab Service',
    label: 'Service',
    icon: '🏥',
    description: 'Sample shipped to central laboratory',
    bgColor: 'bg-slate-50',
    textColor: 'text-slate-600',
    borderColor: 'border-slate-200',
  },
};

export const getProductTypeConfig = (productType) => {
  if (!productType) return PRODUCT_TYPES.CENTRAL_LAB;
  return Object.values(PRODUCT_TYPES).find(pt => pt.id === productType) || PRODUCT_TYPES.CENTRAL_LAB;
};

// ============================================
// Category Metadata
// ============================================
export const createCategoryMeta = (buildInfoSources = {}) => ({
  MRD: {
    title: 'Molecular Residual Disease',
    shortTitle: 'MRD Testing',
    description: 'Molecular Residual Disease (MRD) testing detects tiny amounts of cancer that remain in the body after treatment, often before any symptoms or imaging findings appear. These tests analyze circulating tumor DNA (ctDNA) from a blood sample to identify whether cancer cells persist at the molecular level. MRD results help oncologists make critical decisions about whether additional treatment is needed, assess the effectiveness of therapy, and monitor for early signs of recurrence during surveillance.',
    patientTitle: 'Tests After Treatment',
    patientDescription: 'These blood tests check if any cancer cells remain after surgery or treatment. Finding leftover cancer early can help your doctor decide if you need more treatment.',
    color: 'orange',
    tests: mrdTestData,
    sourceUrl: buildInfoSources.MRD || '',
    domain: DOMAINS.ONCO,
  },
  ECD: {
    title: 'Early Cancer Detection',
    shortTitle: 'Early Detection',
    description: 'Early Cancer Detection (ECD) tests screen for cancer in people who have no symptoms, with the goal of catching the disease at its earliest and most treatable stages. These tests look for cancer signals in blood or stool samples using various biomarkers including ctDNA methylation patterns, tumor-derived proteins, genetic mutations, and stool DNA markers. Some tests screen for a single cancer type (like colorectal), while multi-cancer early detection (MCED) tests can screen for dozens of cancer types simultaneously.',
    patientTitle: 'Cancer Screening Tests',
    patientDescription: 'These tests look for signs of cancer before you have any symptoms using a blood draw or stool sample. Finding cancer early, when it\'s easiest to treat, can save lives.',
    color: 'green',
    tests: ecdTestData,
    sourceUrl: buildInfoSources.ECD || '',
    domain: DOMAINS.ONCO,
  },
  TRM: {
    title: 'Treatment Response Monitoring',
    shortTitle: 'Response Monitoring',
    description: 'Treatment Response Monitoring (TRM) tests track how well a cancer treatment is working by measuring changes in circulating tumor DNA (ctDNA) levels over time. A decrease in ctDNA often indicates the treatment is effective, while stable or rising levels may signal resistance or progression—sometimes weeks before changes appear on imaging scans. This sensitive molecular monitoring helps oncologists optimize therapy for most favorable outcomes, potentially switching ineffective treatments earlier and sparing patients unnecessary toxicity.',
    patientTitle: 'Is My Treatment Working?',
    patientDescription: 'These blood tests track whether your cancer treatment is working. They can show results weeks before a scan, helping your doctor adjust treatment if needed.',
    color: 'red',
    tests: trmTestData,
    sourceUrl: buildInfoSources.TRM || '',
    domain: DOMAINS.ONCO,
  },
  TDS: {
    title: 'Treatment Decision Support',
    shortTitle: 'Treatment Decisions',
    description: 'Treatment Decision Support (TDS) tests help guide clinical decisions about cancer treatment. This includes Comprehensive Genomic Profiling (CGP) tests that analyze tumor DNA/RNA to identify targetable mutations and match patients to therapies, as well as risk stratification tests that help determine whether interventions like biopsies are needed. These tests support personalized treatment decisions based on molecular and protein biomarker analysis.',
    patientTitle: 'Find My Best Treatment',
    patientDescription: 'These tests help your doctor decide the best treatment approach for you. They can analyze your tumor\'s characteristics to find specific treatments that may work best, or help determine if procedures like biopsies are necessary.',
    color: 'violet',
    tests: tdsTestData,
    sourceUrl: buildInfoSources.TDS || '',
    domain: DOMAINS.ONCO,
  },
  // CGP - Alias for TDS (Comprehensive Genomic Profiling is the new primary name)
  CGP: {
    title: 'Comprehensive Genomic Profiling',
    shortTitle: 'CGP Tests',
    description: 'Comprehensive Genomic Profiling (CGP) tests analyze tumor DNA and RNA to identify actionable mutations, guide treatment selection, and match patients to targeted therapies and clinical trials. These tests sequence hundreds of cancer-related genes to find alterations that can be targeted with FDA-approved drugs or emerging treatments.',
    patientTitle: 'Find My Best Treatment',
    patientDescription: 'These tests analyze your tumor to find genetic changes that can help your doctor choose the most effective treatment for you.',
    color: 'violet',
    tests: tdsTestData,  // Uses same data as TDS for now
    sourceUrl: buildInfoSources.TDS || '',
    domain: DOMAINS.ONCO,
  },
  // HCT - Hereditary Cancer Testing (new category, empty for now)
  HCT: {
    title: 'Hereditary Cancer Testing',
    shortTitle: 'Hereditary Risk',
    description: 'Hereditary Cancer Testing identifies inherited gene mutations that increase cancer risk. These tests help identify individuals who may benefit from enhanced screening, risk-reducing interventions, or cascade testing of family members.',
    patientTitle: 'Understand Your Cancer Risk',
    patientDescription: 'These tests look for inherited gene changes that may increase your risk of developing certain cancers, helping you and your family make informed decisions about screening and prevention.',
    color: 'purple',
    tests: [],  // Empty for now, will be populated later
    sourceUrl: '',
    domain: DOMAINS.ONCO,
  },
});

export const getTestListByCategory = (categoryId) => {
  const categoryMap = {
    MRD: mrdTestData,
    ECD: ecdTestData,
    TRM: trmTestData,
    TDS: tdsTestData,
    CGP: tdsTestData,  // CGP uses same data as TDS
    HCT: [],           // Hereditary cancer testing - empty for now
  };
  return categoryMap[categoryId] || [];
};

// ============================================
// Filter Configurations
// ============================================
// NOTE: Filter matching should use prefix/contains logic, not exact matching.
// Many fdaStatus and reimbursement values are verbose sentences. The filter
// options below represent categories that should match via prefix/contains:
//   - "CLIA LDT" matches "CLIA LDT - not FDA approved", "CLIA LDT – NOT FDA approved", etc.
//   - "Medicare" matches "Medicare (CRC only)", "Medicare LCD", "Medicare covered", etc.
//   - "FDA Approved" matches "FDA-approved", "FDA PMA-approved", "FDA De Novo cleared", etc.
// Future enhancement: Split into normalized category fields (e.g., fdaStatusCategory) 
// plus free-text notes fields (e.g., fdaStatusNotes) for cleaner filtering.
export const filterConfigs = {
  MRD: {
    productTypes: ['Central Lab Service', 'Laboratory IVD Kit'],
    cancerTypes: [...new Set(mrdTestData.flatMap(t => t.cancerTypes || []))].sort(),
    sampleCategories: [...new Set(mrdTestData.map(t => t.sampleCategory || 'Blood/Plasma'))].sort(),
    fdaStatuses: ['FDA Approved', 'FDA Cleared', 'FDA Breakthrough', 'CLIA LDT', 'CE-IVD', 'RUO', 'Investigational'],
    reimbursements: ['Medicare', 'Commercial', 'Coverage Varies', 'Coverage emerging', 'Not established'],
    approaches: ['Tumor-informed', 'Tumor-naïve'],
    regions: ['US', 'EU', 'UK', 'International', 'RUO'],
    clinicalSettings: ['Neoadjuvant', 'Post-Surgery', 'Post-Adjuvant', 'Surveillance'],
  },
  ECD: {
    productTypes: ['Central Lab Service', 'Laboratory IVD Kit', 'Self-Collection'],
    testScopes: ['Single-cancer', 'Multi-cancer'],  // Matches prefix of actual testScope values
    indicationGroups: [...new Set(ecdTestData.map(t => t.indicationGroup).filter(Boolean))].sort(),
    sampleCategories: ['Blood/Plasma', 'Saliva', 'Stool'],
    fdaStatuses: ['FDA Approved', 'FDA Cleared', 'FDA Breakthrough', 'CLIA LDT', 'CE-IVD', 'RUO', 'Investigational', 'PMA submitted'],
    reimbursements: ['Medicare', 'Commercial', 'Coverage Varies', 'Coverage emerging', 'Self-Pay', 'Not established'],
    approaches: ['Blood-based cfDNA screening (plasma)', 'Blood-based cfDNA methylation MCED (plasma)', 'Stool DNA + FIT'],
    regions: ['US', 'EU', 'UK', 'International', 'RUO'],
  },
  TRM: {
    productTypes: ['Central Lab Service', 'Laboratory IVD Kit'],
    cancerTypes: [...new Set(trmTestData.flatMap(t => t.cancerTypes || []))].sort(),
    sampleCategories: ['Blood/Plasma'],
    fdaStatuses: ['FDA Approved', 'FDA Cleared', 'FDA Breakthrough', 'CLIA LDT', 'CE-IVD', 'RUO', 'Investigational'],
    approaches: ['Tumor-informed', 'Tumor-naïve', 'Tumor-agnostic'],
    reimbursements: ['Medicare', 'Commercial', 'Coverage Varies', 'Coverage emerging', 'Not established'],
    regions: ['US', 'EU', 'UK', 'International', 'RUO'],
  },
  TDS: {
    productTypes: ['Central Lab Service', 'Laboratory IVD Kit'],
    cancerTypes: [...new Set(tdsTestData.flatMap(t => t.cancerTypes || []))].sort(),
    sampleCategories: [...new Set(tdsTestData.map(t => t.sampleCategory || 'Unknown'))].sort(),
    approaches: [...new Set(tdsTestData.map(t => t.approach || 'Unknown'))].sort(),
    fdaStatuses: ['FDA Approved', 'FDA Cleared', 'FDA Breakthrough', 'CLIA LDT', 'CE-IVD', 'NMPA', 'RUO'],
    reimbursements: ['Medicare', 'Commercial', 'Coverage Varies', 'Coverage emerging', 'Not established'],
  },
  // CGP - Uses same filter config as TDS (same data source)
  CGP: {
    productTypes: ['Central Lab Service', 'Laboratory IVD Kit'],
    cancerTypes: [...new Set(tdsTestData.flatMap(t => t.cancerTypes || []))].sort(),
    sampleCategories: [...new Set(tdsTestData.map(t => t.sampleCategory || 'Unknown'))].sort(),
    approaches: [...new Set(tdsTestData.map(t => t.approach || 'Unknown'))].sort(),
    fdaStatuses: ['FDA Approved', 'FDA Cleared', 'FDA Breakthrough', 'CLIA LDT', 'CE-IVD', 'NMPA', 'RUO'],
    reimbursements: ['Medicare', 'Commercial', 'Coverage Varies', 'Coverage emerging', 'Not established'],
  },
  // HCT - Hereditary Cancer Testing (empty for now)
  HCT: {
    productTypes: [],
    cancerTypes: [],
    sampleCategories: [],
    approaches: [],
    fdaStatuses: [],
    reimbursements: [],
  },
};

// ============================================
// Comparison Parameters
// ============================================
export const comparisonParams = {
  MRD: [
    { key: 'productType', label: 'Product Type' },
    { key: 'platformRequired', label: 'Platform Required' },
    { key: 'approach', label: 'Approach' },
    { key: 'method', label: 'Method' },
    { key: 'sampleCategory', label: 'Sample Type' },
    { key: 'cancerTypesStr', label: 'Cancer Types' },
    { key: 'clinicalSettingsStr', label: 'Clinical Settings' },
    { key: 'sensitivity', label: 'Reported Sensitivity (%)' },
    { key: 'sensitivityStagesReported', label: 'Stages in Headline' },
    { key: 'stageIISensitivity', label: 'Stage II Sensitivity (%)' },
    { key: 'stageIIISensitivity', label: 'Stage III Sensitivity (%)' },
    { key: 'landmarkSensitivity', label: 'Post-Surgery Sensitivity (%)' },
    { key: 'longitudinalSensitivity', label: 'Surveillance Sensitivity (%)' },
    { key: 'specificity', label: 'Reported Specificity (%)' },
    { key: 'analyticalSpecificity', label: 'Analytical Specificity (%)' },
    { key: 'clinicalSpecificity', label: 'Clinical Specificity (%)' },
    { key: 'lod', label: 'LOD (detection)' },
    { key: 'lod95', label: 'LOD95 (95% conf)' },
    { key: 'variantsTracked', label: 'Variants Tracked' },
    { key: 'sampleVolumeMl', label: 'Sample Volume (mL)' },
    { key: 'sampleTubeType', label: 'Collection Tube' },
    { key: 'sampleTubeCount', label: 'Tubes Required' },
    { key: 'cfdnaInput', label: 'cfDNA Input (ng)' },
    { key: 'initialTat', label: 'Initial TAT (days)' },
    { key: 'followUpTat', label: 'Follow-up TAT (days)' },
    { key: 'totalParticipants', label: 'Trial Participants' },
    { key: 'numPublications', label: 'Publications' },
    { key: 'fdaStatus', label: 'Regulatory' },
    { key: 'reimbursement', label: 'Medicare' },
    { key: 'commercialPayersStr', label: 'Private Insurance' },
    { key: 'availableRegionsStr', label: 'Availability' },
  ],
  ECD: [
    { key: 'productType', label: 'Product Type' },
    { key: 'platformRequired', label: 'Platform Required' },
    { key: 'testScope', label: 'Scope' },
    { key: 'approach', label: 'Approach' },
    { key: 'method', label: 'Method' },
    { key: 'sampleCategory', label: 'Sample Type' },
    { key: 'cancerTypesStr', label: 'Target Cancers' },
    { key: 'targetPopulation', label: 'Population' },
    { key: 'sensitivity', label: 'Reported Sensitivity (%)' },
    { key: 'stageISensitivity', label: 'Stage I Sens (%)' },
    { key: 'stageIISensitivity', label: 'Stage II Sens (%)' },
    { key: 'stageIIISensitivity', label: 'Stage III Sens (%)' },
    { key: 'stageIVSensitivity', label: 'Stage IV Sens (%)' },
    { key: 'specificity', label: 'Reported Specificity (%)' },
    { key: 'ppv', label: 'PPV (%)' },
    { key: 'npv', label: 'NPV (%)' },
    { key: 'tumorOriginAccuracy', label: 'Origin Prediction (%)' },
    { key: 'leadTimeNotes', label: 'Lead Time vs Screening' },
    { key: 'totalParticipants', label: 'Trial Participants' },
    { key: 'numPublications', label: 'Publications' },
    { key: 'fdaStatus', label: 'Regulatory' },
    { key: 'reimbursement', label: 'Medicare' },
    { key: 'commercialPayersStr', label: 'Private Insurance' },
    { key: 'availableRegionsStr', label: 'Availability' },
    { key: 'clinicalAvailability', label: 'Clinical Availability' },
    { key: 'tat', label: 'Turnaround Time' },
    { key: 'sampleType', label: 'Sample Details' },
    { key: 'listPrice', label: 'List Price (USD)' },
    { key: 'screeningInterval', label: 'Screening Interval' },
    { key: 'cptCode', label: 'CPT Code' },
    { key: 'performanceCitations', label: 'Citations' },
    { key: 'performanceNotes', label: 'Performance Notes' },
  ],
  TRM: [
    { key: 'productType', label: 'Product Type' },
    { key: 'platformRequired', label: 'Platform Required' },
    { key: 'approach', label: 'Approach' },
    { key: 'method', label: 'Method' },
    { key: 'sampleCategory', label: 'Sample Type' },
    { key: 'cancerTypesStr', label: 'Target Cancers' },
    { key: 'targetPopulation', label: 'Population' },
    { key: 'responseDefinition', label: 'Response Definition' },
    { key: 'leadTimeVsImaging', label: 'Lead Time (days)' },
    { key: 'lod', label: 'LOD (detection)' },
    { key: 'lod95', label: 'LOD95 (95% conf)' },
    { key: 'sensitivity', label: 'Reported Sensitivity (%)' },
    { key: 'specificity', label: 'Reported Specificity (%)' },
    { key: 'totalParticipants', label: 'Trial Participants' },
    { key: 'numPublications', label: 'Publications' },
    { key: 'fdaStatus', label: 'Regulatory' },
    { key: 'reimbursement', label: 'Medicare' },
    { key: 'commercialPayersStr', label: 'Private Insurance' },
    { key: 'availableRegionsStr', label: 'Availability' },
  ],
  TDS: [
    { key: 'productType', label: 'Product Type' },
    { key: 'platformRequired', label: 'Platform Required' },
    { key: 'approach', label: 'Approach' },
    { key: 'method', label: 'Method' },
    { key: 'sampleCategory', label: 'Sample Type' },
    { key: 'genesAnalyzed', label: 'Genes Analyzed' },
    { key: 'biomarkersReportedStr', label: 'Biomarkers Reported' },
    { key: 'cancerTypesStr', label: 'Target Cancers' },
    { key: 'targetPopulation', label: 'Population' },
    { key: 'fdaCompanionDxCount', label: 'FDA CDx Indications' },
    { key: 'nccnRecommended', label: 'NCCN Recommended' },
    { key: 'tat', label: 'Turnaround Time' },
    { key: 'sampleRequirements', label: 'Sample Requirements' },
    { key: 'numPublications', label: 'Publications' },
    { key: 'fdaStatus', label: 'Regulatory' },
    { key: 'reimbursement', label: 'Medicare' },
    { key: 'listPrice', label: 'List Price (USD)' },
  ],
  // CGP - Uses same comparison params as TDS
  CGP: [
    { key: 'productType', label: 'Product Type' },
    { key: 'platformRequired', label: 'Platform Required' },
    { key: 'approach', label: 'Approach' },
    { key: 'method', label: 'Method' },
    { key: 'sampleCategory', label: 'Sample Type' },
    { key: 'genesAnalyzed', label: 'Genes Analyzed' },
    { key: 'biomarkersReportedStr', label: 'Biomarkers Reported' },
    { key: 'cancerTypesStr', label: 'Target Cancers' },
    { key: 'targetPopulation', label: 'Population' },
    { key: 'fdaCompanionDxCount', label: 'FDA CDx Indications' },
    { key: 'nccnRecommended', label: 'NCCN Recommended' },
    { key: 'tat', label: 'Turnaround Time' },
    { key: 'sampleRequirements', label: 'Sample Requirements' },
    { key: 'numPublications', label: 'Publications' },
    { key: 'fdaStatus', label: 'Regulatory' },
    { key: 'reimbursement', label: 'Medicare' },
    { key: 'listPrice', label: 'List Price (USD)' },
  ],
  // HCT - Hereditary Cancer Testing params (placeholder)
  HCT: [
    { key: 'productType', label: 'Product Type' },
    { key: 'sampleCategory', label: 'Sample Type' },
    { key: 'genesAnalyzed', label: 'Genes Analyzed' },
    { key: 'tat', label: 'Turnaround Time' },
    { key: 'fdaStatus', label: 'Regulatory' },
    { key: 'listPrice', label: 'List Price (USD)' },
  ],
};

// ============================================
// External Resources & Interlinking
// ============================================
// Authoritative external resources for each category
// Used for category page resource sections and glossary tooltips

export const STANDARDS_BODIES = {
  BLOODPAC: {
    name: 'Blood Profiling Atlas in Cancer (BLOODPAC)',
    shortName: 'BLOODPAC',
    description: 'Cancer Moonshot consortium focused on liquid biopsy standards and data sharing',
    url: 'https://www.bloodpac.org',
    logo: null
  },
  FRIENDS: {
    name: 'Friends of Cancer Research',
    shortName: 'Friends of Cancer Research',
    description: 'Non-profit advancing regulatory science and patient-focused drug development',
    url: 'https://friendsofcancerresearch.org',
    logo: null
  },
  NCI: {
    name: 'National Cancer Institute',
    shortName: 'NCI',
    description: 'U.S. federal government\'s principal agency for cancer research',
    url: 'https://www.cancer.gov',
    logo: null
  },
  FDA: {
    name: 'U.S. Food and Drug Administration',
    shortName: 'FDA',
    description: 'Federal agency responsible for protecting public health through regulation of medical devices',
    url: 'https://www.fda.gov',
    logo: null
  },
  NCCN: {
    name: 'National Comprehensive Cancer Network',
    shortName: 'NCCN',
    description: 'Alliance of cancer centers developing clinical practice guidelines',
    url: 'https://www.nccn.org',
    logo: null
  },
  LUNGEVITY: {
    name: 'LUNGevity Foundation',
    shortName: 'LUNGevity',
    description: 'Lung cancer patient advocacy and research organization',
    url: 'https://www.lungevity.org',
    logo: null
  },
  ILSA: {
    name: 'International Liquid Biopsy Standardization Alliance',
    shortName: 'ILSA',
    description: 'FNIH-hosted global alliance for liquid biopsy standardization',
    url: 'https://fnih.org/our-programs/international-liquid-biopsy-standardization-alliance-ilsa/',
    logo: null
  },
  ASCO: {
    name: 'American Society of Clinical Oncology',
    shortName: 'ASCO',
    description: 'Professional organization for physicians and oncology professionals',
    url: 'https://www.asco.org',
    logo: null
  }
};

export const EXTERNAL_RESOURCES = {
  // General resources applicable across categories
  general: [
    {
      id: 'nci-liquid-biopsy',
      title: 'What Is a Liquid Biopsy?',
      source: 'NCI',
      type: 'definition',
      audience: ['patient', 'clinician'],
      url: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy',
      description: 'Patient-friendly definition of liquid biopsy from the National Cancer Institute'
    },
    {
      id: 'nci-ctdna',
      title: 'Circulating Tumor DNA (ctDNA)',
      source: 'NCI',
      type: 'definition',
      audience: ['patient', 'clinician'],
      url: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ctdna',
      description: 'NCI dictionary definition of ctDNA'
    },
    {
      id: 'nci-liquid-biopsy-blog',
      title: 'Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer',
      source: 'NCI',
      type: 'overview',
      audience: ['patient'],
      url: 'https://www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer',
      description: 'Comprehensive overview of liquid biopsy applications in cancer care'
    },
    {
      id: 'ilsa-overview',
      title: 'International Liquid Biopsy Standardization Alliance',
      source: 'ILSA',
      type: 'standards',
      audience: ['clinician', 'researcher'],
      url: 'https://fnih.org/our-programs/international-liquid-biopsy-standardization-alliance-ilsa/',
      description: 'Global effort to standardize liquid biopsy testing and reporting'
    }
  ],
  
  // MRD-specific resources
  MRD: [
    {
      id: 'bloodpac-mrd-lexicon',
      title: 'BLOODPAC MRD Terminology Lexicon',
      source: 'BLOODPAC',
      type: 'standards',
      audience: ['clinician', 'researcher'],
      url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
      description: 'Standardized terminology for MRD testing including tumor-informed, tumor-naïve, and molecular response definitions',
      isPrimary: true
    },
    {
      id: 'fda-ctdna-guidance',
      title: 'FDA Guidance: Use of ctDNA in Early-Stage Solid Tumors',
      source: 'FDA',
      type: 'regulatory',
      audience: ['clinician', 'researcher'],
      url: 'https://www.fda.gov/media/183874/download',
      description: 'December 2024 FDA guidance on ctDNA for patient enrichment and response endpoints',
      isPrimary: true
    },
    {
      id: 'friends-ctdna',
      title: 'ctDNA as a Clinical Endpoint',
      source: 'FRIENDS',
      type: 'research',
      audience: ['clinician', 'researcher'],
      url: 'https://friendsofcancerresearch.org/ctdna/',
      description: 'ctMoniTR project validating ctDNA as an early efficacy endpoint'
    },
    {
      id: 'friends-ctdna-definition',
      title: 'Circulating Tumor DNA Definition',
      source: 'FRIENDS',
      type: 'definition',
      audience: ['clinician'],
      url: 'https://friendsofcancerresearch.org/glossary-term/circulating-tumor-dna-ctdna/',
      description: 'Technical definition of ctDNA from Friends of Cancer Research'
    },
    {
      id: 'bloodpac-working-groups',
      title: 'BLOODPAC Working Groups',
      source: 'BLOODPAC',
      type: 'standards',
      audience: ['researcher'],
      url: 'https://www.bloodpac.org/how-we-work',
      description: 'Overview of BLOODPAC working groups developing liquid biopsy standards'
    }
  ],
  
  // ECD-specific resources
  ECD: [
    {
      id: 'nci-lbc',
      title: 'NCI Liquid Biopsy Consortium',
      source: 'NCI',
      type: 'research',
      audience: ['clinician', 'researcher'],
      url: 'https://prevention.cancer.gov/research-areas/networks-consortia-programs/lbc',
      description: 'NCI-funded consortium focused on early cancer detection research',
      isPrimary: true
    },
    {
      id: 'nci-ctdna-sensitivity',
      title: 'Increasing ctDNA Detection in Blood',
      source: 'NCI',
      type: 'research',
      audience: ['clinician', 'researcher'],
      url: 'https://www.cancer.gov/news-events/cancer-currents-blog/2024/liquid-biopsy-increase-ctdna-in-blood',
      description: 'Research on improving liquid biopsy sensitivity for early detection'
    },
    {
      id: 'lungevity-biomarker',
      title: 'Biomarker Testing for Lung Cancer',
      source: 'LUNGEVITY',
      type: 'patient-education',
      audience: ['patient'],
      url: 'https://www.lungevity.org/patients-care-partners/navigating-your-diagnosis/biomarker-testing',
      description: 'Patient guide to understanding biomarker and liquid biopsy testing',
      isPrimary: true
    },
    {
      id: 'lungevity-booklet',
      title: 'Biomarker Testing Booklet (PDF)',
      source: 'LUNGEVITY',
      type: 'patient-education',
      audience: ['patient'],
      url: 'https://www.lungevity.org/sites/default/files/request-materials/LUNGevity-biomarker-testing-booklet-112817.pdf',
      description: 'Downloadable patient education booklet on biomarker testing'
    },
    {
      id: 'noonemissed',
      title: 'No One Missed Campaign',
      source: 'LUNGEVITY',
      type: 'patient-education',
      audience: ['patient'],
      url: 'https://noonemissed.org/lungcancer/us',
      description: 'Campaign ensuring all lung cancer patients receive biomarker testing'
    }
  ],
  
  // TRM-specific resources
  TRM: [
    {
      id: 'friends-ctmonitr',
      title: 'ctMoniTR: ctDNA Monitoring for Treatment Response',
      source: 'FRIENDS',
      type: 'research',
      audience: ['clinician', 'researcher'],
      url: 'https://friendsofcancerresearch.org/ctdna/',
      description: 'Multi-stakeholder project validating ctDNA as an early efficacy endpoint',
      isPrimary: true
    },
    {
      id: 'friends-evidentiary-roadmap',
      title: 'Evidentiary Framework for ctDNA',
      source: 'FRIENDS',
      type: 'regulatory',
      audience: ['researcher'],
      url: 'https://friendsofcancerresearch.org/wp-content/uploads/Framework-for-Integrating-Change-in-ctDNA-Levels-as-an-Efficacy-Measure-on-Oncology-Clinical-Trials.pdf',
      description: 'Framework for integrating ctDNA changes as efficacy measures in clinical trials'
    },
    {
      id: 'progress-for-patients',
      title: 'Progress for Patients',
      source: 'FRIENDS',
      type: 'patient-education',
      audience: ['patient'],
      url: 'https://progressforpatients.org',
      description: 'Patient-focused information on cancer treatment advances'
    },
    {
      id: 'fda-ctdna-trm',
      title: 'FDA Guidance: ctDNA for Treatment Response',
      source: 'FDA',
      type: 'regulatory',
      audience: ['clinician', 'researcher'],
      url: 'https://www.fda.gov/media/183874/download',
      description: 'FDA guidance on using ctDNA to measure treatment response'
    }
  ],
  
  // TDS-specific resources
  TDS: [
    {
      id: 'nccn-guidelines',
      title: 'NCCN Clinical Practice Guidelines',
      source: 'NCCN',
      type: 'guidelines',
      audience: ['clinician'],
      url: 'https://www.nccn.org/guidelines/guidelines-detail',
      description: 'Evidence-based clinical practice guidelines for oncology',
      isPrimary: true
    },
    {
      id: 'fda-cdx-list',
      title: 'FDA List of Cleared or Approved Companion Diagnostics',
      source: 'FDA',
      type: 'regulatory',
      audience: ['clinician', 'researcher'],
      url: 'https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools',
      description: 'Complete list of FDA-approved companion diagnostic devices'
    },
    {
      id: 'asco-cgp',
      title: 'Comprehensive Genomic Profiling Education',
      source: 'ASCO',
      type: 'education',
      audience: ['clinician'],
      url: 'https://ascopubs.org/doi/10.1200/EDBK-25-481114',
      description: 'ASCO educational resources on CGP testing and interpretation'
    },
    {
      id: 'lungevity-clinical-value',
      title: 'Clinical Value of Biomarker Testing',
      source: 'LUNGEVITY',
      type: 'patient-education',
      audience: ['patient'],
      url: 'https://www.lungevity.org/learn-about-lungevity/precision-medicine/clinical-value-of-biomarker-testing-in-nsclc',
      description: 'Patient guide to understanding the clinical value of biomarker testing'
    }
  ],
  
  // CGP - Uses same resources as TDS
  CGP: [
    {
      id: 'nccn-guidelines',
      title: 'NCCN Clinical Practice Guidelines',
      source: 'NCCN',
      type: 'guidelines',
      audience: ['clinician'],
      url: 'https://www.nccn.org/guidelines/guidelines-detail',
      description: 'Evidence-based clinical practice guidelines for oncology',
      isPrimary: true
    },
    {
      id: 'fda-cdx-list',
      title: 'FDA List of Cleared or Approved Companion Diagnostics',
      source: 'FDA',
      type: 'regulatory',
      audience: ['clinician', 'researcher'],
      url: 'https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools',
      description: 'Complete list of FDA-approved companion diagnostic devices'
    },
    {
      id: 'asco-cgp',
      title: 'Comprehensive Genomic Profiling Education',
      source: 'ASCO',
      type: 'education',
      audience: ['clinician'],
      url: 'https://ascopubs.org/doi/10.1200/EDBK-25-481114',
      description: 'ASCO educational resources on CGP testing and interpretation'
    }
  ],
  
  // HCT - Hereditary Cancer Testing resources (placeholder)
  HCT: []
};

// Glossary of terms with authoritative source links
export const GLOSSARY = {
  'liquid-biopsy': {
    term: 'Liquid Biopsy',
    definition: 'A test done on a sample of blood to look for cancer cells or pieces of DNA from tumor cells that are circulating in the blood.',
    shortDefinition: 'Blood test that detects cancer DNA or cells',
    sourceUrl: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy',
    source: 'NCI',
    relatedTerms: ['ctDNA', 'cfDNA', 'CTC']
  },
  'ctdna': {
    term: 'Circulating Tumor DNA (ctDNA)',
    definition: 'Small pieces of DNA that are released into the bloodstream when cancer cells die. ctDNA carries the same genetic alterations as the tumor.',
    shortDefinition: 'Tumor DNA fragments in blood',
    sourceUrl: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ctdna',
    source: 'NCI',
    relatedTerms: ['liquid-biopsy', 'cfDNA', 'VAF']
  },
  'cfdna': {
    term: 'Cell-Free DNA (cfDNA)',
    definition: 'DNA fragments circulating freely in the bloodstream, released from both normal and tumor cells. In cancer patients, a portion derives from tumor cells (ctDNA).',
    shortDefinition: 'Free-floating DNA in blood',
    sourceUrl: 'https://friendsofcancerresearch.org/glossary-term/circulating-tumor-dna-ctdna/',
    source: 'Friends of Cancer Research',
    relatedTerms: ['ctDNA', 'liquid-biopsy']
  },
  'mrd': {
    term: 'Molecular Residual Disease (MRD)',
    definition: 'Cancer that remains after treatment at levels too low to detect with standard imaging or laboratory tests, but detectable through sensitive molecular methods.',
    shortDefinition: 'Remaining cancer detected by molecular tests',
    sourceUrl: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
    source: 'BLOODPAC',
    relatedTerms: ['tumor-informed', 'tumor-naive', 'ctDNA']
  },
  'tumor-informed': {
    term: 'Tumor-Informed Assay',
    definition: 'An MRD testing approach that first sequences the patient\'s tumor to identify specific mutations, then designs a personalized test to track those mutations in blood.',
    shortDefinition: 'Personalized test based on tumor sequencing',
    sourceUrl: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
    source: 'BLOODPAC',
    relatedTerms: ['mrd', 'tumor-naive']
  },
  'tumor-naive': {
    term: 'Tumor-Naïve Assay',
    definition: 'An MRD testing approach that uses a fixed panel of common cancer genes without requiring prior tumor sequencing. Faster turnaround but generally less sensitive than tumor-informed approaches.',
    shortDefinition: 'Fixed panel test without prior tumor analysis',
    sourceUrl: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
    source: 'BLOODPAC',
    relatedTerms: ['mrd', 'tumor-informed']
  },
  'vaf': {
    term: 'Variant Allele Frequency (VAF)',
    definition: 'The percentage of sequencing reads containing a specific mutation. In ctDNA testing, VAF reflects the proportion of mutant DNA fragments in the sample.',
    shortDefinition: 'Percentage of DNA with a specific mutation',
    sourceUrl: 'https://friendsofcancerresearch.org/glossary-term/circulating-tumor-dna-ctdna/',
    source: 'Friends of Cancer Research',
    relatedTerms: ['ctDNA', 'lod']
  },
  'lod': {
    term: 'Limit of Detection (LOD)',
    definition: 'The lowest concentration of ctDNA that can be reliably detected by a test. Often expressed as VAF (e.g., 0.01%) or parts per million (ppm).',
    shortDefinition: 'Lowest detectable ctDNA level',
    sourceUrl: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
    source: 'BLOODPAC',
    relatedTerms: ['vaf', 'sensitivity']
  },
  'sensitivity': {
    term: 'Sensitivity',
    definition: 'The ability of a test to correctly identify patients who have the condition (true positive rate). A test with 90% sensitivity will detect 90 out of 100 patients with cancer.',
    shortDefinition: 'Ability to detect true positives',
    sourceUrl: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/sensitivity',
    source: 'NCI',
    relatedTerms: ['specificity', 'ppv', 'npv']
  },
  'specificity': {
    term: 'Specificity',
    definition: 'The ability of a test to correctly identify patients who do not have the condition (true negative rate). A test with 99% specificity will correctly rule out 99 of 100 patients without cancer.',
    shortDefinition: 'Ability to avoid false positives',
    sourceUrl: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/specificity',
    source: 'NCI',
    relatedTerms: ['sensitivity', 'ppv', 'npv']
  },
  'ngs': {
    term: 'Next-Generation Sequencing (NGS)',
    definition: 'High-throughput DNA sequencing technology that can analyze millions of DNA fragments simultaneously, enabling comprehensive genomic profiling.',
    shortDefinition: 'High-throughput DNA sequencing',
    sourceUrl: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/next-generation-sequencing',
    source: 'NCI',
    relatedTerms: ['cgp', 'ctDNA']
  },
  'cgp': {
    term: 'Comprehensive Genomic Profiling (CGP)',
    definition: 'A type of NGS test that analyzes hundreds of genes simultaneously to identify mutations, fusions, and other alterations that may guide treatment decisions.',
    shortDefinition: 'Broad cancer gene panel test',
    sourceUrl: 'https://ascopubs.org/doi/10.1200/EDBK-25-481114',
    source: 'ASCO',
    relatedTerms: ['ngs', 'companion-dx']
  },
  'companion-dx': {
    term: 'Companion Diagnostic (CDx)',
    definition: 'An FDA-approved test that is essential for the safe and effective use of a corresponding drug or biological product, typically identifying patients likely to benefit from a specific therapy.',
    shortDefinition: 'Test linked to specific drug approval',
    sourceUrl: 'https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics',
    source: 'FDA',
    relatedTerms: ['cgp', 'targeted-therapy']
  },
  'methylation': {
    term: 'DNA Methylation',
    definition: 'A chemical modification of DNA that can affect gene expression. Cancer-specific methylation patterns in cfDNA are used by some early detection tests to identify cancer signals.',
    shortDefinition: 'Chemical DNA modification used in cancer detection',
    sourceUrl: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/dna-methylation',
    source: 'NCI',
    relatedTerms: ['cfDNA', 'ecd']
  },
  'chip': {
    term: 'Clonal Hematopoiesis of Indeterminate Potential (CHIP)',
    definition: 'Age-related mutations in blood cells that can be confused with tumor-derived mutations in liquid biopsy tests. Advanced assays use various methods to filter out CHIP.',
    shortDefinition: 'Age-related blood cell mutations that can confound testing',
    sourceUrl: 'https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chip',
    source: 'NCI',
    relatedTerms: ['ctDNA', 'cfDNA']
  },
  'nccn': {
    term: 'National Comprehensive Cancer Network (NCCN)',
    definition: 'An alliance of leading cancer centers that develops clinical practice guidelines used by oncologists worldwide. NCCN guidelines recommend specific biomarkers to test for, though they do not endorse specific commercial assays.',
    shortDefinition: 'Alliance developing cancer treatment guidelines',
    sourceUrl: 'https://www.nccn.org/guidelines/guidelines-detail',
    source: 'NCCN',
    relatedTerms: ['companion-dx', 'cgp']
  },
  'fda-approved': {
    term: 'FDA Approved/Cleared',
    definition: 'Tests that have been reviewed by the FDA and meet analytical and clinical validation requirements. FDA-approved companion diagnostics (CDx) are linked to specific drug therapies.',
    shortDefinition: 'Test reviewed and authorized by FDA',
    sourceUrl: 'https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics',
    source: 'FDA',
    relatedTerms: ['companion-dx', 'ldt']
  },
  'ldt': {
    term: 'Laboratory Developed Test (LDT)',
    definition: 'A test developed and validated by an individual CLIA-certified laboratory rather than a commercial manufacturer. LDTs must meet CLIA quality standards but have not undergone FDA premarket review.',
    shortDefinition: 'Test developed by individual lab, not FDA-reviewed',
    sourceUrl: 'https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests',
    source: 'FDA',
    relatedTerms: ['fda-approved']
  },
  'ctdna-clearance': {
    term: 'ctDNA Clearance',
    definition: 'The transition from detectable to undetectable ctDNA levels, typically measured after treatment. Per BLOODPAC: clearance indicates molecular response but does not guarantee absence of disease.',
    shortDefinition: 'Transition from detectable to undetectable ctDNA',
    sourceUrl: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
    source: 'BLOODPAC',
    relatedTerms: ['mrd', 'molecular-response']
  },
  'molecular-response': {
    term: 'Molecular Response',
    definition: 'A measurable change in ctDNA levels following treatment. Per BLOODPAC MRD Lexicon: can be quantified as fold-change, percent reduction, or transition between detectable/undetectable states.',
    shortDefinition: 'Measurable ctDNA change after treatment',
    sourceUrl: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
    source: 'BLOODPAC',
    relatedTerms: ['ctdna-clearance', 'mrd']
  },
  'bloodpac': {
    term: 'BLOODPAC (Blood Profiling Atlas in Cancer)',
    definition: 'A Cancer Moonshot consortium of 30+ organizations developing standards for liquid biopsy testing. Published the MRD Terminology Lexicon in 2025 to standardize definitions across the field.',
    shortDefinition: 'Consortium developing liquid biopsy standards',
    sourceUrl: 'https://www.bloodpac.org',
    source: 'BLOODPAC',
    relatedTerms: ['mrd', 'ctDNA', 'liquid-biopsy']
  }
};

// Category-specific standards attribution for display
export const CATEGORY_STANDARDS = {
  MRD: {
    primary: 'BLOODPAC MRD Lexicon',
    primaryUrl: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11897061/',
    secondary: 'FDA ctDNA Guidance (Dec 2024)',
    secondaryUrl: 'https://www.fda.gov/media/183874/download',
    attribution: 'Terminology aligned with BLOODPAC Consortium MRD Lexicon'
  },
  ECD: {
    primary: 'NCI Liquid Biopsy Consortium',
    primaryUrl: 'https://prevention.cancer.gov/research-areas/networks-consortia-programs/lbc',
    secondary: 'LUNGevity Foundation',
    secondaryUrl: 'https://www.lungevity.org/patients-care-partners/navigating-your-diagnosis/biomarker-testing',
    attribution: 'Patient resources from LUNGevity Foundation'
  },
  TRM: {
    primary: 'Friends of Cancer Research ctMoniTR',
    primaryUrl: 'https://friendsofcancerresearch.org/ctdna/',
    secondary: 'FDA ctDNA Guidance',
    secondaryUrl: 'https://www.fda.gov/media/183874/download',
    attribution: 'Endpoint validation research from Friends of Cancer Research'
  },
  TDS: {
    primary: 'NCCN Clinical Practice Guidelines',
    primaryUrl: 'https://www.nccn.org/guidelines/guidelines-detail',
    secondary: 'FDA Companion Diagnostics',
    secondaryUrl: 'https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics',
    attribution: 'NCCN guideline-referenced'
  }
};

// ============================================
// SEO Configuration
// ============================================
export const SEO_DEFAULTS = {
  siteName: 'OpenOnco',
  siteUrl: 'https://openonco.org',
  defaultDescription: 'Compare cancer diagnostic tests side-by-side. Independent, transparent data on MRD, early detection, and treatment monitoring tests.',
  defaultImage: 'https://openonco.org/og-image.png',
};

export const PAGE_SEO = {
  home: {
    title: 'Compare Cancer Diagnostic Tests',
    description: 'Independent database comparing 60+ cancer blood tests. MRD, early detection, treatment monitoring - all specs side-by-side.',
    path: '/'
  },
  competitions: {
    title: 'OpenOnco Competitions - Data Completeness Rankings',
    description: 'Vendor data completeness rankings and recognition. See which cancer diagnostic tests have complete, transparent data.',
    path: '/competitions'
  },
  // Primary categories with new plain-language URLs
  MRD: {
    title: 'Cancer Monitoring Tests - MRD & Recurrence Detection',
    description: 'Compare 20+ MRD tests: Signatera, Guardant Reveal, clonoSEQ, Oncodetect. Sensitivity, turnaround time, Medicare coverage.',
    path: '/monitor'
  },
  ECD: {
    title: 'Cancer Screening Tests - Early Detection',
    description: 'Compare early cancer detection tests: Galleri, Shield, CancerSEEK. Multi-cancer screening sensitivity and specificity data.',
    path: '/screen'
  },
  CGP: {
    title: 'Treatment Selection Tests - CGP & Genomic Profiling',
    description: 'Compare comprehensive genomic profiling tests: FoundationOne, Tempus xT, Guardant360. Genes analyzed, FDA companion diagnostics.',
    path: '/treat'
  },
  HCT: {
    title: 'Hereditary Cancer Tests - Genetic Risk Assessment',
    description: 'Compare hereditary cancer risk tests. BRCA, Lynch syndrome, and multi-gene panel testing for inherited cancer predisposition.',
    path: '/risk'
  },
  // Legacy category aliases (backward compatibility)
  TRM: {
    title: 'Cancer Monitoring Tests - MRD & Recurrence Detection',
    description: 'Compare ctDNA tests for tracking cancer treatment response. Lead time vs imaging, sensitivity, clinical validation.',
    path: '/monitor'
  },
  TDS: {
    title: 'Treatment Selection Tests - CGP & Genomic Profiling',
    description: 'Compare comprehensive genomic profiling tests: FoundationOne, Tempus xT, Guardant360. Genes analyzed, FDA companion diagnostics.',
    path: '/treat'
  },
  learn: {
    title: 'Learn About Cancer Blood Tests',
    description: 'Educational guides on liquid biopsy, MRD testing, early cancer detection, and how to interpret test results.',
    path: '/learn'
  },
  about: {
    title: 'About OpenOnco',
    description: 'OpenOnco is a non-profit cancer diagnostic test database built in memory of Ingrid. Our mission is transparent, independent test comparison.',
    path: '/about'
  },
  faq: {
    title: 'Frequently Asked Questions',
    description: 'Common questions about cancer blood tests, liquid biopsy, MRD testing, and how to use OpenOnco.',
    path: '/faq'
  },
  'how-it-works': {
    title: 'How OpenOnco Works',
    description: 'Learn how OpenOnco collects, curates, and presents cancer diagnostic test data.',
    path: '/how-it-works'
  },
  'data-sources': {
    title: 'Data Sources',
    description: 'OpenOnco data sources including FDA filings, peer-reviewed publications, and vendor documentation.',
    path: '/data-sources'
  },
  submissions: {
    title: 'Submit Data or Feedback',
    description: 'Submit corrections, new test data, or feedback to improve OpenOnco.',
    path: '/submissions'
  },
};

// ============================================
// URL Utilities
// ============================================

// Category code to URL path mapping (new plain-language URLs)
const categoryToPath = {
  MRD: 'monitor',
  ECD: 'screen',
  CGP: 'treat',
  HCT: 'risk',
  // Legacy mappings
  TRM: 'monitor',
  TDS: 'treat',
};

export const slugify = (text) =>
  text.toLowerCase()
    .replace(/\+/g, '-plus')
    .replace(/[^a-z0-9]+/g, '-')
    .replace(/(^-|-$)/g, '');

export const getTestUrl = (test, category) => {
  // Use explicit slug if defined, otherwise generate from name
  const slug = test.slug || slugify(test.name);
  const urlPath = categoryToPath[category] || category.toLowerCase();
  return `/${urlPath}/${slug}`;
};

export const getTestBySlug = (slug, category) => {
  const categoryMap = {
    MRD: mrdTestData,
    ECD: ecdTestData,
    TRM: trmTestData,  // Legacy: maps to MRD data eventually
    TDS: tdsTestData,  // Legacy: maps to CGP data eventually
    CGP: tdsTestData,  // CGP uses TDS data array
    HCT: [],           // New category, empty for now
  };
  const tests = categoryMap[category] || [];
  // Check explicit slug field first, then fall back to slugified name
  return tests.find(t => (t.slug || slugify(t.name)) === slug);
};

export const getAbsoluteUrl = (path) => `${SEO_DEFAULTS.siteUrl}${path}`;

// ============================================
// Structured Data Generators (JSON-LD)
// ============================================
export const generateTestSchema = (test, category) => {
  const categoryLabels = {
    MRD: 'Cancer Monitoring & Residual Disease Test',
    ECD: 'Early Cancer Detection Test',
    CGP: 'Comprehensive Genomic Profiling Test',
    HCT: 'Hereditary Cancer Risk Test',
    // Legacy aliases
    TRM: 'Cancer Monitoring & Residual Disease Test',
    TDS: 'Comprehensive Genomic Profiling Test'
  };

  return {
    '@context': 'https://schema.org',
    '@type': 'MedicalTest',
    '@id': getAbsoluteUrl(getTestUrl(test, category)),
    name: test.name,
    alternateName: test.id,
    description: test.indicationsNotes || test.method,
    manufacturer: {
      '@type': 'Organization',
      name: test.vendor
    },
    usedToDiagnose: (test.cancerTypes || []).join(', '),
    relevantSpecialty: {
      '@type': 'MedicalSpecialty',
      name: 'Oncology'
    },
    medicineSystem: 'WesternConventional',
    ...(test.sensitivity && { sensitivityValue: `${test.sensitivity}%` }),
    ...(test.specificity && { specificityValue: `${test.specificity}%` }),
    ...(test.fdaStatus && {
      recognizingAuthority: {
        '@type': 'Organization',
        name: test.fdaStatus.includes('FDA') ? 'FDA' : 'CLIA'
      }
    })
  };
};

export const generateCategorySchema = (category, tests) => {
  const seo = PAGE_SEO[category] || PAGE_SEO.home;

  return {
    '@context': 'https://schema.org',
    '@type': 'ItemList',
    name: `${seo.title}`,
    description: seo.description,
    numberOfItems: tests.length,
    itemListElement: tests.slice(0, 10).map((test, index) => ({
      '@type': 'ListItem',
      position: index + 1,
      item: {
        '@type': 'MedicalTest',
        '@id': getAbsoluteUrl(getTestUrl(test, category)),
        name: test.name,
        manufacturer: {
          '@type': 'Organization',
          name: test.vendor
        }
      }
    }))
  };
};

export const generateOrganizationSchema = () => ({
  '@context': 'https://schema.org',
  '@type': 'NonProfit',
  name: 'OpenOnco',
  url: SEO_DEFAULTS.siteUrl,
  logo: `${SEO_DEFAULTS.siteUrl}/og-image.png`,
  description: 'Non-profit cancer diagnostic test database providing independent, transparent test comparison.',
  foundingDate: '2024',
});

export const generateFAQSchema = (faqs) => ({
  '@context': 'https://schema.org',
  '@type': 'FAQPage',
  mainEntity: faqs.map(faq => ({
    '@type': 'Question',
    name: faq.question,
    acceptedAnswer: {
      '@type': 'Answer',
      text: faq.answer
    }
  }))
});
